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Abstract 
 
Background: Transferring cost-effectiveness information between geographic 
domains offers the potential for more efficient use of analytical resources. 
However, it is difficult for decision-makers to know when they can rely on cost-
effectiveness evidence produced for another context. Objectives: This thesis 
explores the transferability of economic evaluation results produced for one 
geographic area to another location of interest, and develops an approach to 
identify factors to predict when this is appropriate. Methods: Multilevel statistical 
models were developed for the integration of published international cost-
effectiveness data to assess the impact of contextual effects on country-level; whilst 
controlling for baseline characteristics within, and across, a set of economic 
evaluation studies. Explanatory variables were derived from a list of factors 
suggested in the literature as possible constraints on the transferability of cost-
effectiveness evidence. The approach was illustrated using published estimates of 
the cost-effectiveness of statins for the primary and secondary prevention of 
cardiovascular disease from 67 studies and related to 23 geographic domains, 
together with covariates on data, study and country-level. Results: The proportion 
of variation at the country-level observed depends on the appropriate multilevel 
model structure and never exceeds 15% for incremental effects and 21% for 
incremental cost. Key sources of variability are patient and disease characteristics, 
intervention cost and a number of methodological characteristics defined on the 
data-level. There were fewer significant covariates on the study and country-levels. 
Conclusions: Analysis suggests that variability in cost-effectiveness data is primarily 
due to differences between studies, not countries. Further, comparing different 
models suggests that data from multinational studies severely underestimates 
country-level variability. Additional research is needed to test the robustness of 
these conclusions on other sets of cost-effectiveness data, to further explore the 
appropriate set of covariates, and to foster the development of multilevel statistical 
modelling for economic evaluation data in health.  
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1. Introduction 
 
 
To get the most benefit from healthcare resources available, we ought to know 
which technologies provide the best value given a restricted healthcare budget. 
Therefore, health economists conduct economic evaluation studies in order to 
compare different options to spend the limited resources available. Such 
economic evaluation studies may be defined as ‘comparative analyses of 
alternative courses of action in terms of both their costs and consequences’ 
(Drummond et al., 2005a). Hence, ‘for a meaningful comparison, it is necessary 
to examine the additional costs that one health care intervention imposes over 
another, compared to the additional benefits, or utilities it delivers’ (Drummond 
et al., 2005a).  
 
Decision makers from an increasing number of countries require such cost-
effectiveness data to inform the provision and reimbursement of new health 
technologies (Drummond et al., 2009). If a new health technology is to be 
launched in a specific country, manufacturers may therefore need to provide 
evidence not just of safety and clinical efficiency, but also of cost-effectiveness in 
the context of a particular healthcare market. However, this absorbs analytical 
resources, which are scarce and expensive. If economic evaluation results could 
be reliably transferred from one geographic domain to another, this would free 
analysts to study other important questions (Steuten et al., 2008). Therefore, it 
would be helpful to ‘provide evidence for decision makers to establish the 
relevance or to adjust the results of a specific study to their location of interest’ 
(Sculpher et al., 2004).  
 
A key barrier to transferability of economic evaluation results is a lack of 
understanding on the causes of variability in measures of cost-effectiveness. 
There is a plethora of literature discussing potential causes of variability 
(Sculpher et al., 2004; Goeree et al., 2007), but many of the suggested variability 
factors are fuzzy, hard or impossible to measure, and dependent on the health 
technology under consideration. Little is known about the relative impact of such 
 2 
 
variability factors on measures of cost-effectiveness. For instance, Goeree et al. 
(2007) state that ‘there is a lack of empirical studies which prevents stronger 
conclusions regarding which transferability factors are most important to 
consider and under which circumstances.’ In addition to that, Sculpher et al. 
(2004) highlight that ‘research is required to identify (higher-level) covariates 
which are empirically useful [...] in terms of explaining differences in efficiency 
between locations and useful for policy-making purposes’. This opinion is also 
being shared by Drummond et al. (2009) who suggest that ‘more research should 
be undertaken into those sources of local differences that affect economic data 
transferability. This would help justify jurisdiction-specific data requirements and 
inform the selection of jurisdiction-level covariates in statistical models.’  
 
 
 
1.1. Aims and objectives  
 
To fill this research gap, this thesis aims to assess the impact of variability factors 
within and between economic evaluation studies and, ultimately, between 
geographic domains. In order to do so, a quantitative method is required to 
integrate international cost-effectiveness data elicited from published economic 
evaluation studies, which allows for the inclusion of covariates encoding 
variability factors working within and between studies and, ultimately, between 
countries represented in the data. Identifying such a method constitutes the first 
objective of this exercise, and it is argued in this thesis that multilevel statistical 
modelling (MLM) provides this methodological framework.  
 
 
Having identified MLM as an appropriate method for the integration of 
international cost-effectiveness data from published economic evaluation 
studies, the second objective is to develop models which appropriately reflect 
the complex structures which are likely to be present in the data. These models 
need to take into account that cost-effectiveness data is grouped both in the 
studies which it was elicited from, and the countries which this data applies to. In 
addition, some studies provide data for more than one country, and sensible 
 3 
 
assumptions regarding dependencies within this data are required to develop 
models which are suitable for the empirical analysis.  
 
 
Once the appropriate multilevel model structure has been determined, the third 
objective is to control for variability factors working within and between studies 
represented in the data, which may also disclose further variability on country-
level. For this reason, covariates which were drawn from a long list of variability 
factors as previously discussed in the relevant literature (Sculpher et al., 2004; 
Goeree et al., 2007) are being tested systematically within the multilevel models 
developed for the purposes of this project.  
 
 
Only after controlling for factors causing variability in measures of cost-
effectiveness within and between studies, can we appropriately assess the 
impact of country-level covariates. The reason is that variability caused by lower-
level factors may feed through to higher levels. Hence, after controlling for such 
‘lower-level’ covariates, the fourth objective of this project is to investigate 
causes of country-level variability within the MLM framework. As a result, a 
number of country-level covariates may be identified which explain differences 
in incremental net monetary benefits (INMBs) as well as the stochastic 
components of the INMB statistic, i.e. incremental cost (∆C) and incremental 
effects (∆E) respectively. If variability in measures of cost-effectiveness turns out 
to be low between countries, an alternative objective is to assess reasons for a 
lack of country-level variation in international cost-effectiveness data.  
 
 
Finally, the MLM framework offers a number of interesting analytical features, 
which have not yet been applied to the academic domain of economic evaluation 
in health. In particular, MLM allows modelling variation in the response variable 
directly as a function of explanatory variables (e.g. Steele, 2008). This concept of 
the ‘variance function’ could be useful to show how variability in measures of 
cost-effectiveness between studies, or countries, changes as a function of 
explanatory variables. This may help identifying key areas within which 
disagreement between studies, or countries, is particularly high, and hence, the 
transfer of existing data to other geographic domains discouraged. As a result, 
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research resources may be focused on areas of high variability in existing 
international cost-effectiveness data, whilst the transfer of information may be 
rather indicated for situations where variability in existing cost-effectiveness 
evidence is low. For this reason, the final objective of this thesis is to explore 
analytic features of the MLM framework which may allow further insights into 
the geographic transferability of economic evaluation data in health.  
 
 
The remainder of this introductory section provides a brief overview of the 
individual chapters of this thesis.  
 
 
 
1.2. Overview of this thesis 
 
The primary aim of this project is to address the transferability problem of 
economic evaluation in health by analysing what causes variability in measures 
of cost-effectiveness within and between studies, and ultimately, between 
geographic domains. For this reason, the literature concerned with the 
transferability and generalisability of economic evaluation in health is reviewed 
first in Section 2.1, confirming that ‘the methods that have been proposed to 
address the transferability issue have often been relatively ad hoc, with the 
obvious consequence that the methodological literature in this area has evolved 
somewhat nonlinearly over time’ (Manca, 2009). The available literature also 
confirms that ‘there is a lack of empirical studies which prevents stronger 
conclusions regarding which transferability factors are most important to 
consider and under which circumstances’ (Goeree et al., 2007). As a 
consequence, an analytic strategy for the purposes of this project is developed in 
Chapter 2.2, identifying MLM as a promising method for analysing factors 
causing variability in measures of cost-effectiveness.  
 
 
The use of MLM for analysing variability factors for measures of cost-
effectiveness is also in accord with the theoretical framework for the transfer of 
evidence between geographic domains developed in Chapter 2.3. In this section, 
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the transferability problem is described as an ‘analogical inference’, where a 
mapping of relevant attributes between a source domain, about which more is 
apparently known, and a, less studied, target domain is produced to infer 
whether the information of interest may also hold in the target setting (Gentner 
& Markman, 1997; Forbus, 2001; French, 2002). This theoretical framework is 
then linked to the statistical concept of ‘exchangeability’, which forms the 
conceptual basis of MLM. Multilevel modelling makes explicit the 
exchangeability assumption and allows for the assessment of variability factors 
for cost-effectiveness data within studies, between studies, and ultimately, 
between countries through the assumption of conditional independence 
(Drummond et al., 2009). Chapter 2 therefore concludes with systematically 
reviewing the use and applications of MLM in the area of economic evaluation in 
health, and shows that all applications of MLM in this area focus on the analysis 
of individual patient data from multicentre trials or observational studies, within 
which a strict two-level hierarchical data structure is commonly assumed.   
 
 
Hence, using MLM as a mode for meta-regressing secondary cost-effectiveness 
data from published economic evaluation studies, as it is aimed in this project, is 
a novelty in this area, which is why Chapter 3 is dedicated to developing and 
testing methods to integrate cost-effectiveness data from different studies and 
applicable to different geographic domains. Starting with a simple ordinary least 
squares (OLS) regression equation, this chapter introduces, step by step, the 
features required to model complex data structures and (partial) exchangeability 
not just between studies, but also the geographic domains represented in the 
dataset. Within this process, a number of strictly hierarchical as well as cross-
classified models are developed both within a univariate framework, with INMBs 
as single response variable, and a bivariate framework, with the stochastic 
components of the INMB statistics (∆C and ∆E) as a vector of response variables.  
 
 
Models are subsequently tested within a pilot study reported in Chapter 3.4 
using a subset of cost-effectiveness data on statins for the primary and 
secondary prevention of cardiovascular disease (CVD). This intervention was 
chosen as it has been extensively researched in the past, suggesting that data 
from a sufficient number of includable studies and geographic locations will 
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justify the assumption of random parameters on study and country-level 
(Snijders, 2005). Results from the pilot show that the use of MLM for secondary 
data integration is promising and in line with Gelman et al. (2004), who state that 
‘the valid concern is not about exchangeability, but encoding relevant knowledge 
as explanatory variables where possible.’ However, the pilot study also shows the 
importance of making appropriate assumptions about (in-) dependencies in the 
data, especially with respect to measures of cost-effectiveness on country-level 
elicited from multinational economic evaluation studies.  
 
 
A systematic literature review and data abstraction exercise is then reported in 
Chapter 4, which has the aim of populating a dataset with incremental cost, 
incremental effects and INMBs on statins for the primary and secondary 
prevention of CVD; together with additional data encoding potential variability 
factors for measures of cost-effectiveness. In total, 67 relevant studies were 
includable in this empirical exercise, reporting 2094 cost-effectiveness estimates 
applicable to 23 geographic domains. Covariates were derived from a long list of 
potential variability factors as previously reported in the literature (Sculpher et 
al., 2004; Goeree et al., 2007). Results of most studies refer to one geographic 
domain only, whilst six studies are multinational in nature.  
 
 
When carrying out the systematic literature review and abstracting data from 
studies includable in this empirical exercise, it was apparent that some studies 
related to each other, for instance, through common authorship, the use of 
identical data sources, reuse of a previously published decision analytic model 
(DAM), or simply a common source of funding. This may violate the 
independence assumption between studies, which is necessary to fit the MLMs 
developed in Chapter 3. Therefore, Chapter 4 also looks into the ‘genealogy’ of 
economic evaluation studies on the cost-effectiveness of statins in the primary 
and secondary prevention of CVD. Multiple correspondence analysis is used to 
ascertain whether studies are similar with respect to key study characteristics, 
and once a ‘phenotypic’ similarity is disclosed, a ‘genotypic’ relationship between 
studies is aimed to be established. This exercise resulted in some relationships 
being disclosed amongst the studies included in the dataset; however, the 
method does not (yet) prove sensitive or specific enough to justify alternative 
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MLM structures. Rather, a number of explanatory variables are derived with the 
aim of encoding existing relationships between studies, and it is concluded that 
this exploratory task into the genealogy of economic evaluation studies should 
be followed up further in future research.   
 
 
Chapter 5 is concerned with the main empirical analysis of this project, and this 
analysis is partitioned in accord with the objectives outlined above. The first 
objective, assessed in Section 5.1, is to determine the appropriate MLM structure 
for this empirical analysis. This assessment is not just concerned with testing 
which MLM previously developed works well on the data collected, but also 
whether assumptions made in these models are justified for the data. In 
particular, this section shows that appropriate assumptions regarding (in-) 
dependencies are crucial for making correct inferences when analysing 
secondary cost-effectiveness data. For instance, if data from multinational 
studies shows much lower country-level variability, the independence 
assumption between countries may not be justified for this data.  
 
 
The analysis in Section 5.1 also demonstrates the benefits of decomposing the 
INMB statistic into its components ∆C and ∆E in the bivariate framework and 
shows that part of the variability in international cost-effectiveness data on 
statins ‘disappears’ when combining ∆C and ∆E to the INMB statistic. This very 
interesting finding is also subject to further analysis in Section 5.3, which is 
concerned with country-level variability, or the lack thereof, both within the 
univariate and bivariate MLM framework. Finally, Section 5.1 assesses, in depth, 
whether ‘empirical Bayes shrinkage estimation’ may be regarded as appropriate 
in a model which attempts to integrate secondary data from published economic 
evaluation studies, where the weight of a particular study does not depend on 
individual patients considered, but rather on the extent to which subgroup and 
sensitivity analyses have been reported. It is shown that, due to high between 
group variability in the data, shrinkage factors are very high, which means that 
shrinkage is, at most, moderate. More importantly, however, this section argues 
that the impact of shrinkage on study means in this exercise depends not just on 
the respective number of data points from each study, but also on the within and 
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between group variability and the location of each study mean relative to the 
overall regression mean.  
 
 
Section 5.2 is concerned with covariate adjustment on data and study-level, and 
to disclose the maximum amount of variability on country-level through 
controlling for multiple variability factors working within and between studies in 
the dataset. Covariates are drawn from a long list of variability factors as 
obtained from the literature (Sculpher et al., 2004; Goeree et al., 2007) and 
abstracted from the studies included in the systematic literature review reported 
in Chapter 4. Results show, for instance, that the effect of lower-level variability 
factors feeds through to higher levels so that the actual amount of country-level 
variability may only be unravelled by including relevant covariates both on data 
and study-level. The analysis also shows that country-level variability is 
increasing with the inclusion of lower-level covariates in the bivariate model, 
which may allow assessment of covariates on country-level in the bivariate 
framework. However, a different conclusion applies to the univariate framework, 
where country-level variability remains negligible throughout the course of this 
exercise. Section 5.2 also provides a number of interesting findings with respect 
to individual covariates tested on data and study-level, which are also discussed 
in depth in Chapter 6.  
 
 
Section 5.3 is concerned with variability in measures of cost-effectiveness 
between countries and this analysis consists of two parts. Part one analyses 
potential causes for a lack of country-level variability in the univariate MLM with 
INMBs as single response variable. In part two, country-level covariates are 
tested in the bivariate framework, within which considerably more country-level 
variability was identified. To analyse potential causes for a lack of country-level 
variation in the univariate MLM, forest plots with country means and their 
respective confidence intervals are presented for each response variable (INMB, 
∆C and ∆E). In addition, Pearson correlations for mean ∆C and ∆E are highly 
significant and close to unity, indicating that the lack of country-level variability 
in INMBs results from combining ∆C’s and ∆E’s which have similar patterns of 
variability - meaning that variability in one component of the INMB statistic is 
partly being offset by variability in the other component. Testing country-level 
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covariates in the bivariate model show small but significant coefficients for a 
number of explanatory variables and results are subsequently discussed in 
Chapter 6.  
 
 
The final Section 5.4 of the empirical chapter is concerned with additional 
methodological features of the MLM framework which may be beneficial for 
addressing the transferability problem of economic evaluation data in health. 
Random slopes are fitted to covariates in the model and variation in 
international cost-effectiveness data is modelled directly as a function of 
explanatory variables. In this section, it is argued that the concept of the 
‘variance function’ relates to the transferability problem as it may be used to 
determine which of the available cost-effectiveness information is rather 
transferable to the target country, and where to prioritize research resources to 
generate new target specific cost-effectiveness evidence. Results show, for 
instance, that variability between studies is constantly increasing for the 
relationship between INMBs and total cholesterol (TCL) and ∆E’s and TCL 
respectively; so that results may be less transferable the higher the total 
cholesterol level of the target population.  
 
 
A number of issues are identified with respect to the variance function, which 
are discussed in far more detail in the discussion Chapter 6. For instance, can we 
determine a ‘threshold value’ for study-level variability which may be helpful to 
guide the decision on whether or not to transfer existing evidence to the target 
country? Also, are there additional application areas where modelling the 
variance function may be useful, for instance within the context of international 
multicentre trials. Apart from that, Chapter 6 provides a thorough discussion on 
other findings of this project, policy implications, strength and weaknesses of the 
empirical analysis, and suggested areas for further research.  
 
 
 
 
 
  
 10 
 
2. Background 
 
 
This chapter provides the necessary background and develops a research 
strategy for this project. The economic evaluation literature on the transferability 
/generalisability of measures of cost-effectiveness is reviewed, identifying a 
number of general ‘research themes’ within this topic. Based on this summary of 
the relevant literature, a research strategy is developed. Third, to provide a solid 
theoretical basis for this thesis, a theoretical framework is developed for the 
transfer of evidence between geographic domains. The transferability problem 
may best be described as an ‘analogical inference’, where a mapping of relevant 
attributes between a source domain, about which more is apparently known, 
and a, less studied, target domain is produced to infer whether the information 
of interest may also hold in the target setting (Gentner & Markman, 1997; 
Forbus, 2001; French, 2002). This theoretical framework of analogical reasoning 
is then linked to the statistical concept of ‘exchangeability’, which forms the 
conceptual basis of the empirical work of this project.  
 
As a result, multilevel statistical modelling, as previously identified by Rice & 
Jones (1997), Sculpher et al. (2004), Drummond et al. (2009) and others is used 
in this thesis to analyse factors causing variability in measures of cost-
effectiveness. MLM explicitly models the exchangeability assumption and, by 
relaxing this assumption, allows for the assessment of variability factors of 
measures of cost-effectiveness within studies, between studies, and ultimately, 
between geographic domains through the assumption of conditional 
independence (Drummond et al., 2009). The final section of this chapter 
therefore reviews the use and applications of MLM in the area of economic 
evaluation in health, before Chapter 3 reports in detail on the MLM methods 
developed for the purposes of this project and a pilot study to test these 
methods. 
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2.1. Existing literature on the transferability/ 
generalisability of economic evaluation in health  
 
There is a considerable body of literature concerned with the transferability / 
generalisability of economic evaluation data and Manca (2009) states that ‘the 
methods that have been proposed to address the transferability issue have often 
been relatively ad hoc, with the obvious consequence that the methodological 
literature in this area has evolved somewhat nonlinearly over time’. This section 
therefore aims to bring some order into this body of literature. Though it was 
intended to thoroughly discuss relevant publications, this literature review may 
not be labelled as ‘systematic’. The ‘nonlinear’ development of this field of 
research led to a large number of potential search words which also appear very 
regularly in unrelated publications. This makes it difficult defining a sufficiently 
‘sensitive’ search strategy which is also ‘specific’ enough to obtain a manageable 
number of potentially relevant hits from searching scientific databases. On the 
other hand, however, a number of fairly recent key publications exist which draw 
together part of the relevant literature. Therefore, a rather ‘organic’ search 
strategy was applied, starting off from some key publications in the area (for 
instance, Sculpher et al., 2004; Goeree et al., 2007 & 2011; Drummond et al., 
2009) and then systematically following up papers which cited, or were cited, in 
these publications.  
 
One of the first papers focussing on the transferability problem was written by 
Bernie O’Brien (1997). ‘Because replication of trials is an expensive and inefficient 
undertaking’, he argued, ‘analysts need to determine the validity of transferring 
cost-effectiveness data from one country to another’. He further identified six 
‘threats’ to the transferability of economic evaluation data, namely 1) 
demography and epidemiology, 2) clinical practice and conventions, 3) incentives 
and regulations for healthcare providers, 4) relative price levels, 5) consumer 
preferences and 6) opportunity cost of resources. Much of the subsequent work 
on the transferability problem in general, but also on factors causing variability in 
measures of cost-effectiveness in particular (e.g. Drummond & Pang, 2001; 
Sculpher et al., 2004; Goeree et al., 2007) builds upon O’Brien (1997). Barbieri et 
al. (2005), for instance, systematically reviewed the literature to identify 
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economic evaluation studies conducted for two or more countries in order to 
assess their level of variability in measures of cost-effectiveness and the main 
causes of this variation (i.e. variability factors). It was also assessed whether 
differences in results would lead to different decisions in different countries. 
Results suggested that the type of economic evaluation study (i.e. trial based or 
decision analytic modelling based) had some impact on variability, but that the 
‘most important factor was the extent of variation across countries in 
effectiveness, resource use or unit costs, allowed by the researchers chosen 
methodology’. The authors also devised a classification of studies with respect to 
their likely degree of variability in measures of cost-effectiveness.  
 
Another body of literature emerged with respect to critical appraisal methods for 
the transferability potential of economic evaluation in health. In 1999, Späth et 
al. published a paper which aimed to define a method for assessing the eligibility 
of published economic evaluation studies for transfer to various settings in a 
given healthcare system. They built up from work undertaken by Heyland et al. 
(1996), who developed a basic ‘transferability checklist’ to critically appraise the 
potential of transferring economic evaluation data from one context to another. 
Subsequently, a whole body of literature emerged concerning transferability 
checklists, decision charts, or indices, some of the most prominent examples 
were provided by Welte et al. (2004), Boulenger et al. (2005) the EUnetHTA 
adaption toolkit (Turner et al., 2009), EURONHEED (Nixon et al., 2004; Nixon et 
al., 2009) or Antonanzas et al. (2009). Work was also undertaken to validate or 
empirically apply transferability checklists (e.g. Knies et al., 2009; Essers et al., 
2010; Wolfenstetter & Wenig, 2010), and a systematic review on critical 
appraisal tools was recently published by Goeree et al. (2011).  
 
Meanwhile, other researchers looked at the transferability problem from a 
different angle. Their approach was to increase the generalisability of economic 
evaluation data by harmonizing HTA and economic evaluation methods across 
HTA agencies and geographic jurisdictions (e.g. Hjelmgrien et al, 2001). Sculpher 
& Drummond (2006) state that ‘decision makers and analysts need to work 
together and where possible harmonize guidelines on methods for economic 
evaluations whilst recognising legitimate variation in the needs of different 
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healthcare systems.’ However, Birch & Gafni argued already in 2003, that ‘the 
ICER associated with maximising health benefits for the community cannot be 
determined in isolation of the community context.’ Further, ‘the validity of the 
method of valuation cannot be established independent of the setting in which it 
is to be used’ and finally, even if the methods of valuation are valid in each 
setting, the authors pose the questions of whether this implies that ‘numbers 
produced by application of the methods are generalisable across individuals and 
settings.’ Birch & Gafni (2003) conclude that the ‘generalisability of the validity of 
a method of valuation does not imply generalisability of the resulting valuations’ 
and with respect to the transferability problem in general, they conclude that 
‘the economic question of whether an activity adds more to well-being than the 
alternative uses of the same resources in a particular community cannot be 
answered by reference to the costs and consequences of the same activity in a 
different community’. A similar opinion is shared by Vale (2010), who argues that 
‘despite common principles, the process of HTA, and more particularly its 
economic evaluation component, needs to take a national approach toward 
evaluation.’ Nevertheless, significant research into the harmonization of HTA 
guidelines and methods for economic evaluation in health has been carried out, 
for instance within the EUnetHTA WP 4, developing the ‘CORE HTA Model’ 
(EUnetHTA, 2008) or WHO work on ‘generalised cost-effectiveness analysis’, 
which may also be subsumed under this category (Murray et al., 2000; Tan-
Torres Edejer, 2003).  
 
 
Apart from the general research themes as outlined above, authors addressed 
transferability issues of particular relevance for decision analytic modelling 
studies on the one hand, and trial based analysis of individual patient data on the 
other. In 2004, Sculpher et al. published a landmark study on the generalisability 
of economic evaluation in health. In their work, which formed part of the NHS 
R&D HTA programme, they first conducted a number of systematic reviews on:  
 
• Factors causing variability in economic evaluation studies  
• Methods used to assess variability and enhance generalisability  
o in decision analytic modelling based economic evaluations 
o in trial based economic evaluations 
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• A systematic review on economic evaluations undertaken alongside 
multicentre randomised controlled trials and  
• A structured review on model based economic evaluation studies in 
osteoporosis (results of this review were also published separately in 
‘Pharmacoeconomics’ (Urdahl et al., 2006)).  
 
Further to that, Sculpher et al. (2004) produced two case studies, one on 
assessing generalisability in trial based economic evaluations using MLM, and 
another one on making economic evaluation more location specific using 
decision analytic modelling. With respect to DAM, Sculpher et al. (2004) mention 
that ‘it facilitates the synthesis of data from several sources’. As such, decision 
analytic models may be used for instance to: 
 
• adjust trial results to reflect routine practice  
• extend trial results to non-trial locations 
• substitute input parameters with location specific data or 
• build generic models which are then tailored to specific locations.  
 
With respect to trial based economic evaluations, Sculpher et al. (2004) identify 
methods for increasing generalisabiliy relating to a) study design and b) data 
analysis. In terms of the design of studies, methods identified relate to cost 
estimation, currency conversion, centre selection, randomisation, data collection 
and adjustments to bridge data generated under artificial trial conditions to 
routine practice. With respect to the analysis of IPD from trial based economic 
evaluation studies, Sculpher et al. (2004) highlight the paramount importance of 
making explicit assumptions of (partial) exchangeability of economic evaluation 
data between centres and countries represented in multinational RCTs. 
Assuming exchangeability means that there are no a priori reasons to expect 
more or less favourable estimates of cost-effectiveness between centres or 
locations represented in the data (Drummond et al., 2009). According to 
Sculpher et al. (2004), one method to explore issues of (partial) exchangeability 
in economic evaluations alongside RCTs is the use of MLM to ‘analyse data that 
fall naturally into hierarchical structures consisting of multiple macro units 
(contexts) and multiple micro units within each macro unit’ (Rice & Jones, 1997 
cited from Sculpher et al., 2004)  
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With respect to MLM, Sculpher et al. (2004) conclude that further research 
should relate to 1) the overall specification of models, 2) the selection of patient 
and location specific covariates and the specification of their interaction with 
treatment, 3) the appropriate MLM approach when there are a number of levels 
in the data hierarchy (e.g. patients, surgeons, centres, countries), 4) appropriate 
methods when there are few locations in a trial, and 5) the use of Bayesian 
approaches to MLM. Furthermore, the ‘assessment of alternative approaches to 
specifying multilevel models to the analysis of cost-effectiveness data alongside 
multilocation randomised trials’ and the ‘identification of a range of appropriate 
covariates relating to locations (e.g. hospitals) in multilevel models’ were 
identified as overall priorities for further research with respect to the 
transferability / generalisability of economic evaluation in health (Note that the 
MLM literature related to health economic evaluation is also subject of a 
systematic literature review further below in this chapter). 
 
 
The recommendations of Sculpher et al. (2004) with respect to both trial based 
and DAM based economic evaluations were subsequently drawn together and 
published by Drummond et al. (2005). Meanwhile, the transferability literature 
on both trial based and model based economic evaluations developed further. 
Manca & Willan (2006) proposed an algorithm to assist the choice of the 
appropriate analytical strategy when facing transferability issues in practice. 
Different scenarios were considered based on a) whether a country of interest 
participated in a trial and b) whether individual patient level data is available for 
that trial. This work differs from transferability checklists as it assists in 
determining the appropriate method to assess or enhance transferability, not to 
assess the transferability potential of the data itself. Again, the use of MLM was 
proposed as it mediates between the two extreme assumptions of either 
‘pooling’ or ‘splitting’ the data from multinational trials. In addition, the potential 
of assessing both patient and country-level covariates within the MLM 
framework was highlighted as a particular advantage of this analytic approach 
(Manca & Willan, 2006). In the meantime, Mason & Mason (2006) reviewed the 
literature on the generalisability and transferability of economic evaluation in 
health and identified current issues within this area of research, one of which 
being, again, the use of MLM to assess the transferability of findings from trial 
based economic evaluations.  
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Another key paper was recently published by Drummond et al. (2009), which 
addresses issues falling into almost all of the research themes outlined above. 
Based on work by the ISPOR Good Research Practices Task Force, Drummond et 
al. first review what national economic evaluation guidelines suggest with 
respect to the transferability problem, discuss elements which may be deemed 
transferable, and make good research practices recommendations for both trial 
based and decision analytic modelling based economic evaluations. According to 
Drummond et al. (2009), most guidelines recognise the potential for differences 
in effectiveness data and suggest the transferability of relative risk reduction, 
whilst baseline risks should be context specific. With respect to health state 
valuations, only 8 of 21 methods guidelines make any recommendations in terms 
of the transferability of such data. For resource use and unit cost estimates, most 
guidelines agree that both should be reported separately, and all guidelines 
specify that unit cost shall be location specific.  
 
 
Secondly, Drummond et al. (2009) propose an algorithm to determine whether 
simple or more elaborate methods are required for adjusting study results to the 
location of interest. This algorithm consists of four general steps and is partly 
based on Welte’s decision chart for the transferability of economic evaluation 
data. The first step determines whether cost-effectiveness information is 
available, the second step specifies whether this data may be relevant to the 
decision problem and whether the methodology is deemed appropriate (this 
step is based on criteria proposed by Welte et al., 2004). The third step considers 
whether treatment patterns are comparable between the existing data and the 
location of interest, and the final step considers whether the cost-effectiveness 
data is based on a multilocation trial which includes the location of interest.  
 
 
The remainder of the paper published by Drummond et al. (2009) is concerned 
with specific transferability/ generalisability issues with respect to either trial 
based or model based economic evaluation studies. In terms of DAM based 
studies, the authors identify situations when this may be the preferred vehicle 
for economic evaluation in health. Precisely, if: 
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• trials were undertaken wholly outside the jurisdiction of interest and 
one or more components of evidence cannot be generalised across 
jurisdictions 
• to synthesize data from multiple sources of evidence relating to any 
aspect of the analysis 
• To adjust aspects of the trial (e.g. time horizon) to what is considered 
relevant and appropriate in the location of interest  
• To adapt a DAM developed for another country to the country of 
interest 
 
Further issues relating to the geographic transferability of DAM based economic 
evaluation were mentioned, for instance determining the model structure, 
parameter estimation, or analysis as ‘different jurisdictions require different 
analytical methods’.  
 
 
Finally, with respect to IPD analysis from randomised controlled trials, 
Drummond et al. (2009), state that ‘with respect to transferability, analytic 
approaches address two sets of objectives. The first is to evaluate whether there 
is evidence of heterogeneity in patterns of resource use, costs, survival, and / or 
utilities and to explore potential sources of heterogeneity. The second objective is 
to obtain estimates of incremental resource use, cost, and/ or cost-effectiveness 
that are appropriate for decision making within particular jurisdictions that may 
or may not have been included in the trial.’ Accordingly, Drummond et al. (2009) 
identify three categories of statistical methods for analysis of IPD data, namely 1) 
the detection of heterogeneity, 2) fixed effects models and 3) multilevel or 
hierarchical models. With respect to MLM, the authors state that they: 
 
• ‘can appropriately handle the hierarchical nature of the data that 
manifests itself as a lack of independence of the errors between the 
observations’ 
• ‘provide the formal means of estimating jurisdiction specific measures of 
cost-effectiveness’ 
• ‘provide a pooled, random effects estimate across all jurisdictions, 
equivalent to a random effects summary estimate from meta-analysis’  
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• model partial exchangeability through the inclusion of covariates on each 
level of the modelled data hierarchy.  
 
With respect to covariates, the authors mention that ‘currently, evidence is 
lacking as to what types of higher-level covariates may be useful in this regard, 
but candidate variables may include those that are indicative of macroeconomic 
characteristics (e.g. gross national product), capacity constraints (e.g. limited 
availability of intensive care beds), economic incentives (e.g. pressure to minimise 
length of stay), or financing characteristics (e.g. global budgets vs. fee for service 
reimbursement).’ Finally, the authors highlight that the body of literature on 
MLM within economic evaluation is currently evolving so that it may be 
premature to comment on best practices or to suggest situations where 
multilevel modelling may offer advantages over simpler analytic approaches.  
 
Table 2.1 General research themes emerging from the available literature 
1. Assessing factors causing variability in measures of cost-effectiveness 
2. Standardising economic evaluation methodology across HTA bodies and countries to 
increase the generalisability of findings 
3. Developing or testing methods for the critical appraisal of economic evaluation in health 
resulting in transferability checklists, decision charts and indices 
4. Using decision analytic modelling 
a. to adjust trial results to reflect routine practice (though this particular topic 
relates to another ‘facet’ of generalisability which is not the focus here)  
b. to extend trial results to non-trial locations 
c. To apply decision models for one particular location to another or 
d. to build generic models which may then be tailored to specific locations of 
interest 
5. Issues relating to economic evaluation alongside randomised controlled trials 
a. with respect to the design of economic evaluations conducted alongside 
multinational randomised controlled trials and  
b. with respect to developing methods of data analysis which appropriately reflect 
the assumption of (partial) exchangeability between locations, in particular the 
use of multilevel statistical modelling 
 
 
This section aimed to provide an overview of the available literature on the 
transferability / generalisability of economic evaluation in health and identified a 
number of research ‘themes’ to be followed up further within this thesis These 
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themes are also summarized in Table 2.1 above. In addition, MLM has already 
been identified as a promising method to address the transferability problem by 
a number of authors. The following section aims to describe the process within 
which the actual research strategy for this project evolved out of the themes 
identified above.   
 
 
2.2. Development of a research strategy based on the 
available literature 
 
Some of the research themes mentioned in Table 2.1 were dropped early from 
further consideration within the process of determining an appropriate research 
strategy for this project. This holds specifically for research into the 
standardisation of international HTA and economic evaluation methods. For 
instance, at the time the author of this thesis looked into potential areas for 
further research within this project (October 2008 to June 2009) considerable 
work was already in progress with respect to the CORE-HTA model (EunetHTA, 
2008). This model is ‘an attempt to define and standardise elements of an HTA’. 
(EUnetHTA, 2008). It does so by dividing relevant information on the technology 
under assessment ‘into standardised pieces, each of which describing one or 
more aspects of the technology that is likely to be useful when considering the 
adoption or rejection of the technology. (…)  The elements that are most likely 
useful for international sharing of information are defined as core elements.’ 
(EUnetHTA, 2008). The CORE HTA model has since been adapted to two clinical 
intervention areas (one for medical and surgical interventions and one for 
diagnostic technologies) and research into the CORE-HTA model is still going on 
to date (EUnetHTA-web-link). As a result, trying to contribute to this growing 
research area would also mean to compete with at least one large scale 
multinational research collaboration which already builds up from years of 
experience. Findings within this thesis would probably quickly become outdated, 
or even contradicted from newly emerging evidence within this subject.  
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Conducting empirical work concerned with critical appraisal methods for the 
transferability potential of economic evaluation data (i.e. checklists, decision 
charts and indices) was rejected for another reason. Over the years, a number of 
tools emerged within this area (Goeree et al., 2011), and any work related to this 
subject would most likely end up with either empirically testing developed 
methods or contributing towards the development of another transferability 
checklist. Some work has been carried out already to test or empirically apply 
transferability checklists (e.g. Knies et al., 2009; Essers et al., 2010; Wolfenstetter 
& Wenig, 2010), and in the light of a vast number of checklists existing already, it 
was not deemed a high research priority to dedicate this project to the 
development of (yet another) tool for critically appraising the transferability 
potential of economic evaluation in health.  
 
With respect to factors causing variability in measures of cost-effectiveness, a 
different conclusion was reached. Sculpher et al. (2004) systematically reviewed 
the economic evaluation literature to ascertain such variability factors. Both 
conceptual papers discussing variability factors as well as empirical papers trying 
to estimate the variability in cost-effectiveness results were considered. As a 
result, they compiled a list of 27 unique factors suspected to cause variability in 
measures of cost-effectiveness (Table 2.2), and these factors were grouped in 
characteristics of a) the patient, b) the clinician, c) the healthcare system and d) 
wider socioeconomic factors. Sculpher et al. (2004) also reviewed studies which 
empirically tried to assess sources of variation in cost-effectiveness data. 
According to the authors, both decision analytic models and studies based on 
individual patient data have been used to estimate variability between 
geographic locations. In both cases, the most common way to estimate 
variability by location was to substitute location specific unit cost data and 
thereby increasing the applicability of results to the respective target location. 
Apart from unit cost estimates, variation with respect to resource use patterns 
was quite commonly subject of analysis. However, Sculpher et al. (2004) state 
that most studies reviewed were standard economic evaluations with the aim to 
provide results for a number of geographic locations. Only very few studies set 
out with the specific aim to measure variation between locations, and these 
studies were ‘rather descriptive than evaluative’ in nature.  
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Table 2.2: Variability factors reported by Sculpher et al (2004)  
Factor Definition 
Absolute / relative costs Unit costs/prices of inputs into healthcare 
Artificial study conditions Research environment versus routine practice 
Capacity utilisation Level of utilisation of inputs into healthcare 
Case mix Clinical and socio-demographic characteristics of patients undergoing 
treatment 
Clinical practice variation Variation in how healthcare is delivered 
Compliance Adherence to treatment regimen 
Culture / attitudes As affecting clinical practice 
Demography Patient non-clinical characteristics, e.g. sex, age 
Disease Interaction Association of primary disease with risk factors, other morbidity/mortality 
Economies of Scale Greater levels of ‘production’ leads to lower costs 
Epidemiology Incidence/prevalence of disease 
Exchange Rates Conversion rate of different currencies 
Geographical Setting Location such as country, type of facility 
Health State valuations Individuals’ preferences for particular levels of health 
Healthcare resources Inputs into health delivery, e.g. personnel, equipment 
Healthcare system Regulatory and organisational infrastructure 
Historical differences History of organisation/practice 
Incentives Financial and other factors which affect individuals and organisational 
behaviour 
Industry-related bias Sponsor influence on study results 
Joint production Inputs into healthcare delivery are shared between different 
units/departments 
Opportunity cost Health benefits forgone by use of a resource in a particular way 
Perspective Viewpoint of economic analysis 
Skills / Experience Level of training and experience of health  professional 
Technological Innovation Advancement of technology/practice 
Timing of evaluation Stage of conduct of study in the development of  the technology 
Treatment comparators Available treatment options 
 
Following the work of Sculpher et al. (2004), only one further study was found 
which aimed to assess variability in economic evaluation data (Barbieri et al., 
2005). In their work, the authors systematically reviewed the literature to 
identify economic evaluation studies conducted for two or more countries in 
order to assess their level of variability in measures of cost-effectiveness and the 
main causes of this variation (i.e. variability factors). It was also assessed whether 
differences in results would lead to different decisions in different countries. 
Results suggested that the type of economic evaluation study (i.e. trial based or 
DAM based) had some impact on variability, but that the ‘most important factor 
was the extent of variation across countries in effectiveness, resource use or unit 
costs, allowed by the researchers chosen methodology’. The authors rightly claim 
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that - up to this point - their work constitutes ‘the most comprehensive analysis 
of the variation in the results of cost-effectiveness studies, of drugs, in Europe’.  
 
 
Table 2.3: Variability factors reported by Goeree et al. (2007)  
 
Patient Characteristics 
- Demographics (age, gender, race), education, socio-economic status 
- Risk factors, medical history, genetic factors 
- Lifestyle, environmental factors 
- Mortality rates, life expectancy 
- Attitudes toward treatment, culture, religion, hygiene, nutrition 
- Compliance and adherence rates, ethical standards 
- Population values (utilities) 
- Population density, immigration, emigration, travelling patterns 
- Income, employment rates, productivity, work loss time, friction time 
- Type of insurance coverage, user fees, co-payments, deductables 
- Incentives for patients 
 
Disease Characteristics 
- Epidemiology (incidence/prevalence, disease progression, spread) 
- Disease severity, case mix 
- Disease interaction, co-morbidity, concurrent medications 
- Mortality due to disease 
 
Provider Characteristics 
- Clinical practice, conventions, guidelines, norms 
- Experience, education, training, skills, learning curve position 
- quality of care provided 
- Method of remuneration (supplier induced demand) 
- Patient identification 
- Cultural attitudes 
- Incentives for providers, liability 
 
Health care system characteristics  
- Absolute or relative prices 
- Available resources (staff, facilities, equipment), programs, services 
- Organisation of delivery system, structure, level of competition 
- Level of technological advancement, innovation and availability 
- Available treatment options (comparators) 
- Capacity utilisation, economies of scale, technical efficiency 
- Input mix (personnel, equipment), specialisation of labour, joint production 
- Access to programs and services, gatekeepers, historical differences 
- Waiting lists, referral patterns  
- Regulatory and organisational infrastructure, licensing of products 
- Availability of generics or substitutes 
- Market form of suppliers, payment of suppliers, supplier incentives 
- Incentives from institutions 
 
Methodological characteristics 
- Costing methodology, estimation procedures (e.g. productivity cost) 
- Study perspective 
- Study factors (artificial trial conditions, industry related bias) 
- Timing of the economic evaluation 
- Clinical endpoints/outcome measures 
- Discount rates 
- Exchange rates, purchasing power parities 
- Opportunity cost (foregone benefits) 
- Affordability (CE thresholds)  
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Later, Goeree et al. (2007) provided a second systematic review on factors 
causing variability in measures of cost-effectiveness. With their work, they 
basically confirm the results previously published by Sculpher et al. (2004) and 
expand upon the list of factors potentially causing variability in measures of cost-
effectiveness. In total, 77 unique transferability factors were found which were 
grouped by the authors in characteristics of a) the patient, b) the disease, c) the 
provider, d) the healthcare system and e) methodological factors causing 
variability in measures of cost-effectiveness (Table 2.3 above). Most importantly, 
Goeree et al. (2007) confirm what has been identified as a potential gap in 
research before. In their review, the authors clearly state that ‘there is a lack of 
empirical studies which prevents stronger conclusions regarding which 
transferability factors are most important to consider and under which 
circumstances’  
 
 
Hence, for this thesis, it was concluded that a systematic assessment of factors 
causing variability in measures of cost-effectiveness constitutes an important 
research theme to consider. At this point, however, there was no clear strategy 
in terms of how to conceptualise such an assessment. On the highest level, this 
issue relates to a ‘false dichotomy’ (Drummond et al., 2009) namely the question 
of whether to work within the context of individual patient data analysis from 
randomised controlled trials, or within the framework of decision analytic 
modelling to assess the cost-effectiveness of healthcare technologies.  
 
 
With respect to the transferability problem, DAM has been previously used 
mainly to a) adjust trial results to reflect routine practice, b) to extend trial 
results to non-trial locations, c) to adapt decision models for one particular 
country to another or d) to build generic models which are then tailored to 
specific locations of interest (Sculpher et al, 2004; Drummond et al, 2009). 
Clearly, one may reasonably argue that adjusting trial results to routine practice 
(and with it the assessment of relating variability factors) does not closely relate 
to the aim of this project, which is rather concerned with the geographic 
transferability of economic evaluation data. Secondly, it was deemed highly 
unlikely to obtain access to IPD from one or more randomized controlled trials, 
which would be a pre-requisite to carry out work in this area going beyond 
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purely theoretical or conceptual/methodological contributions. Though the 
second subtheme (extending trial results to non-trial locations) falls much more 
into the scope of this thesis, the same problem regarding data availability 
applies, which ruled out this option for the purposes of this project.  
 
 
As a result, considerable time was devoted to explore strategies to analyse 
variability factors using DAM either in terms of making a general model location 
specific or in terms of adapting a model from one jurisdiction to another. With 
each step of adjustment, one may measure the variability in cost-effectiveness 
estimates, thereby analysing the factors which cause this variability in 
international cost-effectiveness data. Though this idea looked appealing at first, 
serious limitations led to the decision of not following up this strategy any 
further. In particular, both the ‘baseline model’ as well as adjustments to the 
model to transfer it to another jurisdiction would be subject to choices and 
assumptions made by the author of this thesis. This obviously bears the risk of 
bias as having influence on the study protocol at any time of the process might 
influence the results towards ‘what someone seeks to show’. This limitation was 
perceived as too strong so that it constituted a knock out criterion for this 
analysis strategy.  
 
 
Having ruled out DAM, multilevel modelling was considered for the assessment 
of factors causing variability in measures of cost-effectiveness. MLM allows 
reflecting complex data structures which arise from non-independence of error 
terms within groups like centres or countries reflected in the dataset (e.g. 
Sculpher et al., 2004), it also allows for the inclusion of covariates at any level of 
the data hierarchy through the assumption of conditional independence 
(Drummond et al., 2009). Variability factors may hence be assessed as covariates 
on different levels of the data hierarchy. However, this method has been 
identified within the context of IPD analysis, and it was deemed unlikely to 
obtain access to such data within this project. Therefore, the work by Barbieri et 
al. (2005), which was summarised above, demonstrated a promising alternative 
solution. Instead of IPD from multinational trials, one may use secondary data 
from published economic evaluation studies to populate a dataset for the 
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assessment of factors causing variability in measures of cost-effectiveness using 
MLM. This approach offers several advantages, for instance: 
 
• Access to secondary cost-effectiveness data from published economic 
evaluation studies is unproblematic. Hence, a systematic literature review 
on a particular healthcare intervention could be carried out to populate a 
dataset with secondary cost-effectiveness data as well as additional 
variables for covariate adjustment on each hierarchical level within the 
MLM framework 
 
• Secondly, despite technical challenges which are addressed in more detail 
in Chapters 3 and 5, the approach of integrating secondary data from 
published studies constitutes a more appropriate basis for the 
assessment of variability factors than the use of IPD from multinational 
trials. Trials usually implement strict protocols which may be identical 
across centres and geographic domains (Ramsey et al., 2005). These 
protocols, though crucial to ensure internal validity of the trial results, 
artificially reduce the variability which is likely to exist between centres 
and countries under real world conditions (Ramsey et al., 2005). 
Secondary data from published economic evaluation studies, which are 
usually designed to inform decisions under real world conditions, may 
better reflect this variability and therefore constitute a more appropriate 
basis for the systematic assessment of variability factors for measures of 
cost-effectiveness. Furthermore, utilising IPD from one trial may not 
allow for the assessment of methodological factors causing variability in 
measures of cost-effectiveness between studies, which has been 
identified as an important source of variability in cost-effectiveness data 
by Barbieri et al (2005).  
 
• With respect to the analytic technique, MLM makes explicit the 
exchangeability assumption, which ‘mediates’ between assumptions of 
either identical (pooling) or independent (splitting) parameters (e.g. 
Spiegelhalter et al., 2000 & 2004). This assumption of exchangeability 
(between studies and countries) may allow for the integration of 
secondary cost-effectiveness data from different studies and different 
geographic domains without ignoring the fact that study and country 
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residuals are not independent. Subsequent chapters may show whether 
this hypothesized advantage may also hold in practice.  
 
• Further, through the assumption of conditional independence (or partial 
exchangeability) one may assess the impact of variability factors 
modelled as covariates on each level of the data hierarchy. As Gelman et 
al. (2004) put it ‘In this way exchangeable models become almost 
universally applicable, because any information to distinguish different 
units should be encoded.’ (Gelman et al., 2004 cited from Manca et al., 
2007).  
 
• If ‘the analyst has identified the appropriate set of covariates for the 
exchangeability assumption to hold; and the characteristics of the country 
of interest are represented appropriately by countries in the dataset’ 
(Drummond et al., 2009), one may then extrapolate from existing data to 
domains for which cost-effectiveness information is currently missing. 
 
• By expansion, one may turn the MLM into a bivariate framework, hence 
allowing for the simultaneous assessment of costs and effects as a vector 
of response variables (Bartholomew, 2008).  
 
• Specific features of the MLM framework may even allow to explicitly 
model the variability in measures of cost-effectiveness as a function of 
explanatory variables (e.g. Rasbash et al., 2009).  
 
 
As a result, it was decided to dedicate the empirical work within this project to 
the analysis of factors causing variability in international cost-effectiveness data 
from published economic evaluation studies using MLM. The following section 
aims to provide a theoretical basis for this research strategy.  
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2.3. Theoretical framework  
 
This section aims to provide a theoretical basis for the use of MLM for the 
analysis of factors causing variability in international cost-effectiveness data from 
published economic evaluation studies. In addition, a working definition for the 
‘geographic transferability’ of economic evaluation data is provided.  
 
 
As with any representation of the real world, a health economic evaluation, 
whether trial-based or model-based, is only useful to ‘the degree to which it 
captures the reality as observed within the original setting’ (Sleigh, 1997). 
Therefore, establishing the relevance of economic evaluation results to any 
setting - including the one for which it was originally designed for - is a process 
within which we need to test whether the characteristics of that setting are 
appropriately reflected in the evaluation. We thus need to establish a 
correspondence between characteristics of the economic evaluation and the 
characteristics of the setting of interest. This is an argument by analogy (Juthe, 
2005; Steel, 2008).  
 
 
Analogical reasoning involves a mapping of attributes between a base domain, 
about which more is apparently known, and a, less studied, target domain 
(Gentner & Markman, 1997; Forbus, 2001; French, 2002). Then, the additional 
information about the base domain is hypothesized to hold in the target by 
virtue of the correspondences of those attributes which determine the 
information of interest (Juthe, 2005; Forbus, 2001; Klix, 2004). Hence, through 
the mapping of attributes we explicitly model our a priori belief that domains are 
similar in aspects which determine the information to be transferred. To 
estimate the attributes of interest for this mapping we need to know a) what 
causes variability in cost-effectiveness data and b) how to quantify the relative 
impact of such factors on measures of cost-effectiveness. There are numerous 
publications speculating about possible variability factors (Sculpher et al., 2004; 
Goeree et al., 2007), but little is known about the quantitative impact of such 
factors. This requires a simultaneous analysis of a number of cost-effectiveness 
studies across geographic domains. However, variability factors do not only 
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impact between geographic domains– there is also variation between studies 
within domains. When focussing on the ‘higher-level variability’, it is hence 
necessary to control for any variability introduced on lower levels.  
 
 
In conclusion, we need a statistical approach which explicitly and simultaneously 
models and tests the a priori belief of similarity between a) cost-effectiveness 
studies, and b) geographic domains. To identify such a quantitative technique, 
we need to define more precisely what we mean by an ‘a priori belief of 
similarity’. This definition is provided by the statistical concept of 
‘exchangeability’ (Spiegelhalter et al., 2000 & 2004).  
 
 
The concept of exchangeability goes back to Bruno de Finetti and has been 
extensively discussed in Bernardo and Smith (1994). It means, in our context, 
that the joint probability distribution of the output parameters for each cost-
effectiveness study is the same for all studies (Bernardo & Smith, 1994; Jeffrey, 
2002). Likewise, without having any additional information on each geographic 
setting, we would not have any expectation of more, or less, favourable 
estimates of cost-effectiveness (Drummond et al., 2009). Hence, we assume that 
each set of cost-effectiveness measures available represents a ‘random sample’ 
of some (hypothetical) population of measures of cost-effectiveness for that 
technology. This is also the standard assumption for random-effects meta-
analysis (Greenland, 2000; Spiegelhalter et al., 2004). Spiegelhalter et al. (2004) 
further state that ‘if a prior assumption of exchangeability is considered 
reasonable, a Bayesian approach to multiplicity is thus to integrate all the units 
into a single model, in which it is assumed that study parameters are drawn from 
some common prior distribution whose parameters are unknown: this is known 
as a hierarchical or multilevel model’ (Spiegelhalter et al., 2004).  
 
 
This class of models is referred to as ‘multilevel’, as allowing study and country 
parameters to vary randomly enables us to fit models for these parameters 
‘above’ the model for the actual cost-effectiveness data (Jackman, 2008). Hence, 
the overall model structure can follow the way the data is ‘clustered’ within 
studies and geographic domains. Note that this, as this thesis will show, 
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constitutes a key challenge when fitting multilevel models to existing cost-
effectiveness data from different geographic domains as we cannot establish a 
strict hierarchical structure between the study and the country-levels in the 
presence of data from multinational studies. This issue of ‘cross-classified data 
structures’ is addressed in more detail in Chapters 3 and 5.  
 
 
Within this multilevel framework, we can model exchangeability whilst also 
controlling for variability factors working within studies, between studies and 
between geographic domains, by allowing for covariate adjustment through the 
assumption of conditional independence (Gelman et al., 2004; Manca et al., 
2007; Drummond et al, 2009). This should enable us to integrate cost-
effectiveness data, and to quantify the impact of variability factors on data, 
study, and country-level. If we are successful in this endeavour, we could then 
extrapolate from existing data to domains for which cost-effectiveness 
information is currently missing. This can be achieved within the proposed 
framework and in accord with the principles of analogical reasoning if and only if 
‘the analyst has identified the appropriate set of covariates for the 
exchangeability assumption to hold; and that the characteristics of the country of 
interest are represented appropriately by countries in the dataset’ (Drummond et 
al., 2009). In this way, as Gelman et al. (2004) points out, ‘exchangeable models 
become almost universally applicable, because any information to distinguish 
different units should be encoded.’ (Gelman et al., 2004, cited from Manca et al., 
2007) 
 
 
Before concluding this chapter with a review on the use of multilevel statistical 
modelling within the area of economic evaluation in health, it may be useful to 
provide a working definition for the ‘geographic transferability’ of economic 
evaluation data, which, so far, has been used more or less interchangeably with 
the term ‘generalisability’. In fact, there may be some confusion around these 
terms, and different authors may provide differing definitions for both concepts. 
This is also summarized in Table 2.4 below. Therefore, based on the theoretical 
framework of analogical reasoning, an alternative working definition for the 
‘geographic transferability’ of economic evaluation data is provided below.  
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Table 2.4: ‘Generalisability’ and ‘transferability’ as defined by health 
economists 
Author 
(year) 
Term defined Definition 
Willke et 
al., 2003 
Generalisability 
and 
transferability 
‘generalisability’ has often been used to refer to the problem of 
whether one can apply or extrapolate results obtained in one 
setting or population to another. Though this includes 
geographic settings, it can include demographic groups and 
various treatment settings, as well as extrapolating from trials 
to general populations. The term ‘transferability has been used 
more specifically in reference to comparing results across 
countries’ 
Drummond 
&Pang 
(2001) 
Generalisability generalisability refers to the extent to which the results of a 
study, as they apply to a particular patient population and/or a 
specific context, hold true for another population and/or in a 
different context 
Sculpher et 
al. (2004)  
Generalisability Adapt the same definition as Drummond and Pang (2001): 
‘generalisability refers to the extent to which the results of a 
study, as they apply to a particular patient population and/or a 
specific context, hold true for another population and/or in a 
different context’  
Drummond 
et al. 
(2005) 
Generalisability Are the results of an HTA undertaken in one country relevant to 
another? Also, within a large country, do the results of a given 
HTA apply in all regions? 
Boulenger 
et al. 
(2005)  
Transferability 
and 
generalisability 
Generalisability is de fined as: the degree to which 
the results of an observation hold true in other settings (‘will a 
specific treatment produce the same results in a different 
location?’).  
 
By adapting a definition by Späth et al (1999), transferability is 
defined as: the data, methods and results of a given study are 
transfer able if (a) potential users can assess their applicability 
to their setting and (b) they are applicable to that setting. 
Mason & 
Mason 
(2006) 
Transferability 
and 
generalisability 
Mason and Mason (2006) define the term ‘generalisability’ as 
consisting of three elements: 1) technical quality, which refers 
to the robustness of the study methodology, 2) applicability, 
which refers to the extrapolation of the original setting of the 
clinical trial, i.e. whether the trial has adequate pragmatic 
qualities to be useful in its original setting and 3) 
transferability, which is the capacity to directly use the 
complete results of the economic evaluation in a setting 
different from the original one in which the technology was 
assessed. 
Manca et 
al.  (2007) 
Transferability 
and 
generalisability 
The authors state that the terms transferability and 
generalisability are used interchangeably. Strictly speaking, the 
former should be interpreted as ‘‘the extent to which results 
from a given setting also apply to other settings,’’ whereas the 
term generalisability should be used to indicate 
the extent to which results can be adapted to apply in other 
settings or can be interpreted for other settings 
Drummond 
et al (2009) 
Transferability 
and 
generalisability 
The Task Force’s working definitions were that economic 
evaluations were generalisable if they applied, without 
adjustment, to other settings. On the other hand, data were 
transferable if they could be adapted to apply to other settings 
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The use of the term ‘generalisability’ for applying economic evaluation evidence 
from one particular context to another is being avoided in this thesis as this term 
may be confused with the statistical concept of ‘generalisability’, which is 
entirely based on inductive reasoning. Induction, in its strict logical sense, is ‘an 
argument that employs premises containing information about some members of 
a class in order to support a generalisation about the whole class’ (Blaug, 1980). 
Hence it is a reasoning process from particular instances, say the participants of a 
trial, to general conclusions, as for example the cost-effectiveness of a new 
health technology compared to current practice in the population from which 
trial participants were originally recruited from. Though inductive reasoning is an 
inference from observed instances to unobserved instances, it is hence essential 
that all instances, the observed ones and the unobserved ones, belong to the 
same class (Steel, 2008). This definition would be very restrictive and only allows 
applying economic evaluation evidence to settings where a relationship between 
the studied sample and the target population can be established.  
 
 
A more practicable definition for the purposes of this thesis would also 
incorporate situations where decisions need to be based on evidence which 
stems from an entirely different context. In the absence of country-specific cost-
effectiveness data, it is common practice that decision makers in one country 
may allocate healthcare resources based on economic evaluation evidence 
originally generated in other countries (Goeree et al., 2007), and inductive 
reasoning, which assumes relatedness between the observed instances and the 
unobserved ones, does obviously not apply in this situation (Steel, 2008). Rather, 
the problem of ‘transferring’ evidence from other contexts may best be 
described as an ‘analogical inference’, where a mapping of relevant attributes 
between a source domain, about which more is apparently known and a, less 
studied, target domain is produced to infer whether the information of interest 
may also hold in the target setting (Gentner & Markman, 1997; Forbus, 2001; 
French, 2002). In order to make inferences about the target setting, researchers 
may therefore look at characteristics of the existing evidence and the target 
context and thereby establish a relationship between the data and the context of 
interest (Juthe, 2005; Forbus, 2001; Klix, 2004, Steel, 2008). If this ‘context’ is a 
geographic entity (for instance another country) we may refer to this process as 
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the assessment of the ‘geographic transferability’ of economic evaluation in 
health.  
 
 
The final section of this chapter reports on a systematic literature review on the 
use of MLM within economic evaluation in health.  
 
 
 
2.4. Systematic literature review on the use of multilevel 
statistical modelling in economic evaluation in health 
 
This systematic literature review on the use of MLM in economic evaluation in 
health was undertaken to inform the current state of research, major application 
areas of the method within this scientific domain, technical features which may 
be of interest for the empirical exercise within this project, as well as trends for 
further research. As the relevant body of literature relates strongly to general 
research on the transferability of health economic evaluation, is relatively small 
and very well cross-referenced, the author of this thesis was aware of many of 
the relevant papers even before the conduct of this systematic review exercise. 
However, to ensure that no important studies are missing from review, 
systematic database searches were conducted both in August 2010 (when 
developing and testing multilevel methods for the purposes of this project), as 
well as in May 2012 (when writing up for submitting this thesis). The following 
subsection reports on the search methods, inclusion and exclusion criteria as 
well as search results. Findings from analysing relevant papers are reported 
thereafter, with particular emphasis on conceptual or methodological features 
which may be relevant for the integration of international cost-effectiveness 
data from existing economic evaluation studies and the analysis of factors 
causing variability in this data.  
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2.4.1. Review methodology 
 
As mentioned, prior to this systematic review, the author was already aware of a 
large proportion of relevant studies. In particular, important papers were already 
under review when looking into the transferability of economic evaluation data 
in general (e.g. Rice & Jones, 1997;  Sculpher et al., 2005;  Manca et al., 2005; 
Drummond et al., 2005; Willan et al., 2005;  Grieve et al., 2007; Manca et al., 
2007; Drummond et al., 2009). Even before searching databases, these studies 
were systematically hand searched for further relevant references and SCOPUS 
was used to check whether subsequent studies citing these papers may be 
includable in this review. However, to ensure that no important papers are 
missing from this review, a systematic database search was also conducted.  The 
databases searched were SCOPUS (Medline, Embase and Science direct), Web of 
Knowledge (Web of Science, Biosis Previews) and HEED, and search strategies for 
individual databases may be obtainable from Appendix 2.  
 
 
Literature searches were performed in August 2010 (when the multilevel 
methodology for this thesis was developed and tested), and repeated in May 
2012 (when writing up the results of this thesis for submission). No country, 
time, or language restriction was initially applied to the literature search. Studies 
concerned with economic evaluation in health which conceptualized, developed, 
empirically tested, or discussed the use of MLM were considered. In turn, this 
means that studies were not includable if they were a) not health related, b) not 
concerned with economic evaluation, and c) multilevel modelling methods were 
neither conceptualized, developed, applied, or discussed.  
 
 
Figure 2.1 below shows the search algorithm for this systematic review. Eight 
papers were initially available from reviewing the general literature on the 
transferability of economic evaluation in health. These papers were first hand-
searched for relevant references and SCOPUS citations, resulting in 20 papers 
eligible for full text review. With respect to database searches, 611 references 
were initially imported to the reference managing software Refworks. 
Subsequently, search results were de-duplicated, resulting in 425 hits remaining 
 34 
 
in the database. These references were screened by titles and abstracts, 
resulting in 21 papers eligible for full text review.  
 
Figure 2.1: Search Algorithm 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Of all papers reviewed in full text, a further 13 were dropped. Five papers 
obtained from searching databases were not concerned with multilevel 
modelling. A further eight studies (two from database searches and six from 
hand search) relate to multilevel modelling within health economics in general, 
but did not relate to health economic evaluation defined as comparative analysis 
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No economic evaluation 5 
(though MLM  
Application within  
Health Economics) 
  
No economic evaluation 6 
(though MLM  
Application within  
Health Economics) 
Obtained through 
hand search  
only 
 
5 
Obtained through 
database search 
only 
 
5 
Obtained 
through both 
searches 
 
9 
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of competing healthcare interventions in particular (Duncan et al., 1996; Duncan 
et al., 1998, Scott & Shiell, 1998; Burgess et al., 2000; Carey, 2000; Or et al., 
2005; Morelle et al., 2009; Lee et al., 2010). Nine papers meeting all inclusion 
criteria were identified both from hand searching references as well as searching 
databases. A further five papers were only obtained through hand search, and 
five papers were only identified from searching databases respectively. Hence, 
19 papers met all inclusion criteria and are analysed below with respect to 
concepts, applications, and / or discussions of MLM in the context of economic 
evaluation in health.  
 
 
2.4.2. Results 
 
Three of 19 papers meeting the final inclusion criteria were conceptual in nature 
(Rice & Jones, 1997; Spiegelhalter et al., 2000; Drummond et al., 2009), and one 
very recent paper critically appraises the use of hierarchical modelling 
techniques to analyse multinational cost-effectiveness data (Manca et al., 2010). 
An ‘introductory account’ of multilevel models within the area of health 
economics has been provided by Rice & Jones (1997), who describe areas within 
this field of research that may benefit from the use of MLM. The authors 
explicitly discuss the use of MLM in economic evaluation alongside multinational 
RCTs and mention that ‘the approach allows exploration of variation arising at 
different levels of the hierarchy and modelling of the correlation structure 
inherent in such data sets and leads to efficient parameter estimates.’  
 
 
In 2000, Spiegelhalter et al. published a review on Bayesian methods in health 
technology assessment within the NHS R&D HTA programme. Within this study, 
Spiegelhalter et al. (2000) explain the concept of exchangeability in the context 
of hierarchical models and state that ‘the general Bayesian approach to 
multiplicity involves specifying a common prior distribution for the substudies 
that expresses a belief in the expected ‘similarity’ of all the individual unknown 
quantities being estimated. This produces a degree of pooling, in which an 
individual study’s results tend to be ‘shrunk’ towards the average result by an 
amount depending on the variability between studies and the precision of the 
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individual study. (….) This is essentially a random effect approach, often labelled 
as ‘empirical Bayes’ or ‘multilevel’ modelling’ The authors further state that  ‘If 
there are known reasons to suspect specific units are systematically different, 
then those reasons need to be modelled.’  
 
 
About the exchangeability assumption between geographic domains in the 
context of cost-effectiveness analysis, Drummond et al. (2009) state ‘the term 
“exchangeable” means that there are no other a priori reasons why one 
jurisdiction may have more or less favourable measures of cost-effectiveness than 
another.’ However, in accord with what has been mentioned by Spiegelhalter et 
al. (2000) above, the authors further state that, ‘making an a priori assumption 
that one does not expect differences in jurisdiction-specific measures of cost-
effectiveness may be unreasonable when the question we are trying to answer is 
whether or not such differences exist.’ To address this issue, Drummond et al. 
(2009) suggest the use of covariates on centre and / or country-level and state 
that ‘currently, evidence is lacking as to what types of higher-level covariates may 
be useful in this regard’. As potential candidates they suggest macroeconomic 
characteristics (e.g. gross national product), capacity constraints (e.g. limited 
availability of intensive care beds), economic incentives (e.g. pressure to 
minimise length of stay), or financing characteristics (e.g. global budgets vs. fee 
for service reimbursement). Drummond et al. (2009) conclude that ‘if the analyst 
has identified the appropriate set of higher-level covariates for the 
exchangeability assumption to hold and that the characteristics of the country of 
interest are reflected appropriately by countries participating in a trial’ one may 
even transfer cost-effectiveness results to centres or countries that did not 
participate in the trial.  
 
 
The vast majority of papers includable in this systematic review exercise develop 
a MLM for the analysis of individual patient cost-effectiveness data and test their 
approach within a case study (for a summary of review results and references of 
respective studies the reader is refereed to Table 2.5 below).  
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Table 2.5: Review Results 
General 
Aim Explaining a concept  
Developing a method + case study 
Empirical application 
Critical appraisal 
3 
13 
2 
1 
1, 2, 16 
3, 4 – 12, 14, 15, 18 
13, 19 
17 
Data source RCT 
Observational data  
Cluster randomized trial  
n.a. (conceptual, review paper) 
8 
4 
3 
4 
3, 5 - 8, 10, 14, 15,  
4, 9, 11, 19 
12, 13, 18 
1, 2, 16, 17 
Multinational data Yes 
No 
n.a. (conceptual, review paper) 
8 
7 
4 
4, 5, 8 – 11, 14, 19 
3, 6, 7, 12, 13, 15, 18 
1, 2, 16, 17 
Transferability explicitly 
addressed through MLM 
Yes 
No  
12 
7 
1, 3 – 11, 16, 17 
2, 12 – 15, 18, 19  
Model specifications in methodological / empirical papers 
Nr of levels Two 15 3 – 15, 18, 19 
Hierarchy modelled Patients in centres 
Patients in clusters (CRTs design) 
Patients in countries 
8 
3 
4 
3, 4, 6, 7, 9, 11, 15, 19 
12, 13, 18 
5, 8, 10, 14 
Vector of response variables Univariate 
Bivariate 
Both univariate and bivariate 
Unclear 
6 
5 
2 
2 
3 – 6, 9, 15 
7, 8, 10, 14, 18 
11, 12 
13, 19 
Response variables modelled  NMB  
Patient cost 
Resource use 
Bivariate: patient cost / effects 
Unclear 
4 
4 
1 
7 
2 
3, 6, 11, 12 
4, 5, 9, 15 
4 
7, 8, 10 – 12, 14, 18 
13, 19 
Other model features in methodological / empirical papers 
Random slopes Yes  
No  
4 
11 
3, 6, 9, 12 
4, 5, 7-8, 10-11, 13-15, 18, 19 
Random slope on which 
variables? 
Treatm. effect varies across centres 
Incontinence status 
n.a.  
3 
1 
11 
3, 6, 12 
 9 
4-5, 7-8, 10-11, 13-15, 18-19 
Variance function modelled? No  15 3 – 15, 18, 19 
Gamma distributions for cost 
data 
Yes 
No 
7 
8 
4, 7, 9, 12, 14, 15, 18 
3, 5, 6, 8, 10, 11, 13, 19 
Multiplicative effects of 
covariates on outcomes 
Yes 
No 
n.a. (conceptual, review paper) 
1 
14 
4 
9 
3-8, 10-15, 18, 19 
1, 2, 16, 17 
Model implementation in methodological / empirical papers 
Software used MLwiN 
WinBugs 
Stata  
R 
Unclear 
5 
8 
3 
1 
2 
3, 4, 6, 11, 13,  
4, 7, 9, 10-12, 14, 18 
12, 15, 19 
15 
5, 8 
Estimation method IGLS / RIGLS 
MCMC 
Unclear 
1 
9 
6 
4,  
3, 4, 6, 7, 10-12, 14, 18 
5, 8, 9, 13, 15, 19 
Covariates suggested / tested  
Patient covariates  
(covariates tested in bold/ italic 
with reference in brackets)  
baseline clinical and  socio-demographic characteristics / age (4, 15, 19) / gender (4, 15) / 
smoking status / pre-stroke living conditions (4) / stroke severity measures (4) / stroke subtype 
(4) / incontinence status (4, 9, 11) / paralysis at admission (4, 9) / presence of diabetes (15) / 
hypertension (15) / previous occurrence of AMI (15) / ‘Karnofsky score’ (19) / predicted 
mortality (19) / referral site (19) / Type of referral (19) indication for referral (19)  
Centre covariates  
(covariates tested in bold/ italic 
with reference in brackets)  
patient throughput / experience of clinical staff / hospital type (teaching vs. non-teaching) / 
financing characteristics (e.g. global budgets vs. fee for service reimbursement (4) / coronary 
angioplasty unit (15) / number of  MIs (15) number of beds in cardiology (15)  
Country covariates  
(covariates tested in bold/ italic 
with reference in brackets)  
GDP / % GDP spent on HC (4, 9, 10, 11) / capacity constraints (e.g. limited availability of intensive 
care beds) / economic incentives (e.g. pressure to minimise length of stay) / dummy for low, 
middle, high income countries / patient co-payment for acute care (4) / country mean life 
expectancy at birth (10) /   
 
 
(1) Rice & Jones (1997) (6)   Manca et al. (2005) (11)  Grieve et al. (2007)        (16)  Drummond et al. (2009) 
(2) Spiegelhalter et al. (2000) (7)   Nixon et al. (2005) (12)  Bachmann et al. (2007) (17)  Manca et al. (2010) 
(3) Sculpher et al. (2004) (8)   Pinto et al. (2005)  (13)  Coupe et al. (2007)         (18)  Grieve et al. (2010) 
(4) Grieve et al. (2005) (9)  Thompson et al. (2006) (14)  Willan et al. (2008)         (19)  Edbrooke et al. (2011) 
(5) Willan et al. (2005) (10) Manca et al. (2007) (15)  Petrinco et al. (2009)            
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Most case studies utilise data from RCTs, whilst three papers focus on the 
analysis of observational data, and two studies develop MLM methods for cost-
effectiveness analysis alongside cluster-randomised trials. Further to that, data 
from a cluster randomized trial is also being analysed in one paper which 
empirically applies MLM for cost-effectiveness analysis, whilst another empirical 
application utilises data from a multinational observational study.  
 
 
Of the 15 papers which either develop and test or empirically apply MLM 
methods, seven studies utilise data collected within one or maximum two 
countries, whilst multinational trials provide the data basis for the remaining 
eight studies under review. The transferability problem of economic evaluation 
data (either between centres, populations, settings or regions within one country 
or between countries) was specifically mentioned as one (though potentially not 
the sole) motivation for considering MLM techniques in 12 of the 19 papers, 
whilst ‘accounting for clustering’, ‘appropriately reflecting the hierarchical data 
structure’ and thereby ‘obtaining more appropriate regression outcomes’ 
appeared to be the main motivation for the use of MLM in the remaining papers 
under review.  
 
 
When moving on to model specifications within methodological or empirical 
papers, it gets obvious that all studies without exception apply a strictly 
hierarchical two-level structure to their respective datasets. Within this two-level 
structure, individual patients are always modelled at level one, whilst level two 
may represent centres (eight studies), clusters (which may coincide with centres) 
as in cluster randomised trials (three studies), or countries (four studies). With 
respect to the response variable, six studies develop a univariate model, whilst a 
bivariate framework was developed in five studies. Two studies apply both, a 
univariate and a bivariate model. The two empirical applications (Coupe et al., 
2007; Edbrooke et al., 2011) are ambiguous in most respects of the MLM 
specification, including the vector of response variables. If a univariate 
framework was applied, the response variable was patient cost (four studies), 
resource use (one study), or net monetary benefit (four studies). If net monetary 
benefit was the response variable, the respective MLM may be classified as a 
multilevel application of Hoch’s net benefit regression framework which models 
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NMB as response variable and uses a treatment dummy to discriminate between 
patients in the respective trial arms, thereby modelling incremental net 
monetary benefit (Hoch et al., 2002)  
 
 
The bivariate models which were developed in seven of the 19 papers under 
review represent a further expansion from this net benefit regression 
framework, within which patient cost and outcomes are decomposed and 
modelled as a vector of response variables. Again, a treatment dummy may 
discriminate between patients in the respective trial arms and thereby allow 
estimation of incremental cost and incremental effects within one model. With 
respect to such bivariate models, Manca et al. (2007) state that ‘this (bivariate) 
approach has three main advantages. First, it facilitates explicit modelling of both 
costs and effects while allowing the inclusion of a set of covariates. Second, it 
exploits the existence of correlation, at the patient level, between costs and 
effects, thereby improving the efficiency of the estimation process when this 
correlation is different from zero. Third, unlike the standard (univariate) net 
benefit regression it does not require a new regression to be estimated for every 
value of the cost-effectiveness threshold.’  
 
 
Further features of the multilevel models developed in the relevant body of 
literature include random slopes (four studies), gamma distributions for cost 
data (seven studies) and multiplicative effects of covariates on outcomes. With 
respect to random slopes, three studies allowed the treatment effect to be 
different across centres, whilst one study (Thompson et al., 2006), allowed for 
heterogeneity of the patient-level variable ‘incontinence status’ on centre level, 
thereby allowing mean costs to vary across centres with respect to whether 
patients are incontinent following the experience of a stroke or not. Fitting a 
random slope to this variable on centre level significantly improved the fit of the 
model. Even though some studies allowed for random slopes of covariates, none 
of them considered the explicit modelling of variation in the outcome variable as 
a function of explanatory variables, hence estimating a ‘variance function’ within 
the multilevel modelling framework.  
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(Thompson et al., 2006) also modelled a multiplicative rather than an additive 
effect of covariates on outcomes. Again focussing on incontinence status as a 
patient covariate, the assumption was that the effect of incontinence may 
multiply the costs by a certain factor rather than adding to costs in each centre. 
Again, model fit improved with this assumption. Furthermore, to better reflect 
the fact that cost data is usually skewed to the right, seven papers modelled 
gamma distributions instead of normal distributions to cost data, and all studies 
observed an improved model fit from doing so.  
 
 
Moving on to covariates assessed within the MLM studies under review, it gets 
apparent that, though it has been suggested as an important area for further 
research already in 2004 (Sculpher et al., 2004), no systematic assessment has 
yet been carried out to analyse covariates on each level of the data hierarchy. 
The inclusion of covariates served, at most, the purpose of testing a concept. 
Further, patient level variables under assessment are usually very disease and 
intervention specific, whilst only very few centre and country variables were 
considered at all; amongst them the percentage of GDP spent on healthcare, 
patient co-payments for acute care and life expectancy at birth within countries. 
As all multilevel models were applied within the context of IPD analysis from one 
single trial or observational study, methodological study characteristics, which 
were previously highlighted as important variability factors (e.g. Barbieri et al., 
2005; Goeree et al., 2007), are identical across observations within trials and 
were therefore never subject to analysis within any of the studies under review.  
 
 
 
2.5. Summary and conclusions 
 
This chapter was concerned with providing the background and developing a 
research strategy for this project. Reviewing the economic evaluation literature 
on the transferability / generalisability of measures of cost-effectiveness showed 
that there is a need to systematically assess factors causing variability in 
international cost-effectiveness data. To do so, the analysis of secondary data 
abstracted from published economic evaluation studies has been proposed. This 
is justified from a pragmatic point of view as it would be highly unlikely to obtain 
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access to IPD within the scope of this project. However, integrating secondary 
data from published economic evaluation studies also allows the assessment of 
variability factors which may not be present in individual patient data from single 
trials or observational studies, especially with respect to methodological 
characteristics of health economic evaluation studies.  
 
 
To facilitate this assessment, MLM was identified as a promising method. A 
systematic literature review on economic evaluation studies proposing or 
applying MLM methods showed that this technique has been considered with 
the particular aim to address the transferability problem of measures of cost-
effectiveness. However, all applications of MLM in economic evaluation in health 
thus far relate to IPD from multicentre studies which may or may not be 
multinational in nature. Accordingly, model hierarchies always consist of two 
levels; more complex data structures, as they may appear when integrating 
secondary cost-effectiveness data (for instance cross-classifications), have not 
yet been proposed. Furthermore, existing studies consider covariates on 
different hierarchical levels only to demonstrate the concept. Accordingly, there 
is still a need to systematically assess covariates on all hierarchical levels 
encoding variability factors for measures of cost-effectiveness.  
 
 
The following Chapter 3 aims to develop MLM methods appropriate for the 
integration of secondary cost-effectiveness data abstracted from international 
economic evaluation studies. This model development builds up from a basic 
ordinary least squares (OLS) regression model and, step by step, introduces the 
features necessary to integrate cost-effectiveness data from different studies 
which are also applicable to different geographic domains. The MLM methods 
developed are subsequently tested in a pilot study utilizing data from 16 
international cost-effectiveness studies on statins in the primary and secondary 
prevention of CVD, before Chapter 4 reports on a systematic literature review 
and data abstraction exercise to populate a dataset for the main empirical 
analysis reported in Chapter 5.   
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3. Multilevel model methodology 
 
 
The previous chapter began by summarizing the literature on the transferability 
and generalisability of economic evaluation in health and a research strategy was 
developed for the purposes of this project. Subsequently, a theoretical 
framework for the use of MLM to analyse variability factors for measures of cost-
effectiveness was also developed, and the health economic evaluation literature 
concerned with MLM was systematically reviewed. As a result, MLM was 
identified as a promising strategy for the integration of international cost-
effectiveness data from existing economic evaluation studies and the assessment 
of factors causing variability in measures of cost-effectiveness.  
 
 
This chapter is concerned with the development of a number of MLMs for the 
purpose of secondary data-integration and the analysis of variability factors 
within this framework. It starts off with a simple OLS regression equation and 
then, step by step, introduces additional features to model complex data 
structures and (partial) exchangeability not just between studies, but also 
geographic domains. The final Section 3.4 of this chapter reports on a pilot study 
using a set of data collected from the health economic literature which entails 
cost-effectiveness information on one health intervention which was measured 
in different studies within, and across, geographic domains. The area of statins 
for the primary and secondary prevention of CVD was chosen for this pilot.  
 
 
The chapter is organised as follows: It first elaborates on the exchangeability 
assumption of international cost-effectiveness data to derive a model suitable 
for secondary data integration in Section 3.1. It then shows how the assumption 
of exchangeability of cost-effectiveness data allows modelling complex data 
structures in a MLM framework. Next, this section expands upon this framework 
to include explanatory variables on each level of the data hierarchy. It then 
elaborates on even more complex data structures, including cross-classification 
of higher levels. Finally, slopes of regression coefficients are allowed to vary 
randomly across higher-level units.  
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As Section 3.1 predominantly concentrates on the right hand side of the 
regression equation and the appropriate hierarchical structure of the model, 
Section 3.2 elaborates on the question of how the dependent variable, i.e. 
‘measures of cost-effectiveness’ of a healthcare technology, ought to be 
expressed. The advantages and disadvantages of the incremental cost-
effectiveness ratio (ICER) and the incremental net monetary benefit (INMB) 
approaches are discussed. Following from that, the net benefit regression 
framework proposed by Hoch et al (2002) is considered for the purposes of this 
exercise. Subsequently, this framework, which was originally developed for the 
analysis of RCT data, is developed into a model which is more suitable for the 
integration of secondary cost-effectiveness data. Net monetary benefits are 
being decomposed and, in accordance with what has been proposed by other 
researchers in the field (Nixon et al., 2005; Pinto et al., 2005; Manca et al., 2007; 
Grieve et al., 2007; Bachmann et al., 2007; Willan et al., 2008; Grieve et al., 
2010), a bivariate model is developed which enables inclusion of incremental 
costs and incremental effects separately as response variables in one regression 
equation.  
 
 
In Section 3.3, the models derived in Sections 3.1 and 3.2 are combined, leading 
to a ‘bivariate multilevel model for secondary data integration’. This model is 
tested in the pilot study in Section 3.4 of this chapter, together with a number of 
two-level specifications and, for comparative purposes, an OLS regression model.  
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3.1. Modelling complex data structures within secondary 
cost-effectiveness data 
 
Suppose we are interested in the cost-effectiveness of a certain healthcare 
technology and we find that this was measured in a number of cost-effectiveness 
studies available from the literature. There is an explicit theory on how the cost-
effectiveness of a healthcare technology ought to be measured, and several 
authors suggest the use of incremental net monetary benefits (INMB’s) as most 
suitable for econometric analysis (e.g. Claxton & Posnett, 1996; Stinnet & 
Mullahy, 1998; Briggs & Fenn, 1998; Tambour et al., 1998; Hoch et al., 2002). 
This theory is addressed in Section 3.2. However, let us leave this theory aside 
for the moment to concentrate on the complex data structures in international 
cost-effectiveness data only. To do so, denote a single cost-effectiveness 
estimate, however it may be measured, with ‘Yi‘(with i=1,....,n). This could be, for 
example, a cost-effectiveness estimate applicable to one particular subgroup of 
patients. In addition, economic evaluation studies frequently report more than 
one single estimate of cost-effectiveness of a particular healthcare technology; 
usually, results are reported for different patient subgroups, and different 
assumptions tested in sensitivity or scenario analyses.  
 
 
1
2
3
4
5
6
7
8
0 5 10 15 20
Y
n
Figure 3.1: Example dataset and single level OLS regression 
without explanatory variables
ei
β0
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Now, consider the following hypothetical situation: after conducting a literature 
review on the cost-effectiveness of a certain healthcare technology, we found 
four includable papers, reporting n= 21 cost-effectiveness estimates in total. The 
resulting dataset with sample data is plotted above in Figure 3.1. The easiest 
solution in this case is to treat parameters from all four studies as ‘identical’ 
(Spiegelhalter et al., 2000, Spiegelhalter et al., 2004; Willan et al. 2005). In this 
situation, all observations of ‘Y’ may be pooled and we completely ignore that 
they stem from different studies available in the literature. Hence, we do not 
reflect the fact that cost-effectiveness estimates are ‘nested’ within studies and 
regard all ‘Yi‘ as if they were obtained from the same source, irrespective from 
the fact that different studies may have employed different methods, 
assumptions, patient groups etc., which most likely causes dependency of cost-
effectiveness results within each study. A very basic econometric model, which is 
also referred to as ordinary least squares (OLS) regression model, simply draws a 
line ‘β0’ through the dataset which minimises its squared distance to each cost-
effectiveness estimate ‘yi‘ (e.g. Maddala, 2001; Grieve et al., 2005). This may be 
expressed as:  
 
 
ii
ey +=
0
β   with   e~N(0, σ	)             (1) 
 
 
Model (1) is also called an ‘empty’, or ‘intercept only model’ as it does not carry 
an explanatory variable which may explain variation in cost-effectiveness 
estimates (Hox, 2010). Such an explanatory variable will be introduced later. In 
the case of this empty model shown in equation (1), the estimator of ‘
0
β ’ is 
simply the mean cost-effectiveness observed across all four studies (Maddala, 
2001). Whereas ‘ ‘ is the so called deterministic component of model (1), ‘ei’ is 
also referred to as the ‘random’, or ‘stochastic’ component of the regression 
equation (Maddala, 2001). The assumptions about ‘ei’ are (Maddala, 2001):  
 
• a mean of zero, i.e. 
( = 0 
• a common variance (homoscedasticity), i.e. ( = 	   
• the errors, or residuals ‘ei’ are mutually independent and  
• errors are normally distributed  
 
0
β
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As mentioned, whilst assuming that parameters of the four studies are 
‘identical’, we can simply apply equation (1) to the data pooled across all four 
studies. Needless to say that complex data structures cannot simply be ignored 
without risking to overestimate accuracy, or to make plainly wrong inferences 
(Manca et al., 2005, Rasbash, 2008, Bartholomew et al, 2008; Hox, 2010).  
 
 
 
Now, rather than simply assuming that studies are ‘identical’ in order to pool the 
data, we may have another look at this dataset first. Figure 3.2 shows the same 
dataset as before, but cost-effectiveness estimates from each study are now 
shown in different colours and shapes. From this illustration it gets immediately 
clear that studies may not be regarded as identical. Studies employ different 
methods and assumptions, rely on different patient groups and apply to different 
geographic settings, etc. Therefore, cost-effectiveness estimates obtained from 
one study may be more similar to each other than they are to estimates from 
other studies. This, however, violates one of the assumptions introduced above, 
namely that the errors ei are ‘mutually independent’ (e.g. Rasbash, 2008). As a 
result, we cannot simply pool the data, but may have to fit a model for each of 
the resulting groups of cost-effectiveness-data separately. Hence, we treat our 
observations of ‘Y’ within each study as completely unrelated from the other 
studies available. In other words, we assume ‘independence’ between studies 
(Spiegelhalter et al., 2000; Spiegelhalter et al, 2004; Willan et al. 2005). To 
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n
Figure 3.2: Example dataset of 21 cost- effectiveness 
estimates, grouped in studies
study 1 study 2 study 3 study 4
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estimate a model for each study, equation (1) may be re-written after 
introducing additional subscripts to make clear that the dataset consists of cost-
effectiveness estimates obtained from more than one single source. Instead of 
using ‘i’ as subscript for all cost-effectiveness estimates in the dataset as before, 
‘i’ is now used as subscript for cost-effectiveness estimates within one single 
study with (i=1,....,ni) and j as subscript for studies with (j=1,...,J), so that Yij 
denotes the ith cost-effectiveness estimate in the jth study. Rewriting equation (1) 
leads to:  
 
ijij ey += 0β     with  e~N(0, σ	            (2) 
 
 
The corresponding least squares lines are illustrated in Figure 3.2. Of course, 
assuming ‘independence’ may not be correct either as studies often do have 
things in common. For instance, they often rely on the same sources of 
effectiveness data, or they share methodological standards, etc. Most 
importantly, however, this assumption would preclude the chance of integrating 
secondary cost-effectiveness data from different published studies, which is the 
aim of this exercise. Hence, just like assuming study parameters to be ‘identical’ 
to allow complete pooling may be regarded as somewhat too crude, one can 
conversely argue that assuming complete ‘independence’ is too restrictive, as 
there must be some similarities between studies which, in theory, allows at least 
some sort of data integration (e.g. Spiegelhalter, 2000)  
 
 
In conclusion, assuming either ‘identical’ or ‘independent’ parameters are two 
extreme assumptions about the data, and it would be much more sensible to 
assume that the data from different sources can be somehow pooled together, 
but without completely ignoring that cost-effectiveness estimates do stem from 
different studies indeed. This may be achieved through the assumption of 
‘exchangeability’ (e.g. Spiegelhalter et al., 2000, Spiegelhalter et al., 2004, 
Sculpher et al., 2004; Manca et al., 2005; Drummond et al., 2009). 
Exchangeability is a concept which goes back to Bruno de Finetti and it has been 
extensively discussed in Bernardo & Smith (1994). Essentially, it means that the 
joint probability distribution of the parameters ‘Ɵ’ (i.e. study mean and variance) 
observed in each of the ‘j’ studies available is the same for any permutation of 
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the index of studies ‘j’ (Bernardo & Smith, 1994; Jeffrey, 2002). In other words, 
without having any additional information on each of the ‘j’ studies, we would 
not have any expectation of more, or less, favourable estimates of cost-
effectiveness to be found in each of the studies (Drummond et al., 2009). In this 
sense, exchangeability is, like Greenland (2000) puts it, a ‘much weaker 
assumption than that studies really are equal; it only says that, without seeing 
the data, we can’t yet tell how they might differ’. Further, exchangeability is 
‘essentially an uncertain and qualitative prior guess about the similarity’ of the 
studies available (Greenland, 2000) 
 
 
Spiegelhalter et al. (2000 & 2004) state that ‘if a prior assumption of 
exchangeability is considered reasonable, a Bayesian approach to multiplicity is 
thus to integrate all the units into a single model, in which it is assumed that 
study parameters Ɵ1, . . . , Ɵj are drawn from some common prior distribution 
whose parameters are unknown: this is known as a hierarchical, or multilevel, 
model’. In other words, we assume that each of the ‘j’ studies available 
represents a ‘random sample’ of some (hypothetical) population of cost-
effectiveness studies for that technology. This is also the standard assumption in 
a traditional random-effects meta-analysis (Spiegelhalter et al., 2000 & 2004). 
The class of models which may be built upon this assumption is called 
hierarchical, or multilevel, because assuming exchangeability enables study 
parameters to vary randomly, and this allows building a model for the study 
parameters on top of the model for the actual cost-effectiveness data (Jackman, 
2008).  
 
 
To sum up, through the assumption of exchangeability we may allow study 
parameters to vary randomly between studies, and this allows building a 
hierarchical model which mediates between the two extreme assumptions of 
either independent or identical parameters. What is important now is to 
translate these findings into a quantitative model for data integration which 
makes explicit the assumption of exchangeability of cost-effectiveness data 
across studies and geographic domains.  
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3.1.1. Modelling exchangeability – ‘empirical Bayes shrinkage 
estimation’  
 
 
Recall model (2) 
 
ijij ey += 0β     with  e~N(0, σ	      (2; repeated) 
 
This model is a single level-model of cost-effectiveness estimates obtained from 
each of the ‘j’ studies. It is also an ‘empty model’ as it does not carry explanatory 
variables on the right hand side of the equation. The subscripts indicate that a 
separate model may be fitted to each study independently. The stochastic 
component ‘e’ allows the cost-effectiveness estimates ‘ ijy ‘ within each study to 
vary randomly, assuming a normal distribution of the error term. This is 
illustrated in Figure 3.2 above, where one regression line, representing mean 
cost-effectiveness, is fitted for each study separately assuming independence of 
data across studies.  
 
 
However, we learned that modelling exchangeability allows study parameters 
(i.e. study mean and variance) to vary randomly between studies too. We also 
learned that this allows placing a model for the study parameters above the 
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Figure 3.3: Variance components model applied to the 
sample dataset
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model for the cost-effectiveness data (Jackman, 2008); which is also illustrated in 
Figure 3.3 above. The black line represents the overall mean regression line; one 
could say the pooled effect over all four studies in the dataset (e.g. Drummond et 
al., 2009). The distance between this pooled effect and the study regression lines 
represents the random variation of the study means from the overall mean 
effect just as the distance between the data and the study regression lines 
represent the random variation of cost-effectiveness data from the individual 
study means (Bickel, 2007; Bartholomew et al., 2008; Steele, 2008; Hox, 2010). 
As this random variation of the data within each study is captured with the 
stochastic error term′	e′, a second error term is needed which encapsulates the 
random variation between the overall mean cost-effectiveness, captured by ‘
0
β ‘, 
and the corresponding study means (Bickel, 2007; Bartholomew et al., 2008; 
Steele, 2008; Hox, 2010). This error term is labelled with ′u′. Just like it was 
assumed that the ′e′ are normally distributed with zero mean and variance ′	’, 
an analogous assumption can be made for ′u′ (Bartholomew et al., 2008; Steele, 
2008; Hox, 2010). Hence, through the inclusion of this second error term ′u′, 
model (2) may be turned into a basic MLM of the form:  
 
 ~(,                  (3)  =  + ! +   with  
!~(0, "	 ~(0, 	 
 
Model (3) is a ‘variance components model’, the simplest form of MLM 
(Bartholomew et al., 2008; Steele, 2008; Hox, 2010). As mentioned, ′′ is the 
overall mean for ′′ (across all studies), ′ + !′ is the mean cost-effectiveness 
within each study, ′!′ is the difference between a studies mean cost-
effectiveness and the overall mean, and ′′ is the difference between the ′′ 
for the ith measurement and the group mean of that study, i.e. ′ =  − ( +!′ (Steele, 2008). The statement ′~(, ′ makes clear that we assume 
the response variable ′′ to be normally distributed (Rasbash et al., 2009). ‘XB’ 
is the fixed part of the model, whereas ′′ denotes the random part over all the 
levels of the data (Rasbash et al., 2009). In the case of model (3), it simply 
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denotes the variances at both the data and the study-level (Rasbash et al., 2009). 
Through the assumption that both error terms ‘!′ and ‘ 	′ are normally 
distributed with zero mean and variance ‘"	′ and ′	′ respectively, the total 
variance can be written as (Steele, 2008; Rasbash et al., 2009):  
 $%$&	'()* = "	 + 	 (4) 
 
This also allows calculating the proportion of the total variance which can be 
attributed to differences between studies, which is referred to as the ‘variance 
partition coefficient’ (VPC) (Steele, 2008; Rasbash et al., 2009) 
 +, = -./-./0-1/ (5) 
 
From equation (5) it can be seen that the VPC tends towards zero if ′σ2	′	 is large 
in comparison to ′σ3	′, meaning that there would be little variation from ‘study 
effects’ in the data (Steele, 2008; Rasbash et al., 2009). On the other hand, if ′σ3	′ 
is large in comparison to ′σ2	′	, then the VPC tends towards one; and we learn 
that there is little variation from ‘within-study differences’ in the data as most 
variation stems from differences between studies (Steele, 2008; Rasbash et al., 
2009). A further assumption of model (3) is that the residuals at the same level 
are uncorrelated with one another, that is: ′cov7u8, u	9 = 0′	 for different 
studies and ′cov7e8:8, e	:	9 = 0′	for different cost-effectiveness values 
obtained from different studies (Rasbash et al., 2009). Finally, it is assumed that 
the residuals at different levels are uncorrelated with one another, that is: 
‘cov7e:8, u:	9 = 0′ for the same or different groups (Rasbash et al., 2009).  
 
To sum up, due to assuming exchangeability we may regard the study 
parameters to be random draws from some prior distribution which allows fitting 
a model for the overall mean cost-effectiveness above the models for the study 
means (e.g. Spiegelhalter et al, 2000 & 2004; Jackman, 2008). We also assumed 
error terms ′!′ and ′′	 to be normally distributed with zero mean and variance ′"	′ and ′	′ respectively (Steele, 2008; Rasbash et al., 2009). The VPC is a 
measure which tells us how much of the total variation in the data may be 
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attributed to the data-level or to the study-level respectively (Steele, 2008; 
Rasbash et al., 2009). However, model (3) needs to be specified further. 
Assuming exchangeability is supposed to ‘mediate’ between the two extreme 
viewpoints of either identical or independent study parameters in the sense that 
it allows for some sort of pooling, but without ignoring the fact that the data 
stems from different studies indeed. As Jackman (2008) puts it, hierarchical 
models help us to find the ‘sweet spot’ between the assumptions of identical 
parameters on the one hand and independent parameters on the other. To be 
able to make comparisons between studies, the study residual ‘!′ needs to be 
estimated (Rasbash et al., 2009). An estimate of ′!′ may be derived by 
calculating the ‘mean raw residual’, that is: (Rasbash et al., 2009).  
 
̅ = < − =  (6) 
 
Where ′<′ is the mean of cost-effectiveness in study ‘j’, and ′>′ is an estimator 
of the overall mean cost-effectiveness (Rasbash et al., 2009). This raw residual is 
then multiplied by a so called shrinkage factor ‘S’ (Steele, 2008; Rasbash et al., 
2009):  
 !? = @̅      where 									@ = -A./-A./0(BA1/CD  (7) 
 
‘)′ is the sample size in study ‘j’, hence the number of cost-effectiveness 
estimates reported in, and abstracted from, that study. ′>	’ and ′>"	′ are 
estimates of the variances of the within-study and between-study error terms 
respectively (Steele, 2008; Rasbash et al., 2009) 
 
 
Now it can be illustrated why the assumption of exchangeability of study 
parameters mediates between the two extremes of either identical or 
independent parameters obtained from different cost-effectiveness studies. If 
the between study variance ′"	’ is assumed to be zero, then this is equal to say 
that all variation in the reported cost-effectiveness measures stems from ‘within-
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study’ variability, hence, the mean study effects are ‘identical’ between studies 
(Steele, 2008; Rasbash et al., 2009). This would mean that there are no 
differences between studies and all cost-effectiveness estimates may be safely 
pooled together. If, on the other hand, ′"	 → ∞′, then the study effects are 
regarded to be independent, meaning that data from different sources may not 
be pooled together (Steele, 2008; Rasbash et al., 2009). Assuming 
exchangeability allows to model that the ‘reality’ might be somewhere in 
between those extreme viewpoints (e.g. Spiegelhalter et al., 2000 & 2004; Willan 
et al., 2005; Manca et al., 2007; Drummond et al., 2009)  
 
 
From what was stated above, it can be seen that ′	"	 → 0′ is the special case 
where the shrinkage factor ′@′ tends towards zero and the study effects are 
completely shrunken towards the overall mean cost-effectiveness estimate ′’ 
(Steele, 2008; Rasbash et al., 2009). If, however, ′	"	′ is high, then the shrinkage 
factor		′@′ tends towards one, meaning that the between study variance is high 
and shrinkage of the study effects towards the overall mean ′′ is small (Steele, 
2008; Rasbash et al., 2009). It is important to note, however, that the extent of 
shrinkage does not only depend on the amount of between study variability	′"	′. 
The higher the number of cost-effectiveness estimates provided by one single 
study (), the more information is provided by that particular study to the 
overall model, and the less will the study mean be shrunken towards the overall 
mean (e.g. Steele, 2008; Rasbash et al., 2009; Drummond et al., 2009). On the 
other hand, if a study provides only few estimates of cost-effectiveness, then 
shrinkage is high as this study ‘borrows’ a lot of information from all other 
studies available (Steele, 2008; Rasbash et al., 2009; Drummond et al., 2009).  
 
 
The mechanism explained above is what the literature refers to as ‘empirical 
Bayes shrinkage estimation’, or ‘empirical Bayes’ (e.g. Spiegelhalter, 2000; Willan 
et al., 2005; Steele, 2008). This process makes explicit the assumption of 
exchangeability between studies, and, by extending the basic model shown in 
equation (3), will also provide a means to model exchangeability between 
geographic domains and to assess variability factors on each level of the data 
hierarchy. The next section expands upon model (3) to: 
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• introduce slope parameters to model dependency of ‘Y’ upon some 
vector of explanatory variables (random intercepts model) 
• adding a third level to the model to simultaneously assess variability in 
cost-effectiveness estimates on data, study and country-level whilst 
dealing with the problem of ‘cross-classification’ of data from 
multinational studies, and finally,  
• assuming both slopes and intercepts of the regression line to vary 
randomly (random-slopes model) 
 
In Section 3.2, the question of how to measure the cost-effectiveness of a 
healthcare technology as a dependent variable within the MLM framework is 
discussed. Finally, before actually testing models in a pilot study which is 
reported on in Section 3.4 of this chapter, the MLMs derived in this section are 
combined with the regression model derived in Section 3.2, resulting in a 
‘bivariate multilevel model for secondary data integration’ with incremental costs 
(∆,) and incremental effects (∆
) as response variables nested in studies and 
geographic domains. However, for now, let us turn back to the variance 
components model illustrated in equation (3) and extend upon it to make it 
more suitable for the purposes of this thesis.   
 
 
 
3.1.2. Extending the basic multilevel model 
 
 
This section expands upon the variance components model shown in equation 
(3) to make it more suitable for the assessment of variability in secondary cost-
effectiveness data between studies and geographic domains. The first step is to 
introduce ‘slope parameters’ to model dependency of ‘Y’ upon some vector of 
explanatory variables. This results in a so called ‘random intercepts model’.  
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3.1.2.1. The random intercepts model 
 
 
Recall model (3):  
 ~(,  (3; repeated) 
 =  + ! +   with 
!~(0, "	 ~(0, 	 
 
This ‘variance components model’ essentially tells whether differences in cost-
effectiveness data exist between studies, which studies have higher, or lower, 
mean cost-effectiveness estimates, and how much of the variation in cost-
effectiveness is attributable to each level of the data hierarchy. Here, a ‘slope 
parameter’, or ‘explanatory variable’, on data-level is being introduced. Consider 
Figure 3.5 below which displays the same sample dataset as before; however, 
the ordering of the data has changed. In the previous section, cost-effectiveness 
estimates from different studies were in no particular order, hence, leaving the 
horizontal axis in the diagram without a meaning. Now, the horizontal axis 
captures additional information, for instance patient characteristics like mean 
age or mean body mass index (BMI). As the variance components model does 
not carry an explanatory variable, we would fail to capture this additional 
information when using model (3). This situation is also illustrated in Figure 3.4 
below, where the slopes of the regression lines are ‘flat’. Now, to capture this 
additional information on the x-axis, we need to introduce a parameter which 
captures the slope of the regression lines (Bickel, 2007; Steele, 2008, Rasbash et 
al., 2009, Hox, 2010). This will then allow explaining some of the variability 
between cost-effectiveness estimates. It will also tell us how much variability will 
remain on both levels (data and study) after controlling for a particular covariate 
(Steele, 2008; Bartholomew et al., 2008, Rasbash et al., 2009, Hox, 2010).  
 
 
 56 
 
  
Introducing an explanatory variable on the data-level turns model (3) into 
(Steele, 2008, Rasbash et al., 2009):  
 ~(,  (8) 
 =  + 8H + ! +   with !~(0, "	 ~(0, 	 
 
Unlike the variance components model shown in equation (3), this ‘random 
intercepts model’ allows taking a look at, and control for, characteristics of cost-
effectiveness estimates collected from the available literature. The fixed part of 
the model is now given by, ′ + 8H′ whereas the random part ‘! + ′ 
remains unchanged (Steele, 2008, Rasbash et al., 2009). ′ + 8H’ is also the 
equation for the pooled regression line, with ′′ being the intercept and ′8H′ 
being the slope of that regression line (Steele, 2008, Rasbash et al., 2009). 
Analogously to the variance components model, the intercepts of the individual 
study regression lines are given by ′ + !’, so that the individual lines are still 
located parallel around the pooled regression line (Steele, 2008, Rasbash et al., 
2009). As the distance between the intercepts of each individual study regression 
line to the pooled regression line is encapsulated in the random component		′!′, 
this class of models is referred to as ‘random intercepts models’ (Steele, 2008, 
Bartholomew et al., 2008, Rasbash et al., 2009) 
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As within the variance components model above, a) residuals for different levels, 
b) residuals at level two for different groups, and c) level one residuals for 
different observations, are uncorrelated, that is (Goldstein, 1999; Steele, 2008; 
Rasbash et al.; 2008, Hox; 2010; CMM-workshops/random intercepts):  
 
a) cov7u8, e889 = 0 b) cov(u8, e	 = 0 c) cov7e88, e	89 = 0 
 cov7u8, e8	9 = 0    cov7e88, e		9 = 0 
 
In addition, we assume the residuals and the covariates to be uncorrelated 
within the random intercepts model, that is (Goldstein, 1999; Steele, 2008; 
Rasbash et al.; 2008, Hox; 2010; CMM-workshops/random intercepts):  
 cov7u, x9 = 0 cov7e, x9 = 0 
 
This leaves us with a ‘block-diagonal’ correlation matrix as shown in Figure 3.6 
below, where all cost-effectiveness measurements within the same study are 
correlated, but all measurements from different studies are uncorrelated 
(Goldstein, 1999; CMM-workshops/random intercepts). ‘P’ is simply the variance 
partitioning coefficient shown in equation (5) above (Goldstein, 1999; CMM-
workshops/random intercepts).  
 
Figure 3.6: Covariance matrix in a two-level hierarchical model 
Study  1 1 1 2 2 2 2 3 3 
 data 1 2 3 1 2 3 4 1 2 
1 1 1 p p 0 0 0 0 0 0 
1 2 p 1 p 0 0 0 0 0 0 
1 3 p p 1 0 0 0 0 0 0 
2 1 0 0 0 1 p p p 0 0 
2 2 0 0 0 p 1 p p 0 0 
2 3 0 0 0 p p 1 p 0 0 
2 4 0 0 0 p p p 1 0 0 
3 1 0 0 0 0 0 0 0 1 p 
3 2 0 0 0 0 0 0 0 P 1 
 
Of course, we may add more than just one explanatory variable, as well as 
interaction terms. However, thus far, the class of explanatory variables 
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introduced relates to the data-level only. Hence, this model may help explaining 
differences which exist, for instance, between different patient subgroups 
assessed within different studies. However, it may not yet be able to capture 
differences between studies, like the timing of an economic evaluation study, or 
the general study design (RCT or decision analytic model). These differences 
relate to level-two of the data-hierarchy. Furthermore, once adding a third level 
to the model which captures geographic domains, we may want to assess what 
explains differences in cost-effectiveness data between countries. This requires 
the inclusion of country-level covariates; hence, we need to add higher-level 
covariates to the model.  
 
 
To provide another justification, Drummond et al. (2009) state: ‘the term 
‘exchangeable’ means that there are no other a priori reasons why one 
jurisdiction may have more or less favourable measures of costs or cost-
effectiveness than another. Making an a priori assumption that one does not 
expect differences in jurisdiction-specific measures of cost-effectiveness may be 
unreasonable when the question we are trying to answer is whether or not such 
differences exist.’ (Drummond et al., 2009). Hence, it is necessary to relax the 
initial assumption of exchangeability of study and country parameters to allow 
for some sort of differences between studies, or countries, which may account 
for more, or less favourable cost-effectiveness estimates of a healthcare 
technology. 
 
There are strong reasons to suggest that the exchangeability assumption does, in 
fact, not hold between geographic domains. For example, as Grieve et al. (2007) 
puts it: ‘in multinational CEA a priori reasoning would suggest that if the 
countries included [...] are at different stages of economic development then 
systematic variations in the relative cost-effectiveness of health care 
interventions would be anticipated. In this context the exchangeability 
assumption would be implausible and a multilevel model that assumed 
exchangeability would be inappropriate.’ Analogously, the same holds between 
studies within one geographic domain. For example, if two studies were 
exchangeable in terms of the health technology under assessment, the 
comparator, and the general study design, but would differ with respect to the 
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elicitation of utility estimates and timing, then the exchangeability assumption 
may be violated in these aspects. Hence, what is needed is a model which ‘avoids 
making such stringent exchangeability assumptions’ (Grieve et al., 2007), and 
rather permits the adjustment of the dependent variable with respect to factors 
which are anticipated to be responsible for more or less favourable cost-
effectiveness estimates between studies and countries. Such models rely on the 
assumption of ‘partial exchangeability’, that is, we assume that the ‘mean 
estimates of cost-effectiveness are exchangeable, but only after covariate 
adjustment.’ (Grieve et al., 2007). Hence, including covariates on both levels of 
the model developed thus far will turn the random intercepts model in equation 
(8) into:  
 
~(,  (9) 
 =  + 8H + 	H + ! +   with !~(0, "	 ~(0, 	 
 
Note that this model only consists of a data and a study-level, and therefore does 
not yet carry country-level covariates. Country-level covariates may be 
considered further below once a country-level has been added to the model. It is 
also important to note that the study-level covariate in equation (9) does not 
carry a ‘i’- subscript as it does not vary within, but only between studies in the 
dataset (e.g. Steele, 2008; Rasbash et al; 2009). This specification enables 
exploring the impact of study-level effects while simultaneously controlling for 
factors on data-level and allowing for the fact that the cost-effectiveness of a 
healthcare technology measured in different studies may be influenced by 
variability factors within and between studies in the dataset. Further, as Steele 
(2008) states, if contextual effects are of interest, then a multilevel approach is 
vital as ‘the standard errors of coefficients of higher-level variables may be 
severely underestimated when a single level model is used’.  
 
Analogously to single level multiple regression analysis, we may also model that 
the effect of one explanatory variable on cost-effectiveness depends on the 
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value of another explanatory variable through interaction effects and interaction 
effects may be included between any set of explanatory variables (Steele, 2008). 
If explanatory variables belong to different levels, corresponding interaction 
terms are referred to as ‘cross-level interactions’ (Steele, 2008). With such cross-
level interactions, we could examine, for instance, the relationship between 
timing of an economic evaluation on study-level and the cost of the intervention 
on data-level. The idea is that intervention cost would change over time and this 
should be reflected in the data elicited from different economic evaluation 
studies which differ, amongst other things, by their respective timing. A random 
intercepts model with a cross-level interaction between data and study-level 
variables is presented in equation (10):   
 
~(,  (10) 
 =  + 8H + 	H + JHH + ! +     with !~(0, "	 ~(0, 	 
 
Again, everything mentioned in this section also holds for covariates relating to 
differences between countries which are considered below once a country-level 
has been added to the model. This will ultimately allow simultaneous assessment 
of variability factors on data-, study- and country-level. As Gelman (2004) puts it, 
‘the valid concern is not about exchangeability, but encoding relevant knowledge 
as explanatory variables where possible. In essence, ‘the usual way to model 
exchangeability with covariates is through conditional independence. In this way 
exchangeable models become almost universally applicable, because any 
information to distinguish different units should be encoded.’ (Gelman (2004), 
cited from Manca et al., 2007). With respect to differences between geographic 
domains, Drummond et al. (2009) state, assuming that ‘if the analyst has 
identified the appropriate set of higher-level covariates for the exchangeability 
assumption to hold; and that the characteristics of the country of interest are 
represented appropriately by countries in the dataset’, the inclusion of higher-
level covariates allows estimation of cost-effectiveness for geographic domains 
which are not included in the dataset. The next section is concerned with adding 
a country-level to the model, which also allows including such higher-level 
covariates encoding differences between geographic domains.  
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However, before moving on to model the country-level within the multilevel 
framework, an important question remains: If our interest is to analyse 
contextual effects between countries, why do we control for variables on lower 
levels of the data hierarchy. The answer is that the variation on higher levels 
depends on what happens on lower levels of the model (Hox, 2010). In a single 
level model, the introduction of additional explanatory variables always 
decreases the variance of the error term or, at least, leaves it unchanged; but it 
never increases (Steele, 2008, Rasbash et al., 2009). However, in a MLM, the 
variance of the error term of the next level might stay unchanged, decrease, or 
even increase with the introduction of a lower-level covariate (Steele, 2008, 
Rasbash et al., 2009). Hence, without controlling for lower-level variables, we 
might get a distorted picture on what happens on study or country-level. Some 
contextual effects might be overestimated; others might be disguised by 
confounders on lower levels of the data hierarchy. For instance, in the case of 
statins for the primary and secondary prevention of CVD, not controlling for the 
annual drug cost on data-level may distort, or disguise the impact of GDP per 
capita on measures of cost-effectiveness on the country-level. To provide 
another example, Sculpher et al. (2004) state that patient factors constitute an 
important source of lower-level variability which potentially ‘feeds through to 
centre or country variations in cost-effectiveness if these subgroups of patients 
are not evenly distributed between locations’.  
 
 
In conclusion, we cannot simply leave all the variation on lower levels of the data 
hierarchy to the relating error term and then concentrate on contextual variables 
on country-level only; we need to investigate what explains variation on lower 
levels first before moving to the next higher level of the data hierarchy (e.g. Hox, 
2010). This has important implications for the design of the empirical analysis. 
With respect to data abstraction, for instance, it makes it necessary to put 
considerable effort into the collection of additional data from includable cost-
effectiveness studies to control for effects on data, and study-level; and this 
before even considering the analysis of contextual effects on country-level. In 
addition, data analysis within the empirical chapter may proceed from the lower 
level to the higher level, as the analysis of country-level covariates may only be 
valid once we appropriately controlled for variability factors on data and study-
level (Steele, 2008; Rasbash et al., 2009; Hox, 2010). Hence, within the empirical 
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exercise there is a strong focus on factors which may introduce variability in 
measures of cost-effectiveness on all levels of the data hierarchy. Fortunately, 
there is extensive literature on what may cause variability in cost-effectiveness 
estimates within and across studies as well as between geographic domains, 
which may also help determining a strategy for this empirical exercise (Sculper et 
al., 2004; Goeree et al., 2007).   
 
 
 
3.1.2.2. Adding a country-level to the multilevel model 
 
To this point, the methodological discussion was limited to a hierarchical model 
with two levels, namely, the data-level, with measures of cost-effectiveness 
collected within each study, and above that, the study-level, with studies 
included in the dataset. The hierarchical structure arises from cost-effectiveness 
estimates being nested within studies, and each estimate of cost-effectiveness 
nests in one study, the higher-level unit, only. The corresponding unit and 
classification diagrams for this situation are illustrated in Figure 3.7 (Rasbash, 
2008). If the problem was to integrate secondary cost-effectiveness data from 
different economic evaluation studies within one geographic domain, then this 
two-level model structure would probably be sufficient for that purpose.  
 
Figure 3.7: Unit and classification diagrams of a two-level hierarchical data 
structure 
Study 
CE-estimate 
Figure 3.7: Unit and classification diagrams of a two-level structure with 
cost-effectiveness estimates being nested in economic evaluation studies 
Classification 
diagram 
Unit diagram 
CE1 CE2 CE1 CE2 CE3 CE4 CE1 CE2 CE3 
Study 1 Study 2 Study 3 
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However, as the aim of this thesis is to assess the ‘geographic transferability’ of 
health economic evaluation data, there must be yet another hierarchical layer 
above the study-level (Figure 3.8), meaning that the two- level model discussed 
thus far may not be suitable to capture the full structure of our data. Hence, the 
first extension to the model to capture this additional layer is to add another 
level analogously to what has been done to move from the single level regression 
framework to the two-level model in Section 3.1.1.  
 
Figure 3.8: Unit and classification diagrams of a three-level hierarchical data 
structure 
 
To do so, reconsider the random intercepts model in equation (9):  
~(,  (9, repeated) 
 =  + 8H + 	H + ! +   with !~(0, "	 ~(0, 	 
 
Extending this model to turn it into a three-level hierarchical model is 
straightforward. We add another error term ‘'K’ for the geographic location, 
and locations receive the subscript ‘k’ (with k=1,....,K countries) (e.g. Rasbash et 
al., 2009).  
 
Study 
CE-estimate 
Figure 3.8: Unit and classification diagrams of a three-level hierarchical 
structure with cost-effectiveness estimates being nested in economic 
evaluation studies and studies being nested in geographic domains 
Classification diagram Unit diagram 
CE1 CE2 CE1 CE2 CE3 CE4 CE1 CE2 CE3 
Study 1 Study 2 Study3 
Country Country 1 Country 2 
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K~(,  (11) 
K =  + 8HK + 	HK + JHK + 'K + !K + K        with  
'K~(0, L	  !K~(0, "	  K~(0, 	  
 
With model (11) we have specified a full three-level hierarchical model with 
covariates on data-, study- and country-level. Unfortunately, however, this 
model does still not capture the full complexity of the data-structure which we 
aim to reflect. An additional problem arises as adding the country-level to the 
current two-level structure may not necessarily result in a strict hierarchy where 
each cost-effectiveness estimate belongs to one study only and each study nests 
in one particular geographic location. Sometimes, a study produces estimates of 
cost-effectiveness for more than one geographic location. For example, an 
economic evaluation conducted alongside a multinational RCT usually reports 
results for each participating jurisdiction. As a result, cost-effectiveness 
estimates for these ‘multinational studies’ are nested within studies, and they 
are also nested within geographic domains. However, studies are not nested 
within geographic domains, and geographic domains are not nested within 
studies. Rather, studies and geographic domains are ‘cross-classified’. To 
illustrate the problem of cross-classified data, consider Figure 3.9. The unit 
diagram shows how cost-effectiveness estimates obtained from specific studies 
may belong to different geographic domains. Figure 3.9 also contains the related 
classification diagram for this situation, which can be regarded as a more general 
case as the hierarchical structures in Figurers 3.7 and 3.8 (Rasbash, 2008). In fact, 
the hierarchical structure is only a special case of the cross-classified model, and 
the existence of these non-hierarchical structures justifies the use of the term 
‘multilevel models’ in preference to the more specific term ‘hierarchical models’ 
(Rasbash, 2008).  
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Figure 3.9: Unit and classification diagrams of a cross-classified data structure 
 
The question is how to expand upon the strictly hierarchical model introduced 
above to allow for cross-classified data. First, we do not longer talk about three 
‘levels’, as studies and countries become classifications on the same level 
(Rasbash et al., 2009). Hence, the model conceptually turns into a two-level, 
cross-classified structure (Goldstein & Sammons, 1997; Rasbash et al., 2009; Hox, 
2010). Next, unique classification identifiers are needed (Rasbash et al., 2009). 
Thus far, within the strictly hierarchical model, one subscript was used for each 
data-level with ‘yijk’ denoting the i
th cost-effectiveness estimate from the jth study 
and kth country. As models with many classifications are possible, the use of 
subscripts may become bulky, which is why other notations exist (Rasbash et al., 
2009). However, in our model with two levels and only two classifications, we 
can comfortably carry on with using subscripts ‘i’, ‘j’ and ‘k’ and simply use 
parentheses to group together the subscripts ‘j’ and ‘k’ to express that studies 
and countries are cross-classified (Hox, 2010). Hence, the three-level random 
intercepts model introduced in equation (11) turns into a two-level cross-
classified model of the form:   
 
 
 
 
CE-
estimate 
Figure 3.9: Unit and classification diagrams of a cross-classified dataset with 
cost-effectiveness estimates classified in different studies and countries.  
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(K~(,  (12) 
(K =  + 8H(K + 	H + JHK + !K + ! + (K        with  
!K~(0, "K	  !~(0, "	  (K~(0, 	  
 
Note that the notation for the country and study error terms also changed 
(Rasbash et al., 2009). As we have now specified that both studies and countries 
are cross-classified on level two, we denote the error terms with ‘!K’ for country 
and ‘! ’ for study rather than ′'K′ and ‘!K′	 in the strictly hierarchical model.  
 
 
The estimation procedure is more complicated for the cross-classified model 
compared to its strictly hierarchical counterpart (Rasbash et al.; 2009, Hox, 
2010). Thus far, the hierarchical structure of the data permitted the structure of 
the covariance matrix to be ‘block-diagonal’ as it was shown in Figure 3.6 in 
Section 3.1.2.1. However, as Rasbash et al. (2009) make clear, the cross-classified 
model requires a non-block diagonal covariance structure. For this reason, to be 
able to estimate cross-classified effects between study and country using 
iterative generalised least squares (IGLS), a third ‘dummy-level’ needs to be 
introduced with one unit that spans the entire dataset (Rasbash et al.; 2009, Hox, 
2010). Then, dummy variables are created on the cost-effectiveness level with 
one dummy variable for each country (Rasbash et al.; 2009, Hox, 2010). Finally, 
coefficients of the dummy variables created are permitted to vary randomly at 
the country-level and, whilst covariances between dummies are assumed to be 
zero, their variances are assumed to be equal (Rasbash et al.; 2009, Hox, 2010). 
Hence, according to Hox (2010), we estimate one variance component for the 
countries to which cost-effectiveness estimates apply to, and by creating a 
separate level for countries, we make sure that the covariance between studies 
and countries is zero. Again, although technically this model uses three data-
levels, it is conceptually a two-level cross-classified model with studies and 
countries being cross-classified on the same level (Rasbash et al.; 2009, Hox, 
2010). As Hox (2010) further states, the third level is ‘just a computational device 
to allow estimation using standard multilevel software’. Therefore, we refer to it 
as ‘dummy-level’ (Hox, 2010). Note that an alternative procedure to estimate 
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cross-classified models in MLwiN, which is also used for the purposes of this 
thesis, is Markov Chain Monte Carlo (MCMC) estimation (Browne, 2012).  
 
 
Acknowledging cross-classification within multilevel models is not new, though, 
to the knowledge of the author, there has not yet been an application of a cross-
classified multilevel-model within the area of economic evaluation in health. 
Several authors used two-level models for the analysis of individual patient data 
collected alongside randomised controlled trials, cluster randomised trials, or 
observational studies (e.g. Grive et al., 2005; Willan et al., 2005; Manca et al., 
2005; Nixon et al., 2005; Pinto et al., 2005; Thompson et al., 2006; Manca et al., 
2007; Grieve et al., 2007; Bachmann et al., 2007; Coupe et al., 2007; Willan et al., 
2008; Petrinco et al., 2009; Grieve et al., 2010; Edbrooke et al., 2011) but 
datasets analysed in these studies were strictly hierarchical; hence, cross-
classification was not an issue. However, acknowledging cross-classification 
allows integrating secondary data of both single-country studies and multi-
country studies, as the latter cause the strict hierarchy between studies and 
countries to break down. The underlying assumption is that data within 
individual studies and countries is dependent, whilst independence is assumed 
between studies and between countries reflected in the dataset. However, there 
are reasons to be critical about the independency assumption of data for 
countries considered within multinational studies. Multinational studies may 
underestimate variability between countries because of, for instance, 
standardised trial protocols (e.g. Ramsey et al., 2005), the use of pooled 
effectiveness or resource use data (e.g. Barbieri et al., 2005), or methodological 
characteristics of the study which may cause cost-effectiveness estimates 
between countries to be more in the same range compared to evidence from 
single country-studies. As a result, underestimated country-level variability in 
multinational studies may affect the overall variability observed between 
countries in the cross-classified model.  
 
 
For this reason, Section 3.4 reports on a pilot study in which MLMs were tested 
before the main empirical analysis was carried out. If country-level variability is 
observed to be suspiciously low in the cross-classified model in the pilot study, 
this may be a reason to consider alternative assumptions regarding the 
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independence of data between countries from multinational studies. One 
alternative may be to fall back to a strictly hierarchical three-level model as 
reported in equation (11), where data from multinational studies are simply 
clustered in a separate group on country-level. However, for the purposes of the 
pilot, the cross-classified model (12) is the main model of interest, which is why 
the remainder of this chapter further elaborates on this particular framework. 
Nevertheless, everything mentioned in the remainder of this chapter holds just 
as much for a hierarchical three-level model. The pilot study in Section 3.4 and 
Chapter 5.1, which is concerned with determining the appropriate MLM 
structure for the main empirical analysis, further elaborate on this matter.  
 
Before moving on to the question of how the dependent variable may be defined 
within the MLM framework in Section 3.2 of this chapter, there is a third 
extension to the model developed thus far. The MLM framework offers the 
unique opportunity to model the variation in the response variable as a function 
of explanatory variables through the inclusion of random slopes to the model. 
This is considered next in Section 3.1.2.3.  
 
 
3.1.2.3. Random slopes and the variance function 
 
 
In the variance components model, the effect of explanatory variables on the 
cost-effectiveness of a healthcare technology is not considered. Therefore, the 
random intercepts model with explanatory variables on each level of the data 
hierarchy was introduced in Section 3.1.2.1. However, within that section, the 
effect of explanatory variables on cost-effectiveness estimates was assumed to 
be the same across all studies (and countries). Hence, all regression lines were 
placed parallel to each other with ′′ being the intercept and ′8H(K′ being 
the slope of the overall regression line and ′ + !′ being the intercepts of the 
individual study regression lines. This was illustrated in Figure 3.5. However, the 
effect of explanatory variables may be different, for instance, for different 
studies in the dataset. In this case, the random intercepts model does not 
adequately capture the reality of such relationships. Therefore, a new class of 
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models is now being introduced, the ‘random slopes model’ (Steele, 2008; 
Bartholomew et al., 2008; Rasbash et al., 2009; Hox, 2010).  
 
 
In contrast to the random intercepts model, each regression line in the random 
slopes model has its individual intercept and slope (Steele, 2008; Bartholomew et 
al., 2008; Rasbash et al., 2009; Hox, 2010). This allows each explanatory variable 
to have an individual effect, for instance, on each study in the dataset, which is 
also illustrated in Figure 3.10. The question is how to expand the random 
intercepts specification to turn it into a random slopes model?  
 
Recall equation (12):  
 (K~(,  (12, repeated) 
(K =  + 8H(K + 	H + JHK + !K + ! + (K        with  
!K~(0, "K	  !~(0, "	  (K~(0, 	  
 
We can turn this model into a random slopes model by adding a random term to 
any of the slope parameters on any level of the model (Steele, 2008; 
Bartholomew et al., 2008; Rasbash et al., 2009; Hox, 2010). For instance, if we 
would like the model to capture that the relationship between patient 
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Figure 3.10: Random slopes model
study 1 study 2 study 3 study 4
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characteristics on data-level and measures of cost-effectiveness may be different 
for different studies in the dataset, we add a random slope on level two for the 
respective patient covariate. The idea is that, just like the random term ′!′ 
allows the intercepts of individual study regression lines to vary randomly, this 
additional random component ′!8′	attached to the regression coefficient will 
allow its respective slope to vary randomly too (Steele, 2008; Bartholomew et al., 
2008; Rasbash et al., 2009; Hox, 2010).  
 
This turns model (12) into:  
 
(K =  + (8H(K + !8 + 	H + JHK + !K + ! + (K  (13) 
 
which can be rearranged so that:  
(K~(,  (14) 
(K =  + 8H(K + 	H + JHK + !K + ! + !8 + (K     with 
 
M!KN~(0, Ω"K			 where  Ω"K = M"K	 N 
P!!8Q ~(0, Ω"    where   Ω" = R "	"8 "8	 S T(KU~(0, Ω			      where   Ω = M	 N 
 
 
As before in the random intercepts model, we can interpret the parameter ′′ 
as the intercept and	′8H8(K′ as the slope of the pooled regression line (Steele, 
2008; Rasbash et al., 2009, CMM-workshops/random slopes). Also analogously 
to the random intercepts model, ′	 ′ is the variance for the within-study error 
term		′(K′ (Steele, 2008). However, in contrast to the random intercepts 
model, the slope is no longer identical between the pooled regression line and 
the individual study regression lines (Steele, 2008; Bartholomew et al., 2008; 
Rasbash et al., 2009; Hox, 2010). Hence, special attention needs to be placed on 
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the interpretation of ′Ω" = R "	"8 "8	 S ′ in which ′"8	 ′ is the variance in 
slopes between studies, ′"	 ′ is the variance in intercepts between studies, and ′"8′ is the covariance between intercepts and slopes between studies (Steele, 
2008; CMM-workshops/random slopes).  
 
 
Specifically, as there is no variation in a random intercepts model between 
slopes of the individual regression lines, the covariance for slopes and intercepts ′"8′ is not defined (Steele, 2008; CMM-workshops/random slopes). However, 
in a random slopes model, both intercepts and slopes may vary randomly 
between studies included in the dataset, making ′"8′ an important parameter 
(Steele, 2008). If the covariance between slopes and intercepts is positive, that 
means there is a pattern of regression lines over the range of the explanatory 
variable which is ‘fanning out’ (Steele, 2008; CMM-workshops/random slopes). 
This is, for example, the case in the sample dataset illustrated in Figure 3.10.  
Conversely, if the covariance ′"8′	is negative, then the regression lines are 
‘fanning in’ (Steele, 2008; CMM-workshops/random slopes). Finally, if the 
covariance is zero, then there is no pattern in the variation of slopes over the 
range of the explanatory variable x (Steele, 2008).  
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Figure 3.11: Random slopes model - pattern of 
variability between slopes
study 1 study 2 study 3 study 4
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Hence, the matrix ‘Ω" = R"	8 "8	 S’ defines the relationship between the 
error terms of the intercepts ′!′ and the error term of the slopes ′!8′ (Steele, 
2008; CMM-workshops/ random slopes). It also turns out that through 
introducing random slopes, the value of the intercept depends on where we 
define the explanatory variable ‘x’ to be zero (Steele, 2008; CMM-workshops/ 
random slopes). Consider Figure 3.11: depending on where the y-axis cuts the x-
axis, we observe different values of the between group error term ′!′, the 
variance of the intercepts between studies ′"	 ′ and the covariance between 
slopes and intercepts ‘"8′ (Steele, 2008; CMM-workshops/ random slopes). 
Specifically, whilst the data-level and country-level variance terms remain 
unchanged with ′	 ′ and ′"K	 ′	 respectively, we now have two random terms at 
the study-level, and the total level two variance may be expressed as a quadratic 
function of the explanatory variable (Steele, 2008; Rasbash, 2009; CMM-
workshops/ variance function): 
 
 7! + !8H89 = "	 + 2"8H8 + "8	 H8	          (15) 
 
Accordingly, the VPC may be expressed as (e.g. Steele, 2008):   
 
+, = -.W/ 0	-.WXYXZD0-.X/ YXZD/-.W/ 0	-.WXYXZD0-.X/ YXZD/ 0-1W/                         (16) 
 
Now that a model has been specified which allows both intercepts and slopes to 
vary randomly across studies, the question is why this concept may be valuable 
for addressing the transferability problem of economic evaluation data. The 
answer is that equation (15) represents a ‘variance function’ which shows how 
study or country-level variance changes over the range of an explanatory 
variable (Steele, 2008; Rasbash et al., 2009; CMM-workshops/ variance function). 
Hence, random slopes models provide us with the opportunity to explicitly 
model variability in measures of cost-effectiveness across studies, or geographic 
domains, as a function of explanatory variables. This is also shown in Figures 3.12 
and 3.13 below. Figure 3.12 shows how the variance in cost-effectiveness data 
between study regression lines depends on the value of the explanatory variable, 
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and this variance between studies has been plotted in Figure 3.13. Being able to 
model means and variances simultaneously offers unique opportunities for 
addressing the transferability problem of health economic evaluation data. For 
instance, Sculpher et al. (2004) mentioned that patient characteristics in 
economic evaluation studies (like age, gender, risk factors, etc.) constitute critical 
variability factors which may feed through to higher levels of the model 
hierarchy.  
 
Modelling variability in measures of cost-effectiveness between economic 
evaluation studies from different geographic domains as a function of (lower-
level) patient characteristics, shows for which range of the respective patient 
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variable in sample dataset
Study level-variance
1
2
3
4
5
6
7
8
2 3 4 5 6
Y
X
Figure 3.12: Random slopes model - repeated
study 1 study 2 study 3 study 4
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factor variability between studies and/or countries is lowest. In other words, we 
infer the range of values for the explanatory variable for which agreement in 
results between studies, or countries, is highest, and transferring evidence to the 
target domain may be most indicated. Conversely, for ranges of the explanatory 
variable for which variability between studies / countries is high, transferring 
evidence to the target domain may not be indicated and one may rather 
conclude commissioning a new study for the target country. In this respect, the 
variance function may be utilised to target research resources more efficiently to 
those study questions for which disagreement in existing international economic 
evaluation data is highest.  
 
For example, suppose the explanatory variable modelled in the sample dataset is 
the mean low density cholesterol level (LDL) of patient subgroups in each study 
and a random slope is specified on study-level, i.e. allowing that the effect of LDL 
on the cost-effectiveness of statins is different between studies. What we learn 
from Figure 3.13 is that the variability in cost-effectiveness estimates increases 
between studies with increasing LDL. Hence, we may be more inclined to transfer 
findings to a new setting for lower LDL patients, whilst suggesting additional 
evidence for the target domain for higher LDL patients. Although we do not have 
clear thresholds to either accept, or decline a given level of variability within the 
data, this approach could help setting more specific research priorities in the 
light of limited research resources; i.e., decision makers could invest research 
resources within one intervention area more targeted to cases of high variation 
in existing cost-effectiveness data, whilst relying on transferred evidence for 
cases which show comparatively low variation in cost-effectiveness estimates 
between studies and / or countries.  
 
Thus far, exchangeability of study parameters was assumed to allow for the 
integration of secondary cost-effectiveness data. This resulted in the variance 
components model introduced in Section 3.1.1. Subsequently, this model was 
extended to include explanatory variables on each level of the data hierarchy in 
Section 3.1.2.1, and more complex data structures were modelled including the 
cross-classification between studies and countries due to multinational study 
data in Section 3.1.2.2. In this particular section, random slopes and the 
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variability in measures of cost-effectiveness were modelled as a function of 
explanatory variables. However, the question of how to define the dependent 
variable in the model, i.e. how to express the cost-effectiveness of a healthcare 
technology as a response variable in a MLM for secondary data integration, 
needs to be addressed next. Section 3.2 elaborates on this question. Finally, in 
Section 3.3, models of both previous sections are combined, resulting in a 
‘bivariate multilevel model for secondary data integration’.   
 
 
3.2. Dependent variable in a model for secondary 
economic evaluation data integration  
 
As mentioned above, in order to develop a multilevel model for secondary data 
integration from international health economic evaluation studies, one has 
determine how to define the dependent variable in the model, i.e. how to 
express the ‘cost-effectiveness’ of a healthcare technology as a response variable 
in a MLM framework. There is an explicit theory on regression analytic modelling 
within health economic evaluation, and analysts suggest the use of the 
‘incremental net monetary benefit framework’ (INMB) as this has more 
favourable statistical properties than other, non-linear, measures of cost-
effectiveness (Claxton & Posnett, 1996; Stinnet & Mullahy, 1998, Briggs & Fenn, 
1998; Tambour et al., 1998). In addition, bivariate modelling has been suggested 
to include measures of incremental costs and incremental effects separately in a 
vector of response variables in one regression framework (Nixon et al., 2005; 
Pinto et al., 2005; Manca et al., 2007; Grieve et al., 2007; Bachmann et al., 2007; 
Willan et al., 2008; Grieve et al., 2010). This section elaborates on how to define 
the response variable, or a vector thereof, within the MLM for secondary data 
integration.  
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3.2.1. Incremental Cost-Effectiveness Ratio (ICER) or Incremental 
Net Monetary Benefits (INMB) 
 
 
From standard health economics textbooks, we can learn that ‘for a meaningful 
comparison, it is necessary to examine the additional costs that one health care 
intervention imposes over another, compared to the additional benefits, or 
utilities it delivers’ (Drummond et al., 2005a). A commonly used summary 
measure for this ‘incremental’ approach is the so called ‘Incremental Cost-
Effectiveness Ratio’ (ICER), that is:  
 [,
\ = ]Z^]_`Z^`_ 	= ∆]∆`	               (17) ,= (mean) cost of intervention ,a= (mean) cost of alternative 
= (mean) effectiveness of intervention 
a= (mean) effectiveness of alternative 
 
The ratio can be interpreted as the additional financial resources which need to 
be invested in order to achieve a unit of health gain compared to an alternative 
strategy (Stinnet & Mullahy, 1998). However, there are several problems 
associated with the ICER as a summary statistic for the cost-effectiveness of a 
healthcare intervention which are well discussed in the relevant literature 
(Drummond et al., 2005a; Claxton & Posnett, 1996; Stinnet & Mullahy, 1998; 
Briggs & Fenn, 1998):  
 
• the ICER may entail information on the relative cost-effectiveness of a 
healthcare intervention, but it is not sufficient to decide upon whether or 
not to implement that healthcare technology. To make this decision, we 
need an external criterion, i.e. a threshold which represents the willingness 
to pay for the additional health outcome achieved. (Drummond et al., 
2005a) This threshold is denoted by (b and the decision rule is to adopt the 
technology if:  
 [,
\ = ]Z^]_`Z^`_ < b		               (18) 
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• The interpretation of ICERs, is not unambiguous without having additional 
information on the location of the new technology on a cost-effectiveness 
plane. In other words, the ICER of an intervention may be identical if it is less 
costly and more effective, or more costly and less effective. Without having 
additional information on the quadrant of the CE plane in which the ICER 
falls, there is no meaningful interpretation of this ratio-statistic (Stinnet & 
Mullahy, 1998). In addition, negative ICER’s are not defined, and hence, are 
not informative for decision making (Briggs & Fenn, 1998) 
 
• A statistical problem that follows from this ambiguity relates to the 
calculation of confidence intervals (CIs) for ICERs if there is a non-negligible 
chance that the ratio may be negative. As the probability distribution of the 
ICER does not carry any information regarding its location on the cost-
effectiveness plane, its distribution and hence the construction of CIs is 
ambiguous (Stinnet & Mullahy, 1998).   
 
• Also, if there is a non-negligible probability of the denominator taking values 
close to zero, then the quantification of sampling uncertainty becomes an 
issue as the moments of the sampling distribution may be undefined (Briggs 
& Fenn, 1998)  
 
Hence, though the ICER follows an incremental approach to cost-effectiveness 
analysis, which is advocated by the relevant literature (Drummond et al., 2005a), 
it possesses some qualities which cast into doubt its usefulness as a dependent 
variable within a regression analytic framework (Claxton & Posnett, 1996; Stinnet 
& Mullahy, 1998; Briggs & Fenn, 1998). To overcome the problems associated 
with ICERs, several health economists advocated the ‘incremental net monetary 
benefit approach’ (INMB) as an alternative (e.g. Stinnet & Mullahy, 1998; Briggs 
& Fenn, 1998; Tambour et al., 1998). INMBs may be calculated simply by 
rearranging equation (18). Recall that we decide to adopt a health technology if:  
 [,
\ = ]Z^]_`Z^`_ < b		          (18, repeated) 
 
Rearranging this equation leads to:  
 b ∗ (
 − 
a > , − ,a             (19) 
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And finally 
 b ∗ (
 − 
a − , − ,a > 0                          (20) 
 
or  
 ∆
 ∗ b − ∆, > 0  (INMB)             (21) 
 
As the INMB is not a ratio-statistic, it essentially solves the problems mentioned 
above. The INMB statistic is defined both for negative and positive values and 
there is no ambiguity in its interpretation with respect to its location on the cost-
effectiveness plane; i.e. a positive (negative) ICER always means that the new 
intervention is more (less) favourable than the comparator technology and, the 
higher the INMB value, the more favourable is the intervention under 
investigation (Stinnet & Mullahy). In other words, whereas ICERs do not obey to 
the law of transitivity, preferences are monotonic in INMBs (Stinnet & Mullahy, 
Hoch et al., 2002). In addition, the lineal form of the INMB statistic solves the 
statistical shortcomings of the ICER, making it more suitable when employing 
regression analytic methods (Hoch et al., 2002), which is the aim of this exercise.  
 
 
 
3.2.2. Net benefit regression for RCT data 
 
 
So far we have learned that the cost-effectiveness of a health care technology 
should be measured in terms of both its incremental costs and incremental 
health effects of one intervention compared to another. Secondly, because of its 
linear form, the INMB approach may be preferred over to the ICER statistic, 
which suffers from several shortcomings in terms of its interpretation and in 
terms of its statistical properties. However, the next task is to employ the INMB 
statistic within a regression analytic framework. We previously defined that: 
 
 ∆
 ∗ b − ∆, > 0  (INMB)       (21, repeated) 
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Hoch et al. (2002) transferred the INMB framework into a linear model suitable 
for net benefit regression in a randomised controlled trial. First, they estimated a 
net benefit value for each subject in a trial setting in the form of.  
 
 f = b ∗ 
 − ,   (22) 
 
 
where ′
′and ′,′ are the observed effects and cost for subject ‘i’ in the trial 
(Hoch et al., 2002). A simple linear regression model was then defined in the 
form of:  
 f =  + g$ + h  (23) 
 
where, ‘’ represents an intercept term, ‘t’ a treatment dummy taking the value 
zero for the standard treatment and the value one for the treatment under 
consideration, and ′hi	is the stochastic error term (Hoch et al., 2002). The 
coefficient ′g′ provides the estimate of the incremental net monetary benefit 
(INMBi = NMB1i – NMB0i) In an extension of model (23), Hoch et al. (2002) 
showed how this regression framework can be exploited to add explanatory 
variables to the regression equation, which then takes the following form:  
 f =  +j kHklkm8 + g$ + h        (24) 
 
 
In this model, there are ‘p’ covariates and the INMB provided by ′g$′ is 
estimated whilst taking into account the impact of these explanatory variables, 
which could be, for example, age, gender, or severity of disease of patients 
participating in the trial (Hoch et al., 2002).  
 
 
Hoch et al. (2002) made a very important contribution as they transferred the 
INMB-statistic into a regression framework. However, three important issues of 
dependency within (secondary) cost-effectiveness data need to be addressed to 
derive a model suitable for the purposes of this thesis. The three dependencies 
to be addressed are: 
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• no independence between intervention and control groups within a 
study if data is combined from different studies 
• no independence of costs and effects within each measure of cost-
effectiveness, and  
• Dependence of the INMB statistic on a (country specific) threshold 
value λ  
 
The following section addresses each of these issues showing that all of them can 
be considered appropriately within a ‘multivariate regression framework’. 
 
 
3.2.3. Decomposing the INMB statistic 
 
 
As mentioned above, there are several dependencies within secondary cost-
effectiveness data from different economic evaluation studies which the 
standard net benefit framework proposed by Hoch et al. (2002) does not 
adequately capture. First of all, as the net benefit regression framework was 
purposely developed for economic evaluations ‘within’ RCTs, it treats both costs 
and effects in the treatment and the control arm as independent. As shown in 
equation (24), the treatment dummy ′g$′ is ‘1’ for the intervention and ‘0’ for 
the control group, assuming zero covariance between the interventions and the 
controls. Within the boundaries of a single RCT (for which the net benefit 
regression framework was developed), this is a perfectly reasonable assumption, 
as the trial protocol is supposed to eliminate dependencies between both 
groups. However, when the intension is to integrate evidence from different 
studies, then estimates from the same study suddenly become highly dependent.  
 
 
The second issue relates to the use of NMBs as dependent variable in the net 
benefit regression framework. In particular, using NMBs on the left hand side of 
the equation means combining estimates on both costs and effects in the 
dependent variable, so that the existence of correlation between the two 
components of the NMB statistic is not being made explicit (note again that in 
Hoch’s net benefit regression framework, NMBs constitute the dependent 
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variable, the incremental approach is introduced through the inclusion of the 
treatment dummy ′g$′ (Hoch et al (2002)). However, each component of the 
NMB statistic is likely to contribute in different amounts to the overall variability 
in measures of cost-effectiveness, and explanatory variables are likely to have a 
differential effect on each of these components (e.g. Manca et al., 2007). Using 
NMB as outcome measure would hence preclude the chance of estimating the 
differential impact of covariates on both costs and effects of the healthcare 
intervention and its respective comparator. One could argue that fitting separate 
models may solve the problem. However, doing so would mean to model the 
opposite extreme, where the existence of correlation between the components 
of net monetary benefits is being ignored altogether. Therefore, several authors 
already suggested the use of bivariate models to overcome the problem of 
dependency between cost and effects of a healthcare technology (Nixon et al., 
2005; Pinto et al., 2005; Manca et al., 2007; Grieve et al., 2007; Bachmann et al., 
2007; Willan et al., 2008; Grieve et al., 2010).  
 
 
In addition to all of the above, the standard net benefit regression framework 
requires a new regression to be estimated for each value of ′b′ as different cost-
effectiveness thresholds might be applicable to different jurisdictions (e.g. 
Manca et al., 2007). A solution to all of these problems may exist in the form of 
multivariate models as they allow for correlation amongst a set of response 
variables. How to derive such a multivariate model is the question for the 
remainder of this section.  
 
 
First of all, instead of calculating the NMB for interventions and controls and 
using ′g$′	 as a treatment dummy, we may first decompose the INMB 
framework, which provides four potential response variables for a multivariate 
model. These four response variables are the costs and effects of the 
intervention, and the costs and effects of the comparator respectively.  
 
 
Denote by ‘Ydi‘ the response on variable ‘d’ with (d=Cint, Eint, Ccomp, Ecomp,) for 
each estimate of INMB ‘I’ with (i=1,....,n).  Modelling costs and effects of both 
intervention and comparator simultaneously as response variables within one 
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regression equation makes explicit the correlation between all components of 
the INMB statistic. However, having more than one dependent variable on the 
left hand side of the equation requires making further adjustments to the overall 
regression equation, which is why response indicators ‘n′ are introduced 
(Bartholomew et al., 2008). These response indicators are dummies being coded 
‘1’ for each observation on variable ‘d’ and ‘0’ otherwise (Bartholomew et al., 
2008). In the current example case, we have a dataset with ‘i=1,...,n’ 
observations of INMB, and ‘d=4’ response variables ′o8 = ,pq′ , ′o	 = 
pq′, ′oJ = ,rstk′ and ′ou = 
rstk′. The respective dataset may look like it is shown 
below in Table 3.1 (Bartholomew et al., 2008): 
 
Table 3.1: Multivariate data structure for two data-points 
 
i d Ydi r1 r2 r3 r4 
1 Cint Y11 1 0 0 0 
1 Eint Y21 0 1 0 0 
1 Ccomp Y31 0 0 1 0 
1 Ecomp Y41 0 0 0 1 
2 Cint Y12 1 0 0 0 
2 Eint Y22 0 1 0 0 
2 Ccomp Y32 0 0 1 0 
2 Ecomp Y42 0 0 0 1 
... ... ... ... ...   
 
 
For instance, as can be seen from Table 3.1, the response indicator ‘r1‘ is equal to 
‘1’ if the row in the dataset refers to the cost measured for the intervention, and 
‘0’ otherwise, and ‘r4‘ is ‘1’ if the row in the dataset refers to the effect of the 
comparator, and ‘0’ otherwise. We can now rewrite our model as:  
 
 
 
 
 
 
 
 
 83 
 
n~f(,                            [25] vn = n ∗ n + !n ∗ n           
 
with  
M!nN~f (0, Ω"     where  Ω" = wxx
xy"	"8 "8	"	 "8	 "		"J "8J "	J "J	 z{{
{|
 
 
 
In a sense, response indicators take over the role of the treatment dummy ′g$	′ 
in Hoch et al’s (2002) net benefit regression framework. However, In model (25), 
an error variance is assigned to each response variable (Bartholomew et al., 
2008) and the model allows the covariances between response variables within 
each measurement of INMB being different from zero as it is shown by the 
covariance matrix ′Ω"′ (Bartholomew et al., 2008). Hence, model (25) represents 
a very basic multivariate model, which takes into account the correlation 
between different components of the INMB statistic. An important advantage of 
this model is that by adding explanatory variables to the equation, one can infer 
differential effects of covariates on each response variable (Bartholomew et al., 
2008). Model (25) turns into:  
 n~f(,                [26] vn = nn + 8nH8n + !nn 
 
with  
M!nN~f (0, Ω"     where  Ω" = wxx
xy"	"8 "8	"	 "8	 "		"J "8J "	J "J	 z{{
{|
 
 
 
Because of the response indicator ′n′ and the covariance matrix ′Ω"′, which 
entails a variance term for each response variable and also allows covariances 
between response variables to be different from zero, we can now fit a different 
intercept to each response variable, while the interactions between the 
explanatory variable ′H′ and the response indicator ‘n′ allow the effect of the 
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explanatory variable ′H’ to differ between response variables (Bartholomew et 
al., 2008). The response variable specific residuals are fitted by permitting the 
intercept of the response indicator ′n′	to vary randomly across the 
measurements of INMB (Bartholomew et al., 2008). Note that models (25) and 
(26) technically belong to the family of MLMs as the response variables are being 
‘nested’ within each estimate of INMB. However, there are important differences 
to standard multilevel models, which is why these models are being referred to 
as ‘simple multivariate models’ (Bartholomew et al., 2008). Acording to 
Bartholomew et al. (2008), these characteristics are: 
 
• the intercept term ′n′ allows for different means of each response 
variable 
• As there is only one error term ‘!n ′	 which is modelled on the level of the 
INMB-measure ‘udi’, this may be viewed as the INMB-specific residuals that 
have different variances for each response variable. In a standard MLM, 
there would be one error term on each level.  
• Finally, the model allows the error term to be correlated across responses. 
 
By modelling a vector of response variables for each component of the INMB 
statistic, the net benefit regression framework has been turned into a 
multivariate model which takes into account correlations between the 
components of INMBs. If published studies on the cost-effectiveness of a 
healthcare intervention would explicitly report data on costs and effects of both 
the intervention and the comparator, then this would be the appropriate model. 
However, a practical limitation lies in the reporting of cost-effectiveness 
evidence. Unfortunately, many publications report their cost-effectiveness 
results only in terms of ICERs or INMBs, without decomposing the measure of 
cost-effectiveness into its components. If this is the case, the study may not be 
includable in this empirical exercise. However, whilst information on cost and 
effects of both the intervention and comparator are almost never reported 
explicitly, quite a number of studies decompose measures of cost-effectiveness 
into incremental cost (∆C) and incremental effects (∆E) respectively.  
 
 
The implication is that the multivariate model with four response variables may 
not be practicable as only very few studies, if any at all, make explicit the 
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required information on all response variables to populate the dataset. If this is 
the case, the next best alternative is to include ∆C and ∆E as a vector of response 
variables in a bivariate regression framework. Though this does not take into 
account the differential impact of intervention and comparator on INMBs, it still 
decomposes the INMB statistic so that we may assess the differential impact of 
explanatory variables on incremental cost and incremental effects whilst taking 
into account the correlation between the two components of the INMB statistic. 
As a result, a simplified, bivariate model is proposed, in which the two response 
variables are ∆C and ∆E of a healthcare intervention. Hence, the vector of 
response variables (d=Cint, Eint, Ccomp, Ecomp,) is replaced by (d= ∆,, ∆
) and model 
(26) turns into:  
 
 }v8v	~ ~(,                            [27] 
 vn = nn + 8nH8n + !nn 
 
8 =  1	(	∆	*%$0	(	∆	*$ 	 = 1 − 8																		with  
 
P!!8Q ~ (0, Ω"      where  Ω" = R"	"8 "8	 S 
 
 
In this section, a bivariate model was developed which makes explicit the 
correlation between the two components of the INMB statistic ∆C and ∆E and 
also allows for differential effects of explanatory variables on each response 
variable. In addition, a MLM with data, study, and country-levels was developed 
in Section 3.1 of this chapter. The next section combines both models, ultimately 
deriving a multilevel model suitable for secondary data integration of 
international health economic evaluation studies.  
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3.3. Bivariate multilevel model for secondary data 
integration  
 
 
In Section 3.1, a MLM was developed which accommodates both a study and a 
country-level to allow integrating data from different studies applicable to 
different geographic domains. In addition, cross-classification was modelled as 
multinational studies provide cost-effectiveness data for more than one country, 
causing the strict hierarchy between data, study and country-level to break 
down. In Section 3.2, the measure of cost-effectiveness suitable for econometric 
analysis was determined. Following from Hoch’s net benefit regression 
framework, a bivariate model was developed with the two components of the 
INMB statistic (∆C and ∆E) as a vector of response variables. In this section, both 
models previously developed are being combined, resulting in a bivariate MLM 
suitable for secondary data integration of economic evaluation studies applicable 
to different geographic domains. To do so, reconsider the random intercepts 
model which makes explicit that data is grouped in studies and countries and 
also allows for cross-classified data structures due to multinational study data:  
 (K~(,  (12, repeated) 
 (K =  + 8H(K + 	H+JHK + !K + ! + (K        with !K~(0, "K	  !~(0, "	  (K~(0, 	  
 
Also, recall the bivariate model shown above in equation (27): 
 }v8v	~ ~(,          (27, repeated) 
 vn = nn + 8nH8n + !nn  
 8 =  1	(	∆	*%$0	(	∆	*$ 	 = 1 − 8																				with  
 P!!8Q ~ (0, Ω"      where  Ω" = R"	"8 "8	 S 
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To combine both models, we posit model (12) above model (27). As model (27) 
may be regarded as a two-level hierarchy with responses ‘∆C’ and ‘∆E’ grouped 
in individual observations, the resulting model technically consists of four levels. 
As mentioned, responses are modelled on the lowest level. Above that is the 
level of individual observations. The third and fourth levels are those of the study 
and the country. However, conceptually, we may still speak of a two-level model 
(Bartholomew et al., 2008). The reasons are that the lowest level is only 
introduced to model a vector of response variables and it does not carry its own 
residual term (Bartholomew et al., 2008). Secondly, studies and countries are 
assumed to be cross-classified on level two of the data hierarchy (Hox, 2010). To 
combine both models, each response variable has its own error variance on each 
level, and the model also allows the covariance between error terms of each 
response indicator to be different from zero on each level of the data hierarchy 
(Bartholomew et al., 2008). This results in the following model:  
 
 
Bivariate random intercepts model for secondary data integration 
 
}v8,(Kv	,(K~~(,   (28) 
 n,(K = (n + 8nH(K + 	nH+JnHK + !nK + !n + n(K ∗ n,(K  
 
8,(K =  1	(	∆	*%$0	(	∆	*$ 	,(K = 1 − 8 
 
with:  
P!,,K!,8,KQ~ (0, Ω"      where  Ω" = R",K	",8K ",8K	 S 
P!,,!,8,Q ~ (0, Ω"      where  Ω" = R",	",8 ",8	 S 
},,(K,8,(K~ ~ (0, Ω"      where  Ω = R,	,8 ,8	 S 
 
 
Now, consider we introduce a random slope on study-level to allow the effect of 
explanatory variables on each response variable to be different between 
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different studies included in the dataset. This means including an additional error 
term for the slope variance and that for each response variable, one has to 
consider not just their slope and intercept variances, but also their respective 
covariances. This results in a 4x4 covariance matrix on level two of the bivariate 
model. The respective model is shown below in equation (29).  
 
 
Bivariate random slopes model for secondary data integration 
 
}v8,(Kv	,(K~~(,   (29) 
 n,(K = (n + 8nH(K + 	nH+JnHK + !nK + !n+!8n + n(K ∗n,(K  
 
8,(K =  1	(	∆	*%$0	(	∆	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P!,,K!,8,KQ~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},,(K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The multilevel models for the purposes of this thesis have now been developed. 
However, before applying these models to the data in the main empirical 
exercise, it was decided to carry out a pilot study. The final Section 3.4 of this 
chapter reports on this pilot study and discusses its results in depth and with 
particular emphasis on the implications for the design and execution of the main 
empirical analysis, which is reported in Chapter 5.  
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3.4. Pilot Study  
 
 
In this section, the models developed above are applied to a set of secondary 
cost-effectiveness data from 16 international economic evaluation studies on the 
primary and secondary prevention of CVD. Starting off from an OLS regression 
equation, multilevel model features, as elaborated on in this chapter, are 
introduced step by step. This demonstrates the relative merits of the MLM 
framework for the integration of international economic evaluation data and 
also gives valuable insights for the design and execution of the main empirical 
analysis. This main empirical analysis, which is reported in Chapter 5, also begins 
with an exercise to determine the appropriate MLM structure for analysing data 
abstracted from 67 international cost-effectiveness studies on statins for the 
primary and secondary prevention of CVD. The design of this exercise was based 
to a large extend on the experiences from this pilot study.  
 
 
The pilot study is organised as follows: Section 3.4.1 states the aim and 
objectives of this pilot. Then, in Section 3.4.2, the methods of analysis are 
explained before the data is introduced in Section 3.4.3. Results are reported in 
Section 3.4.4. Finally, the discussion, which focuses on the implications of pilot 
study findings on the design and execution of the main empirical analysis, are 
reported in Section 3.4.5.  
 
 
3.4.1. Aim and objectives of the pilot study 
 
The primary aim of this pilot is to inform the design and execution of the main 
empirical analysis, which is reported in Chapter 5. This empirical analysis may be 
described as a secondary data integration exercise, based on a systematic 
literature review on the cost-effectiveness of statins in the primary and 
secondary prevention of CVD (details on the systematic literature review and 
data abstraction are available from Chapter 4). Within this exercise, it is aimed to 
apply MLM methods to analyse factors causing variability in international cost-
effectiveness data on each level of the data hierarchy. For this purpose, a 
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multilevel model structure needs to be developed which is suitable for the data 
available. The first part of the main empirical analysis reported in Chapter 5.1 is 
therefore concerned with determining this multilevel model structure. However, 
for the appropriate design of this exercise it was crucial to carry out this pilot 
study. Accordingly, three main objectives are specified for this pilot.  
 
• First, it is important to test the models developed theoretically in Sections 
3.1 to 3.3 of this chapter using real world data. For this reason, the pilot 
study builds up a MLM in the same sequence as it was developed above, 
starting off from an OLS regression equation and subsequently 
elaborating on this model.     
 
• Secondly, as the literature on secondary data integration of economic 
evaluation data is scarce, and some concerns exists over the overall 
validity of such an exercise due to enormous variability, especially in 
socioeconomic data (e.g. Jefferson et al, 1996), it was intended to obtain 
input from the wider health economics and multilevel modelling 
communities. For this reason, a paper on this pilot study has been 
presented at various conferences, including the winter meeting of the 
Health Economists Study Group (HESG) in January 2011 in York, UK, and a 
MLM session at the conference of the European Society of Survey 
Research (ESRA) in July 2011 in Lausanne, Switzerland. The feedback 
obtained from these conferences significantly influenced the design of 
the main empirical analysis and is discussed later in this section.  
 
• Finally, the importance of appropriately controlling for variability on each 
level of the MLM has been stressed already. What follows is that data for 
covariates need to be obtained on each level of the model hierarchy. 
Therefore, a data abstraction form was developed based on the existing 
health economic literature on factors causing variability in economic 
evaluation data. This data abstraction form was tested, revised, and 
improved upon within this pilot study. Note, however, that specifics on 
this aspect of the pilot are reported in full detail in the subsequent 
Chapter 4, which is concerned with the systematic literature review and 
data abstraction exercise to obtain data for the main empirical analysis.   
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The next section introduces the methods of analysis to carry out the pilot study. 
The data for the pilot is summarized thereafter in Section 3.4.3.   
 
3.4.2. Methods of analysis 
 
The example of statins for the primary and secondary prevention of CVD was 
chosen as this is an extensively studied area, with many cost-effectiveness 
studies across many countries, hence allowing for the assumption of random 
parameters on study and country-level. At the time of the pilot study, a 
systematic literature review was not yet completed, so that the pilot uses a 
dataset with studies previously identified by Franco et al. (2005) (details about 
search strategy, study selection process, etc. can be obtained from this source). 
Only studies comparing statins with ‘doing nothing’ were included. Although 
some studies estimate QALYs, most do not, so for this exercise, life years saved 
(LYS) were used as the measure of effect. Studies not reporting incremental costs 
and incremental effects separately were also excluded, as INMB could not be 
calculated for these studies.  
 
As a result, from the 24 papers identified by Franco et al. (2005), a further 7 were 
dropped because of the additional exclusion criteria defined above (Goldman et 
al., 1991; Hay et al., 1991; Goldman et al., 1993; Riviere et al., 1997; Huse et al., 
1998; Pickin et al., 1999; Russel et al., 2001). One further study was not 
obtainable at the time the pilot study was carried out (Grover et al., 2001). From 
the remaining 16 papers, cost-effectiveness estimates were collected for the 
base case, as well as for subgroup analysis, and sensitivity analyses exploring 
variation by: efficacy of intervention, baseline risk, annual drug costs of statin 
therapy, duration of statin therapy in years, costs of CVD related events, and 
discount rates for costs and effects. These sensitivity analyses results were 
considered as they were usually reported in most studies included in this 
exercise, which allowed definition of covariates encoding differences between 
data points for multilevel analyses. However, a number of abstracted cost-
effectiveness estimates had to be dropped from the dataset as they referred to 
less frequently reported forms of sensitivity analyses, and could not be included 
in the multilevel analysis without losing large numbers of studies.  Excluding 
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these sensitivity analyses reduced the pilot study dataset by around 160 
datapoints (25% of all cost-effectiveness estimates abstracted from pilot study 
papers).  
 
If a data-point was considered includable, data on incremental cost and 
incremental effects were abstracted. If only ∆C or ∆E was explicitly reported in 
conjunction with a cost-effectiveness estimate, the missing component of the 
ICER or INMB statistic was calculated by rearranging the formula for ICERs or 
INMBs respectively. For instance, if a study reported an ICER of £16,000 and ∆E 
of 0.5 LYS, ∆C was calculated as ∆, = [,
\ ∗ ∆
 = £8,000. Or if an INMB of say 
£7,000 was reported at a given threshold value (say £30,000) and ∆E of 0.5, ∆C 
was calculated as ∆, = 	∆
 ∗ b − [f = £8,000. Problems did arise, for 
instance, if a study reported cost-effectiveness as ICERS, and the use of statins 
resulted in cost-savings. As studies rightly omitted negative ICERs, this meant, 
however, that ∆C and ∆E could not be calculated and the respective data point 
had to be dropped. This resulted in a loss of a further 36 data points within the 
pilot study dataset. The discussion in Chapter 6 will explicitly discuss potential 
reasons for bias that might arise from excluding certain data-points and studies 
from the dataset. In particular, there is a risk that such exclusions may result in a 
violation of the assumption of random parameters which is essential for fitting 
multilevel models.  
 
Abstracting data for the pilot study in this way resulted in a total of 464 data 
points, clustered in 16 studies, and applicable to 16 geographic domains. The fact 
that there were 16 studies and 16 countries included in the dataset was a 
coincidence as some studies were multinational in nature, hence, reporting data 
on more than one country and thereby introducing the cross-classification 
problem. Local currencies were transferred to Pound Sterling using Purchasing 
Power Parities (PPP) and updated to 2009 using country specific GDP deflators 
(Shemilt et al., 2008; OECD, 2010). For countries which adopted the Euro, historic 
currencies were first converted to Euros using irrevocable Euro conversion rates 
as adopted by the Council of the European Union on January 1, 1999 (IMF, 2010).  
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As a first step, models were fitted to the data without any covariates. 
Accordingly, the most fundamental model in this pilot study was an empty OLS 
regression equation. Building up from that, two-level hierarchical models were 
fitted with a) data clustered in countries only and b) data clustered in studies 
only. Finally, a cross-classified model, which accommodates both a study and 
country-level, was specified and fit to the pilot study data. All models were 
implemented in a univariate version with INMB as the only response variable and 
a bivariate version with ∆C and ∆E as a vector of response variables. For 
univariate models, a cost-effectiveness threshold level (λ) of £30,000 per LYS was 
assumed. This does not equate to £30,000 per QALY gained, as most additional 
years of life will be lived in less than perfect health states. Random slopes were 
not tested within this pilot study as, at the time it was carried out, the author 
was not yet successful in fitting them to the models of interest. Table 3.2 
provides an overview of the models tested within this pilot study.  
 
Table 3.2: Model specifications applied to the data within the pilot study 
 Univariate 
model with 
INMB as 
response 
variable 
Bivariate model 
with ∆C and ∆E 
as vector of 
response 
variables 
Variance 
components 
model 
without 
covariates 
Random 
intercepts 
model 
with 
covariates 
Random 
slopes 
model 
OLS regression model √ √ √ √ x 
Two-level hierarchical 
model with data and 
country-level 
√ √ √ √ x 
Two-level hierarchical 
model with data and study-
level 
√ √ √ √ x 
Cross-classified model with 
data, study and country-
level 
√ √ √ √ x 
 
After implementing models as variance components models without covariates, 
a set of explanatory variables was tested in each model. All continuous variables 
were centred around their mean values, which has the advantage that the 
intercept is easier to interpret as it represents the predicted INMB (∆C, ∆E) for 
average values for each explanatory variable (Steele, 2008; Rasbash et al., 2009; 
Hox, 2010). The set of potential explanatory variables within this pilot study 
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analysis was drawn from a long list of variability factors suggested by previous 
authors (Sculpher et al., 2004; Goeree et al., 2007). For this purpose, a data 
abstraction form was developed, tested and improved upon within this pilot 
study. However, the details on the development of the data abstraction form, 
which was one of the key objectives of this pilot study, are presented in Chapter 
4, which is concerned with a systematic literature review, data abstraction 
exercise, and genealogy study of cost-effectiveness papers on statins in the 
primary and secondary prevention of CVD.   
 
 
Within the boundaries of this pilot study, a much reduced dataset, with only a 
few covariates found to be significant when fitting multilevel models, was used. 
As a result, All models include three variables on data-level (mean pre-treatment 
total cholesterol level (TCL), age and percentage of females in the sample), and 
two variables on the country-level (GDP per capita and total life expectancy at 
birth). Although a range of study-level covariates was tested (e.g. general study 
design, timing, or the method of effect calculation, to name a few), the pilot 
study did not result in a set of study-level covariates which captured significant 
variation across the studies included in the dataset. Observations with missing 
values were generally rare for the explanatory variables included in this pilot, 
and listwise deletion was applied as a simple ad hoc strategy for dealing with 
missing values within this pilot study (note, however, that missing values were 
more of a concern in the main empirical analysis which is reported in Chapter 5. 
Therefore, to minimise the potential for bias and overestimated precision, a 
much more elaborated approach for dealing with missing values is applied in 
Section 5.2 of the empirical chapter, where the purpose is to test covariates 
within the MLM framework).  
 
 
All models were implemented in MLwiN using Markov Chain Monte Carlo 
(MCMC) estimation (Rasbash et al., 2009a; Browne, 2012). Though models could 
also be implemented using iterative generalised least squares (IGLS), it is a more 
complex procedure, which is why it has been strongly advocated to use MCMC 
for cross-classified and especially for bivariate models in MLwiN (Browne, 2012; 
and personal communication with Prof William Browne, CMM, Bristol). A 
detailed step by step guide on how to implement models in MLwiN can be found 
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in Appendix 3. The statistical software package MLwiN was chosen for this 
exercise as it is special MLM software with unique capacities to specify complex 
data structures (Rasbash et al., 2009a). Though it is acknowledged that there are 
other software applications allowing to fit multilevel models (e.g. HLM, STATA or 
R), the author found the features offered by MLwiN particularly useful. In 
addition, the Centre for Multilevel Modelling in Bristol, which developed the 
software package MLwiN, is sponsored through the Economics and Social Science 
Research Council (ESRC) which enables free access to an unrestricted version of 
MLwiN to all researchers based in a UK academic institution.  
 
 
Before reporting on the results of the pilot study, the dataset is introduced next 
in more detail, including descriptive statistics for the response variables and 
explanatory variables tested within this pilot.  
 
 
3.4.3. Pilot study data 
 
 
Table 3.3 provides details on the studies included in the dataset. Further 
information on the studies included may also be obtainable from Franco et al. 
(2005). Most studies were based on decision analytic modelling (DAM), although 
three (Caro et al., 1997; Jonsson et al., 1996; Jonsson et al., 1999) were directly 
based on clinical trial data. Studies included populations without any known 
history of CVD (primary prevention), those with at least one prior event of CVD 
(secondary prevention), or both. Subgroup analysis was usually performed with 
respect to age, gender, and pre-treatment cholesterol level. As can be seen in 
Table 3.3, when assuming a threshold value (λ) of £30,000, mean INMBs within 
each study range from £-2,670 (Pharoa et al., 1996) to over £48,660 (Grover et 
al., 1999), with an overall mean INMB of £11,632 across all studies included in 
the dataset.  
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Table 3.3: Study characteristics and descriptive statistics 
Study Nj* K** 
Study 
type+ 
Prev. 
cat.++ 
Age 
range 
Mean 
TCL 
mmol/L 
Mean 
∆C 
2009 
GBP 
Mean 
∆E LYS 
 
Mean INMB 
λ= £30.000, 
2009 GBP 
Ashraf et al., 1996  9 1 2 2 60 6.00 1228 0.157 3472 
Caro et al., 1997  1 1 1 1 45-64 7.01 2758 0.098 182 
Grover et al., 1999  48 1 2 2 40-70 6.50 16387 2.169 48669 
Grover et al., 2000  52 1 2 3 40-70 6.51 25874 1.73 26021 
Hamilton et al., 1995  20 1 2 1 30-70 7.22 19734 0.97 9396 
Johannesson et al.,1997 39 1 2 2 35-70 6.75 1120 0.22 5433 
Muls et al., 1998  15 1 2 2 60 6.00 1885 0.16 2815 
Perreault et al., 1998 36 1 2 1 44-57 8.14 18698 0.64 452 
Pharoah et al., 1996 46 1 2 3 45-64 7.10 5452 0.09 -2671 
Szucs et al., 1998 42 1 2 2 45-65 5.41 3575 0.29 5041 
Szucs et al., 2000 8 1 2 2 45-65 5.62 3588 0.41 8562 
Van Hout et al., 2001 5 1 2 3 25-75 ? 11524 0.93 16436 
Jonsson et al., 1996 18 10 1 2 35-70 6.74 1791 0.24 5409 
Jonsson et al., 1999 109 11 1 2 35-70 6.74 1342 0.30 7723 
Ganz et al., 2000 12 1 2 2 75-84 ? 3856 0.26 3794 
Martens et al., 1994 4 1 2 1 45 5.56 7223 0.19 -1485 
Sum: 464 16 Mean: 57.06 6.66 8678 0.677 11632 
* 
** 
+ 
 
++ 
 
Number of INMB estimates clustered within a study 
Number of countries included in that study 
1 = Primary modelling (directly based on observations from trial data) / 2 = Secondary modelling (studies 
based on any form of decision analytic model (DAM))  
Prevention category: 1 = primary prevention / 2 = secondary prevention /3 = both 
 
See also Franco et al (2005) for additional information on study characteristics [49] 
 
 
Table 3.4: Country characteristics 
 
Country Nk* J** 
GDP***+ 
per capita 
Health care 
spending***+ 
% of GDP 
Life exp. at 
birth***+ 
years 
Mean ∆C 
2009 
GBP 
Mean 
∆E 
 LYS 
 
Mean INMB 
λ=30.000, 
2009 GBP 
Australia 1 1 21541 8.0 77.83 1967 0.240 5233 
Belgium 23 3 22556 7.8 76.84 1855 0.201 4180 
Canada 160 5 22696 9.5 78.05 20179 1.483 24297 
Denmark 11 1 25259 8.0 75.95 854 0.305 8290 
Finland 11 1 20968 7.4 76.88 1687 0.305 7458 
France 8 2 21556 9.6 78.28 1101 0.285 7437 
Germany 62 4 23289 10.8 76.84 3137 0.305 6006 
Italy 12 2 22460 7.6 78.58 1092 0.299 7891 
Netherlands 5 1 26933 8.2 77.83 11524 0.932 16436 
New Zealand 1 1 17143 7.3 76.73 3012 0.240 4188 
Norway 8 2 27416 7.6 78.09 1371 0.285 7168 
Portugal 12 2 14324 7.9 75.39 2013 0.299 6970 
Spain 12 2 17554 7.4 78.55 1542 0.299 7441 
Sweden 58 3 22161 8.5 78.83 1127 0.238 6007 
UK 59 4 20241 6.9 76.91 4607 0.135 -562 
USA 21 2 29919 14.0 76.17 2730 0.213 3656 
Sum / mean 464 16 22473 9.05 77.58 8678 0.677 11632 
* 
** 
**** 
 
+ 
Number of INMB estimates clustered within a country 
Number of studies providing INMB estimates for that country 
As INMB measurements within one country may stem from several studies with differential timing, the values in 
these columns represent means across the years for which INMB values are reported 
Source: OECD Health Data, 1999 [69] 
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Table 3.4 provides some characteristics and summary statistics of the countries 
included. As INMB measurements within one country may stem from several 
studies with differential timing, values elicited on GDP per capita, healthcare 
spending as percentage of GDP and life expectancy at birth are presented as 
mean values across the years for which INMB measures were reported. Again, 
there is considerable spread in mean INMB’s across countries, ranging from £-
552 (UK) to £24,296 (Canada), assuming λ= £30,000. Looking at the third column 
in both tables, we can see that most studies (14 out of 16) report data applicable 
to one geographic domain only. However, two studies (Jonsson et al., 1996; 
Jonsson et al., 1999) report data which applies to several geographic domains, 
resulting in studies and countries being cross-classified. Further descriptive 
statistics of response variables and explanatory variables tested within this pilot 
study are available from Tables 3.5 and 3.6 below.  
 
 
Table 3.5: Descriptive statistics of continuous variables tested in the pilot 
 
Variable   
(in 2009 £-
Sterling) 
Level 
Obs. missing in % Min Max Mean Std. Dev. 
incr_cost response 464 0 0% 10.44 64259 8678 11231 
incr_effect response 464 0 0% .00885 5.4 0.677 0.944 
inmb response 464 0 0% -42959 140518 11632 23407 
age Data 448 16 3.45% 30 70 57.06 7.57 
gender Data 449 15 3.23% 0 1 32.03% 40.20% 
tcl Data 447 17 3.66% 5.4 9.9 6.66 0.942 
dr_cost Data 464 0 0% 0 10% 3.55% 1.77% 
dr_effect Data 464 0 0% 0 10% 3.17% 2.10% 
GDP/capita Country 16 0 0% 13071 31653 22473 2729 
total_hcs Country 16 0 0% 6.8 14.1 9.03 1.62 
public_hcs Country 16 0 0% 4.7 8.5 6.72 0.85 
le_birth Country 16 0 0% 75.06 79.20 77.57 0.92 
 
 
The mean age across all patient subgroups considered in the studies included 
was 57.06 (SD 7.57), and 32.03% (SD: 40.2%) of all patients considered were 
female. The overall mean TCL was 6.66 mmol/L (SD: 0.942), and the majority of 
patients already experienced at least one CVD event in the past (65.73%). The 
most common statin under assessment was simvastatin (57.76%), followed by 
pravastatin (19.83%) and lovastatin (12.28%). Moving on to methods applied in 
the studies, the mean discount rates were 3.55% for costs and 3.17% for effects 
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respectively. The time horizon was most commonly between 6 to 10 years 
(40.30%) or above 20 years (46.55%). Most studies were based on DAM (13 out 
of 16), and CVD risk reduction was the most common way to capture treatment 
effectiveness (11 out of 16 studies), whilst 5 studies measured the impact of 
statins on cholesterol levels and then extrapolated findings to life years saved 
using risk equations. Finally, 50% of all studies were industry funded, whilst the 
general funding source was unclear in 25% of the studies included in the dataset.  
 
Table 3.6: Descriptive statistics of categorical variables tested in the pilot 
 
Variable 
category 
Level Frequency In % cumulative 
Intervention 
- Pravastatin 
- Simvastatin 
- Lovastatin 
- Fluvastatin 
- unclear 
data 
 
92 
268 
57  
1 
46 
 
19.83% 
57.76% 
12.28% 
0.22% 
9.91% 
 
19.83% 
77.59% 
89.87% 
90.09% 
100% 
CHD history 
- no 
- yes 
- both 
data 
 
117 
305 
42 
 
25.22% 
65.73% 
9.05% 
 
25.22% 
90.95% 
100% 
Time horizon 
- 0 to 5 years 
- 6 to 10 years 
- 11 to 20 years 
- > 20 years 
data 
 
43 
187 
18 
216 
 
9.27% 
40.30% 
3.88% 
46.55% 
 
9.27% 
49.57% 
53.45% 
100% 
Funding 
- Government 
- Industry 
- University 
- Industry + Government 
- No funding source 
- unclear 
Study 
 
1 
8 
1 
1 
1 
4 
 
6.25% 
50% 
6.25% 
6.25% 
6.25% 
25% 
 
6.25% 
56.25% 
62.50% 
68.75% 
75.00% 
100% 
General study design 
- IPD 
- DAM 
Study 
 
3 
13 
 
18.75% 
81.25% 
 
18.75% 
100% 
Method of effect calculation 
- CVD risk reduction 
- Cholesterol reduction 
Study 
 
11 
5 
 
68.75% 
31.25% 
 
68.75% 
100% 
Timig 
- 1992 
- 1993 
- 1995 
- 1996 
- 1997 
- 1998 
- 1999 
Study 
 
1 
1 
6 
4 
1 
2 
1 
 
6.25% 
6.25% 
37.50% 
25.00% 
6.25% 
12.50% 
6.25% 
 
6.25% 
12.50% 
50.00% 
75.00% 
81.25% 
93.75% 
100% 
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3.4.4. Results 
 
 
Table 3.7 shows results for running variance components models without 
explanatory variables in a univariate framework with INMB as response variable; 
whilst Table 3.8 contains results of running the same models as bivariate models 
with ∆C and ∆E as a vector of response variables. Model 1 in each table 
represents an empty OLS regression model, where the intercept is simply the 
pooled mean INMB (∆C, ∆E) across all studies and countries. Models 2a and 2b 
are variance components models which take into account 2-level hierarchical 
data structures with data clustered in countries (model 2.a) or studies (model 
2.b) respectively. Model 3 is a cross-classified model which considers that data is 
grouped both in studies and countries simultaneously. Though theoretically 
irrelevant, MLwiN encounters problems if the discrepancy in the error variance 
of the response variables in the bivariate model is high, which is why ∆C was 
linearly transformed by dividing it by 100 (personal communication with R. 
Pillinger, CMM Bristol).  
 
 
Table 3.7: Univariate variance components models run on pilot study data 
 
 
Model 1 
 
(single level OLS) 
Model 2.a 
(2-level model with 
data clustered in 
countries only) 
Model 2.b 
(2-level model with 
data clustered in 
studies only) 
Model 3 
(Cross-classified 
model with data 
clustered in studies 
and countries) 
Fixed part: 
Intercept 
(λ=£30.000) 
£11629 £8224 £10209 £9581 
Random part:  	(Study) -- -- 198216240 193738848  	(Country) -- 46423764 -- 341225  	(Data) 549323520 467745120 343737600 343655648 
VPC - study 
VPC – country 
VPC - data 
-- 
-- 
100% 
-- 
9.03% 
90.97% 
36.57% 
-- 
63.43% 
36.03% 
0.06% 
63.91% 
DIC 10654 10579 10436 10436 
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Table 3.8: Bivariate variance components models run on pilot study data 
 
 
Model 1 
(single level OLS) 
Model 2.a 
(2-level model with 
data clustered in 
countries) 
Model 2.b 
(2-level model with 
data clustered in 
studies) 
Model 3 
(Cross-classified model 
with data clustered in 
studies and countries) 
 
∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E 
Fixed part:  
Intercept  £87.66 0.685 £36.03 0.372 £73.34 0.510 £83.69 0.597 
Random part:  	(Study) -- -- -- -- 10185 0.632 8629 0.558  	(Country) -- -- 3289 0.320 -- -- 43.37 0.005  	(Data) 13049 0.921 5824 0.575 5028 0.427 5057 0.429 
VPC - study 
VPC – country 
VPC - data 
-- 
-- 
100% 
-- 
-- 
100% 
-- 
36.09% 
63.91% 
-- 
35.75% 
64.25% 
66.95% 
-- 
33.05% 
59.68% 
-- 
40.32% 
62.85% 
0.32% 
36.83% 
56.25% 
0.5% 
43.25% 
DIC 6538 6130 5927 5928 
 
Model 2a in Table 3.7 shows that 9.03% of the total variation is attributable to 
differences between countries, and comparing models 1 and 2a using the 
deviance information criterion (DIC) (Browne, 2012) shows that model 2a is a 
better fit. However, moving on to model 2b, which also assumes a two-level 
hierarchy, but with INMB values clustered in studies rather than countries, we 
observe that there is much stronger variation between studies than between 
countries (36.57% as opposed to 9.03%), and that this model fits the data even 
better than model 2a. Moving on to the cross-classified model 3, where INMB 
values are clustered in both studies and countries, we see that the variation 
attributable to the country-level virtually disappears. However, the DIC indicates 
that model 3 is not a better fit than model 2b. Finally, moving on to the bivariate 
framework in Table 3.8, we observe a drastic improvement in the DIC statistic for 
all model specifications. As within the univariate framework, the study-level in 
model 2.b shows much more variability than the country-level in model 2.a. Also 
in accord with the univariate model in Table 3.7, we observe that the country-
level variability virtually disappears in the cross-classified framework. Moreover, 
the VPC for studies drastically increases, with a variance component of 62.85% 
and 56.25% on study-level for ∆C and ∆E respectively.  
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Figure 3.14 confirms the findings reported in Table 3.7. The two forest plots 
provide mean INMB values (assuming λ=£30,000) and their respective 95% 
confidence intervals. The pooled estimate presented at the bottom of Figure 
3.14 is the result obtained from the empty OLS-regression model in Table 3.7. 
The figure shows considerably more variation when sorting the data by studies 
rather than countries.   
 
Figure 3.14: Variation in INMB values on country and study-level 
 
 
 
Finally, a set of explanatory variables was tested in each model (Tables 3.9 and 
3.10). All models include three variables on the data-level (mean pre-treatment 
total cholesterol level (TCL), age and percentage of females in the sample), and 
two variables on the country-level (GDP per capita and total life expectancy at 
birth). Although a range of study-level variables were tested (e.g. general study 
design, timing, funding source, or the method of effect calculation), this pilot 
study did not result in a set of study-level covariates which captures some of the 
variation across the studies included in the dataset.  
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Table 3.9: Univariate random intercepts models run on pilot study data 
 
 
Model 1 
(single level OLS) 
Model 2.a 
(2-level model with data 
clustered in countries) 
Model 2.b 
(2-level model with data 
clustered in studies) 
Model 3 
(Cross-classified model 
with data clustered in 
studies and countries) 
Fixed part: 
Intercept  £12107 £9762 £8396 £8066 
TCL 
(SE) 
-1145 
(1139) 
-1675* 
(1137) 
4013*** 
(1119) 
4031*** 
(1114) 
Age 
(SE) 
-1045*** 
(138) 
-807*** 
(138) 
-974*** 
(116) 
-976*** 
(118) 
% women 
(SE) 
-11159*** 
(2587) 
-13346*** 
(2509) 
-13876*** 
(2112) 
-13904*** 
(2106) 
GDP 
(SE) 
1.48*** 
(0.46) 
1.63*** 
(0.66) 
0.12 
(0.45) 
0.13 
(0.46) 
Life exp. at 
birth (SE) 
5358*** 
(1155) 
648 
(2034) 
364 
(1278) 
356 
(1285) 
Random part: σ3	 	(Study) --  210684928 279913696 σ3:	 	(Country) -- 55614192  413570 σ2	 	(Data) 449880704 400137568 269516096 273600160 
VPC - study 
VPC – country 
VPC - data 
-- 
-- 
-- 
-- 
12.2% 
87.80% 
43.87% 
-- 
56.13% 
50.05% 
0.07% 
49.39% 
DIC 10175 10141 9986 9985 
* 
** 
*** 
Significant at the 10%-level 
Significant at the 5%-level 
Significant at the 1%-level 
 
 
Table 3.10: Bivariate random intercepts models run on pilot study data 
 
 
Model 1 
(single level OLS) 
Model 2.a 
(2-level model with data 
clustered in countries) 
Model 2.b 
(2-level model with data 
clustered in studies) 
Model 3 
(Cross-classified model 
with data clustered in 
studies and countries) 
 
∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E 
Fixed part:  
Intercept  £87.75 0.685 £52.18 £0.482 £66.44 0.451 £67.75 0.465 
TCL 
(SE) 
-7.63* 
(4.26) 
-0.063 
(0.041) 
-11.68*** 
(3.15) 
-0.091*** 
(0.035) 
-8.50*** 
(3.16) 
0.095*** 
(0.034) 
-8.70*** 
(3.20) 
0.097*** 
(0.034) 
Age 
(SE) 
-9.70*** 
(0.51) 
-0.067*** 
(0.005) 
-7.40*** 
(0.39) 
-0.052*** 
(0.004) 
-7.82*** 
(0.33) 
-0.058*** 
(0.004) 
-7.77*** 
(0.33) 
-0.058*** 
(0.003) 
% women 
(SE) 
58.77*** 
(9.70) 
-0.176* 
(0.093) 
35.69*** 
(7.07) 
-0.328*** 
(0.079) 
29.16*** 
(5.99) 
-0.377*** 
(0.063) 
28.97*** 
(5.92) 
-0.376*** 
(0.063) 
GDP 
(SE) 
0.01*** 
(0.002) 
0.000 
(0.000) 
0.009*** 
(0.003) 
0.000 
(0.000) 
-0.001 
(0.001) 
0.000 
0.000 
-0.001 
(0.001) 
0.000 
(0.000) 
Life exp. at 
birth (SE) 
12.77*** 
(3.75) 
0.220 
(0.042) 
11.29 
(10.65) 
0.311 
(0.131) 
-1.08 
(3.61) 
0.004 
(0.038) 
-1.02 
(3.84) 
0.001 
(0.041) 
Random part:  	(Study) -- -- -- -- 6319 0.557 6859 0.628  	(Country) -- -- 3503 0.502 -- -- 12.24 0.003  	(Data) 6375 0.592 3082 0.391 2181 0.246 2174 0.245 
VPC - study 
VPC – country 
VPC - data 
-- 
-- 
100% 
-- 
-- 
100% 
-- 
53.19% 
46.81% 
-- 
56.22% 
43.78% 
74.34% 
-- 
25.66% 
69.37% 
-- 
30.63% 
75.82% 
0.14% 
24.04% 
71.69% 
0.35% 
27.96% 
DIC 6148.773 5706.022 5320.925 5321.919 
* 
** 
*** 
Significant at the 10%-level 
Significant at the 5%-level 
Significant at the 1%-level 
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As TCL is a risk factor for CVD, and as statins reduce TCL, one would expect a 
positive relationship between TCL and INMB as well as TCL and ∆E; and a 
negative relationship between TCL and ∆C due to cost of future CVD events 
avoided. For age, prediction is less straightforward. One may expect a positive 
relationship between age and INMB as older people have a higher risk of a CVD 
event. However, this relationship may also be negative beyond a certain age, as 
older patients may have less to gain from cholesterol reduction (Ward et al., 
2007). The effect of gender is clearer, as men are generally at higher risk and 
therefore likely to benefit more from statin therapy, especially in primary 
prevention (Ward et al., 2007). A positive relationship between the cost-
effectiveness of statins and GDP per capita was hypothesized, as a higher level of 
economic attainment may correlate with higher future healthcare costs 
potentially avoided through statin therapy. Likewise, a positive relationship 
between INMB and life expectancy at birth was expected, as avoiding a CVD 
event in societies with a higher life expectancy leads to more life years saved.  
 
We can see from Table 3.9 and 3.10 that the prediction for age and gender has 
been confirmed by each model. However, Models 1 and 2a in Table 3.9 show a 
non-significant negative relationship between the INMB for statins and TCL. 
Accordingly, the relationship between TCL and ∆E is negative for the bivariate 
versions of models 1 and 2.a in Table 3.10, and this negative relationship is even 
highly significant in model 2.a. The reason may be that, within the data, TCL has 
both an effect within, as well as between studies. Whilst the relationship 
between INMB and TCL may be positive within each study, it may be negative 
between studies. This could be the case, for instance, as studies which focus on 
high risk groups generally report lower INMB-values; although, within that study, 
the anticipated positive relationship between TCL and INMB still applies. Figure 
3.15 below illustrates what happens within and between studies by plotting 
INMB against TCL and highlighting the predictions for some of the studies in the 
dataset. Whilst the between study regression line is negative, the positive within 
study effect still applies. In conclusion, using a model which does not 
acknowledge that data is clustered in studies (models 1 and 2a) may simply lead 
to wrong inferences as these models do not make explicit the distinction 
between within and between study effects (Steele, 2008; Rasbash et al., 2009).  
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Another interesting finding relates to the country-level variables in the dataset. 
Using a single level OLS, one would infer that both GDP per capita and life 
expectancy at birth are positive and highly significant for INMB and ∆C, which 
accords expectations. However, in models 2b, and 3, neither GDP nor life 
expectancy at birth is significant. The reason may be that treating country-level 
variables as if they referred to the data-level spuriously inflates the amount of 
information they provide, and hence, overestimates precision (e.g. Steele, 2008). 
To obtain correct standard errors, one therefore needs to take into account the 
correct structure of the data.  
 
 
Finally, it can be seen that after covariate adjustment on data and country-level, 
about 50% of the overall variation in the data refers to the study-level in the 
univariate model 3 and country-level variation remains negligible. Even higher 
study-level variation is observed in the bivariate cross-classified model, with 
75.8% and 71.7% of the total variation attributable to differences between 
studies. Also, this model provides further insights into the differential impact of 
covariates on ∆C and ∆E. For instance, within models 2.b and 3, TCL is negatively 
related with ∆C, whilst the relationship to ∆E is positive. This accords 
expectations, as people with higher cholesterol levels have generally more to 
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gain from statin therapy which reduces ∆C through potential cost avoided and 
also increases life years saved. However, the DIC statistic does not improve 
between model 2b and 3 both in the univariate and bivariate framework.  
 
 
 
3.4.5. Discussion 
 
 
The primary aim of this pilot was to inform the design and execution of the main 
empirical analysis, which is reported in Chapter 5. The three main objectives of 
this pilot were i) to test the MLMs developed in this chapter, ii) to obtain 
feedback from the wider health economists and multilevel modeller’s 
communities, and iii) to inform the design of a data abstraction form which is 
used in a systematic literature review reported in the subsequent Chapter 4. 
Accordingly, this discussion starts off with general issues regarding the 
performance of the MLMs tested in this pilot study. Thereafter, the discussion 
addresses issues raised by participants of various conferences where this work 
was presented. This feedback proofed particularly helpful for the design and 
execution of the main empirical analysis, which is reported in Chapter 5.  
 
 
3.4.5.1. Discussing the results of this pilot study 
 
 
The analysis within this pilot study seems to confirm three key points. First, 
ignoring the clustering which occurs naturally when integrating secondary cost-
effectiveness data, induces the risk of overestimated precision and, potentially, 
wrong inferences about factors causing variability in measures of cost-
effectiveness (Steele, 2008; Rasbash et al., 2009, Hox, 2010). This can be seen by 
comparing the single level specification (model 1) with the more sophisticated 
multilevel models. Secondly, when the aim is to examine the exchangeability 
assumption between geographic domains by assessing country-level covariates, 
one cannot simply ignore the grouping which occurs naturally on study-level. 
This gets apparent from a comparison of models 2a and 2b. Finally, multinational 
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studies provide data on more than one geographic domain, which causes the 
strict hierarchy between studies and countries to break down. The cross-
classified model allows acknowledging that data is clustered in studies and 
countries simultaneously. However, the results of the two-level hierarchical 
model with measures of cost-effectiveness clustered in studies (model 2b) are 
similar to those of the cross-classified model 3, where negligible country-level 
variation and no improvement in the DIC statistic were observed. This indicates 
that the more elaborated cross-classified model is not an improvement in fit. 
Hence, particular emphasis needs to be placed on this matter to inform 
appropriate MLM structures for the main empirical analysis.  
 
 
There may be several potential causes for the observation that the cross-
classified model did not perform better than the two-level hierarchical model 
with data clustered in studies only. Some of those causes may be related to the 
pilot study data itself, others however, concern the assumptions made to fit a 
cross-classified model and may therefore lead to alternative model structures to 
be tested in the main empirical analysis. The key question is whether the explicit 
modelling of a country-level itself may proof redundant as differences between 
studies constitute an overriding source of variability in measures of cost-
effectiveness, or whether the issue of cross-classification and related 
assumptions about (in-)dependencies within the data may be responsible for the 
fact that model 3 failed to be an improvement in fit.   
 
 
A reason to defend the cross-classified model relates to the identification and 
use of appropriate covariates, especially on study-level. Whilst this pilot aimed to 
test the feasibility and potential of the analytical framework, there is 
considerable work to be done to find this set of covariates to control for 
variability in measures of cost-effectiveness. This holds especially true for study-
level covariates, as the pilot study clearly showed that this is a dominating source 
of variability in measures of cost-effectiveness. Furthermore, within the 
multilevel framework, controlling for variability on data and study-level may 
disclose further variability between countries, and hence, may constitute a pre-
requisite for making correct inferences for higher-level covariates (e.g. Sculpher 
et al., 2004; Steele, 2008; Hox, 2010). Therefore, within the main empirical 
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exercise, a much larger set of potential covariates on all levels may be tested, 
drawn from a long list of variability factors published in the relevant literature 
(Sculpher et al., 2004; Goeree et al., 2007). However, operationalizing these 
variability factors is not straightforward. There are challenges around defining, 
measuring and selecting covariates. These issues are considered in far more 
detail in the subsequent Chapter 4, which is concerned with a systematic 
literature review and data abstraction exercise to generate a dataset on the cost-
effectiveness of statins in the primary and secondary prevention of CVD.  
 
 
Secondly, as shown in Table 3.3, 14 out of 16 studies included in the pilot study 
are strictly hierarchical as they provide data on one geographic domain only. 
Only two studies (Jonsson et al., 1996; Jonsson et al., 1999) introduce the 
problem of cross-classification between studies and countries. As these two 
studies provide 127 data points (27.4% of the whole dataset), this provides 
strong justification for not simply dropping these studies and loosing valuable 
data. A second reason to defend model 3 originates from the two included cross-
classified studies themselves; though it also discloses a problem which needs to 
be addressed within the main empirical analysis. Having a closer look at these 
two studies (Jonsson et al., 1996; Jonsson et al., 1999) we learn that both 
originate from the same country, and that they use the same set of effectiveness 
and resource use data for all countries. Hence, adaptation of the cost-
effectiveness results to each jurisdiction was achieved only through the use of 
country-specific unit cost estimates. It is not uncommon in economic 
evaluations, both trial based and model based, to apply data collected in one 
country to other locations of interest, without appropriately recognizing or 
exploring issues of transferability (Barbieri et al., 2005). It is suggested that this 
may explain the lack of additional geographic variation found in the cross-
classified model. One way to address this problem in the main empirical analysis 
may be through a categorical variable capturing the degree of ‘context specificity’ 
of measures of cost-effectiveness, and the author identified a potentially 
appropriate system to classify data which has been previously developed by 
Barbieri et al. (2005). Again, further details on this matter are obtainable from 
the subsequent Chapter 4 as well as Section 5.2 of the empirical exercise, which 
is concerned with covariate adjustment on data and study-level.  
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However, if the same problem relating to the two affected studies in the pilot 
study dataset generally applies to multinational economic evaluation studies, 
this may cast into doubt key assumptions necessary to fit the cross-classified 
model. Precisely, the cross-classified model assumes dependency of data within 
studies and also within countries, whilst independence is assumed between 
studies and between countries represented in the dataset. The two multinational 
studies included in the pilot both originate from the same country, and 
adaptation of cost-effectiveness results to each jurisdiction was achieved only 
through the use of country-specific unit cost estimates; whilst all other input 
parameters were transferred from the primary target country. This practice, 
which has not been without criticism within the health economics literature 
(Barbieri et al., 2005) may lead to drastically underestimated variability in 
measures of cost-effectiveness between countries included in multinational 
studies, hence, casting into doubt the independence assumption of data for the 
countries modelled in those studies. This data may then ‘infect’ individual 
country-parameters in the cross-classified model as it is assigned to their 
respective target domains. In other words, measurements from multinational 
studies are being spread across the countries which they refer to and 
independence of data is assumed between those countries. As this data is, in 
fact, not independent, this may cause drastically underestimated country-level 
variability, and therefore redundancy of the country-level in the cross-classified 
model.  
 
 
In conclusion, an alternative model structure may be necessary which does not 
assume independence of data from multinational studies on country-level but 
still allows utilizing this data for the purposes of assessing variability factors on 
data and study-level. As mentioned, the cross-classified model assigns data from 
both single-country-studies and multinational studies to their respective study 
on study-level, hence assuming that this data is dependent within studies and 
independent between studies. Exactly the same is assumed on country-level 
though this assumption may not hold for multinational studies. Instead of simply 
dropping the affected data points which may result in a considerable loss of 
valuable data, the data from multinational studies may be ‘pooled’ in a distinct 
group on country-level, thereby removing its influence on other country-
parameters. Obviously, as some countries in the dataset are only considered 
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within those multinational studies, this would mean to lose some parameters on 
country-level. However, what is gained is the chance to analyse the full dataset 
with all studies originally includable in this exercise whilst still obtaining ‘clean’ 
country-level estimates from all the other studies in the dataset. Secondly, the 
problem of cross-classification in the data does no longer exist so that a strictly 
hierarchical three-level model with data being clustered in studies and studies 
being clustered in countries (as shown in equation (11) in Section 3.1.2.2), 
applies. However, most importantly this strategy addresses what has been 
discussed in the literature before (Ramsey et al., 2005; Barbieri et al., 2005), 
namely that multinational studies might not appropriately reflect country-level 
variability, which may also be the cause for (severely) underestimated country-
level variation observed in the cross-classified model in this pilot study.  
 
In conclusion, the main empirical analysis, which is reported in Chapter 5, starts 
off with an exercise on the appropriate MLM structure for analysing the data 
obtained from the systematic literature review and data abstraction exercise. 
One key aspect of this exercise is to investigate the appropriateness of the 
independency assumption of multinational study data on country-level, which 
leads to a direct comparison of the cross-classified model, and an alternative 
three-level hierarchical model structure which clusters multinational study data 
in a separate group on country-level.  
 
 
3.4.5.2. Feedback from presenting this pilot study to a wider health 
economics and multilevel modelling audience 
 
 
Next to testing the MLMs theoretically developed in this chapter, a second 
objective of this pilot study was to generate feedback on the proposed method 
of secondary data integration from published economic evaluation studies to 
analyse factors causing variability in international cost-effectiveness data from a 
wider health economics and multilevel modelling audience. For this reason, the 
pilot study was presented at a number of seminars and conferences. The 
remainder of this section discusses the invaluable feedback obtained.  
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One of the most valuable comments received relates to the above discussion 
regarding the appropriate MLM structure. In particular, a three-level hierarchical 
model was proposed instead of the cross-classified data-structure because of the 
negligible country-level variation in the cross-classified model and the suspicion 
that this might be due to inappropriate assumptions regarding the independence 
of data from multinational studies on country-level. At the time of carrying out 
the pilot study, the author was not clear on how to fit a three-level hierarchical 
model to the data without dropping measurements from multinational studies. 
However, before completing the systematic literature review and data 
abstraction exercise for the main empirical analysis, alternative model structures 
were developed which acknowledge that data from multinational studies is not 
independent on country-level. These data structures were subsequently tested 
and their performance compared to the cross-classified framework. Results are 
reported in great detail in Section 5.1 of the empirical chapter.  
 
 
The impact of shrinkage on study and country parameters may constitute an 
issue for the integration of secondary data from international economic 
evaluation studies. Shrinkage partly depends on the number of observations 
within a particular group, so that the ‘gravity’ of a study increases with the 
number of cost-effectiveness estimates provided to the overall dataset. If the 
unit of observation is an individual within a randomized controlled trial, this 
makes perfect sense as the weight of a study is proportional to the number of 
patients under assessment. However, as the data for this exercise stems in part 
from decision analytic modelling studies, the respective number of cost-
effectiveness estimates may only reflect the rigor with which subgroup and 
sensitivity analyses have been conducted and reported within a particular study. 
As a result, MLMs may bias towards those studies which report in greater detail 
on the results of subgroup or sensitivity analysis, irrespective of the quality of the 
particular study or the strength of evidence underlying the input data for 
decision analytic models. This important issue is addressed in great depth in 
Section 5.1.5 of the empirical chapter.  
 
 
As a further development of the MLMs tested within the pilot study, it was 
suggested to consider fitting random slopes to acknowledge that the relationship 
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between measures of cost-effectiveness and explanatory variables may be 
different for different studies (or countries) in the dataset. Moreover, fitting 
random slopes to the data allows modelling the variation in international cost-
effectiveness data directly as a function of explanatory variables. At the time of 
carrying out the pilot study, the author did not yet succeed in fitting random 
slopes models, however, this has been subsequently achieved within the main 
empirical analysis and details are reported in Section 5.4 of the empirical 
chapter.  
 
 
Finally, a number of comments received relate to the impact of particular 
variability factors on the results of economic evaluation studies. For instance, the 
impact of ‘time’ on the cost and efficiency of the intervention, differential 
discount rates, and further methodological characteristics of studies under 
assessment were mentioned. For this reason, the following Chapter 4, which is 
concerned with a systematic literature review and data abstraction exercise, 
reports on the development of a data abstraction form, which is based on a long 
list of potential variability factors as obtained from the relevant economic 
evaluation literature (Sculpher et al., 2004; Goeree et al., 2007). A key objective 
of the main empirical analysis in Chapter 5 is then to test these variability factors 
within the MLM framework and to ascertain a set of covariates which controls 
for part of the variability in measures of cost-effectiveness on each level of the 
model hierarchy.  
 
 
Further comments received from researchers involved with economic evaluation 
in health, MLM, or both, which are not particularly related to the design and 
execution of the main empirical analysis, may be discussed later in the overall 
discussion section in Chapter 6. The following chapter reports on a systematic 
literature review and data abstraction exercise to populate a dataset for the 
main empirical analysis. As the pilot study before, this exercise focusses on the 
cost-effectiveness of statins in the primary and secondary prevention of CVD. 
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4. Systematic literature review, data abstraction and 
‘genealogy’ study 
 
 
The previous chapter was concerned with the MLM methods relevant for the 
empirical exercise within this project. In Section 3.1 of Chapter 3, a number of 
MLM structures were theoretically developed, including a three-level hierarchical 
model with measures of cost-effectiveness clustered in studies and countries, as 
well as a two-level cross-classified model where the hierarchy between studies 
and countries breaks down due to data from multinational studies. Then, in 
Section 3.2., the dependent variable, or a vector thereof, was specified. INMBs 
were identified as the appropriate response variable in a univariate model, and 
the INMB statistic was decomposed into its stochastic components ∆C and ∆E in 
a bivariate MLM. Finally, the models developed in Chapter 3 were tested in a 
pilot study utilizing data from 16 international economic evaluation studies on 
the cost-effectiveness of statins in the primary and secondary prevention of CVD, 
and this was reported and discussed with particular emphasis on the design of 
the main empirical exercise in Section 3.4 of the previous chapter.  
 
 
In this chapter, the primary aim is to develop a dataset to carry out this empirical 
exercise. Specifically, the chapter begins with a systematic literature review on 
the cost-effectiveness of statins in the primary and secondary prevention of CVD. 
This intervention was chosen as it has been extensively researched in the past, 
meaning that a sufficient number of includable studies and geographic locations 
is hypothesized to be present in the data to justify the assumption of random 
parameters on study and country-level (Snijders, 2005). This assumption of 
random parameters on higher levels is crucial for fitting multilevel models 
(Snijders, 2005).  
 
 
After carrying out a systematic literature review, the second task to populate a 
dataset for the main empirical analysis is to develop a data abstraction form to 
collect data on the response variables as well as covariates to be tested on data 
and study-level. This process starts with reviewing the relevant literature to 
obtain a long list of factors potentially causing variability in international cost-
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effectiveness data. Subsequently, variability factors are operationalized and a 
data abstraction form is developed. This form, which was also extensively tested 
and improved upon during the pilot study reported in the previous chapter, is 
used to obtain data from the studies includable in this empirical exercise. Details 
on this process are reported in Section 4.2.  
 
 
Finally, the systematic literature review, which resulted in 67 studies includable 
in this empirical exercise, showed that there may be a number of potential 
relationships between published economic evaluation studies. Such relationships 
may relate to common authorship, partly or fully recycled models, or the use of 
identical data sources, to name a few. As a result, the independency assumption 
of data between studies may be violated analogously to the problems introduced 
by multinational study data on country-level as discussed within the pilot study. 
For this reason, an explorative analysis of the ‘genealogy’ of economic evaluation 
studies is reported to either inform alternative data structures, or at least, to 
derive further covariates encoding potential relationships between economic 
evaluation studies. This genealogy study differs from the other two sections of 
this chapter as it addresses an important research question in its own right 
rather than being a pure prerequisite for the main empirical analysis. Results of 
this explorative exercise into the genealogy of economic evaluation studies are 
reported in Section 4.3 of this chapter.  
 
 
 
4.1. Systematic literature review on the cost-effectiveness 
of statins for the primary and secondary prevention of 
CVD 
 
 
The primary aim of this systematic review is to populate a dataset for the 
empirical analysis. As the MLM methodology applied in the empirical exercise 
relies on the assumption of random parameters on study and country-level (e.g. 
Spiegelhalter et al., 2004), decisions were made in order to achieve sufficient 
numbers of higher-level units for this assumption to hold. First, with statins for 
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the primary and secondary prevention of CVD, the author chose an extensively 
studied intervention area for the purposes of this project. Secondly, a highly 
sensitive search strategy was developed to ensure sufficient numbers of 
includable studies applicable to as many countries as possible. However, this 
does not mean that any study concerned with the cost-effectiveness of statins in 
the primary and secondary prevention of CVD is includable in this systematic 
review. Rather, a number of strict inclusion and exclusion criteria were defined 
to ensure that only studies providing information in a format that is suitable for 
secondary data integration as laid out in the MLM methods Chapter 3 would 
enter this exercise. The following Section 4.1.1 outlines the search strategy as 
well as inclusion and exclusion criteria for this systematic review. Subsequently, 
search results are presented in Section 4.1.2. The second part of this chapter is 
concerned with the development of a data abstraction form to populate a 
dataset for the main empirical analysis within this project. As part of this section, 
descriptive statistics of studies included in this exercise are reported. The final 
Section 4.3 of this chapter focusses on the genealogy of economic evaluation 
studies.   
 
 
4.1.1. Review Methodology 
 
 
To devise a highly sensitive search strategy which identifies a large number of 
includable studies on the cost-effectiveness of statins in the primary and 
secondary prevention of CVD, a number of existing systematic review papers on 
this intervention area were consulted to learn about respective search strategies 
applied. Probably one of the most rigorous reviews within this area was 
undertaken by Ward et al. (2007), who aimed to ‘identify and evaluate studies 
exploring the cost-effectiveness of statins in primary and secondary prevention of 
CHD and CVD in the UK.’ Though the literature review in this thesis is not limited 
to a UK setting, some principles from Ward et al. (2007) were adapted and 
developed further for the purposes of this project.  
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Table 4.1: Databases searched 
 
Search 
Engine 
Databases searched Comments 
Ovid - British Nursing Index 
- Medline 
- Search performed April 15
th
, 
2011 
SCOPUS - Embase 
- Medline 
- Science Direct 
- Search performed April 16
th
, 
2011 
- Medline was not dropped from 
this search as the SCOPUS 
search engine differs from Ovid 
which may have led to 
differences in search results 
Ebsco Host - Academic Search Complete 
- Busines Source Premier 
- CINAHL 
- Search performed April 16
th
, 
2011 
HEED  - Search performed April 19
th
, 
2011 
CRD - Database of Abstracts of Reviews of Effects 
(DARE) 
- Health Technology Assessment Database 
(HTA) 
- NHS Economic Evaluation Database (NHS EED) 
- Search performed April 19
th
, 
2011 
Cochrane 
Library 
- Cochrane Database of Systematic Reviews 
(CDSR) 
- Cochrane Central Register of Controlled Trials 
- Cochrane Methodology Register 
- Database of Abstracts of Reviews of Effects 
(DARE) 
- Health Technology Assessment Database 
(HTA) 
- NHS Economic Evaluation Database (NHS EED) 
- Search performed April 21
th
, 
2011 
- Cochrane database of systematic 
reviews was searched as review 
papers were hand searched for 
relevant references 
- DARE, HTA and NHS EED were 
included as the Cochrane search 
engine differs from CRD, which 
may have led to differences in 
search results 
Pubmed  - Search performed April 19
th
, 
2011 
- Though Medline and Pubmed 
are essentially identical, a 
separate search was performed 
in PubMed as a different search 
engine applies which may have 
led to differences in search 
results 
Web of 
knowledge 
- Web of Science 
- Biosis Reviews 
- Search performed April 19
th
, 
2011 
JStor  - Search performed April 19
th
, 
2011 
- Search results subsequently 
dropped from further 
assessment 
Wiley  - Search performed April 20
th
, 
2011 
- Search results subsequently 
dropped from further 
assessment 
 
 
Literature searches were performed between April 15th and April 21st 2011 using 
the databases listed in Table 4.1 above. Some databases may have been 
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searched more than once as they form part of several search engines used. 
However, as search engines may differ, so may search results, which is why it 
was decided not to drop the respective search results but rather to deal with 
potential duplicates after exporting results to the reference managing software 
RefWorks. Two databases (Jstor and Wiley) were initially searched but search 
results were subsequently dropped from further analysis (more details on this 
matter are available in the next section). For Medline searched via OVID, the 
same search strategy as developed by Ward et al. (2007) was applied, though 
results were not limited by geographic setting or publication year. For other 
search engines, the search strategies are reported in Appendices 4.1 to 4.10.  
 
 
As mentioned above, no country or language restriction was initially applied to 
the literature search as it was aimed to represent as many geographic domains 
as possible in the resulting dataset. However, at a later stage, it was decided to 
drop papers which were not written in either English or German language as 
resources to translate studies written in other languages were not available. As 
with geographic origin, no time restriction was placed on the literature search as 
it was aimed to reflect the whole continuum of statin related cost-effectiveness 
literature in the dataset and as ‘timing’ may be one potential explanatory within 
the main empirical analysis.  
 
 
Only studies following an incremental approach were includable in this review 
exercise, and as comparator technology, only i) ‘doing nothing, ii) ‘other statin’ or 
iii) ‘same statin in different dosage’ were considered. Studies which compared 
the intervention to any combination of statins and other technologies (e.g. statin 
vs. statin plus dietary advice, statin vs. statin plus ACC, or statin vs. statin plus 
antihypertensive drug), were not includable as differences in combinations of 
therapies potentially introduce further variability in measures of cost-
effectiveness which cannot be easily controlled for through explanatory variables 
within the MLM framework.  
 
 
Even If the appropriate intervention and comparator technologies were 
considered, studies were only includable if the ICER or INMB statistic was 
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decomposed into its stochastic components ∆C and ∆E. Otherwise, it may not be 
possible to either re-combine ∆C and ∆E to INMBs with a common threshold 
value λ for the univariate multilevel model or to run a bivariate model with ∆C 
and ∆E as a vector of response variables. Further, studies were only includable if 
effectiveness was measured either in life years saved (LYS) or quality adjusted 
life years (QALYs). Hence, studies reporting intermediate outcomes such as 
cholesterol reduction or change in cardiovascular events due to statin prevention 
were not includable in this review exercise.  
 
 
Studies utilizing individual patient data and decision analytic modelling studies 
were suitable for this exercise. In addition, studies which adapted published 
results to other geographic settings were includable if results were not simply 
‘currency adjusted copies’ of the original data. Finally, only adult populations 
were considered for this systematic review. 
 
 
In contrast to other systematic reviews, this exercise did not a priori define a 
minimum set of methodological requirements. There were several reasons for 
this. First, methods standards may differ between geographic domains, so that it 
may be difficult to define a particular set of minimum requirements without 
biasing search results towards particular settings. Secondly, the main empirical 
exercise aims to control for variability factors on different levels of the data 
hierarchy through the assumption of conditional independence (e.g. Drummond 
et al., 2009). Hence, differences in study methods may be partly controlled for 
through the inclusion of appropriate covariates on data and study-level. Finally, it 
was aimed to explicitly rate study quality through the use of ‘QHES’, which is a 
validated quality checklist for economic evaluation studies in health (Ofman et 
al., 2003). The results of this quality assessment may then be used as a further 
explanatory in the MLM framework. More details on the use of QHES within this 
empirical exercise are available from Section 4.2 of this chapter, which is 
concerned with the development of an abstraction form to populate a dataset 
for the main empirical exercise of this project.  
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4.1.2. Search Results 
 
 
Figure 4.1 below shows the search algorithm applied in this systematic literature 
review. After searching individual databases, 4589 search results were exported 
to the reference managing software ‘RefWorks’. Though review papers, meta-
analyses, opinion pieces etc. are not includable in the empirical, they were not a 
priori excluded from electronic searches. Rather, the RefWorks search facility 
was used after importing results to filter out relating references. This resulted in 
788 hits. Secondly, titles and abstracts of these 788 references were screened 
and de-duplicated, resulting in a list of 33 highly relevant review papers or meta-
analyses. Finally, 28 review papers which were accessible via Brunel University 
subscriptions or inter library loans, were hand searched for potentially relevant 
references of original research articles on the cost-effectiveness of statins in the 
primary and secondary prevention of CVD (references of these 28 papers are 
available from Appendix 4.11). This resulted in a list of 90 references.  
 
 
One advantage of first hand searching systematic review papers for potentially 
relevant references is that one may use results to obtain an indication of 
‘sensitivity’ of the initial electronic search performed. If an electronic search picks 
up a high number of references also obtained from hand searching review 
papers, this search may be deemed as fairly sensitive. In total, 77 of 90 (85.56%) 
references obtained from hand searching relevant review papers were also 
picked up by electronic searches. However, some databases provided much 
better results than others, with the most successful searches performed in 
PubMed and OVID. Conversely, two databases (Jstor and Wiley) picked up less 
than 2% of references obtained from hand searching review papers. Hence, 
these databases may not focus on research in the relevant area, which is why the 
respective search results were dropped from further assessment and omitted in 
the search algorithm below.  
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Figure 4.1: Search Algorithm  
 
 
 
 
 
 
 
*    Without Medline   
**  England/Wales, Scotland, and UK as separate geographic entities  
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After screening out and hand searching relevant review papers, 3757 hits 
remained in the database. These search results were first de-duplicated, 
resulting in 1793 references. Secondly, titles and abstracts of these 1793 
references were screened twice. A first screening round reduced references to 
430, and a second - more thorough - screening of titles and abstracts reduced 
potentially relevant references to 143. Subsequently, a full text review was 
conducted of the 143 references from electronic searches plus the 90 references 
previously obtained from hand searching relevant systematic review papers, 
resulting in 233 references eligible for full text review. Of these 233 references, a 
further 166 were excluded. 96 papers were excluded as they did not constitute 
an original research article or report. Five papers did not perform a cost-
effectiveness or cost-utility analysis. A further 21 papers did not decompose the 
ICER or INMB into its components ∆C and ∆E, and twelve papers did not report 
health outcomes in terms of LYS or QALYs. 15 papers focused on the wrong 
population, intervention or comparator and seven papers were written in any 
other language than English or German. Finally, ten papers were excluded for 
other reasons, most commonly the fact that access was neither provided 
through Brunel University subscriptions nor inter library loans from the British 
Library. As a result, 67 studies were eligible for this empirical exercise, of which 
39 studies were initially obtained from hand searching systematic review papers 
for potentially relevant references, and a further 28 references from electronic 
searches. References of includable studies are available from Appendix 4.12.  
 
 
The 67 studies obtained were subsequently abstracted to populate a dataset for 
the main empirical analysis, which is reported in Chapter 5. To do so, a data 
abstraction form needed to be developed and tested which ascertains 
information on the response variables as well as potential variability factors for 
measures of cost-effectiveness on data and study-level. The development of this 
data abstraction form is reported next in Section 4.2 of this chapter, which also 
includes some key descriptive statistics of the studies included in this systematic 
review exercise. Finally, Section 4.3 of this chapter is concerned with an exercise 
into the ‘genealogy’ of international economic evaluation studies on the cost-
effectiveness of statins in the primary and secondary prevention of CVD.  
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4.2. Developing a data abstraction form and populating a 
dataset for the main empirical analysis 
 
 
The previous section described how studies includable in the empirical exercise 
were identified through a systematic literature review on the cost-effectiveness 
of statins in the primary and secondary prevention of CVD. This section describes 
how a data abstraction form to populate a dataset for the empirical analysis was 
developed. In general, this exercise began with screening the relevant literature 
for potential variability factors for measures of cost-effectiveness to obtain a 
long list of potential variables on the abstraction form. Secondly, the variability 
factors mentioned in the literature were operationalized so that data could be 
abstracted in a format which is suitable for quantitative analysis in the MLM 
framework. The third step was to test the resulting data abstraction form within 
the pilot study which was previously reported in Chapter 3.4. Experiences from 
the pilot study were then used to improve upon the data abstraction form. In 
some instances that meant to change the scale of a continuous variable, or to 
add or delete categories of categorical variables. In other cases, experiences 
from the pilot study led to dropping variables either because studies failed to 
report the relevant data or because responses would not vary within and 
between studies in the dataset. Finally, the resulting abstraction form was used 
to obtain data from the 67 studies includable in this empirical exercise.  
 
 
The following Section 4.2.1 reports on the development and use of the data 
abstraction form as it was outlined above. Subsequently, descriptive statistics of 
studies included in this empirical exercise are reported in Section 4.2.2. Finally, in 
Section 4.3, the data obtained is used within an empirical exercise on the 
‘genealogy’ of economic evaluation studies on the cost-effectiveness of statins in 
the primary and secondary prevention of CVD.  
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4.2.1. Development and use of a data abstraction form 
 
 
The development of a data abstraction form started off from a long list of factors 
potentially causing variability in measures of cost-effectiveness as previously 
discussed within the relevant literature. Two papers were of utmost relevance, 
namely Sculpher et al. (2004) and Goeree et al. (2007). Both papers 
systematically reviewed the economic evaluation literature in health to obtain 
factors which may be responsible for variation in international cost-effectiveness 
data. Sculpher et al. (2004) obtained a list of 27 variability factors relating to a) 
the patient, b) the clinician, c) the healthcare system or d) wider socioeconomic 
factors. Goeree et al. (2007) confirmed and updated the list of Sculpher et al. 
(2004). Their systematic literature review resulted in 77 unique variability factors 
based on characteristics of a) the patient, b) the disease, c) the provider, d) the 
healthcare system and e) methodology used in the analysis. The results of 
Goeree et al. (2007) constitute the ‘long list’ of potential variability factors on 
which the development of the data abstraction form is based upon. It is 
acknowledged that the ‘space of variability factors’ is generally unlimited, so that 
factors neither mentioned by Sculpher et al. (2004) nor by Goeree et al. (2007) 
may also be important. However, as their work is supposed to represent a 
comprehensive list of those factors which other health economists previously 
suspected to be responsible for variability in cost-effectiveness data, their results 
may be regarded as the most appropriate starting point for this analysis.   
 
 
Though Sculpher et al. (2004) and Goeree et al. (2007) made an invaluable 
contribution to the field, the variability factors mentioned in their papers needed 
further refinement to be practicable within this data abstraction exercise. Some 
factors mentioned are somewhat ‘fuzzy’, not measurable without further 
adjustment or simply not applicable to the intervention area of statins in the 
primary and secondary prevention of CVD. In addition, a number of variability 
factors specifically relate to variation between geographic domains. These 
factors are considered explicitly within Section 5.3 of the empirical chapter 
where country-level variability is assessed within the MLM framework. However, 
for the purposes of developing a data abstraction form for the studies included in 
this empirical exercise, country-level characteristics were not considered as the 
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relevant data may not be obtainable from the majority of studies but rather from 
alternative data sources like WHO, World Bank or OECD databases. In terms of 
the variability factors reviewed by Goeree et al. (2007), this relates specifically to 
the group of ‘healthcare system characteristics’ (see Figure 4.2 below).  
 
Figure 4.2: Flow chart showing how the data abstraction form was developed 
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Table 4.2: Response variables, ID-variables and covariates on data-level 
 
Variable 
name 
Description Level Nature of variable 
Response variables 
Incr_effect incremental effectiveness of intervention Dependent variable continuous 
Incr_cost incremental cost of intervention in 2010 £-Sterling Dependent variable continuous 
INMB INMB in 2010 £-Sterling Dependent variable continuous 
Level-IDs 
country_id Which country does the CE-estimate refer to? Level 3 ID (country) Level ID no covariate 
Study_id Which study does the CE-estimate refer to? Level 2 ID (study) Level ID no covariate 
Data_id Data-level identifier Level 1 ID (data) Level ID no covariate 
Group 1a  covariates: Patient and disease characteristics 
age_cat What was the age of the sub-population modelled Level 1 (data) ordered, categorical 
gender_cat 
What was the gender of the population (percentage of men in 
population) 
Level 1 (data) ordered, categorical 
CVD_hist What was the CHD related medical history Level 1 (data) unordered, categorical 
Tcl What was the total cholesterol level baseline Level 1 (data) Continuous 
Hdl What was the high density lipoprotein level at baseline Level 1 (data) Continuous 
Ldl What was the low density lipoprotein level Level 1 (data) Continuous 
Hypert What was the percentage of hypertensive people in the subsample Level 1 (data) Continuous 
Sbp What was the mean systolic blood pressure at baseline Level 1 (data) Continuous 
Diab What was the percentage of diabetic patients at baseline Level 1 (data) Continuous 
smokers What was the percentage of smokers at baseline Level 1 (data) Continuous 
risk_cat What was the risk category of the subsample Level 1 (data) ordered, categorical 
Group 1b covariates: Intervention and comparator 
intervention What was the brand name of the intervention drug? Level 1 (data) unordered, categorical 
comparator What was the brand name of the comparator drug? Level 1 (data) unordered, categorical 
act_comp Was the comparator no active intervention? Level 1 (data) unordered, binary 
tdd_int What was the total daily dose of the intervention Level 1 (data) ordered, categorical 
tdd_comp What was the total daily dose of the comparator Level 1 (data) ordered, categorical 
Cost-int What are the annual drug cost of the intervention in 2010 £-Sterling Level 1 (data) Continuous 
Unitcost_int What was the unit cost of the intervention Level 1 (data) Continuous 
Cost_comp What are the annual drug cost of the comparator in 2010 £-Sterling Level 1 (data) Continuous 
Unitcost_co
mp 
What was the unit cost of the comparator Level 1 (data) Continuous 
Incr_cost What was the incremental annual drug cost  of the intervention Level 1 (data) Continuous 
Group 1c covariates: Methodological characteristics on data-level 
outc_measu
re 
How was health outcome reported in the study Level 1 (data) unordered, binary 
elicitation If QALYS were used, what was the method of preference elicitation? Level 1 (data) unordered, categorical 
population 
If QALYS were used, what do the utility values reflect (patient / 
population values) 
Level 1 (data) unordered, categorical 
DRC What was the discount rate on costs  Level 1 (data) Continuous 
DRB What was the discount rate on benefits Level 1 (data) Continuous 
duration What was the treatment duration modelled Level 1 (data) ordered, categorical 
extrapol Was there any extrapolation beyond the latest follow up? Level 1 (data) unordered, binary 
horizon What was the time horizon? Level 1 (data) ordered, categorical 
hor_eq_dur Does the time horizon equal the treatment duration? Level 1 (data) unordered, binary 
Persp_rep 
What was the study perspective as reported by the authors of the 
article 
Level 1 (data) unordered, categorical 
Persp_cost_
concl 
What was the study perspective on costs as concluded by the reviewer Level 1 (data) unordered, categorical 
Persp_ben_c
oncl 
What was the study perspective on outcomes as concluded by the 
reviewer 
Level 1 (data) unordered, categorical 
data_class How was the datapoint classified Level 1 (data) unordered, categorical 
basecase Was the data point result of a base case or sensitivity analysis? Level 1 (data) unordered, binary 
source_effec
ts 
From which source (trial, meta-analysis) was effectiveness data taken 
from 
Level 1 (data) unordered, categorical 
Barbieri_sco
re_1 
How context specific is the CE estimate judged from the input 
parameters 
Level 1 (data) unordered, categorical 
Barbieri_sco
re_2 
How context specific is the CE estimate judged from the input 
parameters 
Level 1 (data) unordered, categorical 
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Table 4.3: Covariates on study-level 
  
Variable name Description Level Nature of variable 
Group 2a covariates: General Study characteristics 
language In which language was the paper written? Level 2 (study) unordered, binary 
paper_origin 
In which country was the paper written (if authors from 
several jurisdictions were involved, where is the lead author 
based? 
Level 2 (study) unordered, categorical 
Timing What is the timing of the economic evaluation Level 2 (study) unordered, categorical 
fund_inst What was the primary source of funding (institution) Level 2 (study) unordered, categorical 
fund_man 
If funding source was private, which manufacturer was 
involved? 
Level 2 (study) unordered, categorical 
Author_group
_long 
Variable which encodes relationships between published 
papers in terms of common authorship 
Level 2 (study) unordered, categorical 
Author_group
_short 
Variable which encodes relationships between published 
papers in terms of common authorship 
Level 2 (study) unordered, categorical 
Group 2b covariates: Methodological characteristics on study-level 
gen_des What was the general study design? Level 2 (study) unordered, categorical 
prim_des If primary modelling, what was the specific study design? Level 2 (study) unordered, categorical 
sec_des If secondary modelling, what was the specific study design Level 2 (study) unordered, categorical 
effect_calc Method of effect calculation Level 2 (study) unordered, categorical 
multinational Was the study multinational Level 2 (study) unordered, binary 
infl_adj Were cost estimates in the model adjusted for inflation? Level 2 (study) unordered, categorical 
adj_method 
If cost estimates were adjusted for inflation, what was the 
adjustment method 
Level 2 (study) unordered, categorical 
cur_conv Was currency converted Level 2 (study) unordered, binary 
conv_method 
If currency was converted, what was the conversion method 
used by the authors? 
Level 2 (study) unordered, categorical 
scope What was the scope of assessment Level 2 (study) unordered, categorical 
Group 2c covariates: Study Quality indicators 
qhes_cata 
What was the overall QHES category given a strict 
application of the QHES criteria 
Level 2 (study) ordered, categorical 
qhes_catb 
What was the overall QHES category given a pragmatic 
application of the QHES criteria 
Level 2 (study) ordered, categorical 
Qhes_conta 
What was the overall QHES score given a strict application of 
the QHES criteria? 
Level 2 (study) continuous 
Qhes_contb 
What was the overall QHES score given a practicable 
application of the QHES criteria? 
Level 2 (study) continuous 
 
 
Further, experiences from the pilot study showed that studies on the cost-
effectiveness of statins in the primary and secondary prevention of CVD usually 
do not explicitly report information on healthcare providers involved in 
delivering the intervention. At most, studies considered a fixed cost-component 
per annum for GP involvement in screening appropriate patients, titration and 
monitoring. In addition, some studies considered a lump sum for distributing 
statins through pharmacies. However, in both cases, this forms part of the 
annual cost of intervention, and is therefore considered as an ‘intervention 
characteristic’. Beyond this, provider characteristics were generally not reported 
and respective variability factors were therefore dropped from further 
consideration after carrying out the pilot study.  
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On the other hand, neither Sculpher et al. (2004) nor Goeree et al. (2007) 
consider a separate group of variability factors relating to the intervention and 
the comparator under assessment. However, even for a relative homogeneous 
group of agents as it may be the case for statins in the primary and secondary 
prevention of CVD, differences may exist which feed through to the cost and / or 
effectiveness of treatment. Additionally, total daily dosages may differ between 
patients, which again may cause variability in measures of cost-effectiveness. For 
these reasons, variables entered the abstraction form relating to the statins 
under assessment, total daily dosages, as well as unit cost and annual drug cost 
of both intervention and comparator.  
 
 
For the remaining variability factors mentioned by Goeree et al. (2007) relating 
to a) the patient, b) the disease and c) methods used in health economic 
evaluations, literature was consulted to define variables for the data abstraction 
form which are suitable for subsequent quantitative analysis within the MLM 
framework. Patient and disease characteristics potentially causing variability in 
the cost-effectiveness of statins were operationalized by consulting literature on 
CVD risk factors and risk estimation. There is a vast literature available on CVD 
risk factors and a number of validated tools are available to estimate patients 
CVD related risk over a certain time period. Probably the most prominent CVD 
risk estimation tool is the Framingham risk equation (Anderson et al., 1991). 
However, in recent years the Q-Risk tool (Hippisley-Cox et al., 2007; Hippisley-
Cox et al., 2008) has gained popularity (Cooper et al., 2008). Hence, risk 
equations were used to ascertain a long list of patient and disease characteristics 
potentially relevant for the cost-effectiveness of statins in the primary and 
secondary prevention of CVD. This long list of patient and disease characteristics 
was then tested in the pilot study, where data was abstracted from 16 studies 
previously identified by Franco et al. (2005). It turned out that some covariates 
included in risk equations are generally not (or at least not frequently) reported 
in the statins related cost-effectiveness literature. This holds, for instance, for 
left ventricular hypertrophy (Anderson et al., 1991), BMI (Hippisley-Cox et al., 
2008), Family history of CVD (Hippisley-Cox et al., 2007; Hippisley-Cox et al., 
2008), social status, social deprivation (Hippisley-Cox et al., 2007; Hippisley-Cox 
et al., 2008), a townsend deprivation score (Hippisley-Cox et al., 2008), ethnicity 
(Hippisley-Cox et al., 2007; Hippisley-Cox et al., 2008), as well as rheumatoid 
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arthritis, chronic renal disease and atrial fibrillation  (Hippisley-Cox et al., 2008). 
As a result, only those patient and disease characteristics listed in Figure 4.2 as 
well as Table 4.2 above remained part of the data abstraction form, whilst 
variables less frequently reported were dropped from further analysis. The final 
data abstraction form for this empirical exercise is provided in Appendix 4.13. 
 
 
The data collected on individual patient and disease characteristics of patient 
subgroups subsequently allowed applying the original Framingham risk equation 
(Anderson et al., 1991) to obtain an overall score on 10 year CVD related risk. 
Framingham was chosen as the risk equation is - in contrast to QRISK I and II - 
freely available so that a model could be set up in MS Excel and, secondly, as the 
pilot study showed good availability of data for most risk factors considered in 
this risk equation. In addition, Framingham is probably still the most prominent 
tool in the literature, and even though alternatives exist, its use is still 
recommended by NICE (Cooper et al., 2008). Initially, it was intended to use the 
resulting estimate of 10 year CVD risk as a further continuous explanatory within 
subsequent multilevel analysis. However, there were several obstacles:  
 
 
First, not all studies included in the systematic review report the data required to 
populate the Framingham equation. Hence, if data was not obtainable from a 
cost-effectiveness study included in the systematic review exercise, alternative 
data sources were considered to fill gaps in the dataset. For instance, literature 
on RCTs providing data to populate the economic model proved particularly 
helpful to obtain missing information on patient subgroups considered. 
However, if neither the study included in this review exercise nor accompanying 
literature provided the data required to apply the Framingham risk equation, 
assumptions had to be made about the data. For instance, if data on TCL, HDL 
and triglycerides was available, but authors did not report an estimate of pre-
treatment LDL, the ‘Friedewald Function’ (Friedewald et al., 1972) was used to fill 
this gap. Likewise, if only diastolic blood pressure (DBP) was reported, 
assumptions were made about systolic blood pressure (SBP). In particular, if DBP 
was elevated, it was assumed that the same holds for SBP and vice versa. If 
neither DBP nor SBP was reported, but a patient’s hypertension status was 
positive, an elevated SBP was assumed. Finally, diabetes, smoking and 
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hypertension status were considered as continuous variables capturing the 
proportion of patients being affected by any of the stated conditions. Further 
details on the variables considered in the data abstraction form and the way they 
were operationalized for the purposes of this empirical analysis are available 
from Tables 4.2 and 4.3 above and Appendix 4.13.  
 
 
After filling gaps in the data for patient and disease factors, the Framingham risk 
equation was used to estimate patient subgroups 10-year CVD related risk. 
However, the resulting score was not applicable to data points which referred to 
secondary prevention with statins as Framingham is only valid for patients who 
have not experienced a CVD event (Anderson et al., 1991). A previous CVD event 
drives the subsequent CVD risk so that results from the Framingham risk 
equation, which does not take into account CVD history, are invalid (Anderson et 
al., 1991). Unfortunately, this precludes the chance to use the resulting risk 
estimate as a continuous variable in the MLM framework. As an alternative, a 
categorical variable was defined with categories relating to a 10 year CVD risk of 
<10% (very low), 10% to <20% (low), 20% to <30% (medium), 30% to <40% 
(high), >40% (very high) and ‘secondary prevention’. The resulting variable ‘RISK-
CAT’ is tested as an explanatory in the MLM framework in Chapter 5.2. 
 
 
Finally, methodological characteristics as mentioned by Goeree et al. (2007) 
were operationalized using standard health economics textbooks and key 
publications on economic evaluation in health. One source which proved 
particularly useful was the ISPOR online tool which summarizes HTA guidelines 
around the world (ISPOR, 2011). Five key challenges relate to the variability in 
cost-effectiveness data as a result of differences in study methods. First, some 
methods may only change between studies included in the dataset (for instance 
the general study design), whilst other methodological characteristics may also 
change within one study (for instance the discount rate on costs and effects). The 
MLM framework offers an excellent opportunity to assess the impact of different 
methods on data and study-level on measures of cost-effectiveness as it allows 
inclusion of covariates on each hierarchical level. As a result, the data abstraction 
form contains methodological characteristics on data and study-level 
respectively (Figure 4.2 above and Appendix 4.13).  
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Secondly, it is perhaps impossible to encode all study characteristics potentially 
causing variability in measures of cost-effectiveness within and between studies 
in terms of covariates for quantitative analysis. As a result, the data abstraction 
form may be regarded as an attempt to capture the most important 
methodological characteristics based upon those variability factors which have 
been previously discussed by other researchers. Accordingly, the reader may 
think of further variability factors relating to study methodology for future 
analysis. Presenting pilot study results at various conferences and seminars 
helped to expand upon the list of potential explanatory variables to consider in 
the main empirical analysis. Hence, this exercise aims to reflect both those 
factors previously mentioned in the literature as well as the feedback received 
from presenting the pilot study at various conferences and seminars.  
 
 
The third challenge relates to the aim of incorporating study quality into the 
analysis. Study quality was frequently mentioned as a potential variability factor 
for measures of cost-effectiveness and fellow researchers highlighted that this 
exercise should not simply assign corresponding variability to the respective 
error term. Rather, one should aim to capture study quality somehow and 
include this information as a further covariate in the model. There are a number 
of quality checklists available within the economic evaluation literature and in a 
first attempt to capture study quality, the author considered the use of a 
checklist developed by Drummond & Jefferson (1996), which was developed with 
the aim to ‘improve the quality of submitted and published economic articles’ 
(Drummond & Jefferson, 1996). Hence, the pilot study data abstraction form 
initially included 35 yes/no items referring to the above named checklist. 
However, the checklist developed by Drummond & Jefferson (1996) proved to be 
rather related to the quality of reporting economic evaluation results, and not 
the methodological rigour with which the study was initially conducted. Though 
this critique may apply to some extend to any quality checklist for economic 
evaluations, it was decided to consider alternatives for the empirical analysis.  
 
 
The ‘Quality of health Economics Studies’ (QHES) instrument, developed by 
Ofman et al. (2003), was chosen for a number of reasons: First, the QHES 
instrument is the only quality checklist which provides individual scores for each 
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dimension considered. These scores were generated using ‘random-effects 
general least-squares regression based on a conjoint analysis of survey results 
from 120 international health economists’ (Ofman et al., 2003). Adding together 
individual scores for each item allows assigning an overall quality score to each 
study, with a perfect quality score of 100. This score may be used as an 
explanatory variable in the MLM analysis. Secondly, the QHES instrument was 
validated in a survey by 60 experts (30 clinicians and 30 health economists) in six 
disease categories. Third, QHES proved relatively straightforward to apply in this 
empirical exercise, with only 16 criteria to consider. However, there were also 
some problems associated with QHES. In particular, Ofman et al. (2003) designed 
some dimensions on their checklist with multiple subcategories. Hence, an 
individual study may score ‘yes’ in one subcategory but ‘no’ in others. For 
instance, consider question eight of the QHES checklist:  
 
‘Did the analytic horizon allow time for all relevant and important outcomes? 
Were benefits and costs that went beyond 1 year discounted (3% to 5%) and 
justification given for the discount rate?’ 
 
Unfortunately, the developers of QHES did not specify what to do if a study does, 
for instance, consider a sufficient analytic horizon, but discounted costs with 6% 
and effects with 1.5%. Or alternatively, if both analytic horizon and discount rate 
are appropriate, but no justification is given for the choice of the discount rate. 
As a result, some assumptions were made to apply QHES to the 67 studies 
included in this systematic review exercise and two QHES-scores were calculated 
for each study considered. First, criteria were applied in their strictest sense, 
meaning that a score of zero was assigned to a QHES dimension if any of the 
subcategories was answered with ‘no’. Secondly, however, the item score was 
divided by the number of subcategories, and a partial score was assigned for 
each of the subcategories answered with ‘yes’. Obviously, this less stringent 
application of the QHES instrument led to generally higher overall QHES scores.  
 
 
Nevertheless, the results of applying quality checklists should always be 
considered with highest caution. All checklists considered for this exercise rely on 
judgements which may sometimes bias results. In addition, there may always be 
the concern that not all important quality dimensions were considered or, in the 
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particular case of QHES, the weights reflected in individual item scores may not 
perfectly reflect the relative importance of individual criteria on the checklist. To 
take into account the resulting uncertainty in results, continuous QHES scores 
were also converted into categorical variables in this thesis, with five categories 
with increments of 20 QHES points ranging from  ‘0’ to ‘100’.  
 
 
The fourth challenge with respect to study methods relates to the geographic 
source of input parameters. Barbieri et al. (2005) grouped studies with respect to 
this source of variability. Accordingly, there may be differing degrees of ‘context 
specificity’ in measures of cost-effectiveness. To assess this potential source of 
variability, information was first collected from studies to record the geographic 
origin of the data used to populate the economic model. Hence, data was 
collected to record the geographic origin of a) resource use data, b) unit cost 
estimates, c) effectiveness data and d) utility values. Secondly, covariates were 
derived which group data with respect to its ‘geographic specificity’ of input 
parameters. For clarification, Table 4.4 relates the geographic source of the input 
data to the target country considered in the economic analysis. If all input 
parameters are taken from the target country, the highest context specificity is 
assumed. This context specificity decreases with an increasing number of input 
parameters obtained from other geographic domains.  
 
 
Table 4.4: Context specificity of Input parameters  
(adapted from Barbieri et al, 2005) 
 
 Context specificity of input parameters 
Group Utility weights Effectiveness Resource Use Unit cost 
Type 4 Yes Yes Yes Yes 
Type 3 No Yes Yes Yes 
Type 2 No No Yes Yes 
Type 1 No No No Yes 
 
 
As a result, variables entered the dataset which aim to encode the context 
specificity of input parameters. One variable (Barbierie_score_1) aims to reflect 
different combinations of input parameters being drawn directly from the target 
country, whilst another variable (Barbieri_score_2) counts the number of context 
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specific categories of input parameters, resulting in 4 categories according to 
what has been presented in Table 4.4 above. The raw data to derive such 
covariates has been omitted from further analysis.   
 
 
The final challenge with respect to methodological characteristics of studies 
included in this empirical exercise relates to the potential number of relevant 
methods characteristics to consider in the MLM framework. In other words, if a 
large number of methodological characteristics are abstracted from the relevant 
literature, it is questionable whether one can simultaneously accommodate all 
relevant variables in the MLM framework. Hence, what would be desirable is a 
summary measure which captures a ‘methodological profile’ of studies included 
in the dataset. For this reason, the use of multiple correspondence analysis was 
considered – the ‘categorical equivalent to principal component analysis’ (Le 
Roux & Rouanet, 2010) - to group together studies of similar methodological 
profile. Those studies may then be assigned a score which can be used as an 
explanatory variable in the MLM. This idea was subsequently developed further 
into a study on the ‘genealogy’ of economic evaluation studies, The underlying 
assumption is that studies which are ‘phenotypically’ similar may share a 
‘genotypic’ relationship, for instance in terms of common authorship, common 
funding source or reuse of a previously developed DAM. The importance of this 
question arises out of the assumption of independence between studies included 
in the dataset. This assumption, which is necessary between groups on study-
level in the multilevel framework, may be violated if studies are very similar, and 
this similarity is not simply a coincidence but rather the result of an existing 
relationship between the studies in question. Section 4.2.3 is concerned with this 
genealogy study.  
 
 
After deciding on the variables to collect data for, an abstraction form was 
implemented in MS Access for the purposes of the pilot study. However, one key 
advantage of MS Access, which is the possibility to link tables with subtables to 
create a data hierarchy, hence avoiding redundancies in datasets, turned out to 
be a disadvantage for this particular exercise. The reason is that MLwiN requires 
data for higher-level variables assigned to each data point, so that the above 
mentioned redundancies occur (Rasbash et al., 2009). Hence, for the main 
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empirical analysis, a data abstraction form was implemented in MS Excel so that 
data for higher-level covariates could simply be copied to each respective data 
point. This format allowed instant exporting of the resulting dataset to STATA 12 
and MLwiN. A word document containing the final data abstraction form is also 
available from Appendix 4.13.   
 
 
The following section summarizes some key descriptive statistics based on the 
data abstracted from the studies included in this empirical exercise. 
Subsequently, the genealogy study is reported in Section 4.3 of this chapter.  
 
 
 
4.2.2. Descriptive statistics of studies included in the empirical 
exercise 
 
 
The first section of this chapter reported on a systematic literature review to 
identify studies on the cost-effectiveness of statins in the primary and secondary 
prevention of CVD which meet the inclusion criteria for this empirical exercise. 
The second section was concerned with the development of a data abstraction 
form which was based on a long list of potential variability factors for measures 
of cost-effectiveness as previously discussed in the relevant literature. This 
section reports some descriptive statistics of studies included in this empirical 
exercise which are also relevant for the genealogy study reported further below. 
Note that Section 5.2.3 of the empirical chapter also reports on descriptive 
statistics, missing values and correlations between explanatory variables for all 
covariates in the dataset. Further, descriptive statistics for all covariates are 
available from Appendix 5.  
 
 
67 studies were includable in this systematic literature review. References of 
these 67 studies can be found in Appendix 4.12. In addition, Table 4.6 at the end 
of this section lists all 67 studies with key characteristics discussed in this section. 
61 studies are ‘single country’ studies, providing measures of cost-effectiveness 
for one geographic domain only. The remaining six studies (8.96%) are 
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multinational in nature, providing data on more than one geographic domain. 
The countries considered in these six multinational studies are Denmark, France, 
Italy, New Zealand, Norway and Portugal. Table 4.5 below shows the distribution 
of studies per country.  
 
Table 4.5: Distribution of studies per target country 
 
Country Frequency Percent Cummulative 
Australia 1 1.49% 1.49% 
Belgium 2 2.99% 4.48% 
Brazil 1 1.49% 5.97% 
Canada 12 17.91% 23.88% 
Finland 2 2.99% 26.87% 
Germany 5 7.46% 34.33% 
Hong Kong 1 1.49% 35.82% 
Hungary 1 1.49% 37.31% 
Japan 1 1.49% 38.81% 
Netherlands 3 4.48% 43.28% 
Spain 1 1.49% 44.78% 
Sweden 4 5.97% 50.75% 
Switzerland 1 1.49% 52.24% 
UK 7 10.45% 62.69% 
UK (Engl./Wales) 7 10.45% 73.13% 
UK (Scotland) 1 1.49% 74.63% 
USA 11 16.42% 91.04% 
Multinational* 6 8.96% 100% 
Total 67 100% -- 
*Denmark, France, Italy, New Zealand, Norway and Portugal 
 
 
Note that some studies provided data applicable to ‘England/Wales’, others 
provided data for ‘Scotland’ and finally, some studies referred to the ‘UK’ as a 
whole. Accordingly, three distinct geographic entities were defined. 61 out of 67 
studies were written in English language. The timing of studies (which is not the 
year of publication) ranges from 1988 to 2009, with two peaks between 1995 to 
1998 and 2005 to 2007 respectively (see Figure 4.3 below). Industry was involved 
in the funding of 39 publications (58.21%), whilst funding was unclear for a 
further 17 studies (25.37%). If industry funding was available, the manufacturers 
most commonly involved were Pfizer with 13 studies and Merck with 12 studies. 
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Figure 4.3: Timing of economic evaluation studies included in this empirical 
exercise 
 
 
Simvastatin was by far the most commonly assessed intervention, followed by 
pravastatin, atorvastatin, lovastatin, rosuvastatin and fluvastatin. In most 
studies, the intervention was compared to ‘doing nothing’ whilst 17 studies also 
considered other statins as comparator. The mean annual drug cost of the 
intervention (converted to £-Sterling using Purchasing Power Parities (PPP) and 
updated to 2010 using country specific GDP deflators (Shemilt et al., 2008; OECD, 
2010) is £521.59. The annual drug cost is highest for lovastatin at £932.14 (SD: 
515.14), followed by pravastatin at £858.00 (SD: 236.67), atorvastatin at £503.89 
(SD: 232.19), simvastatin at £477.70 (SD: 312.81), rosuvastatin at £337.28 (SD: 
247.16) and fluvastatin at £ 293.08 (SD: 103.10) respectively.  
 
 
Methods on study-level show that most studies (61; 91.04%) rely on secondary 
modelling, whilst only six studies (8.96%) made direct use of individual patient 
data. For secondary modelling, the most common model used was a Markov 
state transition model (41; 61.19%). Seven studies (10.45%) were based on 
decision trees, and other modelling approaches involved life tables, or discrete 
event simulation. An important question is how effectiveness was measured and 
modelled within a study, and there are two general approaches. Most studies 
(61.19%) modelled the reduction in risk of experiencing a CVD event in the future 
to estimate incremental effectiveness. 26 studies (38.81%), however, used the 
intermediate outcome of cholesterol reduction to approximate its impact on CVD 
1990 1995 2000 2005 2010
Timing of economic evaluation studies
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risk, which then resulted in an estimation of life years or QALYs saved. Moving on 
to the outcome measure itself, QALYs were considered in 32 (47.76%) out of the 
67 studies. If QALYs were considered, the utility weights represent population 
values in 15 studies (22.39%), patient values in 13 studies (19.40%), and in 4 
studies (5.97%) it was unclear whether utility weights represent patient or 
population preferences.  
 
 
The majority of 35 studies (52.24%) explicitly looked into the effect of statins on 
coronary heart disease (CHD) and cerebrovascular disease (CD), whilst 18 studies 
(26.87%) looked at CHD only. 11 studies (16.42%) looked at CHD, CD and 
peripheral arterial disease (PAD). Inflation adjustment of cost estimates to a 
common baseline year was explicitly reported in 18 studies (26.87%), whilst this 
was unclear in 35 cases (52.24%), If inflation adjustment was applied, the most 
common method was to use the healthcare component of the target countries 
consumer price index with 10 studies (14.93%). Currency conversion of any kind 
was applied in 15 studies (22.39%), and the most common method of currency 
conversion was the use of real exchange rates (11, 16.42%). In terms of context 
specificity, by far the most measures of cost-effectiveness (49.33%) where 
generated with unit cost and resource use data from the target country, whilst 
effectiveness estimates and utility weights were transferred from another 
jurisdiction. Only 56 data points (2.67%) were generated with all data sources 
from the target domain.  
 
 
Table 4.6 below summarizes some key characteristics of all 67 studies included in 
this empirical exercise. Full descriptive statistics as well as missing values analysis 
and analysis of correlations between explanatory variables are provided in 
Section 5.2.3 of the empirical chapter as well as in Appendix 5.  
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Table 4.6: Key study characteristics – summary table 
 
ID Authors  
(pub. year) 
Timing Multi-
country 
Target country Primary 
Modelling 
Outcome 
measure 
Industry 
Funding 
1 Ashraf et al. (1996)  1995 No USA No LYS Yes 
2 Caro et al. (1997) 1996 No UK (Scotland) Yes LYS Yes 
3 Grover et al. (1999) 1996 No Canada No LYS Unclear 
4 Grover et al. (2000) 1996 No Canada No LYS Yes 
5 Hamilton et al. (1995) 1992 No Canada No LYS Yes 
6 Johanneson et al. (1997) 1995 No Sweden No LYS Yes 
7 Muls et al. (1998) 1995 Yes Belgium  No LYS Yes 
8 Perreault et al. (1998) 1995 No Canada  No LYS No 
9 Pharoah et al. (1996) 1995 No UK (England/Wales) No LYS No 
10 Szucs et al. (1998) 1996 No Germany No LYS Unclear 
11 Szucs et al. (2000a) 1998 No Germany No LYS Unclear 
12 van Hout et al. (2001) 1999 No Netherlands No LYS Unclear 
13 Jönsson et al. (1996) 1995 Yes Multi-country Yes LYS Yes 
14 Jönsson et al. (1999) 1997 Yes Multi-country Yes LYS Yes 
15 Ganz et al. (2000) 1998 No USA No LYS / QALYs No 
16 Grover et al. (2001) 1998 Yes Multi-country No LYS Yes 
17 Martens et al. (1994) 1993 No Canada No LYS Yes 
18 Alonso et al. (2008) 2005 No Spain No LYS Yes 
19 Annemans et al. (2010) 2009 No Belgium  No LYS / QALYs Yes 
20 Araujo et al. (2007) 2007 No Brazil  No LYS Unclear 
21 Lindgren et al. (2010)  2007 No UK (England/Wales) No LYS / QALYs Yes 
22 Grover et al. (2008) 2002 No Canada No LYS Yes 
23 Franco et al. (2007) 2003 No Netherlands No LYS No 
24 Greving et al. (2011) 2008 No Netherlands No QALYs No 
25 HPS Group (2009) 2006 No USA No LYS / QALYs Yes 
26 Khoury et al. (2009) 2007 No Canada No LYS / QALYs Yes 
27 Kongnakorn et al. (2009) 2005 No USA No LYS / QALYs Yes 
28 Morris (1997) 1996 No UK No LYS Unclear 
29 Morris & Godber (1999) 1997 No Canada No LYS Yes 
30 Rosen (2010) 2007 No USA No LYS / QALYs Yes 
31 Scuffham et al. (2005) 2002 No UK No LYS / QALYs Yes 
32 Scuffham et al. (2006) 2005 No Hungary No LYS / QALYs Yes 
33 Tailor et al. (2009) 2005 Yes Multi-country No LYS / QALYs Unclear 
34 Tonkin et al. (2006) 1998 No Australia Yes LYS Yes 
35 Wagner et al. (2009a) 2007 No Canada No LYS / QALYs Yes 
36 Wagner et al. (2009b) 2006 No Canada No LYS / QALYs Yes 
37 Berger et al. (1997) 1996 No Germany No LYS Unclear 
38 Obermann et al. (1997) 1993 No Germany No LYS Yes 
39 Davies et al. (2006) 2005 No UK No QALYs Yes 
40 Spaans et al. (2003) 1996 No Canada No LYS Unclear 
41 Soini et al. (2010) 2007 No Finland No LYS / QALYs Yes 
42 Peura et al. (2008) 2006 No Finland No LYS / QALYs Yes 
43 Slejko et al. (2010) 2008 No USA No QALYs Unclear 
44 Nherera et al. (2010) 2009 No UK (England/Wales) No QALYs Unclear 
45 Szucs et al. (2000b) 1997 No Switzerland No LYS Unclear 
46 Sigvant et al. (2011) 2009 No Sweden No LYS / QALYs Yes 
47 Johannesson et al (1996) 1991 No Sweden Yes LYS Yes 
48 Troche et al. (1998) 1995 No Germany No LYS Unclear 
49 Szucs et al. (2004) 2003 Yes Multi-country No LYS Unclear 
50 Nagata et al. (2005) 2002 No Japan No QALYs Unclear 
51 Lindgren et al. (2007) 2005 Yes Multi-country No LYS / QALYs Yes 
52 HPS Group (2006) 2005 No UK No LYS / QALYs Yes 
53 Tsevat et al. (2001) 1996 No USA No QALYs Yes 
54 Raikou et al. (2007) 2004 No UK Yes LYS / QALYs Yes 
55 Ramsey et al. (2008) 2005 No USA No LYS / QALYs Yes 
56 Scuffham et al. (2004) 2002 No UK (England/Wales) No LYS / QALYs Yes 
57 Hjialte et al. (1989) 1988 No Sweden No LYS Unclear 
58 Caro et al. (2003) 1998 No USA No LYYS Yes 
59 CDC Group. (2002) 1997 No USA No LYS / QALYs No 
60 Chau et al. (2001) 1998 No Hong Kong No QALYs Yes 
61 Grover et al. (2003) 2000 No Canada No LYS Yes 
62 Glick et al. (1992) 1988 No UK No LYS Yes 
63 NICE (2008) 2007 No UK (England/Wales) No QALYs No 
64 Drummond et al. (1993) 1990 No UK No LYS No 
65 Chan et al. (2007) 2005 No USA No LYS / QALYs No 
66 Ward et al. (2007) 2004 No UK (England/Wales) No QALYs No 
67 Ara et al. (2009)     2008 No UK (England/Wales) No QALYs No 
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4.3. ‘Genealogy’ study of the statin related cost-
effectiveness literature  
 
 
When carrying out the systematic literature review and abstracting data from 
studies, it became apparent that some studies are related to each other, for 
instance, through common authorship, the use of identical data sources, reuse of 
a previously published DAM, or simply a common source of funding. This, 
however, may violate the independence assumption between studies, which is 
necessary to fit the MLMs developed in Chapter 3. If two studies are related, one 
may consider pooling them in one group on study-level rather than defining 
separate groups for each of the 67 studies included. Though this may reduce 
parameters on study-level, it may also be regarded as more appropriate to fit 
MLMs to the data, especially when two related studies are very similar in many 
aspects. Therefore, the aim of this final section of Chapter 4 is to look into the 
‘genealogy’ of economic evaluation studies on the cost-effectiveness of statins in 
the primary and secondary prevention of CVD. Though the motivation of this 
study arises out of the aim of critically appraising the independency assumption 
between studies in the MLM framework, this exploratory task into relationships 
and potential similarities between studies as a consequence of such relationships 
constitutes an interesting piece of original research in its own right, which could 
also be followed up further in future work.   
 
 
The aim of this exercise is to look into the genealogy of economic evaluation 
studies includable in this empirical exercise. There are two primary objectives: 
the first is to assess whether there may be alternative hierarchical structures to 
those assumed in the multilevel methods chapter and pilot Study which may fit 
the data better and hence would need to be acknowledged in the MLM. In other 
words, it is to consider whether modelling data clustered in published papers is 
the most reasonable hierarchical structure, or whether it is indicated to look into 
alternative data structures based on the relationships between published papers. 
This could lead, for instance, to studies which belong to one group (however this 
group may be defined) being aggregated on level two of the data hierarchy so 
that data is no longer clustered in papers, but rather in groups of papers. If it is 
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concluded that modelling data clustered in single papers remains the most 
appropriate hierarchical structure, the second objective is to derive covariates to 
capture some of the observed relationships between papers. Hence, instead of 
informing alternative model hierarchies, this exercise could lead to a number of 
covariates which encode relationships between papers and thereby allow their 
influence on the variability in measures of cost-effectiveness to be assessed.  
 
 
Both objectives relate back to an important issue in MLM, namely whether to 
capture something as a level or as a covariate (Rasbash et al., 2009). In 
conclusion, looking into the genealogy of studies, i.e. the relationships between 
papers which exist within the sample of papers included in this exercise, is a 
necessary step towards the theoretical validation of the model structure 
assumed in this study. This assessment, however, is explorative in nature, 
meaning that there is neither a strong body of literature to build upon nor is it 
clear whether this exercise may actually lead to results robust enough to inform 
alternative model structures. Nevertheless, beyond the primary objectives of this 
exercise, the issue of study genealogy constitutes an important research 
question in its own right, which deserved little attention thus far and should 
therefore also be considered in future research.  
 
 
 
4.3.1. Problem  
 
 
Relationships between published economic evaluation studies may exist on 
several dimensions like common authorship, recycling previously published 
DAMs, or using identical data sources, just to name a few. It is one thing to test 
the influence of such relationships on the response variable by including 
respective covariates into a MLM, but to inform an entire alternative model 
structure, one would have to establish not just an existing relationship, but also 
show that studies are similar in terms of characteristics determining the 
response variable so that one may group studies together on level two. For this 
reason, it is imperative not just to look into the ‘genotypic’ existence of 
relationships between published economic evaluation papers, but also to look at 
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the ‘phenotypic’ similarity in terms of study characteristics influencing the results 
of the affected studies. In very simple terms, things which are related (on one 
level) ought to look similar (on that level), if they don’t, we shall continue to treat 
them as independent! 
 
 
Only looking at differences in the response variable is not sufficient as results 
may appear unrelated due to differences on other levels, which would then draw 
a curtain over actual similarities of the affected studies. For instance, two studies 
could be absolutely identical in terms of the economic model applied and a 
number of key study methods which determine measures of cost-effectiveness, 
but differ with respect to the patient population under assessment - a data level 
characteristic. This patient characteristic, for example mean TCL, may cause 
substantial variability in measures of cost-effectiveness even though the two 
studies are almost identical. In conclusion, after controlling for TCL on data-level, 
one may regard study parameters to be identical, which would then justify 
pooling both studies in one group on study-level. Only looking at the response 
variable, i.e. the cost-effectiveness of the intervention, may not be sufficient as 
INMBs may differ sharply due to the difference in mean TCL amongst patient 
subgroups considered in both studies.  
 
 
Two papers in the dataset (Grover et al., 1999 and Grover et al., 2000) illustrate 
the above mentioned example. Though both papers are related through 
common authorship, and remarkably similar in terms of model structure, data 
sources and a number of additional study characteristics, their respective mean 
INMBs differ considerably (£47803 vs. £26230). A key difference likely to be 
responsible for this strong variation in mean INMBs between both papers is that 
one paper considers patients suffering from diabetes whilst the other paper does 
only consider patients without that condition. This difference, however, may not 
be captured on study-level, but rather on data-level so that one could regard 
parameters of both studies to be identical after controlling for diabetes status on 
data-level. Hence, one may argue in favour of pooling both studies in one group 
on study-level even though their respective mean INMBs differ considerably.  
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4.3.2. Method 
 
 
The question is then how to establish this similarity between related studies. It is 
difficult enough ascertaining simple relationships between published papers for 
covariate adjustment. However, performing a detailed assessment of similarity 
for 67 studies included in the dataset and also determining a ‘threshold’ above 
which we shall no longer consider two studies as independent but rather pool 
them on study-level, would lead into a study of considerable complexity and 
uncertain outcome in terms of its usefulness for informing alternative MLM 
structures. Though this appears to be a very important research question, it is 
questionable whether this project, which focusses on a different matter, can 
accommodate a case study of this magnitude with uncertain outcome.  
 
 
As an alternative to a full ‘qualitative’ assessment of relationships and resulting 
similarities between published economic evaluation studies, this exercise 
therefore looks into methods which may be used to build upon the existing 
dataset. In other words, if a quantitative method existed which is capable of 
disclosing patterns in the existing data which may then show whether economic 
evaluation studies can be pooled on study-level, this could then be used as a less 
time consuming alternative. After studying techniques for the analysis of 
multivariate data, several candidate methods were considered.  
 
 
One multivariate method often used to assess patterns in data is factor analysis 
(FA). According to Acock (2011), FA is a collection of methods that does 
exploratory analysis to ascertain whether there are items that may be clustered 
in particular groups. In this form of analysis, the observed variables are 
presented in terms of ‘linear combinations of a few random variables, called 
factors’ (Rencher, 2002). As Rencher (2002) further states, ‘the goal of factor 
analysis is to reduce the redundancy among the variables by using a smaller 
number of factors.’ These factors are, unlike the observations, unobserved and 
therefore also referred to as ‘latent variables’. Factor analysis may be used to 
assess patterns in the observed data and to reduce the complexity in a dataset 
by presenting groups of correlated variables in a smaller number of uncorrelated 
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factors (Acook, 2011). A related method to this is principal component analysis 
(PCA), which is also used to assess patterns in the data and to reduce the 
complexity of the dataset (Rencher, 2002). However, there are differences 
between both methods: Most importantly, ‘principal components are defined as 
linear combinations of the original variables, whilst in factor analysis, original 
variables are expressed as linear combinations of the factors’ and secondly ‘PCA 
explains large part of the total variance of the variables whilst in FA, we seek to 
account for the covariances or correlations among the variables.’ (Rencher, 
2002).  
 
 
It is important to note that there is considerable confusion around the 
terminology of these methods. What is referred to as PCA in one textbook, may 
be labelled as principal components factor analysis (PCF) in another one. 
Accordingly, software packages are not consistently using the same terminology 
for the same methods as STATA, for example, labels as PCF what SPSS refers to 
as PCA (Acook, 2011). Though this may further add to the confusion, one thing is 
common to all methods introduced above. Whilst they are, in theory, very 
appropriate for assessing patterns in the data in the way required for this 
genealogy study, they are only defined for continuous variables (Rencher, 2002; 
Kolenikov & Angeles, 2004; Acook, 2011), whilst the vast majority of variables to 
consider for this assignment is categorical in nature. For this reason, a package 
developed by Kolenikov & Angeles (2004) was considered as an alternative, 
which implements ‘polychoric principal components analysis’ into the software 
environment STATA. However, as Kolenikov & Angeles (2004) state, this method 
may only be valid for continuous as well as ordered categorical variables, which 
again leaves out the majority of variables relevant for this assessment.  
 
 
In conclusion, as neither FA, PCA nor polychoric PCA appeared to be applicable to 
unordered categorical data, an alternative methodology was considered for this 
exercise, commonly referred to as multiple correspondence analysis (MCA). The 
term ‘correspondence analysis’ stems from the French term ‘Analyse Factorielle 
de Correspondence’ which was defined by Benzéri et al. (1973) and the technique 
is also referred to as the ‘categorical equivalent to PCA’ (Le Roux & Rouanet, 
2010). The aim of this form of analysis is to visualise the raw data in a low-
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dimensional space (usually two dimensions) which then helps to identify patterns 
in this data (Bartholomew et al., 2008). It does so by converting categories of 
variables into points on a plane (the biplot), and the researcher may then analyse 
the resulting cloud and sub-clouds of points in this geometric space (Le Roux & 
Rouanet, 2010).   
 
 
There are actually two clouds to consider. The ‘cloud of categories’ shows the 
chi-square distance between categories of variables, the ‘cloud of individuals’ 
reflects dissimilarities in response patterns of ‘individuals’ - or rather ‘studies’ in 
the case of this genealogy exercise ( Le Roux & Rouanet, 2010). Hence, the cloud 
of categories would tell us whether certain combinations of categories of 
variables are more common than others. If this is the case, then the respective 
categories would appear close to each other on the biplot. Though this is an 
important aim of correspondence analysis, it is not what we are primarily 
interested in within this genealogy study. Rather, the primary aim is to analyse 
the cloud of individuals which shows which studies share common response 
patterns in terms of those categories.  
 
 
Consider Figure 4.4 below. The biplot on the top shows the cloud of categories 
for the two variables ‘Funding institution’ and ‘QHES’. From this biplot, we can 
learn that the lowest QHES scores most commonly appear in studies which did 
not disclose their funding sources. Conversely, government/ research council 
funded studies appear close to a QHES score of 80 to 100. In between are the 
industry funded studies, which most commonly score between 60 and 80 QHES 
points. The interesting question is now which studies actually have similar 
response patterns in terms of funding source and QHES score, and this is exactly 
what the cloud of studies on the bottom of Figure 5.4 shows. Hence, markers of 
studies which are absolutely identical in terms of the categories of variables 
under consideration, overlap on the biplot. The more differences between 
combinations of categories, the greater is the distance between studies on the 
biplot.  
 
 
 
 144 
 
Figure 4.4: Example of a MCA on ‘funding source’ and ‘study quality’ 
 
Cloud of categories 
Cloud of studies 
 
 
 
Hence, the idea of using this technique in this genealogy study is simply that 
studies which are very similar in terms of their response patterns (i.e. the 
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individuals (Bartholomew et al., 2008; Le Roux & Rouanet, 2010). If this is the 
case, the respective studies could be pooled within the same group on study-
level within subsequent MLM analysis. Hence, MCA is not employed to ascertain 
combinations of categories that are more common than others (cloud of 
categories), but rather to assess which studies share common response patterns 
(cloud of individuals) even if the underlying data is diverse In nature.  
 
 
Of course, the more variables we include in this assessment, the less likely it may 
be to find studies which are completely alike in terms of their response patterns. 
In other words, the diversity between pairs of studies is likely to increase with an 
increasing amount of individual characteristics to look at. On the other hand, 
with an increasing amount of study characteristics, similarity may be less likely a 
coincidence but rather the result of studies actually being related in some way. In 
conclusion, biplots will be produced with different subsets of variables, starting 
off with the complete set of variables presented in Table 4.7 below, and then 
subsequently dropping variable by variable in increasing order of relevance to 
the response patterns observed. The more variables we drop, the less diverse are 
the response patterns, and the more points on the cloud of individuals may 
coincide (Bartholomew et al., 2008; Le Roux & Rouanet, 2010). However, the 
more variables are being dropped, the more likely it gets that similarities 
between studies are not a result of actual relationships but rather a coincidence, 
as they are based on viewer study characteristics under consideration.   
 
 
Accordingly, after disclosing similarities between studies in this way, a 
subsequent step is to validate findings by looking into the actual studies and 
trying to find the underlying relationship which may have caused the observed 
similarity. In a way, we confirm the ‘genotypic’ relationship after disclosing 
‘phenotypic’ similarity. If there is no apparent relationship, then the observed 
similarity should not be considered when re-grouping data on study-level in 
subsequent multilevel analysis.  
 
 
To sum up, MCA helps to assess which studies share common characteristics and 
should therefore be regarded as similar. It does so by utilising the data already 
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collected within the literature review and data-abstraction exercise reported 
earlier in this chapter and therefore constitutes a time-saving alternative to a full 
qualitative assessment of relationships between studies and their resulting 
similarities in terms of study-characteristics. Nevertheless, it needs to be 
emphasized that this whole exercise is explorative in nature, and what may work 
in theory, may not lead to unambiguous results in practice, e.g. due to noise in 
the data or other factors distorting the results.  
 
 
 
4.3.3. Data 
 
 
As detailed above, this genealogy study starts off from the data already available 
from the literature review and data abstraction exercise. This data was collected 
from 67 economic evaluation papers which were published on the cost-
effectiveness of statins in the primary and secondary prevention of CVD. Only 
papers which decomposed the ICER or the INMB statistic were included as only 
this allows calculating as response variable an INMB with a common threshold 
value or running a bivariate MLM with incremental cost and incremental effects 
as a vector of response variables. Covariates were defined from a long list of 
potential variability factors which were previously reported in Sculpher et al. 
(2004) and Goeree et al. (2007). A number of variables entered the data 
abstraction exercise which may also be useful for the purposes of ascertaining 
relevant relationships between published papers. As a result, a very rich dataset 
was obtained with data collected on more than 80 distinct variables on data and 
study-level (details may also be obtained from previous sections of this chapter).  
 
 
Certainly, not all of these variables may be relevant for this genealogy exercise. 
Rather, it is indicated to first hypothesize about potential relationships between 
published papers and then determine which study characteristics encoded as 
variables in the dataset may be affected by any relationship between papers. 
This is equivalent to choosing covariates for a regression analytic model, where 
one would only include candidate variables of which a relationship to the 
dependent variable is anticipated. Hence, as the basic principle ‘garbage in, 
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garbage out’ applies just as much to MCA as it does to regression analytic 
modelling, it is indicated to first think about what may be affected if two studies 
are related in some way, and then to screen the dataset for the existence of 
appropriate candidate variables.  
 
 
It is appreciated that, out of the potentially unlimited space of existing 
relationships and study characteristics affected by such relationships, this 
exercise may only look into a very limited number of obvious candidates. This 
underpins the character of this exercise as an explorative study into the 
genealogy of economic evaluation studies and one may think of a more 
systematic approach to the selection of variables for future research. Potential 
relationships which were considered are ‘common authorship’, ‘recycled model’, 
‘common funding source’ and whether studies were based on the same ‘methods 
guideline’. The existing dataset was then screened for variables which are 
considered sensitive to the existence of any of these relationships between 
papers and therefore includable in the MCA. Results may be obtained from Table 
4.7. Based on this data, biplots were produced with different subsets of 
variables, starting off with the complete set of variables presented in Table 4.7, 
and then subsequently dropping variable by variable in increasing order of 
relevance to the response patterns observed. The more variables we drop, the 
less diverse are the response patterns, and the more points on the cloud of 
individuals should coincide. However, the more variables we drop, the more 
likely it gets that similarities between studies are simply coincidence, as they are 
based on viewer study characteristics under consideration.   
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Table 4.7:  Potential candidate variables for MCA 
 
Variable Description Level Nature 
outc_measure How was health outcome reported in the study Level 1 (data) unordered, binary 
elicitation 
If QALYS were used, what was the method of 
preference elicitation? 
Level 1 (data) 
unordered, 
categorical 
population 
If QALYS were used, what do the utility values 
reflect (patient / population values) 
Level 1 (data) 
unordered, 
categorical 
DRC What was the discount rate on costs  Level 1 (data) 
Continuous 
(converted to 
ordered, categorical) 
DRB What was the discount rate on benefits Level 1 (data) 
Continuous 
(converted to 
ordered, categorical) 
duration What was the treatment duration modelled Level 1 (data) ordered, categorical 
extrapol 
Was there any extrapolation beyond the latest 
follow up? 
Level 1 (data) unordered, binary 
horizon What is  the time horizon? Level 1 (data) ordered, categorical 
Persp_rep 
What was the study perspective as reported by 
the authors of the article 
Level 1 (data) 
unordered, 
categorical 
Persp_cost_concl 
What was the study perspective on costs as 
concluded by the reviewer 
Level 1 (data) 
unordered, 
categorical 
intervention 
What was the brand name of the intervention 
drug? 
Level 1 (data) 
unordered, 
categorical 
comparator 
What was the brand name of the comparator 
drug? 
Level 1 (data) 
unordered, 
categorical 
source_effects 
From which source (trial, meta-analysis) was 
the effectiveness data taken from 
Level 1 (data) 
unordered, 
categorical 
paper_origin 
In which country was the paper written (if 
authors from several jurisdictions were 
involved, where is the lead author based? 
Level 2 (study) 
unordered, 
categorical 
multinational Was the study multinational Level 2 (study) unordered, binary 
fund_inst 
What was the primary source of funding 
(institution) 
Level 2 (study) 
unordered, 
categorical 
fund_man 
If funding source was private, which 
manufacturer was involved? 
Level 2 (study) 
unordered, 
categorical 
gen_des What was the general study design? Level 2 (study) 
unordered, 
categorical 
prim_des 
If primary modelling, what was the specific 
study design? 
Level 2 (study) 
unordered, 
categorical 
sec_des 
If secondary modelling, what was the specific 
study design 
Level 2 (study) 
unordered, 
categorical 
effect_calc Method of effect calculation Level 2 (study) 
unordered, 
categorical 
Timing What is the timing of the economic evaluation Level 2 (study) 
unordered, 
categorical 
cur_conv Was currency converted Level 2 (study) unordered, binary 
conv_method 
If currency was converted, what was the 
conversion method used by the authors? 
Level 2 (study) 
unordered, 
categorical 
scope What was the scope of assessment Level 2 (study) 
unordered, 
categorical 
 
Note that descriptive statistics of the variables considered in this exercise were 
already reported in the previous section of this chapter. In addition, full 
descriptive statistics are available from Chapter 5.2.3 and Appendix 5.   
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4.3.4. Results and discussion 
 
 
Figure 4.5 shows the results of performing a MCA to ascertain similarities in 
study characteristics between published economic evaluation papers included in 
this empirical exercise. Each point on the biplot represents one study, and the 
distance between individual points is determined by differences in the response 
patterns of studies. In other words, studies which share common response 
patterns should be in very close proximity on the biplot. If studies are absolutely 
identical in their response patterns, their markers on the biplot should coincide.  
 
 
Figure 4.5a shows a pattern which one could almost refer to as random. In other 
words, there are virtually no apparent clusters on the plot, meaning that the 
existence of common response patterns in studies is very low. However, with 
decreasing number of categorical variables included in the assessment, one can 
observe that points on the biplot increasingly group together in clusters. This is in 
line with expectations as the more study characteristics are compared, the less 
likely it should be that two studies are completely alike. Results therefore have 
face validity. However, what is worrying is that the combinations of coinciding 
points on the biplot change and therefore appear to be sensitive to the choice of 
covariates to include. In other words, if we observe two studies response 
patterns to be very similar in biplot 4.5a then ideally we should observe this 
result to be robust in all four biplots. In fact, we observe one such example with 
studies 15 and 65 coinciding exactly on all four biplots, but for other pairs of 
studies (e.g. 39 and 44 on biplot 4.5a) this close proximity disappears with 
dropping variables from the assessment.  
 
 
After analysing biplots, the next step in this case study is to ascertain whether 
there are any apparent relationships between the studies with similar response 
patterns which coincide on the biplots presented in Figure 4.5. For this reason, a 
full text review was conducted for each pair (or group) of studies circled in red in 
Figure 4.5. This is a descriptive exercise and results can be obtained from Table 
4.8 below.  
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As can be seen from Table 4.8, it was possible to establish a direct relationship 
between papers in almost 50% (10 out of 21) of the matches on the biplots 
shown in Figure 4.5. These relationships were mostly based on common 
authorship (7 of 10). In one case, the relationship between two papers, which 
were identical in terms of data sources and the model to estimate cost-
effectiveness, was almost undetectable as the authors completely failed to cross-
reference their papers. A link could only be established through the funding 
source, which was identical in both papers (Annemans et al., 2010; Khoury et al., 
2009). The strong link between these two papers would still be hidden in the 
dataset if one would only look into genotypic relationships between studies and 
not the phenotypic similarities between those studies.  
Figure 4.5: Biplots showing clouds of studies with decreasing number of study 
characteristics under consideration 
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Table 4.8: Descriptive analysis of relationships between published papers 
appearing in close proximity on the cloud of studies 
 
Papers coinciding on 
biplots 
Biplots on 
which 
papers 
coincide 
Description of the relationship between papers 
coinciding on biplots  
Descriptive 
analysis 
accords 
MCA?  
IDs: 1 / 25 / 58 
Ashraf et al. (1996); HPS 
collaborative Group (2009); 
Caro et al. (2003) 
c There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers.   
No 
IDs: 2 / 34 
Caro et al. (1997); Tonkin et 
al. (2006) 
c There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 3 / 4 
Grover et al. (1999); Grover 
et al. (2000) 
c / d There is a strong link between both papers in terms 
of common authorship, as both papers were 
published by Grover et al. This may explain the use 
of the identical model (CVD life expectancy model) 
as well as similar data sources.  
Yes 
IDs: 5 / 25 
Hamilton et al. (1995); HPS 
Collaborative Group (2009) 
b There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 5 / 41 
Hamilton et al. (1995); Soini 
et al. (2010) 
d There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 9 / 64 
Pharoah (1996);  
Drummond et al. (1993) 
a There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 10 / 45  
Szucs et al. (1998); Szucs et 
al. (2000)  
 
c / d There is a strong relationship between published 
papers. Both papers share common authorship, and 
economic models are almost identical. Whilst data 
sources vary for effectiveness data, cost data is 
taken from the same sources. Both studies share the 
same origin, and papers are published in German.  
Yes 
IDs: 11 / 38 
Szucs et al. (2000); 
Obermann et al. (1997) 
c / d Both papers were published in Germany, and hence, 
similar methods standards may apply. However, 
sources of effectiveness and cost data differ, and 
there is no apparent relationship in authorship.  
Yes 
IDs: 13 / 14 
Jonsson et al. (1996); 
Jonsson et al. (1999) 
d Both studies share a strong relationship through 
common authorship and the fact that they rely on 
the analysis of RCT data from 4S. Whilst ID 13 
(Jönssen et al (1996)) focusses on the cost-
effectiveness of simvastatin as assessed within the 
whole 4S trial population, ID 17 (Jönsson et al (1999) 
focus on diabetic patients from that cohort only.  
Yes 
IDs: 15 / (36) / 65 
Ganz et al. (2000); Wagner 
et al. (2009);  Chan et al. 
(2007) 
a / b / c / 
(d) 
Two studies (Wagner et al (2009) and Chan et al 
(2007)) are partly based on the same effectiveness 
data from the IDEAL trial. All three studies rely on a 
Markov model to estimate cost-effectiveness of 
statins. However, there are no further apparent 
relationships between the three papers.  
No 
IDs: 18 / 55 
Alonso et al. (2008);  
Ramsey et al. (2008)  
b There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 19 / 26 / 58 
Annemans et al. (2010); 
Khoury et al. (2009); Caro 
et al. (2003) 
d Studies by Annemans (2010) and Khoury (2009) were 
both funded by Pfizer. Both studies rely on data from 
CARDS. The DAM used in both studies is identical. 
Interestingly, though both papers are very similar 
and obviously related, no reference has been made 
by their authors to each other. The third paper (Caro 
et al (2003)) does not have an apparent relationship 
to the other two papers mentioned. 
Yes 
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IDs: 22 / 61 
Grover et al. (2008); Grover 
et al. (2003) 
c There is a strong link between both papers in terms 
of common authorship. This is also reflected in the 
use of the identical DAM (CHD life expectancy 
model) and further similarities in terms of study 
methods and unit cost sources etc.  
Yes 
IDs: 24 / 56 
Greving et al. (2011); 
Scuffham et al. (2004) 
d There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 35 / 36 
Wagner et al. (2009a);   
Wagner et al. (2009b)  
b There is a very strong link between both papers in 
terms of authorship, methods and data sources Yes 
IDs: 40 / 52 / 62 
Spaans et al. (2003); HPS 
coll. Group (2006);  Glick et 
al. (1992) 
d There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 42 / 61 
Grover et al. (2003);  Peura 
et al. (2008)  
d There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 43 / 53 
Slejko et al. (2010); Tsevat 
et al. (2001) 
d There is no apparent relationship in terms of 
common authorship, use of the same model, funding 
source or identical data sources between the papers 
No 
IDs: 44 / 63 
Nherera et al. (2010);  NICE 
lipid guideline 67 (2008) 
d Strong relationship in terms of authorship model 
structures, study methods and data sources Yes 
IDs: 63 / 67 
NICE lipid guideline 67 
(2008);  
Ara et al. (2009) 
c Transition probabilities in the HTA report from ARA 
et al partly taken from the study by Cooper et al, 
which led to the NICE guideline 67.   
Yes 
IDs: 66 / 67 
Ward et al. (2007); Ara et 
al. (2009)  
d Both studies are related through common 
authorship and they were also both conducted as 
part of the HTA Programme. Both studies were 
conducted by SCHARR and the DAM underlying both 
studies is known as the SCHARR-model  
Yes 
 
 
Though the findings reported above indicate that the method applied to 
investigate the genealogy of economic evaluation studies is very promising, there 
is still concern in terms of basing an alternative MLM structure upon it. For 
instance, the method produced roughly 50% of ‘false positive’ matches on the 
respective biplots, and one can almost be certain that a number of ‘false 
negative’ relationships are still hidden in the dataset. This means that the results 
reported above are, at most, partially disclosing existing relationships within the 
data. This method may, with further refinement in a systematic exercise as it is 
suggested for future research, be very useful to investigate links between 
economic evaluation studies and the extent to which studies replicate each 
other. However, within this project, the method did not appear to be ‘sensitive’ 
and ‘specific’ enough to base alternative MLM structures upon its findings. 
Potential reasons may lie, for instance, in the choice of variables to enter the 
MCA. As these variables were drawn from existing data which was not purposely 
collected for this genealogy study, one may argue that important study 
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characteristics were missing from this assessment. Furthermore, this case study 
showed that MCA results are very sensitive with respect to the categorical 
variables considered, which most certainly asks for a much more systematic 
approach to variable selection when considering MCA to assess similarities 
between economic evaluation studies in future research. 
 
 
On the other hand, it was not possible to allocate more time to this exercise 
which is, though related to the question of the appropriate MLM structure, not 
crucially relevant for addressing the transferability problem. Changing the MLM 
structure by pooling individual studies to groups of studies may have an effect on 
the results when running the respective models. However, there are also a 
number of valid reasons to retain the current multilevel structure even if some 
papers are found to be very similar in some aspects. For instance, pooling papers 
would mean that the number of level two units decreases, potentially casting 
into doubt the assumption of random parameters on that level (Snijders et al., 
2005).  Furthermore, even if studies are similar in most aspects, pooling them 
would obviously have an impact on those study-level covariates which still show 
differences between those studies. For instance, within the affected studies 
shown in Table 4.8, timing constitutes an important difference even if all other 
observed study-level characteristics are identical. When pooling those studies, 
differential timing may no longer be assessable as a study-level covariate within 
the multilevel framework.  
 
 
It is also important to note that parameters of studies become, in theory, fully 
exchangeable after adjusting for the appropriate covariates (e.g. Gelman et al., 
2004), so that the question of similarity between economic evaluation studies 
may be entirely shifted to the matter of covariate adjustment. Finally, the 
current model shows level two units in its most disaggregated form. One may 
argue that further aggregation may also lead to false inferences because of the 
ecological fallacy (e.g. Hox, 2010). This holds especially true in a situation when 
there is no clear cut between two studies which may be pooled because of their 
apparent similarity, and two studies which are similar in some aspects, but not 
‘similar enough’ to justify pooling in the researchers judgement.  
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Nevertheless, though it may not be indicated to alter the MLM structures 
theoretically developed and tested in Chapter 3 based on the results of this 
genealogy study, there are important findings which may impact on the 
remainder of this empirical exercise. Precisely, not considering existing 
relationships between published economic evaluation studies with respect to the 
MLM structure does not mean that this project ignores such relationships 
altogether. In line with the assumption of partial exchangeability, one may 
consider links between studies in terms of covariates on study-level. First, each 
of the variables considered above to assess similarity between economic 
evaluation studies will be tested individually for significance in the multilevel 
framework. This analysis of covariates is reported in Chapter 5.2.  
 
 
In addition, one may further look into the issue of common authorship to group 
studies accordingly. For this matter, authors of all 67 studies included in this 
empirical exercise were first listed in a spreadsheet, resulting in a list of 351 
authors. Next, authors of the respective studies were ordered alphabetically, so 
that it was relatively straightforward to group studies of common authorship 
together (note that this part of the assessment did purposely not distinguish 
between first and co-authorship). This way, it was possible to ascertain the most 
frequent authors in the dataset, namely S.A. Grover and B. Jonsson, each 
involved in seven studies, L. Coupal (six studies) as well as T.D. Szucs and H. 
Zowall, with five studies each in the dataset. Finally, authors and studies were 
grouped according to the most frequent relationships in terms of authorship, 
resulting in twelve groups of studies (Table 4.9 below). It turned out that only 18 
studies in the dataset were not linked through common authorship to any of the 
other studies considered. Considering all links between studies results in one 
large group of related studies and a further six smaller groups. Only considering 
the strongest links between studies and ignoring some relationships between 
groups of studies results in the above mentioned 12 groups of papers related 
through common authorship. Finally, two categorical variables were generated 
for testing in the multilevel framework in Chapter 5.2. The hypothesis is that 
results from studies from one group of authors may be more in the same range 
compared to results from other groups of authors so that variability in measures 
of cost-effectiveness is lower for studies of common authorship.  
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Table 4.9: Relationships between papers in terms of common authorship 
 
Nr Authors Studies of common authorship 
0 No links through common authorship 
1, 7, 9, 10, 12, 17, 18, 19, 20, 
23, 24, 24, 38, 46, 48, 50, 60, 65 
1 Caro, Shepherd, McGuire, Klittich 2, 27, 33, 54, 58, 64 
2 Roberts, Merike, Wagner, Johnson, Goetghebeur, Sullivan 26, 27, 35, 36, 43, 55 
3 Grover, Coupal, Zovall, Hamilton, Lavoie 3, 4, 5, 8, 16, 22, 40, 61 
4 Pandya, Taylor, Weinstein, Thompson, Drummond 30, 33, 35, 53, 59, 62, 64 
5 Jonnsson, Pedersen, Wedel, Johannesson, Olsson, Kjekhus, Lindgren 6, 13, 14, 21, 36, 47, 51, 57 
6 Berger, Szucs, Maerz, Schaefer, Kuntz, Klose 11, 15, 37, 45, 49, 53 
7 Davies, Martikanen, Niskanen, Soini 39, 41, 42 
8 Neil, Calvert, Minhas, Nherera, Thorogod, Fuller 44, 54, 59, 63 
9 Ward, Ara, Pandor 27, 66, 67 
10 Scuffham, Chaplin 31, 32, 56 
11 Mihaylova (HPS-Group) 25, 52 
12 Morris 28, 29 
 
 
 
4.3.5. Conclusion 
 
 
This case study showed that MCA is a promising method to look into similarities 
between existing economic evaluation studies and thereby assessing the extent 
to which evidence replicates itself. Applied to an extensively studied area such as 
statins for the primary and secondary prevention of CVD, the author could show 
a fair degree of overlap between phenotypic similarities between studies 
detected by the method, and genotypic relationships between those studies 
assessed within a subsequent descriptive analysis. Future research may look into 
more systematic ways of variable selection and additional analytic options 
offered by the method to refine its results. In terms of this empirical analysis, 
however, it is not recommended to alter the multilevel model structure but 
rather to acknowledge existing links between economic valuation studies in 
terms of covariates on study-level.  
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5. Empirical Analysis 
 
 
In Chapter 3, a number of MLMs were developed for the integration of 
secondary cost-effectiveness data measured as incremental net monetary 
benefits (INMB). These models were then developed further into a bivariate 
framework for the explicit and simultaneous assessment of incremental cost and 
incremental effects in one model. The models were then put to the test and 
compared to a standard OLS regression model fitted to a pilot dataset on the 
cost-effectives of statins in the primary and secondary prevention of CVD. It 
turned out that the MLM framework consistently outperformed the OLS 
framework, and that the hierarchical structure assumed in each model was a key 
factor for the overall fit of the model. Hence, from the pilot study reported in 
Chapter 3.4 it got apparent that a key question for the empirical work of this 
project is to test which MLM works best for the purposes of this exercise. This 
chapter brings together the MLM methods developed in Chapter 3, the findings 
from the pilot study reported in Chapter 3.4, and the data obtained from a 
systematic review and data abstraction exercise on the cost-effectiveness of 
statins in the primary and secondary prevention of CVD, which was the focus of 
the previous Chapter 4.  
 
 
The primary aim of this chapter is to run the models developed on the data 
abstracted to address the transferability problem of economic evaluation data in 
health between geographic domains. The chapter first addresses the question of 
the most appropriate MLM structure before the focus is on covariate adjustment 
on data and study-level in Section 2 of this empirical exercise. Both issues need 
to be addressed prior to the assessment of country-level variability – or the lack 
thereof – which is assessed in detail in Section 3 of this chapter. Specifically, the 
potential to assess country-level covariates and implications of findings with 
respect to the transferability of economic evaluation data between countries are 
considered. Finally, a case study within which random slopes are added to the 
model demonstrates how the multilevel framework may be applied to explicitly 
model variation in the data as a function of explanatory variables. The case study 
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shows how this ‘variance function’ addresses the core of the transferability 
problem as it makes explicit the variability in the relationship of measures of 
cost-effectiveness and explanatory variables. For values of the explanatory 
variable for which variability in measures of cost-effectiveness is low, 
transferring evidence to the target domain may be rather indicated compared to 
values of the explanatory variable for which variability in international cost-
effectiveness data is particularly high.   
 
 
Accordingly, four fundamental objectives are addressed and elaborated on 
throughout the course of this chapter. The first objective is to determine the 
appropriate model structure which best fits the data on the cost-effectiveness of 
statins in the primary and secondary prevention of CVD. This involves not just 
testing which multilevel structure previously developed works well on the data 
collected, but also whether assumptions made in these models are justified for 
the data. The starting point of this first exercise is to run the models developed in 
Chapter 3 and tested in the pilot study on the full dataset without the inclusion 
of any covariates. Thereafter, it is tested whether the assumption of 
independence between countries is also justified for the subset of data which 
stems from multinational studies as not just the relevant economic evaluation 
literature, but also findings from the pilot study indicate that this might not be 
the case. It turns out that this issue is intrinsically tied to the issue of cross-
classification in the data. Finally, the issue of ‘shrinkage’ within the multilevel 
framework is addressed further, and it is elaborated on the question whether 
this constitutes a potential source of bias when analysing not individual patient 
data but rather secondary data from economic evaluation studies. MLM features 
such as ‘weighting’ are considered in response to this issue. Note that links 
between economic evaluation studies, e.g. in terms of common authorship, and 
the question whether such links shall be considered in terms of model structure 
or covariates, was the focus of the genealogy study reported in Chapter 4. 
Hence, this question is not picked up again before section two, which is 
concerned with covariate adjustment on data and study-level. 
 
 
All models are first run as variance components models without the inclusion of 
any slope parameters. This serves several objectives. First, it allows to assess 
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whether there is variation in INMBs (as well as ∆C and ∆E in the bivariate 
framework), within and between studies, and also between countries included in 
the dataset (Steele, 2008; Rasbash et al., 2009; Hox, 2010). It also allows 
quantifying this variability on each level modelled (Steele, 2008; Rasbash et al., 
2009; Hox, 2010). Furthermore, it can be assessed which studies, and countries, 
are outliers in terms of cost-effectiveness of the technology under consideration 
before adjusting for any covariates (Rasbash et al., 2009, CMM workshops / 
variance components). Finally, the variance components model serves as a 
benchmark for further analysis (Rasbash et al., 2009; Hox, 2010). As a result of 
analysis one of this empirical exercise we determine a multilevel model structure 
which is then carried forward to the second part of this chapter.  
 
 
The objective for the second part of this empirical exercise is to systematically 
assess covariates on data and study-level which were drawn from a long list of 
variability factors as obtained from the relevant literature on the transferability 
of economic evaluation data (Sculpher et al., 2004, Goeree et al., 2007). This 
assessment does not just serve the aim to infer which covariates may be related 
to INMB, ∆C or ∆E of statins in the primary and secondary prevention of CVD. 
Rather, in a multilevel framework, changing anything on a lower level might have 
an impact on each subsequent level (e.g. Hox, 2010). Hence, the inclusion of 
lover level covariates in the multilevel framework could potentially disclose 
further variation between countries included in the dataset, so that controlling 
for lower-level covariates is imperative for the assessment of variability factors 
on country-level (Hox, 2010). Hence, the second objective is to assess whether 
the model carried forward from Section 5.1 of this exercise performs better in 
this sense after the inclusion of covariates on data and study-level.  
 
After all the efforts taken to disclose country-level variability, it may be 
concluded that this source of variation is, in fact, present in the data, which then 
allows further analysis of potential causes of this variability between countries. 
This would be done by including country-level covariates in the model (Sculpher 
et al., 2004; Drummond et al., 2009). However, if country-level variability 
remains low throughout the course of this exercise, this could have a number of 
reasons. There may be, for instance, another model specification which fits the 
data better and which was not explicitly modelled in this study; or the 
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‘appropriate set of covariates to include’ was not yet found (Drummond et al., 
2009). Finally, it could in fact mean that there is simply not much of the 
variability in international cost-effectiveness data due to differences between 
countries, as most of this variability relates to differences within and between 
studies included in the dataset. Assessing these questions depending on the 
actual amount of variability disclosed on country-level both in the univariate and 
bivariate framework is the focus of Section 5.3 of this chapter.  
 
 
Finally, the fourth objective of this empirical exercise is to explore additional 
analytic features which are unique to the MLM framework. In particular, the final 
section of the empirical analysis looks into fitting random slopes to the model 
and, related to that, the concept of the ‘variance function’, where the variation in 
cost-effectiveness data may be explicitly modelled as a function of explanatory 
variables (Steele, 2008; Rasbash et al., 2009). When fitting covariates to the 
model in the second and third part of this exercise, it is assumed that intercepts 
of study regression lines vary randomly whereas the slopes of these regression 
lines are assumed to be fixed. This leads to parallel regression lines between 
studies included in the dataset (Steele, 2008; Rasbash et al., 2009). However, the 
relationship between measures of cost-effectiveness and explanatory variables 
may be different for different studies (or countries), which means that not just 
the intercepts, but also the regression slopes for these variables may differ 
between higher-level units. This has been previously acknowledged by some 
health economists who used MLM in the context of trial based economic 
evaluation (Sculpher et al., 2004; Manca et al., 2005; Thompson et al., 2006; 
Bachmann et al.; 2007). However, what is entirely new to the domain of 
economic evaluation in health is the concept of the variance function. Precisely, 
if one allows for random slopes, the variance on the level for which a random 
slope was modelled becomes a quadratic function of the explanatory variable 
(Steele, 2008) which may be used to express variation in measures of cost-
effectiveness data as a function of covariates in the model.  
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Figure 5.1.: Overall analysis plan for the empirical exercise of this project 
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This concept relates to the transferability problem at its core as one may argue 
that for values of the explanatory variable for which variation in higher-level 
units (i.e. studies and/or countries) is low, additional evidence for the target 
country may also be more likely to be in the same range in terms of cost-
effectiveness. In contrast, the higher this variation, the more indicated it may be 
to produce new target specific evidence. Hence, the variance function may be 
used to target research resources more specifically to those questions for which 
variance in international cost-effectiveness data is particularly high. 
 
The analysis strategy as outlined above is also in accord with what is 
recommended in the MLM literature. A bottom up approach is usually 
advocated, starting with the simplest possible model and then including 
parameters which are tested for significance after they have been added (e.g. 
Hox, 2010). This procedure starts by building the fixed part of the model, and 
then continues to the random components (Rasbash et al., 2009; Hox, 2010). It 
ensures to keep the model as simple as possible and thereby complies with the 
‘lex parsimoniae’ (Occam’s Razor). The simplest possible model is the variance 
components model without explanatory variables (Steele, 2008; Rasbash et al., 
2009; Hox, 2010). It is therefore also referred to as ‘intercepts only model’ as the 
regression lines in this model are parallel and ‘flat’ (Hox, 2010). After having 
specified the variance components model, covariates are tested. This is done by 
proceeding from the lower level to the higher level as changes on the lower level 
might impact anything observed on subsequent levels (Steele, 2008; Rasbash et 
al., 2009; Hox, 2010). Hence, data-level covariates are tested first, and once the 
model is fully specified on data-level, study-level and country-level covariates 
may be added. Once a full random intercepts model has been specified in that 
way, the next step is to test the random part of the model, hence fitting random 
slopes of covariates. Testing random slopes is executed on a parameter by 
parameter basis, as not doing so might lead to an ‘overparameterized model with 
serious estimation problems’ (Hox, 2010). It is acknowledged that covariates 
which were not significant with fixed slopes may be significant in a random slope 
specification (Rasbash et al., 2009; Hox, 2010). However, searching amongst the 
full dataset on a parameter by parameter basis (i.e. even separately for each 
category in a categorical variable) is not realistic in terms of the time effort 
involved and also not the purpose of the case study reported in Section 5.4, so 
that it was decided to scale down on this particular exercise.  
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The remainder of this chapter is organized alongside the four fundamental 
objectives defined above. Hence, the following Section 5.1. reports on various 
variance components models in the univariate and bivariate framework. 
Thereafter, covariates on data and study-level are assessed systematically for the 
inclusion in the multilevel model carried forward from part one of this empirical 
exercise. This is reported in Section 5.2. The covariates under consideration were 
drawn from a long list of variability factors as obtained from the relevant 
literature (Sculpher et al., 2004; Goeree et al., 2007) and further details about a 
systematic literature review and data abstraction exercise are also obtainable 
from the previous Chapter 4. Discussing the choice of covariates within each 
level of the model and each subgroup of variables constitutes a key challenge in 
this empirical exercise due to the theoretically unlimited space of variability 
factors and consequently the large number of covariates abstracted from the 
studies includable in this project. After having specified a full random intercepts 
model with data and study-level covariates in Section 5.2., the following Section 
5.3 focusses on the country-level by either including covariates, or considering 
potential reasons for a lack of country-level variability on that level.  
 
Independent of the outcome of the exercise as outlined above, the final Section 
5.4 of this chapter demonstrates the value of fitting random slopes and to model 
variation in international cost-effectiveness data as a function of explanatory 
variables. It is argued that the concept of the ‘variance function’ addresses the 
transferability problem as it may be applied to target research resources more 
specifically to those questions for which variation in measures of cost-
effectiveness is particularly high. 
 
All multilevel analyses are carried out in MLwiN (Rasbash et al., 2009a) and 
performed in a univariate framework with INMBs as response variable, and also 
in a bivariate framework with the two stochastic components of the INMB 
statistic (∆C and ∆E) as a vector of response variables. Additional analyses 
(descriptive statistics, principal component factor analyses, multiple 
correspondence analyses etc.) were carried out in STATA 12.   
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5.1. Objective one: Determining the appropriate 
multilevel model structure 
 
 
The aim of this empirical exercise is to address the transferability problem of 
health economic evaluations by fitting a multilevel model to international data 
on the cost-effectiveness of statins in the primary and secondary prevention of 
CVD. This allows the assessment of variability factors on each level of the 
modelled data hierarchy. In the MLM methods Chapter 3, a number of 
alternative model structures have been developed, starting off from a single 
level OLS regression and ending up with a cross-classified bivariate model which 
allows not just directly assessing a country-level in the presence of cross-
classified data from multinational studies, but also decomposes the INMB 
statistic by modelling both ∆C and ∆E as a vector of response variables. These 
alternative model structures were then tested in a pilot study in Chapter 3.4, 
which was carried out on a reduced dataset on the cost-effectiveness of statins. 
This pilot study already showed that, due to ignoring that data in studies is not 
independent, the OLS regression model and the two-level model which clusters 
data in countries only, were clearly outperformed by those multilevel structures 
which did explicitly account for a study-level.  
 
 
However, it was also observed that the cross-classified model, which takes into 
account that data is clustered in both studies and countries and also allows the 
inclusion of data from multinational studies which are responsible for the cross-
classification problem, did not perform any better than the two-level hierarchical 
model which completely ignores the existence of a country-level. Not just was 
there no improvement in model fit due to the inclusion of a country-level, there 
was also a lack of noteworthy variability on the country-level itself. As a potential 
reason for this finding it was hypothesized that the assumption of independence 
between geographic domains may not be adequate for those studies in the 
dataset which are ‘multinational’ in nature and thereby introduce the issue of 
cross-classification as their data may not appropriately reflect the variation in 
cost-effectiveness attributable to differences between the countries considered. 
In other words, if data from multinational studies is less affected by variability on 
country-level, this potentially ‘lays a curtain’ over the overall country-level 
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variability present in the rest of the data from non-multinational studies and 
therefore casts into doubt whether the assumption of independence between 
countries actually holds for those studies. The suspicion that data from 
multinational studies may not be as context specific as generally assumed, e.g. 
due to standardised trial protocols (e.g. Ramsey et al., 2005), or the fact that not 
all data required to populate an economic model is country-specific (e.g. Barbieri 
et al., 2005), has been discussed before in the economic evaluation literature. 
Therefore, it is indicated to investigate whether the assumption of independence 
on country-level actually holds for data from multinational studies before settling 
on a MLM structure to be carried forward to the analysis of potential variability 
factors in the second part of this empirical exercise.  
 
Finally, as this is also intrinsically tied to determining the appropriate model 
structure, additional assumptions required to fit a MLM to this dataset on the 
cost-effectiveness of statins are considered before adding covariates to the 
model. The fact that this exercise utilizes secondary data and not individual 
patient data requires further attention as the ‘gravity’ of a study in a multilevel 
framework partly depends on the number of data points provided by that study, 
and this, in turn, affects the amount of shrinkage that study is subject to (Steele, 
2008; Rasbash et al., 2009). Hence, as data points do not represent actual 
individual patients, a studies’ ‘weight’ in the overall model might only depend on 
the extensive reporting of subgroup and/or sensitivity analyses. Therefore, it is 
to consider whether this constitutes a potential thread to the validity of results 
and, if so, whether there are any strategies available, such as adding weights to 
individual studies or to bootstrap studies and resample data before fitting the 
MLM, which could efficiently counteract this potential source of bias.  
 
 
The following Section 5.1.1 details the analysis strategy to investigate the 
appropriate multilevel structure for the remainder of this empirical exercise. 
Subsequently, the data and methods of analysis to carry out this assessment are 
explained in Sections 5.1.2 and 5.1.3. Section 5.1.4 reports and discusses the 
results of the running various variance components models before Section 5.1.5 
picks up on the issue of shrinkage as a potential source of bias in the assessment 
of secondary data from international cost-effectiveness literature.  
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5.1.1. Plan of analysis for part one of this empirical exercise  
 
 
The starting point of this analysis is the cross-classified model developed in the 
MLM methods Chapter 3 which was already applied to the pilot study dataset in 
Chapter 3.4. This model offers the most flexibility in terms of accommodating 
both a study and country-level and simultaneously allows for cross-classified 
data structures due to multinational studies being part of the dataset. However, 
this model also comes with considerable complexity, and its relative value 
depends upon its ability to capture variability on each level of the data hierarchy. 
Pilot study results indicate, however, that the cross-classified model may not 
capture a sufficient amount of country-level variability to permit the assessment 
of covariates on that level. Hence, if variability between countries is low, then we 
first need to rule out that model assumptions may cause this failure to capture 
variability in measures of cost-effectiveness on country-level.  
 
As outlined in the introduction to this section, one reason may be the impact of 
multinational trial data on between-country variability as data from 
multinational trials is suspected to draw a curtain over potentially existing 
country-level variability in the cross-classified model. It is hypothesized that data 
from multinational trials shows much lower between-country variability, and this 
data ‘infects’ country parameters in the cross-classified model and drags them 
towards each other in the MLM. Potential reasons for this lower country-level 
variability have been discussed in the literature (e.g. Ramsey et al., 2005). The 
easiest way to address this issue would obviously be to simply drop the data 
from multinational studies from any further analysis. This would result in a 
strictly hierarchical dataset which would allow assessing whether country-level 
variation would increase as compared to the cross-classified model. However, 
though this model is also run to receive some benchmark values on country-level 
variation without multinational studies in the dataset, dropping data means 
losing valuable observations, and especially in a multilevel context, where one 
needs a certain number of units on higher levels to assume random parameters 
(Snijders, 2005), this may not be the preferred strategy as the number of studies 
and countries in the dataset may be affected too. In addition, one would 
compare two different models being applied to two different subsets of the data, 
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meaning that differences in model fit are not directly comparable across both 
experiments. 
 
 
There is an alternative analysis strategy which offers additional insights into the 
causes of country-level variability, or the lack thereof, in the dataset. It all comes 
back to the question of whether subsets of the data are actually independent. 
The cross-classified model assigns data from both single-country-studies and 
multinational studies to their respective study on study-level, hence assuming 
that this data is dependent within studies and independent between studies. 
Exactly the same is assumed on country-level though this assumption may not 
hold for multinational studies. Therefore, instead of dropping the affected data 
points, the data from multinational studies may simply be ‘pooled’ in a distinct 
group on country-level, thereby removing its influence on other country-
parameters. Obviously, as some countries in the dataset are only considered 
within those multinational studies, this would mean to lose some parameters on 
country-level. However, what is gained is the chance to analyse the full dataset 
with all studies originally includable in this exercise whilst still obtaining ‘clean’ 
country-level estimates from all the other studies in the dataset. Secondly, the 
problem of cross-classification in the data does no longer exist so that a strictly 
hierarchical three-level model with data being clustered in studies and studies 
being clustered in countries, applies. However, most importantly this strategy 
addresses that multinational studies might not appropriately reflect country-
level variability, which may also be the cause for (severely) underestimated 
country-level variation as observed in the pilot study.  
 
 
In conclusion, if the suspicion that data from multinational studies may draw a 
curtain over existing country-level variation is supported by the data, much 
higher country-level variation would be observed when running such a three-
level hierarchical model on a dataset where data from multinational studies is 
pooled in a separate group on country-level. To rule out that the model 
architecture itself conceals country-level variability, a cross-classified model is 
also run on an ‘intermediate’ dataset, where some data from multinational 
studies has been pooled on country-level, and the rest of that data has been 
assigned to their respective target countries. If the problem lies in the data and 
not in the model architecture that allows for cross-classification, then country-
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level variation would be somewhere in between the fully cross-classified model 
and the alternative three-level model which pools all data from multinational 
studies on country-level.  
 
It is important to note that, instead of pooling data from multinational studies on 
country-level, it was also considered to do the opposite, namely splitting data 
from these studies on study-level. This would introduce a strict 1:1 relationship 
between ‘hypothetical’ studies and the respective countries modelled in the 
affected studies and thereby also eliminate the cross-classification problem. 
However, though the number of countries would remain unaffected, this would 
spuriously inflate the number of studies on study-level. Doing so would have 
strong implications on the random part of the model, potentially resulting in 
severely underestimated study-level variability (e.g. Steele, 2008). To understand 
this issue it is useful to draw an analogy to the OLS regression model which 
overestimates precision for higher-level covariates if the underlying data is not 
independent (Steele, 2008; Rasbash et al., 2009; Hox, 2010). Furthermore, whilst 
the assumption of dependent country-level data within those multinational 
studies is supported by the relevant literature (e.g. Ramsey et al., 2005; Barbieri 
et al., 2005), the assumption of independent data on study-level with respect to 
those countries is most certainly not. On top of that, if country-level variability 
increased in such a model, this could simply be due to some of the study-level 
variability being ‘dragged’ to the country-level because of the strict 1:1 
relationship between hypothetical study-groups and countries within these 
multinational studies. Finally, comparing the cross-classified model to a three-
level hierarchical model where data from multinational studies is pooled on 
country-level allows looking into the issue of whether multinational study data 
shows lower country-level variability, which constitutes in itself an important 
finding from this empirical exercise. On the other hand, splitting data on study-
level would not permit any additional insights into this important issue.  
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In conclusion, models in this first exercise will be run on: 
• the fully cross-classified dataset 
• A cross-classified dataset where data from multinational studies for some 
countries is pooled in one group, whilst data for other countries has been 
assigned to their respective country groups (intermediate dataset) 
• the full dataset where cross-classification has been completely eliminated 
due to pooling data from multinational studies on country-level 
(hierarchical dataset) 
• a reduced dataset where all multinational studies were dropped for 
comparative purposes (reduced dataset) 
 
The main models of interest are the cross-classified MLM, the three-level 
hierarchical model and, for comparative purposes following the results from the 
pilot study, the two-level hierarchical model which ignores the existence of a 
country-level. In addition, the two-level model which clusters data in countries 
only and the OLS regression model, which completely ignores complex data 
structures, are also implemented to confirm findings from the pilot study in 
terms of their worse fit compared to the above mentioned model specifications.  
Table 5.1 shows the analysis plan for this first exercise with the dataset being 
subject to different assumptions as introduced above on the vertical axis and the 
respective MLMs to fit on the horizontal axis. 
 
Table 5.1:   Analysis strategy for the first exercise to determine the appropriate 
multilevel model structure 
Dataset 
Models 
Cross-
classified 
dataset 
Intermediate 
dataset 
Hierarchical 
dataset 
Reduced 
dataset 
Cross-classified model X X -- -- 
Three-level hierarchical 
model 
-- -- X X 
Two-level model with data 
clustered in studies 
X X 
Two-level model with data 
clustered in countries 
X X X X 
OLS regression model X X 
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Because assumptions regarding independence on country-level as introduced 
above leave the data and study-levels unaffected, the two-level model which 
clusters data in studies only yields identical results for the cross-classified, the 
intermediate and the hierarchical dataset. Only the reduced dataset may yield 
different results due to all data points from multinational studies being dropped 
from this analysis. The same holds for the OLS regression model as this 
specification does not consider any complex data structures. Only the two-level 
hierarchical model, which clusters data in countries, may differ in its results 
between different assumptions regarding the data on country-level as these 
directly impact on the respective model output.  
 
Before further specifying all models to be run in this exercise, the following 
section introduces the data which is used for this analysis in more detail.  
 
5.1.2. Data for exercise one 
 
Chapter 4 already reported on a systematic literature review on the cost-
effectiveness of statins in the primary and secondary prevention of CVD and 
explained how the form for abstracting data from these studies was developed 
from a long list of potential variability factors drawn from the relevant economic 
evaluation literature and used to populate a dataset for this empirical exercise. 
This chapter also reports on the efforts taken to prepare the dataset for further 
analysis and the resulting dataset is now being used for the analysis as outlined 
above. The intervention of statins in the primary and secondary prevention of 
CVD was chosen as it has been extensively researched in the past, meaning that 
a sufficient number of includable studies and geographic locations was 
hypothesized to be present in the data to justify the assumption of random 
parameters on study and country-level which is crucial for fitting multilevel 
models (Spiegelhalter et al., 2000; Spiegelhalter et al., Rasbash et al., 2009; 2004; 
Hox, 2010).  
 
 
During the systematic literature review, 67 studies were found to be includable 
in this exercise, providing in total 2094 estimates of incremental net monetary 
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benefit where the authors also decomposed the INMB statistic, hence explicitly 
reporting data on ∆C and ∆E of the healthcare intervention. This data is clustered 
in 23 different geographic locations. As some data is applicable to the UK as a 
whole, but other data only to England/Wales on the one hand or Scotland on the 
other, three distinct categories were introduced to the dataset to reflect these 
geographic entities. Table 5.2 provides an overview of the geographic locations 
represented in the data and Figure 5.2 is a Venn-diagram which groups data 
according to the respective studies being ‘multinational’ or ‘single country’ in 
nature. Note that Table 5.2 differs from Table 4.5 in Chapter 4.2.2 as it shows the 
distribution of data points – not studies – per country.  
 
Table 5.2: Geographic locations represented in the dataset  
 
Country Frequency In % Cummulative  
Data points for that 
country from 
multinational studies 
% of data points for 
that country from 
multinational studies 
Australia 13 0.62% 0.62% 1 7.69% 
Belgium 30 1.43% 2.05% 8 26.67% 
Brazil 2 0.1% 2.15% -- -- 
Canada 422 20.15% 22.30% 16 3.79% 
Denmark* 13 0.62% 22.92% 13 100% 
Finland 39 1.86% 24.79% 13 33.33% 
France* 24 1.15% 25.93% 24 100% 
Germany 133 6.35% 32.28% 39 29.32% 
Hong Kong 8 0.38% 32.66% -- -- 
Hungary 4 0.19% 32.86% -- -- 
Italy* 28 1.34% 34.19% 28 100% 
Japan 6 0.29% 34.48% -- -- 
Netherlands 70 3.34% 37.82% -- -- 
New Zealand* 1 0.05% 37.87% 1 100% 
Norway* 10 0.48% 38.35% 10 100% 
Portugal* 12 0.57% 38.92% 12 100% 
Spain 40 1.91% 40.83% 36 90% 
Sweden 81 3.87% 44.70% 34 41.98% 
Switzerland 3 0.14% 44.84% 1 33.33% 
UK 408 19.48% 64.33% 36 8.82% 
UK (Engl./Wales) 475 22.68% 87.01% -- -- 
UK (Scotland) 11 0.53% 87.54% -- -- 
USA 261 12.46% 100% 16 6.13% 
Total 2094 100% 100% 288 13.75% 
*  Data for this country was only available from multinational studies  
 
As can be seem from Table 5.2 and Figure 5.2, the vast majority of data stems 
from single-country-studies with 1806 data points from 61 studies applicable to 
17 geographic domains. On the other hand, 16 countries were considered in six 
multinational studies yielding a total of 288 data points. These 288 data points 
from multinational studies introduce the cross-classification problem to the 
dataset as it causes the strict hierarchical structure between studies and 
countries in the remaining data to break down. Of the 16 geographic domains 
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considered in these multinational studies, six only appear in those studies adding 
up to 88 data points, meaning that none of the single-country-studies provides 
data for any of those countries (Denmark, France, Italy, Netherlands, New 
Zealand and Norway). The remaining ten countries considered in multinational 
studies add up to 200 data points which, in the cross-classified model, would 
impact on country-parameters of those countries which were also considered in 
single-country-studies. Table 5.2 shows that this impact ranges between roughly 
4% (Canada) to up to 90% (Spain) of all data points for those ten countries being 
drawn from multinational studies. It is hypothesized that this fact, plus the 
existence of countries only considered in multinational studies, significantly 
reduces country-level variation in the fully cross-classified model as data from 
multinational studies severely underestimates country-level variation in the cost-
effectiveness of statins for the primary and secondary prevention of CVD.   
 
Figure 5.2: Venn-diagram ordering country-specific data according to the 
nature of the underlying economic evaluation study 
 
 
 
 
 
 
 
 
The easiest way to eliminate this impact is obviously be to drop all six studies 
from further analyses. To yield estimates of country-level variability without the 
influence of data from multinational studies, a three-level hierarchical model is 
implemented on this reduced dataset for comparative purposes. In a sense it 
constitutes the ‘opposite extreme’ to the full, cross-classified dataset, resulting in 
1806 data-points clustered in 61 studies and 17 countries. However, an 
alternative solution is to pool data from multinational studies on country-level. 
This allows keeping data from all multinational studies in the dataset and only 
reduces the number of parameters on country-level by the respective amount of 
Nk (country) = 17 
Nj (study) = 61 
Ni (data) =1806 
 
Countries assessed in 
‚single-country studies’ 
only 
Nk (country) = 6 
Nj (study) = 4 
Ni (data) =88 
 
Countries assessed in 
‚multinational studies’ 
only 
Nk (country) = 10 
Nj (study) = 2 
Ni (data) =200 
 
Data from multinational 
studies applicable to 
countries also assessed in 
single-country-studies 
 
 
Total:         Ni (data) =2094        Nj (study) = 67       Nk (country) = 23 
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countries considered only in multinational studies. Hence, this dataset, which is 
also strictly hierarchical in nature, consists of 2094 data points from 67 studies 
and 17+1 countries (the additional country-group refers to the data from 
multinational studies being pooled in a separate group on country-level).   
 
In addition, an ‘intermediate solution’ is considered which also reduces the 
impact of data from multinational studies on country-parameters, but still 
requires fitting a cross-classified model to the data. All six countries which only 
appear in multinational studies (Denmark, France, Italy, New Zealand, Norway 
and Portugal) are still considered as separate groups on country-level. On the 
other hand, data from multinational studies which refers to one of the ten 
countries already existing in the dataset (i.e. the ‘overlapping’ part of the Venn-
diagram in Figure 5.2.) is pooled in a separate group on country-level. This means 
that 88 data points from multinational studies are assumed to be country 
specific, resulting in the maximal number of 23 country-specific groups on that 
level. The remaining 200 data points from multinational studies are pooled in a 
further group on country-level, so that this dataset consists of 2094 data points 
from 67 studies and 23+1 countries. The value of this additional analysis lies in 
the fact that it introduces cross-classification on a ‘lower scale’, and if low 
country-level variability in the fully cross-classified model as observed in the pilot 
study is only due to the data from multinational studies showing much less 
variability then the rest of the data, then running a MLM on this intermediate 
dataset would result in country-level variation being somewhere in between the 
fully cross-classified dataset and the three-level hierarchical dataset where all 
data points from multinational studies are being pooled on country-level.  
 
 
Table 5.3 below summarizes the four resulting datasets which are used to assess 
the appropriate model structure for further analysis. Further details on the 
studies included in this empirical exercise are also available from Chapter 4, 
which reports on the systematic literature review on the cost-effectiveness of 
statins for the primary and secondary prevention of CVD.  
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Table 5.3:  Datasets for determining the appropriate multilevel model structure 
Dataset 
Nr. and 
name  
Assumptions regarding data structure 
Data 
structure 
Ni 
(data) 
Nj 
(study) 
Nk 
(country) 
Data points 
from 
multinational 
studies 
pooled on 
country-level 
1a 
cross-
classified 
data within multinational studies is 
independent on country-level  
 
 All data from multinational studies 
grouped to respective target 
countries 
Cross-
classified 
2094 67 23 0 
1b 
inter-
mediate 
Part of the data from multinational 
studies is dependent on country-
level.  
 
 Data from multinational studies for 
ten 
 countries pooled on country-level  
Cross-
classified 
2094 67 23+1 200 
1c 
hier-
archical 
All data from multinational studies 
dependent on country-level 
 
 All data from multinational studies 
pooled on country-level 
3-level 
hier-
archical 
2094 67 17+1 288 
1d 
reduced 
All data from multinational studies 
dependent on country-level 
 
 All data from multinational studies 
dropped 
3-level 
hier-
archical 
1806 61 17 0 
 
Now that several variants of the dataset for assessing the appropriate MLM 
structure have been introduced (which all differ by the assumptions made 
regarding independence of cost-effectiveness data on country-level), the actual 
variables required for this analysis are introduced next. As only the response 
variables (INMB, ∆C and ∆E) are modelled as clustered in studies and geographic 
locations without the inclusion of any covariates, the few variables required are 
i) an ID-variable for the study the data point was drawn from, ii) an ID-variable 
for the country the data point refers to and iii) data on the response variables of 
interest (i.e. INMB, ∆C and ∆E). As all data points obviously refer to a specific 
study, the country of interest was always specified in each study, and as the 
reporting of INMBs, ∆C and ∆E was a study inclusion criterion, there is no data 
missing in any of these variables. Descriptive statistics for the three response 
variables can be found below in Table 5.4.  
Table 5.4:  Descriptive statistics of response variables for exercise one 
 
Variable Obs Mean Std. Dev. Min Max 
∆C 2094 £ 8871.77 £ 15061.75 £ -3688.47 £ 178653.1 
∆E 2094 0.636 0.908 -.03 5.4 
INMB 2094 £ 10209.56 £25422.09 £ -151053.1 £ 150430.5 
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Obviously, when multiplying the raw mean ∆E of 0.636 with the threshold value 
λ of 30.000 assumed in this exercise and subtracting the raw mean ∆C of 
8871.77, one arrives almost exactly at the mean INMB of £ 10209.56 measured 
in 2010 £-Sterling.  
 
 
5.1.3. Methods of analysis for exercise one 
 
 
As detailed in the plan of analysis, the models of interest in this first exercise are 
the cross-classified specification with data nested in studies and geographic 
locations, where studies and countries are cross-classified and, secondly, the 
three-level hierarchical model, where data is clustered in studies and studies are 
clustered in countries respectively. Both models are compared to a simpler two-
level hierarchical model which groups data in i) studies only and ii) countries 
only. In addition, the respective OLS regression model, which does not take into 
account complex data structures, is implemented to confirm findings from the 
pilot study. All models are run in a univariate version with INMB as the only 
response variable and a bivariate version with ∆C and ∆E as a vector of response 
variables. Table 5.5 shows the unit diagrams as well as the respective algebraic 
forms of these models. Details on complex data structures, MLM methodology, 
and the algebra presented below are also provided in Chapter 3.  
 
 
Table 5.5 summarizes all five models to be run in this first exercise to determine 
the appropriate multilevel model structure. As mentioned, models 1.a and 1.b 
both take into account that international cost-effectiveness data is nested in the 
studies it was drawn from and the countries it refers to. However, model 1.a. 
assumes that studies and countries are cross-classified due to the data drawn 
from multinational studies being grouped to their respective target countries 
whilst model 1.b assumes a strict hierarchical order between studies and 
countries as data from multinational studies may either be dropped or pooled in 
a separate group on country-level. Models 1.c and 1.d are both two-level models 
which either assume that data is only clustered in the studies it was drawn from 
(model 1.c) or the countries it refers to (model 1.d). Model 1.e. is an empty OLS 
regression model which ignores the existence of complex structures in the data.
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Table 5.5. Multilevel Models for Exercise one 
Model summary Unit diagrams Univariate model 
specification 
Bivariate model specification 
 
Model 1 a  
 
Cross-classified variance 
components model with cost-
effectiveness data clustered in 
studies and countries where 
studies and countries are cross-
classified.  
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Model 1 b 
 
Three-level hierarchical variance 
components model with cost-
effectiveness estimates being 
nested in economic evaluation 
studies and studies being nested 
in geographic domains.  
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Models 1.c and 1.d 
 
Two-level variance components 
model with either: 
- cost-effectiveness data 
clustered in studies only 
(model 1.c) or   
- cost-effectiveness data 
clustered in countries only 
(model 1.d) 
 
~(,   = +! +  
 
With !~(0, "	  ~(0, 	  
}v,v	8~ ~(,  
 n, = (n+!n + n ∗ n, 
 8, =  1	(	∆	*%$0	(	∆	*$        	, = 1 − 8 
With: 
P!,,!,8,Q ~ (0, Ω"      where  Ω" = R",	",8 ",8	 S 
P,,,8,Q ~ (0, Ω      where  Ω = R,	,8 ,8	 S 
 
Model 1.e 
 
Empty ordinary least squares 
regression model which ignores 
complex data structures 
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Study 1 / 
Country A 
 
Study 2 / 
Country B 
Study 3 /  
Country C 
CE CE CE CE CE CE CE CE 
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All models consist of an intercept term ′β′, and an error term for each 
hierarchical level. The subscripts refer to these levels with ‘i’ representing level 
one, ‘j’ level two, and ‘k’ level three so that ‘v:’ is the error term for level three, ′u:’ the error term for level two and ‘e:’the error term for level one 
respectively. As the cross-classified model, though conceptually a three-level 
model, is regarded as a two-level structure with countries and studies cross-
classified at level two, the error terms are denoted with ‘u:’ and ‘u′ 
respectively (Rasbash et al., 2009; Hox, 2010). For the univariate specification, it 
is assumed that INMB is normally distributed at each level of the model which is 
denoted with ‘y:~N(XB,Ω’. 
 
 
Decomposing the INMB statistic offers a number of advantages in this exercise 
(Nixon et al., 2005; Pinto et al., 2005; Manca et al., 2007; Grieve et al., 2007; 
Bachmann et al., 2007; Willan et al., 2008; Grieve et al., 2010). First, there is no 
need to run models at different threshold values λ, which is necessary to 
combine ∆C and ∆E to INMBs. Secondly, the correlation between the two 
stochastic components of the INMB statistic is explicitly modelled. Finally, once 
covariates are included, a bivariate model allows assessing the differential 
impact of covariates on each response variable whilst acknowledging that ∆C and 
∆E are, themselves, correlated. The hierarchical structure assumed in these 
bivariate models is exactly identical to the hierarchy assumed in their univariate 
counterparts. However, a bivariate normal distribution is now assumed for the 
two response variables ∆C and ∆E. Furthermore, a response indicator ‘r’ is 
included which is 1 for ∆C and 0 for ∆E and a separate level for this response 
indicator has been fitted below the data-level. Finally, the bivariate model 
estimates one error variance for each response variable plus their respective 
covariance on each level. Again, further details on the multilevel methodology 
applied in this empirical exercise are also available from Chapter 3.  
 
 
All datasets and the respective models to fit have now been specified for this 
first experiment. Hence, the next step is to actually implement and run these 
models within the software environment MLwiN using Markov Chain Monte 
Carlo (MCMC) estimation (Rasbash et al., 2009a; Browne, 2012). Though all 
models could also be implemented using iterative generalised least squares 
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(IGLS), it is a far more complex procedure, which is why it has been strongly 
advocated to use MCMC for cross-classified and especially for bivariate models in 
MLwiN (Rasbash et al., 2009 and personal communication with Professor W.J. 
Browne, CMM, Bristol). A detailed step by step guide on how to implement all 
models in MLwiN can be found in Appendix 3. The statistical software package 
MLwiN was chosen for this exercise as it is special MLM software with unique 
capacities to specify complex data structures as developed in this empirical 
exercise (Rasbash et al., 2009a). Though it is acknowledged that there are other 
software applications allowing to fit MLMs (e.g. HLM, STATA or R),the features 
offered by MLwiN proved particularly useful to deal with complex structures 
such as cross-classification, or multivariate MLMs, or even a combination 
thereof. In addition, the Centre for Multilevel Modelling in Bristol, which 
developed the software package MLwiN, is sponsored through the UK Economics 
and Social Science Research Council, which enables free access to an unrestricted 
version of MLwiN to all researchers based in a UK academic institution.  
 
 
The following section reports on the results of this first exercise to determine the 
appropriate multilevel structure for secondary cost-effectiveness data from 
different geographic domains.  
 
 
5.1.4. Results of exercise one  
 
 
Table 5.6 provides the results of running the univariate models and Table 5.7 
shows the corresponding results for the bivariate model specifications. When 
looking at the fixed part of each model (i.e. their intercepts) within the univariate 
framework first, one may conclude that results of the cross-classified and three-
level hierarchical model (models 1.a. and 1.b) are very much in the same range 
(between £7191 and £7266). Only when applying the three-level hierarchical 
model to the reduced dataset, the intercept is slightly lower, producing an 
overall mean INMB of £6606 measured in 2010 £-Sterling. Assumptions about 
the country-level do not affect the two-level hierarchical model which clusters 
data in studies only (model 1.c.), which is why this model has only been run once 
with the full dataset and once with the reduced dataset. Results correspond very 
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strongly with models 1.a and 1.b (£7269 for the full dataset and £6707 for the 
reduced dataset without data from multinational trials). However, intercepts of 
the two-level model which clusters data in countries (model 1.d) and the OLS 
regression model (model 1.e) clearly differ from the results of the other models. 
As the intercept of an empty OLS regression model simply reduces to the raw 
mean of the response variable, results reported for model 1.e in Table 5.6 are 
identical to the raw mean INMB reported in Table 5.4. Interestingly, the two-
level model, which clusters data in countries only, corresponds much stronger 
with this OLS regression model for the cross-classified and intermediate datasets 
whilst not assuming independence of data from multinational studies on 
country-level clearly affects the intercept of model 1.d. This observation already 
indicates the importance of appropriately reflecting complex data structures and 
making reasonable assumptions about dependencies in the data when analysing 
secondary cost-effectiveness data from published economic evaluation studies.  
 
 
The intercepts of the bivariate model specifications reported in Table 5.7 are 
considered next. First, for the bivariate model, ∆C was linearly transformed by 
dividing each value of this response variable by 100. Though theoretically 
irrelevant, MLwiN may encounter convergence problems if, in a multivariate 
model, there is a large difference in error variances between the different 
response variables; as it is the case for the error variances of ∆C and ∆E (personal 
communication with Professor W.J. Browne and R. Pillinger, CMM, Bristol). 
When looking at the results, a reassuring observation is that re-combining the 
two response variables ∆C and ∆E to INMB’s assuming a threshold value λ of 
£30,000 resembles the values reported for the intercepts of the univariate 
models in Table 5.6, though some variation is likely due to the random nature of 
the MCMC estimation process and the different model specifications (Browne, 
2012). As for the univariate model specifications, models 2.a. and 2.b produce 
very similar intercepts. Likewise, model 2.c, which clusters data in studies only, 
shows similar results to the cross-classified and the three-level hierarchical 
model. However, when decomposing the INMB statistic, it suddenly becomes 
apparent that the similarity in the intercepts between model 1.d and 1.e in the 
univariate framework is likely to be a coincidence only as, in the bivariate 
framework, the corresponding values for ∆C and ∆E differ sharply. Only re-
combining ∆C and ∆E to INMB’ leads to the observed resemblance in results as in 
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the univariate models. This is a very compelling argument for decomposing the 
INMB statistic and indicates that some variability in measures of cost-
effectiveness may simply ‘disappear’ when combining ∆C and ∆E to INMBs.  
 
Hence, a first look at the variance components models reported in Tables 5.6 and 
5.7 already reveals that different assumptions about the hierarchical structure of 
a dataset may have strong implications on the fixed part of the model. However, 
if models which only differ with respect to their hierarchical structure do 
produce different results, one needs to choose one model specification which 
may fit the data best. For this purpose, one may compare the deviance of each 
model (Steele, 2008; Bartholomew et al., 2008; Rasbash et al, 2009; Hox, 2010).  
Generally, when estimating a multilevel model using IGLS, the deviance is the 
difference in the -2*log(likelihood) values for a fitted model and a saturated 
model (Steele, 2008; Bartholomew et al., 2008; Rasbash et al, 2009; Hox, 2010). 
When estimating a model using MCMC, the deviance information criterion (DIC) 
is the mean deviance at each iteration of the MCMC estimation procedure 
(Browne, 2012).  This DIC also accounts for the number of parameters in the 
model so that the values reported in Tables 5.6 and 5.7 are directly comparable 
between competing model specifications (Browne; 2012). However, as Browne 
(2012) clarifies, the ‘stochastic nature of the MCMC algorithm leads to some 
random variability in the DIC diagnostic depending on starting values and 
random number seeds’. If differences in the DIC diagnostic are small, this should 
hence be confirmed with different seeds and/or starting values. (Browne, 2012) 
 
 
Comparing the DIC diagnostic across different model specifications in Tables 5.6 
and 5.7 clearly confirms the findings from the pilot study. The OLS regression 
model, which fails to capture any complex data structures, and the two-level 
hierarchical model, which clusters data in countries only, thereby ignoring that 
data is also clustered in economic evaluation studies, are clearly outperformed 
by the more elaborated model specifications which take into account the 
existence of a study-level. This fact holds both within the univariate and bivariate 
framework.  
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Table 5.6: Results for running univariate models in exercise one: 
Model 
 
 
Dataset 
Model 1.a 
Cross-classified model 
(data in studies and countries) 
Model 1.b 
Three-level hierarchical model 
(data in studies and countries 
Model 1.c. 
Two-level hierarchical model 
(data in studies) 
Model 1.d. 
Two-level hierarchical model 
(data in countries) 
Model 1.e. 
OLS regression model 
(no complex data structures) 
INMB INMB INMB INMB INMB 
1.a. 
Cross-classified 
dataset 
Nk = 23 
Nj = 67 
Ni = 2094 
 
 
Intercept 
(λ=£30,000) 
7241 -- 7269 10244 10207 
σ3:	 	(Country) 247200 -- -- 141402544 -- σ3	 	(Study) 252676864 -- 253045104 -- -- σ2	 	(Data) 290686048 -- 290676352 557439040 646884928 
VPC - country 
VPC – study 
VPC - data 
0.05% 
46.48% 
53.47% 
-- 
-- 
-- 
-- 
46.54% 
53.46% 
20.23% 
-- 
79.77% 
-- 
-- 
100% 
DIC 46749 -- 46749 48112 48424 
Dataset  INMB INMB INMB INMB INMB 
1.b. 
Intermediate 
dataset 
Nk = 23+1 
Nj = 67 
Ni = 2094 
 
Intercept 
(λ=£30,000) 
7266 -- 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
10389 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
"K	 	(Country) 312401 -- 149956464 "	 	(Study) 252744640 -- -- 	 	(Data) 290719328 -- 546511168 
VPC - country 
VPC – study 
VPC - data 
0.06% 
46.48% 
53.46% 
-- 
-- 
-- 
21.53% 
-- 
78.47% 
DIC 46748 -- 48111 
Dataset  INMB INMB INMB INMB INMB 
1.c. 
Hierarchical 
dataset 
Nk = 17+1 
Nj = 67 
Ni = 2094 
 
Intercept 
(λ=£30,000) 
-- 7191 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
7725 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
"K	 	(Country) -- 2482226 89529856 "	 	(Study) -- 251875168 -- 	 	(Data) -- 290664096 555042432 
VPC - country 
VPC – study 
VPC - data 
-- 
-- 
-- 
0.46% 
46.21% 
53.33% 
13.89% 
-- 
86.11% 
DIC -- 46749 48103 
Dataset  INMB INMB INMB INMB INMB 
1.d. 
Reduced 
dataset 
Nk = 17 
Nj = 67 
Ni = 1806 
 
Intercept 
(λ=£30,000) 
-- 6606 6707 6308 7885 "K	 	(Country) -- 4017363 -- 62504128 -- "	 	(Study) -- 233477872 236665968 -- -- 	 	(Data) -- 257023552 256972576 473493920 541458816 
VPC - country 
VPC – study 
VPC - data 
-- 
-- 
-- 
0.81% 
47.21% 
51.97% 
-- 
47.94% 
52.06% 
11.66% 
-- 
88.34% 
-- 
-- 
100% 
DIC -- 40097 40097 41200 41443 
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Table 5.7: Results for running bivariate models in exercise one: 
Model 
 
 
Dataset 
Model 2.a 
Cross-classified model 
(data in studies and countries) 
Model 2.b  
Three-level hierarchical model 
(data in studies and countries 
Model 2.c. 
Two-level hierarchical model  
(data in studies) 
Model 2.d. 
Two-level hierarchical model  
(data in countries) 
Model 2.e. 
OLS regression model 
(no complex data structures) 
∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E 
1.a. 
Cross-classified 
dataset 
Nk = 23 
Nj = 67 
Ni = 2094 
 
 
Intercept 
(λ=£30,000) 
62.36 0.448 -- -- 65.18 0.456 53.47 0.494 88.72 0.636 "K	 	(Country) 212 0.004 -- -- -- -- 2937 0.298 -- -- "	 	(Study) 8161 0.419 -- -- 8073 0.427 -- -- -- -- 	 	(Data) 10857 0.314 -- -- 10867 0.313 18933 0.592 22717 0.826 
VPC - country 
VPC – study 
VPC - data 
1.10% 
42.44% 
56.46% 
0.54% 
56.85% 
42.61% 
-- 
-- 
-- 
-- 
-- 
-- 
-- 
42.62% 
57.38% 
-- 
57.70% 
42.30% 
13.43% 
-- 
86.57% 
33.48% 
-- 
66.52% 
-- 
-- 
100% 
-- 
-- 
100% 
DIC 28734 -- 28734 31262 32134 
Dataset  ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E 
1.b. 
Intermediate 
dataset 
Nk = 23+1 
Nj = 67 
Ni = 2094 
 
Intercept 
(λ=£30,000) 
62.06 0.438 -- -- 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
58.36 0.529 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
"K	 	(Country) 680 0.028 -- -- 4863 0.388 "	 	(Study) 7302 0.386 -- -- -- -- 	 	(Data) 10874 0.314 -- -- 18776 0.587 
VPC - country 
VPC – study 
VPC - data 
3.61% 
38.73% 
57.67% 
3.85% 
53.02% 
43.13% 
-- 
-- 
-- 
-- 
-- 
-- 
20.57% 
-- 
79.43% 
39.79% 
-- 
60.21% 
DIC 28736 -- 31265 
Dataset  ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E 
1.c. 
Hierarchical 
dataset 
Nk = 17+1 
Nj = 67 
Ni = 2094 
 
Intercept 
(λ=£30,000) 
-- -- 60.02 0.418 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
62.10 0.465 
Same as above 
(different assumptions 
regarding the data on  country-
level do not affect estimation 
results as the existence of a 
country-level has not been 
acknowledged in this model) 
"K	 	(Country) -- -- 2082 0.118 6270 0.365 "	 	(Study) -- -- 6984 0.362 -- -- 	 	(Data) -- -- 10869 0.313 18818 0.603 
VPC - country 
VPC – study 
VPC - data 
-- 
-- 
-- 
-- 
-- 
-- 
10.44% 
35.03% 
54.52% 
14.88% 
45.65% 
39.47% 
24.99% 
-- 
75.01% 
37.71% 
-- 
62.29% 
DIC -- 28733 31267 
Dataset  ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E ∆C/100 ∆E 
1.d. 
Reduced 
dataset 
Nk = 17 
Nj = 67 
Ni = 1806 
 
Intercept 
(λ=£30,000) 
-- -- 62.79 0.405 68.49 0.449 63.36 0.426 91.61 0.568 "K	 	(Country) -- -- 2585 0.145 -- -- 7466 0.379 -- -- "	 	(Study) -- -- 7338 0.318 8654 0.402 -- -- -- -- 	 	(Data) -- -- 11959 0.251 11954 0.251 20438 0.421 24912 0.648 
VPC - country 
VPC – study 
VPC - data 
-- 
-- 
-- 
-- 
-- 
-- 
11.81% 
33.53% 
54.65% 
20.31% 
44.54% 
35.15% 
-- 
41.99% 
58.01% 
-- 
61.56% 
38.44% 
26.76% 
-- 
73.24% 
47.38% 
-- 
52.63% 
-- 
-- 
100% 
-- 
-- 
100% 
DIC -- 24573 24573 26539 27464 
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However, when comparing the cross-classified (model 1.a), the three-level 
hierarchical (model 1.b), and the two-level hierarchical model which clusters 
data in studies only (model 1.c), one recognises that their respective DIC values 
are almost identical. This also holds both for the univariate and bivariate model 
specifications. Furthermore, the minimal difference in DIC is likely to be a result 
of the random nature of the MCMC estimation process as very small changes in 
the DIC are likely to occur with each run of the model (Browne, 2012). As the DIC 
accounts for differences in the number of parameters estimated in each model 
(Browne, 2012), these model specifications may hence be regarded as equivalent 
in terms of their fit to the data (Note that for the reduced dataset the DIC is 
clearly lower in all model specifications. This is, however, not a result of 
improved model fit, but rather of dropping some observations from the dataset). 
As a result, including a study-level into the hierarchy modelled seems to be very 
important to appropriately reflect the structure of the data whilst adding a 
country-level does, at this point, not improve the model fit much further. 
Accordingly, and also in line with the pilot study results, models 1.d and 1.e may 
no longer be considered in this exercise.  
 
 
Though there is roughly equivalence in model fit between the two-level 
specification, which clusters data in studies only, and the more elaborated three-
level hierarchical and cross-classified models, this does not mean that the more 
complex models will not fit the data better once covariates are considered. On 
the other hand, the two-level model does not permit the explicit assessment of 
country-level covariates, which is a key objective of this empirical exercise. For 
these reasons, it was decided to take a model specification which explicitly 
considers the country-level forward to the second part of this empirical exercise, 
which is concerned with covariate adjustment on data and study-level. However, 
this still leaves one choice open before considering covariates, which is the 
choice between the cross-classified model, which treats data from multinational 
studies as independent between countries (model 1.a), and the three-level 
hierarchical model, which assumes that data from multinational studies is not 
country-specific and thereby clusters this data in a separate group on country-
level (model 1.b). As is was hypothesized that data from multinational studies 
draws a curtain over potentially existing country-level variability, it is indicated to 
have a closer look at the random part of the respective models.   
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Moving on to this random part of the MLMs presented in Tables 5.6 and 5.7 
shows even more clearly the importance of making appropriate assumptions 
regarding dependencies within the data. When comparing the variance 
partitioning coefficient (VPC) between the cross-classified and the three-level 
hierarchical models, it can be observed that country-level variability is constantly 
increasing with decreasing influence of data from multinational studies on 
individual country-level parameters. In other words, it appears that data from 
multinational studies is much less affected by variability on country-level which 
‘drags’ country-means towards each other in the cross-classified model and 
thereby ‘camouflages’ the country-level variability which actually does exist 
within the data from single-country-studies. Gradually removing this influence of 
data from multinational studies on individual country-level parameters 
increasingly uncovers this country-level variability in the rest of the data. This has 
also been visualised in Figure 5.3. It can be observed that the country-level VPC 
in Figure 5.3 constantly increases for all response variables in the univariate and 
bivariate framework starting from the cross-classified model, where all data from 
multinational studies was assigned to its respective target countries, up to the 
three-level hierarchical model applied to the reduced dataset, where all data 
from multinational studies was dropped. Interestingly, the effect of treating data 
from multinational studies as dependent on country-level is much stronger in the 
bivariate than in the univariate framework. This indicates that part of the 
country-level variability in international cost-effectiveness data may be disguised 
when combining ∆C and ∆E to INMBs, which shows ever more clearly the 
importance of decomposing the INMB statistic within the bivariate framework.  
 
In conclusion, the assumption of independence of data from multinational 
studies on country-level may not be justified, which does not mean, however, 
that this data shall be dropped from the remainder of this empirical exercise. 
Rather, this first exercise indicates that the influence of this data on individual 
country-parameters may be removed by grouping it in a separate cluster on 
country-level, thereby acknowledging the fact that this data is not independent 
between countries. This is exactly what happens within the hierarchical dataset, 
which shows significantly increased country-level variability for both ∆C and ∆E in 
the bivariate model. To sum up, results from this first experiment show that the 
three-level hierarchical model applied to a dataset, which clusters all data from 
multinational studies in a separate group on country-level, may be carried 
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forward to subsequent analyses as the assumption of independence of 
multinational study data on country-level, which also introduces the cross-
classification problem, appears to be questionable.   
 
Figure 5.3:    Country-level variability with respect to assumptions about (in-) 
dependence of data on country-level 
 
 
After having made a choice regarding the appropriate model structure to take 
forward to the second part of this empirical exercise, it may be useful to take a 
step back to have a further look at the fixed part of this model before moving on 
to have a closer look at the impact of ‘shrinkage’ within the multilevel framework 
in Section 5.1.5. Specifically, with information on the overall mean regression 
coefficient and the study residuals, which can be obtained from MLwiN (Rasbash 
et al., 2009), one can estimate the respective study means in the multilevel 
framework. Also, MLwiN provides the data required for estimating confidence 
intervals around these study means (Rasbash et al., 2009), so that it is possible to 
build forest plots for all the studies included in the dataset. These forest plots 
differ from the caterpillar plots which can be produced directly in MLwiN. 
Caterpillar plots report as ‘zero’ on the vertical axis the overall regression mean, 
so that one may infer whether a study significantly departs from this overall 
regression mean (Rasbash et al., 2009). On the other hand, the forest plots 
presented in Figure 5.4 below, which were produced after estimating models in 
MLwiN and importing data to Ms Excel, show on the horizontal axis actual INMB, 
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∆C or ∆E. Hence, one may infer, for instance, which studies have confidence 
intervals crossing zero, meaning that there is a chance that the response variable 
may also be negative. In addition, the forest plots provide a visual presentation 
of the data which makes it easy to locate outliers, and which studies report more 
or less robust results judged from the actual size of the confidence intervals. 
Finally, one can draw conclusions across the three forest plots due to the 
relationship of a studies mean INMB and the means of the components of the 
INMB statistic ∆C and ∆E. 
 
 
From Figure 5.4.a. it gets apparent that, whilst the majority of studies report a 
mean INMB which is positive at a threshold value of £30.000, their respective 
confidence intervals almost always include zero. Few studies even report a 
negative mean INMB (updated to 2010 £-Sterling) which are highlighted in red in 
Figure 5.4.a (Hjalte et al., 1989; Glick et al., 1992; Drummond et al, 1993; 
Martens et al., 1994; Pharoah et al., 1996; Perreault et al., 1998; Hamilton et al., 
1999; Morris & Godber, 1999; CDC Group, 2002; Nagata et al., 2005; Franco et 
al., 2007). One can also observe a few strong outliers reporting much higher 
INMBs than the rest of the studies in the dataset. Amongst these studies are 
Alonso et al. (2008), Grover et al. (1999), Grover et al. (2000), Grover et al. 
(2001), Grover et al. (2003) and a study from Spaans et al. (2003) which was also 
co-authored by S.A. Grover. The fact that the outliers in the dataset appear to be 
strongly related through ‘common authorship’ is an observation which relates 
back to the genealogy study reported earlier in Chapter 4, and will also be 
further assessed in Section 5.2 of this empirical chapter when considering study-
level covariates which resulted from the genealogy study.  
 
 
However, when looking across the three forest plots presented below, one can 
draw further conclusions in terms of these outliers. For instance, higher mean 
INMBs appears to be correlated to both higher ∆C and ∆E, so that part of the 
positive effect of elevated ∆E on INMBs may be offset by higher ∆C. The bivariate 
model specification, where the INMB statistic is decomposed into its stochastic 
components, may be useful to further assess the relationship between cost-
effectiveness data and covariates whilst taking into account that ∆C and ∆E are, 
themselves, correlated. This is again a strong argument for decomposing the 
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INMB statistic in this exercise as it allows additional insights into causes of 
variability in international cost-effectiveness data.   
 
 
Finally, the level-two residuals obtained from MLwiN and used to generate the 
forest plots below were subject to ‘shrinkage’ when estimating the respective 
MLM (Rasbash et al., 2009). This means that not just the overall regression 
mean, but also the individual study means are affected depending on their 
respective number of data points and variances at each level of the data 
hierarchy. As a result, study means presented below are ‘dragged’ towards the 
overall regression mean depending on the number of data points abstracted 
from those studies as well as the within and between study variability (Steele, 
2008; Rasbash, 2009; Hox, 2010). A potential problem arises as this exercise does 
not deal with individual patient data, where shrinkage depends on the number of 
individuals included in a study, but rather with secondary cost-effectiveness 
data, where the number of data points per study depends on the rigour with 
which subgroup and sensitivity analyses were conducted and reported. Hence, 
whilst shrinkage is supposed to balance out the fact that studies in a dataset are 
of different size, this fact demands further attention when dealing with 
secondary cost-effectiveness data, where the number of data points abstracted 
from one study does not necessarily reflect the weight it should have relative to 
other studies in the dataset. The actual impact of shrinkage factors on the results 
of this exercise and the associated potential for bias when applying MLM 
techniques to secondary cost-effectiveness data from published economic 
evaluation studies is considered below in Section 5.1.5. 
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Figure 5.4: Forest Plots of INMBs, ∆Cs, and ∆Es for all 67 studies included in the dataset 
  (Estimates from 2-level model with data clustered in studies – study means shrunken towards overal mean depending on within study variability and number of data points from that study) 
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FIgure 3a: Forest plot of INMB's 
(shrunken study means and respective 95% 
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Figure 3b: Forest plot of incremental cost 
(shrunken study means and respective 95% 
CI's) 
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FIgure 3c: Forest plot of incremental effects
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Study IDs  01: Ashraf et al (1996)  02: Caro et al (1997) 03: Grover et al (1999) 04: Grover et al (2000) 05: Hamilton et al (1995) 06: Johanneson et al (1997) 07: Muls et al (1998) 08: Perreault et al (1998) 09: Pharoah et al (1996) 10: Szucs et al (1998) 
11: Szucs et al (2000a) 12: van Hout et al (2001) 13: Jönsson et al (1996) 14: Jönsson et al (1999) 15: Ganz et al (2000) 16: Grover et al (2001) 17: Martens et al (1994) 18: Alonso et al (2008) 19: Annemans et al (2010) 20: Araujo et al (2007) 
21: Lindgren et al (2010)  22: Grover et al (2008) 23: Franco et al (2007) 24: Greving et al (2011) 25: HPS Group (2009) 26: Khoury et al (2009) 27: Kongnakorn et al (2009) 28: Morris (1997) 29: Morris, Godber (1999) 30: Rosen (2010) 
31: Scuffham et al (2005) 32: Scuffham et al (2006) 33: Tailor et al (2009) 34: Tonkin et al (2006) 35: Wagner et al (2009a) 36: Wagner et al (2009b) 37: Berger et al (1997) 38: Obermann et al (1997) 39: Davies et al (2006) 40: Spaans et al (2003) 
41: Soini et al (2010) 42: Peura et al (2008) 43: Slejko et al (2010) 44: Nherera et al (2010) 45: Szucs et al (2000b) 46: Sigvant et al (2011) 47: Johannesson et al (1996) 48: Troche et al (1998) 49: Szucs et al (2004) 50: Nagata et al (2005) 
51: Lindgren et al (2007) 52: HPS Group (2006) 53: Tsevat et al (2001) 54: Raikou et al (2007) 55: Ramsey et al (2008) 56: Scuffham et al (2004) 57: Hjialte et al (1989) 58: Caro et al (2003) 59: CDC Group (2002) 60: Chau et al (2001) 
61: Grover et al (2003) 62: Glick et al (1992) 63: NICE (2008) 64:Drummond et al (1993) 65: Chan et al (2007) 66: Ward et al (2007) 67: Ara et al (2009)           : overall regression mean (not identical to raw mean estimates)  
 
*INMBs as reported in Figure 2.a may be calculated by multiplying ∆E from Figure  2c with a threshold value λ of 30000 and subtracting ∆C reported in Figure 2.b. Small differences are the result of shrinkage and the 
random nature of the MCMC estimation procedure.  
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5.1.5. Shrinkage as a potential source of bias in the analysis of 
secondary cost-effectiveness data 
 
Before moving on to the assessment of covariates, it is important to consider the 
impact of shrinkage in the MLM framework. As mentioned in Chapter 3, 
assuming exchangeability, which is a necessary assumption to fit MLMs, is 
supposed to ‘mediate’ between the two extreme viewpoints of either identical 
or independent study parameters in the sense that it allows for some sort of 
pooling, but without ignoring the fact that the data stems from different studies 
indeed (Spiegelhalter et al., 2000; Spiegelhalter et al., 2004; Gelman et al., 2004; 
Rasbash et al., 2009; Hox, 2010). As a result, shrinkage factors ‘drag’ group 
means towards the overall regression mean depending on their respective 
number of lower-level units as well as the within and between group variability 
(Steele, 2008; Rasbash et al., 2009). This makes perfect sense, for instance, when 
the lowest level consists of patients in randomised controlled trials. The extent of 
shrinkage towards the overall regression mean would then depend on the 
number of patients in each trial as well as the within and between trial variability 
(Spiegelhalter et al., 2000). 
 
However, this empirical exercise deals with secondary economic evaluation data 
abstracted from existing studies published on the cost-effectiveness of statins in 
the primary and secondary prevention of CVD. Hence, the data in this exercise 
does not represent individual patients which would instantly justify empirical 
Bayes shrinkage estimation. Rather, data points reflect estimates of cost-
effectiveness of statins as reported by the authors of the respective studies 
included in this exercise. The number of data points within each study is hence 
depending on the extent to which authors performed and reported on subgroup 
and sensitivity analysis in their papers. This means that differences in the way 
data and models were utilised to perform subgroup and / or sensitivity analyses, 
or even just the way results have been reported in the respective papers, may 
already account for differences on group sizes, which then affects study means in 
the MLM through shrinkage estimates. As a result, there is an argument around 
the appropriateness of shrinkage estimation if the underlying data stems from 
existing economic evaluation studies and does not represent individual patients. 
Before moving on to covariate adjustment, this section therefore looks deeper 
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into this issue by discussing the underlying concept, show the actual impact of 
shrinkage estimates within the variance components models reported above, 
and discusses alternative strategies which were considered to ‘counterweigh’ the 
effect of shrinkage within this secondary data integration exercise.  
 
 
5.1.5.1. Empirical Bayes shrinkage estimation within the multilevel modelling 
framework 
 
To quantify the impact of shrinkage on the results presented above, one needs 
to make explicit the connection between the MLM, where residuals are 
estimated for each hierarchical level and shrinkage estimates ‘mediate’ between 
the two extreme assumptions of either identical or independent study 
parameters, and the respective non-hierarchical OLS model, which does not 
account for complex data structures. Empirical Bayes shrinkage estimates ‘drag’ 
study means towards the overall regression mean (e.g. Steele, 2008; Rasbash et 
al., 2009). This section shows that the OLS regression model, which does not take 
into account that data is clustered in studies, is simply a special case of the MLM 
where shrinkage estimates are assumed to be zero (e.g. Willan et al., 2005; 
Steele, 2008; Rasbash et al., 2009). Further, in an empty OLS regression model, 
the intercept is simply the raw mean of the response variable (e.g. Maddala, 
2001). In conclusion, we may quantify the effect of shrinkage by comparing study 
means as obtained from the variance components model presented above with 
the individual study means calculated from the raw data.  
 
As detailed in the multilevel methods Chapter 3, to be able to make comparisons 
between studies in the multilevel framework, the study-level residual ‘u′ needs 
to be estimated (Steele, 2008; Rasbash et al., 2009). An estimate of ‘u′ may be 
derived by calculating the ‘mean raw residual’, that is: (Steele, 2008; Rasbash et 
al., 2009; CMM-workshops/variance components).  
 ̅ = < − =   (1, repeated from Chapter 3) 
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Where’ y<′ is the mean of the response variable in study ‘j’, and ′β′ is an 
estimator of the overall mean of the response variable. This raw residual is then 
multiplied by the shrinkage factor ‘S’ (Spiegelhalter et al., 2004; Willan et al., 
2005; Steele, 2008; Rasbash et al., 2009):  
 
 !? = @̅      where 									@ = -A./-A./0(BA1/CD  (2, repeated from Chapter 3) 
In (2), ′n′ is the sample size in study ‘j’, hence the number of data points 
reported in that study (Steele, 2008; Rasbash et al., 2009). ′σA2	′ and ‘σA3	’ are 
estimates of the variances of the within-study and between-study error terms 
respectively (Steele, 2008; Rasbash et al., 2009). The respective level one 
residual is given as (CMM-workshops/variance components):  
 
 e? = y − 7β + β8x89 − u?                (3) 
 
Now it can be illustrated why the assumption of exchangeability of study 
parameters mediates between the two extremes of either identical or 
independent parameters obtained from different cost-effectiveness studies. If 
the between study variance ′σ3	’ is assumed to be zero, then this is equal to say 
that all variation in the reported cost-effectiveness measures stems from ‘within-
study’ variability, hence, the mean study effects are ‘identical’ between studies. 
This would mean that there are no differences between studies and all cost-
effectiveness estimates may be safely pooled together. In terms of equations (2) 
and (3), if ‘S’ is zero in (2), then  ′!?’ will be zero too, and (3) reduces to: 
 e? = y − β − β8x8                (4) 
 
 
This is simply the residual as defined for the OLS regression model (e.g. Maddala, 
2001) If, on the other hand, ‘σ3	 → ∞′, then the study effects are regarded to be 
independent, meaning that data from different sources may not be pooled 
together. Hence, assuming exchangeability allows to model that the ‘reality’ 
might be somewhere in between those extreme viewpoints. To sum up,  
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	′σ3	 → 0′ is the special case where the shrinkage factor ′S = A/A/0A/ ′ tends 
towards zero and the study effects are completely shrunken towards the overall 
mean of the response variable ′β’. A pooled OLS regression model may be 
equivalent in this case. If 	′σ3	’ is high, then the shrinkage factor			′S = A/A/0(A/ ’ 
tends towards unity, meaning that the between country variance is high and 
shrinkage of study effects towards the overall mean ′β′ is small ( Steele, 2008) 
 
 
However, the extent of shrinkage does not only depend on the amount of 
between study variability	′σ3	’. The higher the number of data points provided by 
one single study (n, the more information is provided by that particular study 
to the overall model, and the less will the study mean be shrunken towards the 
overall mean (Steele, 2008; Rasbash et al., 2009; Hox, 2010). On the other hand, 
if a study provides only few estimates of cost-effectiveness, then shrinkage is 
high as this study ‘borrows’ a lot of information from all other studies available 
(Steele, 2008; Rasbash et al., 2009; Hox, 2010).  
 
 
It has now been shown that by assuming the shrinkage factor ‘S’ to be zero, a 
MLM, where data is grouped in economic evaluation studies, reduces to an OLS 
regression equation. Hence, to quantify the effect of shrinkage within the 
variance components models reported above, one may simply compare the 
study means of the variance components model with the intercepts estimated by 
an OLS regression model being fit to a) the pooled data and b) the data from 
each study separately to model both the assumptions of a) identical and b) 
independent parameters. However, we may further simplify this procedure. In an 
OLS regression equation, the intercept is given by (e.g. Maddala, 2001):  
 β =	y − β8 ∗ x                             (5) 
 
Where ′y′ is the overall mean of the response variable and ‘β8’ represents a 
vector of explanatory variables (e.g. Maddala, 2001). However, in the variance 
components models above covariates have not yet been considered so that the 
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equivalent OLS regression would be an empty model without any slope 
parameters. Hence, (5) reduces to: 
 β =	y                              (6) 
 
which means that, in an empty OLS regression model, the intercept is identical to 
the raw mean of the response variable. In conclusion, we may show the effect of 
shrinkage in the variance components model reported above by simply 
calculating the study means in the MLM as the group departure from the overall 
intercept (  + !) and comparing the result to the raw study means calculated 
as (e.g. Maddala, 2001):  
 
  = 8pD ∗ ∑ pm8                              (7) 
 
to assume independent parameters or the raw mean of the pooled data for 
identical study parameters calculated as: 
 
  = 8p ∗ ∑ pm8                                (8) 
 
Note that, alternatively, one may simply insert values for the within and between 
group variances ′σA2	’ and ‘σA3	 	′, which can be obtained from MLwiNs equation 
window after running the respective model as well as the study group sizes ‘n′ in 
equation (2) to calculate the shrinkage factor for each study in the MLM and 
then divide the level two residuals ′!> ′ which are also obtainable from MLwiN  
by ‘S’ to get the mean raw residual ′’ (Rasbash et al., 2009) When adding this 
mean raw residual to the overall regression mean ′′, one receives 
approximately the raw means calculated with equation (7) (Rasbash et al., 2009) 
The following section reports both study means estimated by the variance 
components model reported above., the raw means calculated with equations 
(8) and (9), and the respective shrinkage factors calculated with equation (2).  
Results are then compared in a graph displayed in Figure 5.5. Finally, the impact 
of shrinkage in this empirical exercise and resulting concerns when applying 
MLM techniques to secondary cost-effectiveness data are discussed before 
moving on to part two of this empirical work, which is concerned with covariate 
adjustment in the MLM framework.  
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5.1.5.2. Quantifying the impact of empirical Bayes shrinkage estimates on 
study means 
 
 
Table 5.8. shows raw study means, shrunken study means and shrinkage factors 
for INMB, ∆C and ∆E and the results from Table 5.8 are also visualised in Figure 
5.5 below. Note that the shrinkage factor (S) is not the ratio of the raw study 
means and shrunken study means as it is applied to shrink the ‘mean raw 
residuals’ (̅) to obtain study-level residuals ‘u’ which are then added to the 
overall regression mean ′′ to obtain shrunken study mean values (Steele, 2008; 
Rasbash et al., 2009, CMM workshops / variance components). For most studies 
in the dataset, the shrinkage factor, which is bound between 0 and 1, is above 
0.9. Furthermore, for ∆E shrinkage factors are even closer to unity, indicating 
that study means for ∆E are even less shrunken towards the overall regression 
mean (Steele, 2008). The reason for this is given in equation (2) above. Shrinkage 
factors are closer to zero (i.e. so that shrinkage is stronger), if ′n′ is small or ′σA2	′ 
is large compared to ′σA3	′ (Steele, 2008). In other words, if there are only few 
data points in one group (so that we have little information about that group), or 
if within group variability is high compared to between group variability 
(indicating low dependency of data within groups), then study means are pulled 
more strongly towards the overall mean (Steele, 2008; Rasbash et al., 2009; 
CMM workshops / variance components) Finally, as shrinkage factors are applied 
to the mean raw residual and not directly to study means, shrinkage has a 
stronger impact on outliers in the dataset than it has for studies close to the 
overall regression mean (Steele, 2008; Rasbash et al., 2009; CMM workshops / 
variance components) 
 
 
Between group variability is generally high within the given dataset, indicating 
high dependency of the data within studies and therefore providing a strong 
justification for the use of MLM. Accordingly, shrinkage factors are generally 
high, meaning that shrinkage towards the overall regression mean is, at most, 
moderate. In addition, as ∆E shows even higher between group variability than 
INMB or ∆C (which is getting obvious when comparing the respective variance 
partitioning coefficients reported in Table 5.8), shrinkage factors are even closer 
to unity, meaning that study means are even less shrunken towards the overall 
regression mean. Nevertheless, though high dependency within groups generally 
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leads to higher shrinkage factors, which decreases the impact of shrinkage on 
study means, Figure 5.5 shows that for few studies shrinkage does have quite 
some impact within the MLM framework. The length of the horizontal line for 
each study in Figure 5.5 indicates the difference between the raw and the 
shrunken study means. It was mentioned that shrinkage has a stronger effect on 
outlying studies, and this is getting visible when comparing, for example, studies 
18 and 19 (Alonso et al., 2008; Annemans et al., 2010) in Figure 5.5a. As ‘nj‘ is 
identical in both studies (nj = 4), their respective shrinkage factors are also 
identical with 0.78. However, as the mean raw residual is much higher for the 
outlying study by Alonso et al. (2008), shrinkage has a much stronger impact on 
its respective study mean. In conclusion, the impact of shrinkage on study means 
in this exercise depends not just on the respective number of data points 
abstracted from each study, but also on the within and between group variability 
in the data and the location of each study mean relative to the overall regression 
mean.  
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Table 5.8:   Raw and shrunken study means plus shrinkage factors  
 
 INMB ∆C ∆E 
raw mean 10210 88.71 0.64   7233 65.18 0.46 ¡A¢     (vpc) 253045104    (46.54%)  8073    (42.62%) 0.43    (58.11%) ¡A£     (vpc) 290676352    (53.46%) 10867    (57.38%) 0.31    (41.89%) 
Study Nj 
Raw 
mean 
Shrunke
n mean 
Shrinkage 
factor 
Raw 
mean 
Shrunke
n mean 
Shrinkage 
factor 
Raw 
mean 
Shrunken 
mean 
Shrinkage 
factor 
1 13 3344 3626 0.92 12.49 16.97 0.91 0.15 0.17 0.95 
2 11 750 1391 0.91 21.9 25.36 0.89 0.10 0.12 0.94 
3 144 48242 47869 0.99 168.14 168.08 0.99 2.17 2.16 0.99 
4 52 26763 26284 0.98 251.3 247.41 0.97 1.73 1.71 0.99 
5 60 -12201 -11856 0.98 413.31 403.61 0.98 0.97 0.97 0.99 
6 25 5216 5269 0.96 13.12 15.71 0.95 0.22 0.22 0.97 
7 18 2837 3079 0.94 18.63 21.49 0.93 0.16 0.17 0.96 
8 60 -1748 -1605 0.98 147.88 145.34 0.98 0.44 0.44 0.99 
9 46 -2782 -2557 0.98 55.63 55.28 0.97 0.09 0.10 0.98 
10 42 4836 4862 0.97 37.79 38.47 0.97 0.29 0.29 0.98 
11 8 8356 8192 0.87 37.94 42.61 0.86 0.41 0.41 0.92 
12 5 16143 14435 0.81 118.16 110.26 0.79 0.93 0.87 0.87 
13 19 5320 5404 0.94 18.8 21.90 0.93 0.24 0.25 0.96 
14 109 7639 7605 0.99 14.25 14.99 0.99 0.30 0.30 0.99 
15 29 2537 2677 0.96 50.25 50.41 0.96 0.25 0.26 0.98 
16 112 54616 54087 0.99 155.08 155.37 0.99 2.34 2.32 0.99 
17 7 -1580 -344 0.86 51.54 50.65 0.84 0.12 0.15 0.91 
18 4 45443 36677 0.78 324.81 276.24 0.75 2.60 2.28 0.85 
19 4 6601 6751 0.78 0.74 17.30 0.75 0.22 0.25 0.85 
20 2 1773 3774 0.64 -1.23 22.40 0.60 0.06 0.15 0.73 
21 2 207 2808 0.64 3.93 24.02 0.60 0.02 0.13 0.73 
22 22 9960 9790 0.95 41.25 43.27 0.94 0.47 0.47 0.97 
23 4 -2470 -276 0.78 37.71 40.30 0.75 0.04 0.11 0.85 
24 61 399 492 0.98 5.58 6.69 0.98 0.03 0.04 0.99 
25 100 13937 13814 0.99 58.5 58.88 0.99 0.66 0.66 0.99 
26 6 3199 3836 0.84 5.01 15.17 0.82 0.12 0.15 0.89 
27 8 3960 4324 0.87 18.6 24.88 0.86 0.19 0.21 0.92 
28 2 -2885 823 0.64 63.8 57.46 0.60 0.12 0.22 0.73 
29 17 -2361 -1753 0.94 66.61 64.75 0.93 0.14 0.16 0.96 
30 6 3961 4471 0.84 13.94 22.81 0.82 0.18 0.20 0.89 
31 7 5718 5927 0.86 0.82 11.46 0.84 0.19 0.21 0.91 
32 4 1220 2566 0.78 26.05 33.37 0.75 0.13 0.18 0.85 
33 24 3101 3273 0.95 33.49 34.79 0.95 0.22 0.22 0.97 
34 12 7103 7088 0.91 18.96 23.99 0.90 0.30 0.31 0.94 
35 12 1737 2214 0.91 4.84 10.10 0.90 0.07 0.09 0.94 
36 4 439 1973 0.78 4.46 16.98 0.75 0.03 0.09 0.85 
37 7 6343 6481 0.86 20.57 27.92 0.84 0.28 0.29 0.91 
38 36 6411 6401 0.97 22.54 24.16 0.96 0.29 0.29 0.98 
39 52 8447 8375 0.98 68.41 68.41 0.97 0.51 0.51 0.99 
40 10 53221 48311 0.90 131.69 136.26 0.88 2.21 2.08 0.93 
41 16 4422 4562 0.93 40.45 41.99 0.92 0.28 0.29 0.96 
42 10 5399 5579 0.90 40.21 42.99 0.88 0.31 0.32 0.93 
43 1 9484 8302 0.47 31.15 52.05 0.43 0.42 0.43 0.58 
44 7 4196 4585 0.86 30.94 35.83 0.84 0.24 0.26 0.91 
45 2 11142 9706 0.64 17.57 39.46 0.60 0.43 0.42 0.73 
46 12 2202 2593 0.91 -0.49 5.65 0.90 0.07 0.09 0.94 
47 8 -17 900 0.87 10.4 16.36 0.86 0.03 0.07 0.92 
48 1 -7224 557 0.47 89.34 65.71 0.43 0.06 0.24 0.58 
49 4 1890 3085 0.78 6.6 19.52 0.75 0.09 0.14 0.85 
50 6 -8381 -5848 0.84 96.56 84.09 0.82 0.04 0.10 0.89 
51 20 3 369 0.95 11.05 13.65 0.94 0.04 0.05 0.96 
52 168 18730 18608 0.99 1.72 2.53 0.99 0.63 0.63 1.00 
53 4 4947 5467 0.78 103.52 92.40 0.75 0.51 0.51 0.85 
54 12 11700 11260 0.91 29.1 34.19 0.90 0.49 0.48 0.94 
55 6 4297 4781 0.84 -7.52 5.55 0.82 0.12 0.15 0.89 
56 22 2178 2406 0.95 3.26 6.50 0.94 0.08 0.09 0.97 
57 2 -7375 -1950 0.64 156.85 110.41 0.60 0.28 0.36 0.73 
58 62 6432 6406 0.98 20.33 21.32 0.98 0.28 0.28 0.99 
59 9 -5655 -4171 0.89 156.66 139.94 0.87 0.33 0.36 0.92 
60 8 3729 4132 0.87 11.05 18.28 0.86 0.16 0.18 0.92 
61 12 79387 72846 0.91 153.63 161.60 0.90 3.16 2.98 0.94 
62 3 -14167 -8149 0.72 325.66 230.16 0.69 0.61 0.65 0.80 
63 4 5746 6094 0.78 18.29 30.06 0.75 0.25 0.28 0.85 
64 128 -19034 -18834 0.99 363.39 359.08 0.99 0.58 0.58 0.99 
65 7 1230 2095 0.86 51.21 51.45 0.84 0.21 0.24 0.91 
66 322 1352 1337 1.00 23.8 38.47 1.00 0.17 0.17 1.00 
7 72 1659 1722 0.98 26.11 26.67 0.98 0.14 0.15 0.99 
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Figure 5.5: Differences between raw study means and shrunken study means 
 
(Graph plots the mean INMB, ∆C and ∆E for each study as obtained from 1) the raw data and 2) from a two-level MLM so that means are shrunken towards overal mean depending on within study 
variability, between study variability and number of data points from that study) 
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Figure 5.5a. Difference between raw 
study means and shrunken study 
means in INMBStudy ID
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Figure 5.5b. Difference between raw 
study means and shrunken study means 
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Figure 5.5c. Difference between raw 
study means and shrunken study means 
in ∆EStudy ID
01: Ashraf et al (1996)  02: Caro et al (1997) 03: Grover et al (1999) 04: Grover et al (2000) 05: Hamilton et al (1995) 06: Johanneson et al (1997) 07: Muls et al (1998) 08: Perreault et al (1998) 09: Pharoah et al (1996) 10: Szucs et al (1998) 
11: Szucs et al (2000a) 12: van Hout et al (2001) 13: Jönsson et al (1996) 14: Jönsson et al (1999) 15: Ganz et al (2000) 16: Grover et al (2001) 17: Martens et al (1994) 18: Alonso et al (2008) 19: Annemans et al (2010) 20: Araujo et al (2007) 
21: Lindgren et al (2010)  22: Grover et al (2008) 23: Franco et al (2007) 24: Greving et al (2011) 25: HPS Group (2009) 26: Khoury et al (2009) 27: Kongnakorn et al (2009) 28: Morris (1997) 29: Morris, Godber (1999) 30: Rosen (2010) 
31: Scuffham et al (2005) 32: Scuffham et al (2006) 33: Tailor et al (2009) 34: Tonkin et al (2006) 35: Wagner et al (2009a) 36: Wagner et al (2009b) 37: Berger et al (1997) 38: Obermann et al (1997) 39: Davies et al (2006) 40: Spaans et al (2003) 
41: Soini et al (2010) 42: Peura et al (2008) 43: Slejko et al (2010) 44: Nherera et al (2010) 45: Szucs et al (2000b) 46: Sigvant et al (2011) 47: Johannesson et al (1996) 48: Troche et al (1998) 49: Szucs et al (2004) 50: Nagata et al (2005) 
51: Lindgren et al (2007) 52: HPS Group (2006) 53: Tsevat et al (2001) 54: Raikou et al (2007) 55: Ramsey et al (2008) 56: Scuffham et al (2004) 57: Hjialte et al (1989) 58: Caro et al (2003) 59: CDC Group (2002) 60: Chau et al (2001) 
61: Grover et al (2003) 62: Glick et al (1992) 63: NICE (2008) 64:Drummond et al (1993) 65: Chan et al (2007) 66: Ward et al (2007) 67: Ara et al (2009)           : pooled mean  
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5.1.5.3. Discussing the ‘appropriateness’ of shrinkage within this secondary 
data integration exercise 
 
Two questions follow from what has been reported above: first, may shrinkage 
lead to some sort of bias in the case of integrating secondary cost-effectiveness 
data where the number of data points per study is generally not indicative for 
the respective size of the underlying study sample. In other words, as shrinkage, 
or the lack thereof, may only be a consequence of differences in the way 
subgroup or sensitivity analyses were performed and reported in the respective 
studies, it may not be justified to shrink studies based on the respective number 
of data points abstracted per study. Secondly, if the answer to the first question 
is yes, is there anything we can do about it in the MLM framework. As 
mentioned, empirical Bayes shrinkage estimation follows directly the assumption 
of exchangeability, and any attempt to ‘counterweigh’ shrinkage would impact 
on the very foundations of multilevel modelling (e.g. Spiegelhalter et al., 2000; 
Spiegelhalter et al., 2004; Steele, 2008). To this extend, this issue is nothing less 
than a fundamental critique on the use of MLM for the integration of secondary 
cost-effectiveness data, and the answer to this question may be much more a 
philosophical than a technical one.  
 
To answer the first question, consider again the case of the two studies with the 
ID’s 18 and 19 (Alonso et al., 2008; Annemans et al., 2010) in Figure 5.5a. As 
mentioned, both studies contribute four data points each to the overall dataset, 
so that their respective group sizes are relatively small compared to other 
studies. We do not judge a priori whether the data points provided by these 
studies are poor guesses of the cost-effectiveness of statins in the primary and 
secondary prevention of CVD. Accordingly, the mean raw residual (̅) calculated 
from the respective data points may be ‘wrong’. This idea holds for each group in 
the dataset, as we cannot judge a priori which study may provide the ‘best guess’ 
regarding the cost-effectiveness of statins (though we will come back to this 
issue when adding covariates to the model). Now, when combining data from 
one group with data from all other groups, this will shrink residuals towards the 
overall average, so that level-two residuals will be less sensitive to outliers in the 
group (Steele, 2008). Figure 5.5a shows that, though group sizes and respective 
shrinkage factors are identical for both studies, the mean of the outlying study 
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18 is shrunken much stronger towards the overall average. Of course, when 
group sizes partly depend on nothing else than differences in the way authors 
reported cost-effectiveness estimates, one may argue that this process will bias 
results towards those studies which provide a large number of data points. 
However, the example of studies 18 and 19 makes clear that group size is only 
one of three factors determining the actual impact of shrinkage on study means 
in this exercise. The other two factors are 1) dependency (i.e. the relation 
between within and between group variability) and 2) location (i.e. the relative 
distance of each group mean from the overall regression mean) (Steele, 2008; 
Rasbash et al., 2009). Hence, to judge the appropriateness of shrinkage and to 
develop a method which may counterweigh potential bias introduced by 
‘artificial’ study sizes in the case of secondary data integration, one has to 
discuss each of the three factors involved in the process. This discussion starts 
with dependency and location before it comes back to the issue of group sizes.   
 
In terms of ‘dependency’ shrinkage appears to be justified just as much in the 
case of secondary data integration as it is for the integration of say individual 
patient data from RCTs. The idea that data from one study may be more similar 
to each other than it is to data from other studies makes intuitive sense in the 
case of secondary cost-effectiveness data. Furthermore, reflecting dependencies 
within the data is the whole purpose of MLM (e.g. Spiegelhalter et al., 2000; 
Spiegelhalter et al., 2004; Willan et al., 2005, Manca et al., 2005), and the fact 
that between group variability is generally high within the variance components 
models reported above provides a strong justification for the use of MLM. On the 
contrary, if one used a method to integrate secondary cost-effectiveness data 
which does not take into account dependencies within that data (as it is the case 
for example with the OLS model applied in the pilot study and in Chapter 3.4), 
one risks making plainly wrong inferences (e.g. Steele, 2008). This has been 
demonstrated quite impressively with the negative relationship between INMB 
and TCL obtained when applying the OLS model to the pilot dataset. Within each 
study, there is always a positive relationship between patients’ cholesterol level 
and the cost-effectiveness of statins, which also accords expectations. However, 
as some studies assess patient groups which are sicker than others, the cost-
effectiveness of statins may be lower even in the presence of higher cholesterol 
levels. Hence, the inability to discriminate between within and between group 
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effects leads to an overall negative relationship between INMB and TCL though 
this is clearly incorrect. Furthermore, the pilot study showed that precession was 
severely overestimated for higher-level variables like GDP per capita in the case 
of the OLS framework. For these reasons, acknowledging dependencies in the 
data through the process of shrinkage appears to be strongly justified within this 
secondary data integration exercise.  
 
A similar conclusion has been reached with respect to ‘location’ of study means 
relative to each other. If we treat each study in the dataset as a random sample 
of cost-effectiveness estimates from a wider ‘population’ of cost-effectiveness 
estimates for a particular health technology (e.g. Spiegelhalter et al., 2000; 
Spiegelhalter et al. 2004), then it makes intuitive sense to drag outlying studies 
towards the overall study mean. In this sense, we simply combine the data from 
the outlying group with the information provided by all the other groups to bring 
study-level residuals closer to the overall average. This makes study-level 
residuals less sensitive to outlying elements. As mentioned, we do not judge a 
priori whether the information provided by one study is actually a ‘poor guess’ of 
the cost-effectiveness of statins (though we may account for this later when 
including covariates to the equation). Rather we reduce the impact of outlying 
elements of the group by dragging them closer towards the overall average. In 
other words, if there was no shrinkage when integrating secondary cost-
effectiveness data, then the impact of outliers on the overall regression mean 
would be much stronger. This can be observed when comparing the variance 
components models 1.a, 1.b. or 1.c above with the respective OLS regression 
model 1.e. Within the OLS regression model, full weight is given to outliers which 
report mean INMBs way above the other studies in the dataset, thereby pulling 
the overall mean INMB clearly above the regression mean within the multilevel 
framework. Hence, also with respect to ‘location’, shrinkage appears to be 
justified for the integration of secondary cost-effectiveness data.  
 
What is left is the impact of ‘group size’, and it is arguable whether the ‘nj’ for 
each study appropriately reflect the size, and thereby the ‘weight’ each study 
should carry in this exercise. On the other hand, it is certainly no straightforward 
task to determine an appropriate weight per study when some studies in this 
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exercise rely on actual patient data from RCTs, and others rely on combining data 
from different sources within a DAM. Even assigning the same weight to each 
study on these grounds may appear questionable. In other words, any attempt 
to re-weigh studies to ‘counterweigh’ the effect of group sizes within the process 
of shrinkage (assuming there is a way to account for this in the model which is 
also discussed below) may be similar to trading one source of potential bias with 
another one.  
 
However, let us consider once more the thought that INMBs in this exercise 
constitute a random sample from a hypothetical space of cost-effectiveness 
estimates (e.g. Spiegelhalter et al., 2000; Spiegelhalter et al., 2004). A priori, we 
do not judge whether one estimate may be more likely than another one (e.g. 
Spiegelhalter et al., 2004). If this assumption holds, however, then we have to 
accept that studies which provide more data points based on subgroup and 
sensitivity analyses also provide a larger ‘slice’ of the space of potential cost-
effectiveness estimates for that particular health technology. Even though these 
data points do not reflect individual patients, we ought to accept that, a priori, 
they should not be treated anyhow differently. From this perspective, shrinkage 
makes sense even when dealing with secondary cost-effectiveness data. On top 
of that, reporting subgroup and sensitivity analyses is regarded as a crucial factor 
when judging the quality of a particular economic evaluation study. In this 
respect, shrinkage simply assigns a higher weight to those studies which better 
comply with quality checklists in this matter (e.g. Drummond et al., 1996, Ofman 
et al., 2003; Evers et al., 2005). Furthermore, we may control for differences 
between studies through covariate adjustment (e.g. Drummond et al., 2009; 
Manca et al., 2010). For instance, one may rate study quality using an 
appropriate checklist and then control for this factor through the inclusion of a 
respective covariate on study-level. Within this empirical exercise, this is 
considered using the validated QHES instrument (Ofman et al., 2003). 
Furthermore, a number of study-level covariates are included to account for 
differences between studies. As a result, after adjusting for the appropriate 
covariates, data from different studies should become, in theory, exchangeable 
(Gelman et al., 2004; Manca et al., 2007; Drummond et al., 2009).  
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Before discussing potential strategies to counterweigh shrinkage, one further 
aspect of the problem needs to be considered which was not yet specifically 
addressed. The problem of shrinkage in the integration secondary data from 
health economic evaluations is very intuitive on study-level as it was detailed 
above. However, what does this mean for country-level parameters? Clearly, 
shrinkage on country-level follows the same logic in the sense that country-group 
size, location of the country-mean relative to other country parameters, and the 
relation of within and between country variability determines the amount of 
shrinkage per country (Steele, 2008, Rasbash et al., 2009). However, does the 
same critique apply with respect to country-group sizes? Unlike the number of 
data points abstracted from one particular study, which clearly depends on the 
rigour with which analysts exploited the data to perform subgroup and sensitivity 
analyses, country-group sizes additionally depend on the number of studies 
conducted in a specific country. In other words, countries for which more 
economic evaluation data from different studies are available receive a higher 
weight through shrinkage in the multilevel model. This is in complete accord with 
the logic behind empirical Bayes shrinkage estimation (e.g. Spiegelhalter et al., 
2000; Spiegelhalter et al., 2004) as it gives higher weight to geographic domains 
for which more data is available and, conversely, drags countries for which the 
evidence base is poor closer to the overall mean. From this perspective, one may 
argue whether shrinkage is not perfectly justified in secondary data integration 
on country-level, irrespective of the nature of the underlying economic 
evaluation study (i.e. IPD analysis or DAM). In addition to that, data from 
different studies becomes, in theory, exchangeable once the researcher 
controlled for the appropriate set of covariates (Gelman et al., 2004; Manca et 
al., 2007; Drummond et al., 2009). Hence, it may be controlled for such 
differences in Section 5.2 of this empirical exercise, which is concerned with 
covariate adjustment on data and study-level, as this may also feed through to 
variability observed between geographic domains. The ultimate aim is to disclose 
the actual amount of variability between countries, which is then further 
assessed in Section 5.3 of this empirical exercise.   
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5.1.5.4. Strategies to address the issue of group sizes within secondary data 
integration 
 
Though the above section provides a number of reasons to believe that 
shrinkage may also be appropriate in the case of integrating secondary data from 
published economic evaluation studies, it is acknowledged that the issue of 
group sizes on study-level may demand further attention. Hence, if one does not 
follow the argument as outlined above, it is indicated to develop a strategy to at 
least try to address the issue of shrinkage on study-level within the method of 
analysis chosen for this empirical exercise. Otherwise, as mentioned above, this 
issue may turn into a fundamental critique on the use of MLM for the integration 
of secondary cost-effectiveness data. For this reason, several strategies were 
considered to address the issue of study group sizes within the current exercise.  
 
For example, as a relatively straightforward approach it was considered to 
bootstrap data from each study individually and then to draw a random sample 
for each study of identical size. This would have led to identical ‘nj’ for each study 
in the dataset. However, it would have definitely changed the relationship 
between ′σA2	′  and ′σ> 3	′ so that shrinkage factors would not only be adjusted with 
respect to group size, but also with respect to the balance of within and between 
group variability. In other words, the potential bias introduced by artificial group 
sizes would have been traded against a potential bias with respect to changing 
the degree of dependency within the data. On top of that, this would have 
meant to bootstrap not just data for the response variable for each study 
individually, but also covariates once these are added to the model, which would 
have amounted to considerable efforts to implement this strategy.  
 
As an alternative, it was considered to use MLwiNs weighting facility to adjust for 
differences in the ‘nj’ for studies included in this empirical exercise (CMM, 2011).  
The idea is that information from particular studies is ‘oversampled’ in the 
current dataset as it stems from studies where subgroup and sensitivity analyses 
were carried out more extensively (CMM, 2011). Hence, one may argue that out 
of the space of cost-effectiveness estimates, some did have a greater 
‘probability’ of being selected into the sample than others. Without weighting, 
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however, the model assumes that each data point did have the same chance of 
being selected into the sample (CMM, 2011). The probability of being selected 
into the sample may depend on certain variables referred to as ‘Z’. Furthermore, 
a set of covariates is considered within the multilevel framework in the second 
part of this exercise, which is denoted with ‘X’. According to (CMM, 2011), as 
long as there is no interaction between any variable out of Z on which the 
probability of being selected into the sample depends, and any variable out of X 
which enters the MLM as a covariate, results will be unbiased. Conversely, 
however, if there is a relationship between a covariate out of X and anything 
which may affect the probability of being selected into the sample out of Z, then 
the results may be biased (CMM, 2011).  
 
The problem of weighting in this secondary data integration exercise is a very 
complex one, and, in line with what has been outlined above, many issues arise 
for instance in terms of i) is this the appropriate method to address the issue of 
study group sizes within secondary data integration, ii) if so, when to assign 
those weights, iii) how to assign those weights to data points of studies and, on a 
practical note, iii) how to implement the respective model in a particular 
software environment (MLwiN). Related to the latter issue, CMM (2011) state 
that ‘at present the weights facility is not available when using MCMC estimation 
(since the method of implementing weights for MCMC would be radically 
different from the method for likelihood or quasi-likelihood estimation and 
require further methodological work and programming which has not yet been 
undertaken)’. However, the models developed in this empirical exercise could, in 
line with what has been strongly advocated by members of the Centre for 
Multilevel Modelling in Bristol (personal communication with Professor W. 
Browne and R. Phillinger, CMM), only be implemented with success when using 
MCMC estimation procedures. This fact precludes the use of the weighting 
facility in MLwiN at this point in time so that it is strongly recommended to 
further look into this issue once an appropriate software environment exists 
which allows running complex multilevel models using MCMC whilst also 
applying weights to studies. This matter is therefore assigned to potential areas 
for further research as it cannot be fully addressed within this thesis.  
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5.1.5.5. Conclusion 
 
In conclusion, this assessment showed that the impact of shrinkage is, at most, 
moderate within this empirical exercise and the problem arises predominantly 
on study-level. On the contrary, it is arguable whether the logic behind 
shrinkage, which gives higher gravity to geographic domains for which more data 
is available, is not justified between countries included in this empirical exercise. 
Differences in the nature of cost-effectiveness data may be addressed through 
covariate adjustment, so that data should become, in theory, exchangeable after 
controlling for the appropriate set of covariates. In addition to that, the 
moderate impact of shrinkage on study parameters within this empirical exercise 
is a result of high dependency of the data within studies, meaning that between 
study variability is high compared to within study variability, which leads to 
shrinkage factors being relatively close to unity. Furthermore, the relative 
location of study means with respect to the rest of the data seems to have a 
stronger impact on shrinkage than the actual number of data points provided by 
each study. Both ‘dependency’ and ‘location’, as factors influencing the impact of 
shrinkage, are perfectly justified for the integration of secondary cost-
effectiveness data. For the third factor, ‘group size’, it is recommended to further 
look into methodologies for assigning appropriate weights to studies in the 
dataset and then to implement this information within the respective multilevel 
models, given that a software may soon be available which allows assigning 
weights when using MCMC estimation procedures.  
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5.1.6. Summary and conclusions for the first part of this empirical 
exercise 
 
The first section of this empirical chapter was concerned with determining the 
appropriate MLM structure for the integration of published economic evaluation 
data from international studies on the cost-effectiveness of statins in the primary 
and secondary prevention of CVD. This assessment was not just concerned with 
testing which MLM structure previously developed works well on the data 
collected, but also whether assumptions made are justified for the data.  
 
 
Starting off with the models previously developed in the MLM methods Chapter 
3 and tested in the pilot study, this section showed that appropriate assumptions 
regarding (in-) dependencies of the data are crucial for making correct inferences 
when analysing secondary cost-effectiveness data. The pilot study already 
showed that, due to ignoring that data within studies is not independent, the 
OLS regression model and the two-level hierarchical model, which clusters data 
in countries only, were clearly outperformed by those MLM structures which did 
explicitly account for a study-level. This finding was clearly confirmed by the 
analysis reported in this section. However, it was also observed in the pilot study 
that the cross-classified model does not outperform the two-level hierarchical 
model which groups data in studies and that the country-level does not show 
noteworthy variability. As a potential reason for this finding, it was hypothesized 
that the assumption of independence between countries may not be adequate 
for those studies in the dataset which are ‘multinational’ in nature and thereby 
introduce the issue of cross-classification. If data from multinational studies is 
less affected by variability on country-level, this potentially ‘lays a curtain’ over 
the overall country-level variability present in the rest of the data from non-
multinational studies and therefore casts into doubt whether the assumption of 
independence between countries actually holds for data of those studies.  
 
For this reason, a three-level hierarchical model, which groups data in studies 
and studies in countries, was run both on a reduced dataset, where data from 
multinational studies was dropped, as well as the full dataset where this 
multinational study data was grouped in a separate cluster on country-level. To 
confirm that the lack of country-level variability in the cross-classified model 
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results from the data and not technical issues with model specification and 
implementation, a cross-classified model was also run on an ‘intermediate’ 
dataset, where some multinational study data was assigned to its respective 
target countries, and the remaining data clustered in a separate country group, 
thereby introducing the cross-classification problem on ‘a lower scale’.  
 
 
This analysis has clearly shown that the country-level variability observed in the 
model crucially depends on assumptions regarding independence of data from 
multinational studies on country-level. Whilst country-level variability was 
negligible for the cross-classified model, it increased dramatically within the 
bivariate three-level hierarchical framework, both for the full as well as the 
reduced dataset. In addition, running the cross-classified model for the 
intermediate dataset resulted in country-level variability somewhere in between 
the fully cross-classified model and the three-level hierarchical structure. These 
results clearly confirm that country-level variability may be underestimated in 
multinational studies, which constitutes an important finding from this research 
in its own right. Consequently, it was decided to take forward the three-level 
hierarchical model to the second part of this empirical exercise, as only this 
model makes appropriate assumptions regarding (in-) dependencies in the 
dataset, permits the simultaneous assessment of covariates on data, study, and 
country-level, and allows using the full dataset through grouping multinational 
study data in a separate group on country-level.  
 
 
The analysis as detailed above also demonstrates the benefits of decomposing 
the INMB statistic into its components ∆C and ∆E within the bivariate framework. 
First, one does not need to re-run models for different threshold values. 
Secondly, the correlation between the two stochastic components of the INMB 
statistic is explicitly modelled. Finally, once covariates are included, a bivariate 
model allows assessing the differential impact of covariates on each response 
variable whilst acknowledging that ∆C and ∆E are, themselves, correlated. When 
comparing the univariate and bivariate versions of the tree-level hierarchical 
model, it got apparent that part of the variability in international cost-
effectiveness data ‘disappears’ when combining ∆C and ∆E to the INMB statistic.  
This very interesting finding is subject to further analysis in Section 5.3 of this 
empirical chapter, which is concerned with country-level variability, or the lack 
thereof, in both the univariate and bivariate MLM framework.  
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Finally, this section assessed, in depth, whether Empirical Bayes shrinkage 
estimation may be regarded as appropriate in a model which attempts to 
integrate secondary data from published economic evaluation studies, where the 
weight of a particular study does not depend on individual patients considered, 
but rather on the extent to which subgroup and sensitivity analyses have been 
reported. It could be shown that, due to high between group variability in the 
data, shrinkage factors are generally very high, which means that shrinkage is, at 
most, moderate. More importantly, however, this section argued that the impact 
of shrinkage on study means in this exercise depends not just on the respective 
number of data points abstracted from each study, but also on the within and 
between group variability in the data (i.e. dependencies) and the location of each 
study mean relative to the overall regression mean. With respect to 
‘dependency’ and ‘location’, it was argued that shrinkage is perfectly justified 
within this secondary data integration exercise. For the third factor, ‘group size’, 
a distinction was made between country groups and study groups. With respect 
to countries, it was argued that the logic behind shrinkage, which gives higher 
gravity to geographic domains for which more data is available, may also be 
justified for countries included in this empirical exercise, even if the underlying 
data stems from published economic evaluation studies. With respect to studies, 
there may be arguments both in favour as well as against the appropriateness of 
shrinkage and it is recommended to further look into methods for assigning 
appropriate weights to studies in the dataset and then to implement this 
information in the respective MLM; provided that a software may soon be 
available which allows assigning weights when using MCMC estimation.  
 
The discussion section (Chapter 6) elaborates further on the findings of this 
particular section. However, important for the next section is the fact that the 
three-level hierarchical model, which clusters data from multinational studies in 
a separate group on country-level, is regarded as the appropriate MLM to take 
forward for further analyses. This model is used to analyse covariates on data 
and study-level, which were drawn from a long list of potential variability factors 
as reported in the literature (Sculpher et al., 2004; Goeree et al., 2007). This 
assessment of data and study-level covariates is the focus in the next Section 5.2 
of this empirical exercise.   
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5.2. Objective two: assessing variability factors on data 
and study-level 
 
The previous section was concerned with determining the appropriate MLM 
structure which best describes complex data structures as present in a set of 
international cost-effectiveness data abstracted from multiple economic 
evaluation studies and applicable to multiple geographic domains. Within that 
section, a number of alternative model architectures were compared, ranging 
from an OLS regression model, which ignores the existence of complex data 
structures, up to a cross-classified MLM, which groups international cost-
effectiveness data both in the studies it was abstracted from and the countries it 
refers to. Models which account for the existence of a study-level clearly 
outperformed the OLS regression model and the two-level hierarchical model 
which pools data in countries only. Furthermore, it turned out that the 
independency assumption of data from multinational studies on country-level 
disguises country-level variability, and that therefore a three-level hierarchical 
model, which pools data from multinational studies in a separate group on 
country-level, better fits the data. It was therefore concluded to carry forward 
this three-level hierarchical model to the second part of this empirical exercise, 
where the purpose is to assess variability factors which may account for part of 
the variation in international cost-effectiveness data.  
 
Covariates on data and study-level are systematically assessed which were drawn 
from a long list of variability factors as obtained from the literature (Sculpher et 
al., 2004; Goeree et al., 2007) and abstracted from the studies included in the 
systematic literature review (as reported in Chapter 4). This may not just help 
gaining an insight into the most important variability factors on data and study-
level, but also potentially disclose further variability on country-level (Hox, 2010), 
which is the focus of assessment in Section 5.3. of this empirical chapter. The 
following Section 5.2.1 outlines the plan of analysis for this part of the empirical 
exercise. Subsequently, methods and data to assess factors potentially causing 
variability in international cost-effectiveness data are introduced in Sections 
5.2.2 and 5.2.3 Results of this assessment are presented in Section 5.2.4., before 
moving on to the third part of this empirical exercise, where the aim is to assess 
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country-level variability – or the lack thereof – in measures of cost-effectiveness 
elicited from international economic evaluation studies.  
 
 
5.2.1. Plan of analysis for part two of this empirical exercise  
 
The key objective of this exercise is to control for variability on data and study-
level and thereby to potentially disclose further country-level variability (e.g. 
Hox, 2010). If successful, this may support the hypothesis that differences in 
cost-effectiveness results are, at least in part, due to differences between 
geographic domains, which would justify the three-level structure and also allow 
testing covariates on country-level. Within a MLM, anything introduced on a 
lower level might also impact on higher levels, but not vice versa (Hox, 2010). 
Hence, by introducing covariates on data and study-level, further country-level 
variability may be disclosed which may then be systematically assessed in Section 
5.3 of this empirical exercise.   
 
In other words, if differences between the cost-effectiveness of a health 
technology between studies are not just due to differences between those 
studies, but also due to differences between the geographic locations these 
studies were originally conducted for, then explicitly modelling a country-level 
better fits the data than applying a framework where data is clustered in studies 
only. The underlying assumption is that of (partial) exchangeability not just 
between studies but also between countries represented in the dataset 
(Spiegelhalter et al., 2000 & 2004; Drummond et al., 2009). In part one of this 
empirical exercise, this issue was addressed before including covariates to the 
model and equivalence of the three-level hierarchical model and its two-level 
counterpart, which ignores the existence of a country-level, was observed in 
terms of their respective DIC statistic. In this section, covariates are added to the 
model on data and study-level, and the explicit recognition of a country-level in 
the three-level hierarchical model allows the assessment of changes in country-
level variability through the inclusion of lower-level covariates.  
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This is also in accord with what is recommended in the MLM literature. A bottom 
up approach is usually advocated, starting off with the simplest possible model 
and then including parameters which are tested for significance after they have 
been added (Hox, 2010). The simplest model is a variance components model 
which does not include any explanatory variables (Steele, 2008; Rasbash et al., 
2009). This model specification was the focus of the previous Section 5.1. In this 
section, however, covariates are added to the model whilst assuming slopes of 
covariates to be fixed, resulting in a random intercepts specification (Steele, 
2008, Rasbash et al., 2009; Hox, 2010). This is achieved by proceeding from the 
lower level to the higher level (Hox, 2010). Hence, data-level covariates are 
tested first, and only once the model is fully specified on data-level, study-level 
covariates may be added. Once a full random intercepts model with data and 
study-level covariates has been specified, the next step is to test covariates on 
country-level, given that sufficient variability in measures of cost-effectiveness 
exists between geographic domains. This, however, is the focus of the 
subsequent Section 5.3 of this empirical exercise.   
 
Having outlined an overall analysis strategy for this exercise, it is necessary to 
operationalize this analysis strategy for the current dataset on the cost-
effectiveness of statins in the primary and secondary prevention of CVD. As a 
first step, one has to determine which covariates in the dataset belong to which 
level, how covariates within levels may best be arranged in subgroups of ‘similar 
tenor’, and which sequence should be applied when analysing subgroups of 
covariates. This helps braking down the hugely complex task of determining the 
‘appropriate set of covariates’ (Drummond et al., 2009) out of a large pool of 
candidate variables and is the focus in Section 5.2.1.1. Subsequently, an analysis 
strategy is determined for assessing covariates within subgroups in Section 
5.2.1.2. This involves producing bivariate statistics, checking for correlations, but 
also to look into potential additional covariates which may be derived from the 
raw data, e.g. through the use of data reduction techniques. Finally, further 
aspects of the analysis strategy with respect to missing values are addressed in 
Section 5.2.1.3, before moving on to Section 5.2.2 which introduces the full 
dataset and reports on descriptive statistics of covariates.  
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5.2.1.1. Covariates, levels, and subgroups of covariates within levels 
 
The overall strategy of building a full random intercepts model is to proceed 
from the lower level to the higher level (Hox, 2010). Hence, data-level covariates 
are tested first, and only once the model is fully specified on data-level, study-
level covariates may be added. This means that, as a very first step, the variables 
available from the dataset must be assigned to their respective levels. Note that 
the variables considered in this section are only those which are directly 
obtainable from the studies included in this empirical exercise and which 
consequently relate to the data and study-level only. Country-level covariates 
(including wider socioeconomic factors and healthcare system characteristics), 
which may be obtainable from alternative data sources (e.g. WHO databases), 
are considered in Section 5.3 of this empirical chapter, which is entirely involved 
with the assessment of country-level variability. To learn more about data and 
study-level covariates, Chapter 4 gives further details on how covariates were 
defined for this empirical exercise.  
 
 
As already mentioned in Chapter 4, the theoretically unlimited space of 
variability factors potentially relevant for this empirical exercise was initially 
confined to a long list of factors based upon work from Sculpher et al. (2004) and 
Goeree et al. (2007), who both systematically reviewed the literature involved 
with economic evaluation in health to compile a list of 77 unique factors 
potentially causing variability in economic evaluation data. Based upon this list of 
variability factors, a data abstraction form was devised, which initially comprised 
more than 200 variables. Subsequently, this data abstraction form was tested 
and modified in a pilot study by abstracting data from a subset of 16 papers 
included in this empirical exercise. Details on both the development of the data 
abstraction form and the pilot study are available from Chapters 3 and 4. After 
the pilot study was completed, it was decided to drop around 90 variables, either 
because data was not available from the studies or because variation was 
minimal or entirely missing within as well as between studies included in the 
pilot. Hence, the main data abstraction exercise started off with a form 
(implemented in MS Excel), which comprised around 100 variables, both on data 
and study-level (this form is obtainable in MS Word format in Appendix 4.13).  
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Following the systematic literature review, 67 studies were found includable in 
this empirical exercise, and data was abstracted from these studies. After 
cleaning and preparing the resulting data for MLM analysis, 66 variables were 
imported to STATA 12, which includes both the three response variables (INMB, 
∆C and ∆E) as well as ID-variables for each level of the data hierarchy, but 
excludes any of the derived variables, e.g. from applying data reduction 
techniques (for instance principal components factor analysis). Descriptive 
statistics of these variables are presented below in Section 5.2.2.  
 
 
During the course of data abstraction, it became apparent that some variables 
vary within studies, whilst others may only vary between studies. This 
observation is the only basis on which covariates are assigned to either the data 
or the study-level. For most variables, this decision is clear cut, for instance INMB 
values are usually reported for subgroups of patients with different cholesterol 
levels within a study, so that TCL varies within studies and is therefore a data-
level covariate. On the other hand, timing is obviously a variable which never 
varies within, but most certainly between studies and should therefore be 
assigned to the study-level. However, for some variables this decision was not as 
clear cut. For instance, the economic perspective of the analysis was initially 
considered a study-level covariate, until some studies were found which varied 
their perspective (e.g. Wagner et al., 2009a). Hence, the economic perspective 
may no longer be regarded as a study-level covariate as there is variation within 
this categorical variable on data-level. Accordingly, the MLM software MLwiN, 
which is used to run the MLMs in this exercise, would automatically assign this 
variable to the data-level (Rasbash et al., 2009; Rasbash et al., 2009a). As a 
result, from 60 covariates (not considering response variables, id-variables and 
derived variables), 19 variables were assigned to the study-level, whilst the 
remaining 41 variables show variation within studies and were therefore 
assigned to the data-level. In this context it should also be noted that the 
inclusion of sensitivity analyses results in this empirical exercise was responsible 
for shifting a number of variables, initially considered as clear study-level 
covariates, to the data-level, as authors assessed the impact of varying the 
respective variables within their studies. This holds, for example, for the annual 
drug cost of the intervention, the discount rate, the economic perspective, the 
time horizon or the duration of treatment with statins in years.  
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Hence, in terms of the analysis plan, the 41 variables on data-level are assessed 
first before proceeding to include study-level covariates. However, though this 
already brings some structure into this exercise, one needs to devise an order 
with which variables are tested within each level. For this reason, subgroups of 
variables are defined and then ordered to further structure this exercise. As 
before when deriving variables for data abstraction, the studies by Sculpher et al. 
(2004) and Goeree et al. (2007) served as a starting point for this task. Sculpher 
et al. (2004) grouped variability factors into i) patient factors, ii) clinician factors, 
iii) healthcare system factors and iv) wider socioeconomic factors, whilst Georee 
et al. (2007), who basically confirmed and extended the list of variability factors 
reported by Sculpher et al. (2004), grouped such factors in i) patient 
characteristics, ii) disease characteristics, iii) provider characteristics, iv) 
healthcare system characteristics and v) methodological factors.  
 
 
As country-level variation is not the focus of this part of the empirical exercise, 
variables relating to the healthcare system or wider socioeconomic factors are 
not considered at this point (but rather in Section 5.3 of this empirical chapter). 
Furthermore, variables relating to clinician factors or provider characteristics are 
not present in the dataset as studies did scarcely report data on these potential 
variability factors (the respective variables were dropped after completing the 
pilot study). Hence, most variables considered here encode patient 
characteristics, disease characteristics, or methodological factors. However, not 
all variables in the dataset fall into these categories, which is why further groups 
of variables were defined. These groups are intervention and comparator 
characteristics, general study characteristics and study quality indicators. This 
resulted in a system of six groups of covariates with three groups on data-level 
and study-level respectively, and this is also presented in the flow chart displayed 
in Figure 5.6 below.  
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Figure 5.6: Flow chart outlining the process of covariate assessment within this empirical exercise 
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Accordingly, Tables 5.9 and 5.10 contain groups of covariates on data and study-
level, and also specify the anticipated relationship between each covariate and 
the respective response variable (INMB, ∆C or ∆E). The last two columns of 
Tables 5.9 and 5.10 report on existing studies which either support or contradict 
the anticipated relationship between covariates and response variables.  For 
most studies which were used to inform prior expectations on the relationship 
between response variables and covariates, actual estimates of incremental cost, 
incremental effects and INMBs were compared within each study across 
subgroups of patients, different parameter ranges for sensitivity analyses or 
different scenarios considered within these studies. Most of these publications 
where decision analytic modelling studies, whilst three studies analysed 
individual patient data (Jönnson et al., 1999; Raiku et al., 2007; Tonkin et 
al.,2006). Only one study in Table 5.9 reports marginal effects from using a form 
of hierarchical modelling applied to secondary cost-effectiveness data from 
published studies (Franco et al., 2005).  
 
 
As reported in Table 5.9, a large number of studies support the relationships 
anticipated between patient and disease characteristics and response variables 
(INMB, ΔC and ΔE). For instance, 12 studies are in support of a negative 
relationship between INMB and the age of patients, amongst those a high quality 
report by the National Institute for Health and Clinical Excellence, which states 
that better cost-effectiveness estimates associated with commencing treatment 
at younger age ‘reflect the greater potential to prevent events, and thus the 
higher utility and cost benefits accrued from remaining event free health state’ 
(NICE, 2006). Only three studies where found which disagree with this view. 
Evidence is also very conclusive for the relationship between ΔC and ΔE and the 
age of patients, and also for other covariates encoding patient and disease 
characteristics. However, for all other groups of covariates reported in Tables 5.9 
and 5.10, there is very little evidence available so that the empirical exercise is 
rather hypothesis generating than hypothesis testing for covariates other than 
patient and disease characteristics.  
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Table 5.9: Data-level covariates and their anticipated relationship to measures of cost-effectiveness 
 
Variable 
name 
Description Nature of 
variable 
Anticip. relationship  Supporting evidence Contradicting 
evidence INMB ∆C ∆E 
Group 1a  covariates: Patient and disease characteristics 
age_cat 
What was the age of the sub-population 
modelled 
Ord. cat Neg Neg Neg 
INMB: 7, 9-11, 14-16, 23, 24, 26, 31, 33 
/ ∆C:4, 6, 8-11, 14, 16, 23, 24, 26, 31, 
33 / ∆E:4, 6, 9-11, 14-16, 23, 24, 26, 33 
INMB: 8, 13, 31 / ∆C: 
15 / 
∆E: 8, 13, 31 
gender_cat 
gender of the population (% of men in 
population) 
Ord. cat. Pos Neg Pos 
INMB: 5, 6 9-11, 13, 14, 20, 22, 24, 26, 
27, 30, 33 / ∆C: 5, 6, 9-11, 14, 22, 26, 
27, 30, 33 / ∆E: 5, 6, 8-11,13, 14, 20, 
22, 26, 27, 30, 33 
INMB: 8 
∆C:  8, 13 
CVD_hist 
CHD related medical history (% of second. Prev. 
patients ) 
Unord. cat. Pos Neg Pos 
 INMB: 3, 7, 10, 24, 27, 32, 33 / ∆C: 3, 
10, 27, 32  / ∆E: 3,10, 27, 32, 33 
INMB: 11 / ∆C: 11 / 
∆E: 11 
Tcl Total cholesterol level baseline Cont. Pos Neg Pos INMB & ∆E: 6, 9, 10, 26 / ∆C: 6, 9, 10 ∆C: 6, 26 
Hdl High density lipoprotein level at baseline Cont. Neg Pos Neg INMB, ∆C & ∆E: 14, 19 --- 
Ldl Low density lipoprotein level Cont. Pos Neg Pos  INMB:9, 26/ ∆C:9, 20, ∆E:  26 ∆C: 26 
Hypert 
percentage of hypertensive people in the 
subsample 
Cont. Pos Neg Pos 
 INMB:9, 14, 19, 26/ ∆C:19 / ∆E: 9, 
19,26 
 
Sbp Mean systolic blood pressure at baseline Cont. Pos Neg Pos 
 INMB: 6, 9, 14, 26/ ∆C:19 / ∆E: 9, 
19,26 
INMB: 19 
∆C: 6 
Diab Percentage of diabetic patients at baseline Cont. Pos Neg Pos 
INMB: 2, 6, 10, 11, 19, 21, 24, / ∆C: 6, 
10, 11, 19, 31 / ∆E:2, 10, 21 
∆C: 21, / ∆E: 6 
smokers Percentage of smokers at baseline Cont. Pos Neg Pos 
INMB: 2, 9, 14, 21, 26 / ∆C: 9, 14, 28 / 
∆E: 2, 9, 14, 21, 26  
∆C: 21 
risk_cat Risk category of the subsample Ord. cat. 
Pos Neg Pos 
INMB: 7,17, 24 --- 
For primary prevent. only 
Group 1b covariates: Intervention and comparator 
intervention Brand name of the intervention drug? Unord. cat. ? ? 
No 
effect 
 INMB: 25 --- 
comparator Brand name of the comparator drug? Unord. cat. ? ? 
No 
effect 
  INMB: 25 --- 
act_comp 
Comparator ‘doing nothing’ or comparator 
‘other statin’ 
Unord. cat. 
Neg Neg Neg --- 
--- 
For ‘other statin’  
tdd_int 
What was the total daily dose of the 
intervention 
Ord. cat. Pos Neg Pos INMB: 32 / ∆C: 1 /∆E: 1 
INMB:1 
∆E: 32 
tdd_comp What was the total daily dose of the comparator Ord. cat. Neg Neg Neg --- --- 
Cost-int 
What are the annual drug cost of the 
intervention in 2010 £-Sterling 
Cont. Neg Pos n.a. INMB: 24 --- 
Unitcost_int What was the unit cost of the intervention Cont. Neg Pos n.a. INMB: 24 --- 
Cost_comp 
annual drug cost of the comparator in 2010 £-
Sterling 
Cont. Pos Neg n.a. --- --- 
Unitcost_comp What was the unit cost of the comparator Cont. Pos Neg n.a. --- --- 
Incr_cost 
What was the incremental annual drug cost  of 
the intervention 
Cont. - Pos n.a. --- --- 
Group 1c covariates: Methodological characteristics on data-level 
outc_measure How was health outcome reported in the study Binary. ? ? ? --- --- 
elicitation 
If QALYS were used, what was the method of 
preference elicitation? 
Unord. cat. 
? ? ? 
--- --- 
population 
If QALYS were used, what do the utility values 
reflect (patient / population values) 
Unord. cat. 
? ? ? 
--- --- 
DRC Discount rate on costs  Cont. ? ? n.a. --- --- 
DRB Discount rate on benefits Cont. Neg n.a. Neg --- --- 
duration Treatment duration modelled Ord. cat. Pos Pos Pos --- --- 
extrapol Any extrapolation beyond the latest follow up? Binary ? ? ? --- --- 
horizon Time horizon? Ord. cat. Pos Pos Pos INMB: 24 --- 
hor_eq_dur 
Does the time horizon equal the treatment 
duration? 
Binary 
? ? ? 
--- --- 
Persp_rep 
Study perspective as reported by the authors of 
the article 
Unord. cat. 
Pos Neg ?  INMB: 7 
--- 
For ‘societal’ only  
Persp_cost_con
cl 
Study perspective on cost as concluded by the 
reviewer (health insurance perspective omitted) 
Unord. cat. 
 Pos Neg n.a. INMB: 7 
--- 
For ‘societal’ only  
data_class How was the datapoint classified Unord. cat. ? ? ? -- --- 
basecase 
Was the data point result of a base case or 
sensitivity analysis? 
Binary 
? ? ? 
-- --- 
source_effects 
From which source (trial, meta-analysis) was 
effectiveness data taken from 
Unord. cat. 
? ? ? 
-- --- 
Barbieri_score_
1 
How context specific is the CE estimate judged 
from the input parameters 
Unord. cat. 
? ? ? 
-- --- 
Barbieri_score_
2 
How context specific is the CE estimate judged 
from the input parameters 
Unord. cat. 
? ? ? 
-- --- 
(1) Ara et al. (2009), (2) Ashraf et al (1996), (3) Caro et al (2003), (4) CDC-Group (2002), (5) Davies et al. (2006), (6) Drummond et al. (1993), (7) Franco et al. (2005),  
(8) Greving et al. (2011), (9) Grover et al (1999), (10) Grover et al (2000), (11) Grover et al. (2001), (12) Grover et al. (2003), (13) Grover et al. (2008), (14) Hamilton et al 
(1995), (15) HPS (2006), (16) HPS (2009), (17) Huse et al. (1998), (18) Johannesson et al (1997), (19) Jönsson et al (1999), (20) Lindgren et al (2007), (21) Muls et al. 
(1998), (22) Nagata-Kobayashi et al. (2005), (23) Nherera et al (2010), (24) NICE (2006), (25) NICE (2008b), (26) Perreault et al (1998), (27) Pharoah et al (1996), 
(28) Raikou et al. (2007), (29) Sigvant et al. (2011), (30) Soini et al (2010), (31) Tonkin et al. (2006), (32) van Hout et al. (2001), (33) Ward et al. (2007) 
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Table 5.10: Study-level covariates and their anticipated relationship to measures of cost-effectiveness 
 
Variable 
name 
Description 
Nature of 
variable 
Anticipated 
relationshio to  
Supporting 
evidence 
Contradicting 
evidence 
INMB ∆C ∆E 
Group 2a covariates: General Study characteristics 
language In which language was the paper written? Binary ? ? ? --- --- 
paper_origi
n 
In which country was the paper written (if authors from 
several jurisdictions were involved, where is the lead 
author based? 
Unord. cat. ? ? ? --- --- 
Timing What is the timing of the economic evaluation Unord. cat. Pos Neg Pos INMB: 1 --- 
fund_inst primary source of funding (institution) Unord. cat. Pos Neg Pos INMB: 1, 2 --- 
For industry funding  
fund_man 
If funding source was private, which manufacturer was 
involved? 
Unord. cat. ? ? ? --- --- 
Author_grou
p_long 
Variable which encodes relationships between published 
papers in terms of common authorship 
Unord. cat. ? ? ? --- --- 
Author_grou
p_short 
Variable which encodes relationships between published 
papers in terms of common authorship 
Unord. cat. ? ? ? --- --- 
Group 2b covariates: Methodological characteristics on study-level 
gen_des What was the general study design? Unord. cat. Neg ? ? INMB: 1  --- 
For secondary modelling 
prim_des If primary modelling, what was the specific study design? Unord. cat. ? ? ? --- --- 
sec_des If secondary modelling, what was the specific study design Unord. cat. ? ? ? --- --- 
effect_calc Method of effect calculation Unord. cat. 
Neg ? ? 
INMB: 1  --- For modelling 
intermediate outcomes 
multination
al 
Was the study multinational Binary ? ? ? --- --- 
infl_adj Were cost estimates in the model adjusted for inflation? Unord. cat. ? ? n.a. --- --- 
adj_method 
If cost estimates were adjusted for inflation, what was the 
adjustment method 
Unord. cat. ? ? n.a. --- --- 
cur_conv Was currency converted Binary ? ? n.a. --- --- 
conv_metho
d 
If currency was converted, what was the conversion 
method used by the authors? 
Unord. cat. ? ? n.a. --- --- 
scope What was the scope of assessment Unord. cat. Pos Neg Pos INMB: 3 --- 
Group 2c covariates: Study Quality indicators 
qhes_cata 
What was the overall QHES category given a strict 
application of the QHES criteria 
Ord. cat. ? ? ? --- --- 
qhes_catb 
What was the overall QHES category given a pragmatic 
application of the QHES criteria 
Ord. cat. ? ? ? --- --- 
Qhes_conta 
What was the overall QHES score given a strict application 
of the QHES criteria? 
Cont. ? ? ? --- --- 
Qhes_contb 
What was the overall QHES score given a practicable 
application of the QHES criteria? 
Cont. ? ? ? --- --- 
(1) Franco et al (2005), (2) Miners et al (2005), (3) NICE (2006) 
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Nevertheless, even without supporting literature, one can speculate about the 
relationship between covariates and response variables if there is a theory or 
logical argument which supports this prior expectation, which is why columns 
four to six in Tables 5.9 and 5.10 also report on anticipated relationships for 
those covariates for which there was no evidence available from the literature. 
Why a certain direction of change was anticipated for each covariate, however, 
will not be discussed here but rather in Chapters 5.2.4 and 6.3.1 in the light of 
the results from testing covariates within the multilevel models developed in this 
thesis and with reference to the supporting literature (if available).  
 
 
Finally, it is important to define a sequence with which groups of covariates are 
considered in the multilevel analysis. As mentioned by Sculpher et al. (2004), ‘In 
economic evaluation generally, arguably the most important source of variation 
in cost-effectiveness is between subgroups of patients defined in terms of 
demographic and clinical factors’. Sculpher et al. (2004) further state that ‘this 
important source of patient-level variation feeds through to centre or country 
variation in cost-effectiveness if these subgroups of patients are not evenly 
distributed between locations. The amount of literature available to inform 
expected relationships between patient and disease characteristics and response 
variables as reported in Table 5.9 underpins the importance of this group of 
covariates. Therefore, patient and disease characteristics shall be considered first 
in this part of the empirical exercise. Doing so not just controls for differences 
between subgroups of patients on data-level, but also ‘removes’ the potential 
impact on variation between studies and countries in the multilevel framework. 
Note that patient and disease characteristics only refer to differences between 
subgroups of patients as assessed within the studies included in this empirical 
exercise like age, gender, cholesterol level at baseline, CVD related medical 
history or smoking status. Patient and disease characteristics do not refer to 
differences in demographic or disease characteristics between countries. The 
latter will be the focus of Section 5.3 of this empirical study.  
 
 
Following the assessment of patient and disease characteristics, variation caused 
by differences in the intervention and comparator are considered as this group 
of covariates is also suspected to be responsible for some variability in measures 
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of cost-effectiveness of statins in the primary and secondary prevention of CVD. 
There are a number of different statins on the market, which are considered in 
different dosages and assessed with respect to different comparators (either 
‘doing nothing, ‘other statin’ and /or ‘different dosage’) within the studies 
included in this empirical exercise. Hence, one needs to control for this potential 
source of variation, as otherwise the effect of differences in the intervention or 
comparator may feed through to the variability in measures of cost-effectiveness 
observed on study or even country-level. 
 
 
Once the model controls for the appropriate set of patient and disease as well as 
intervention and comparator characteristics, the next group of variability factors 
are methodological differences affecting measures of cost-effectiveness which 
may vary within studies included in the dataset. Hence, factors like the outcome 
measure (LYS or QALYs), the discount rate applied to costs or effects, the time 
horizon, the economic perspective, or whether the respective data point refers 
to base case or sensitivity analysis, may be assessed. This group of covariates is 
also concerned with variation with respect to the sources from which input data 
was drawn. This relates, for instance, to the source of effectiveness data in terms 
of the trial from which this data was obtained. However, another source of 
variation refers the ‘geographic context specificity’ of input parameters.    
 
 
Barbieri et al. (2005) grouped studies with respect to differences in the 
geographic origin of input parameters. Accordingly, there may be differing 
degrees of variability in measures of cost-effectiveness. This source of variation 
may even differ within the studies included in the dataset. To assess this 
potential source of variability, information was first collected from studies to 
record the geographic origin of the data used to populate the economic model. 
Secondly, covariates which group studies with respect to their ‘geographic 
specificity’ of input parameters were derived from the raw data, which are 
subject to multilevel analysis in this section. The idea is analogous to what has 
been observed with respect to data from multinational studies in Section 5.1 of 
this empirical exercise, namely that the highest degree of variation on country-
level may exist in cost-effectiveness data which is based on target country 
specific values for all input parameters. Chapter 4, which is concerned with the 
data abstraction for this empirical exercise, explains in detail how the ideas of 
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Barbieri et al. (2005) were applied to define a set of categorical variables which 
encode variation, or the lack thereof, with respect to geographic locations of 
input parameters. The raw data to derive such covariates has been omitted from 
further analysis.  
 
 
Moving on to the study-level, it was decided that general study characteristics 
(such as timing, paper origin, or the respective funding source) are assessed 
before methodological aspects on study-level are considered. A reason for this 
sequence is that general study characteristics (such as paper origin or timing) 
may partly determine methods on study-level (for example as authors aim to 
follow a specific HTA guideline applicable to a certain geographic location at a 
certain point in time), so that it makes sense to assess general study 
characteristics first. Finally, study quality indicators, resulting from applying the 
QHES instrument (Ofman et al., 2003) to the studies included in this empirical 
exercise, are considered to conclude the assessment of data and study-level 
covariates in this section of the empirical analysis. How data from applying QHES 
was collected and combined to a single score is also described in Chapter 4.  
 
 
 
5.2.1.2. Analysis strategy for covariate Assessment on data and study-level 
 
In the previous subsection, the dataset was divided into subgroups of covariates, 
and a sequence was established with which groups of covariates are considered 
in this empirical exercise. This breaks down the complicated task of determining 
the appropriate set of covariates out of a large number of candidate variables. 
However, what is required to accomplish this task is a strategy to determine the 
appropriate set of covariates for inclusion in the final MLM, and this is the focus 
of this subsection.  
 
First, univariate descriptive statistics are reported, i.e. means and standard 
deviations for continuous variables before and after imputation of missing values 
(the missing value strategy is also outlined further below), and proportions for 
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categorical variables respectively. At the very minimum, this establishes that 
variables considered in this exercise do, in fact, vary (Fielding & Pillinger, 2008). 
In addition, summarizing and describing the data may help hypothesising about 
potential patterns and relationships (Fielding & Pillinger, 2008). Apart from 
descriptive statistics, correlations between subsets of explanatory variables are 
assessed in depth and approaches to reduce redundancies in the dataset are 
applied (which is explained further below). Relationships between covariates and 
response variables are then analysed in more detail by individually entering 
covariates into the respective MLMs to test whether the anticipated relationship 
to the response variable (INMB, ∆C or ∆E) holds, and whether this relationship is 
statistically significant. Finally, a random intercepts model with covariates on 
data and study-level is developed to control for variability on data and study-
level, thereby disclosing the maximum amount of country-level variation, which 
is then further assessed in Section 5.3. of this empirical exercise.  
 
A systematic approach to covariate selection is imperative in this part of the 
empirical exercise. Though of tremendous informative value, it is not sufficient to 
choose variables on grounds of bivariate statistics only. The reason is that a 
covariate may not show the anticipated sign or may not reach statistical 
significance because of a confounding factor which has not been controlled for 
(e.g. Maddala, 2001). Conversely, covariates may individually reach significance, 
but not once tested in conjunction as they may be highly correlated (Maddala, 
2001, Acock, 2010). To aid this choice and to avoid randomly testing subsets of 
covariates within the MLM framework, it is useful to hypothesize about potential 
relationships between explanatory variables, and to put such relationships to the 
test by assessing correlations between explanatory variables. An example in the 
current dataset are the patient and disease characteristics ‘systolic blood 
pressure (SBP)’, ‘hypertension status’ and ‘smoking status’. Hypertension status 
and SBP may be regarded as alternative measures of a similar physiological 
pattern, and, as it constitutes a risk factor for elevated blood pressure, smoking 
status is suspected to be correlated to both SBP and hypertension status. As all 
three variables are continuous (hypertension status and smoking status are 
measured as the percentage of patients affected), pairwise correlations may be 
produced as a first indication of statistical relationships between potential 
explanatory variables (Acock, 2010). Alternatively, polychoric correlations may 
 222 
 
be produced for ordered categorical variables (Kolenikov & Angeles, 2004). For 
unordered categorical variables, dependencies may be tested using a chi2 test of 
association, and the method of multiple correspondence analyses, which plots 
categories of variables in terms of their chi-squared distances on a low-
dimensional space, may be used to further assess patterns in categorical data 
(Bartholomew et al., 2008; Le Roux & Rouanet, 2004) 
 
Hence, subgroups of covariates defined in the previous subsection are analysed 
with respect to correlations in the data and based on these correlations, several 
strategies may be considered. If, for example, two variables are regarded as 
alternative measures of the same concept, then it may be indicated to simply 
choose one variable over the other for inclusion in the MLM based on 
significance, model fit and other issues such as the proportion of missing values 
imputed for each variable. However, if it is suspected that correlated variables 
are interrelated measures of a common underlying but unobserved construct, 
one may consider data reduction techniques. The choice of method thereby 
depends on the nature of the observed variables and potential candidate 
methods were already discussed in the context of the genealogy study reported 
in Chapter 4. One multivariate method often used to assess patterns in data is 
factor analysis (FA). As Rencher (2002) states, ‘the goal of factor analysis is to 
reduce the redundancy among the variables by using a smaller number of 
factors.’ These factors are, unlike the observations, unobserved and therefore 
also referred to as ‘latent variables’. Of particular interest for this part of the 
empirical exercise is what Acook (2010) refers to as ‘principal components factor 
analysis’ (PCF). PCF may be used if one has a set of items which all measure the 
same underlying concept (Acook, 2010) and it may be applied to obtain a ‘factor 
score’ which could be used as a covariate instead of the set of items initially 
observed. The question for choosing amongst the set of covariates is whether 
the factor score itself, or any of the original items leads to better model fit when 
considered alternatively in the MLM.  
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Figure 5.7: Strategy of covariate assessment within subgroups of covariates   
 
 
However, PCF is only valid for continuous data (Rencher, 2002; Acock, 2010;) and 
its application in the current exercise may therefore be rather limited. For this 
reason, a package developed by Kolenikov & Angeles (2004) was considered as 
an alternative, which implements ‘polychoric principal components analysis’ into 
the software environment STATA. However, Kolenikov and Angeles (2004) state 
that this method is only valid for continuous as well as ordered categorical 
variables, which again leaves out the majority of variables relevant for this 
assessment. For this reason, multiple correspondence analysis (MCA) was 
considered, which is also referred to as the ‘categorical equivalent to PCA’ (Le 
Roux && Rouanet, 2010). The aim of MCA is to visualize the raw data in a low-
dimensional space (usually two dimensions) which then helps to identify patterns 
in this data. (Bartholomew et al, 2008). It does so by converting categories of 
variables into points on a plane (the biplot), and the researcher may then analyse 
the resulting cloud and sub-clouds of points in this geometric space (Le Roux, 
Rouanet, 2010). A summary score may then be derived which can be used in the 
MLM as an alternative to the initial set of correlated covariates.  
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To sum up, the choice of covariates follows a rigorous assessment of 
relationships between explanatory variables and response variables as well as 
intercorrelations between explanatory variables. Assessing correlations and 
patterns in the data as well as the application of data reduction techniques aims 
to avoid that multicollinearity between explanatory variables distorts the 
estimation process. This is the focus of Section 5.2.3 of this empirical exercise, 
which starts off with descriptive statistics before reporting on missing data and 
imputation thereof and concludes with a rigorous assessment of correlations 
between subsets of explanatory variables in the dataset. Subsequently, the 
results Chapter 5.2.4 starts off with reporting on bivariate statistics generated 
from testing covariates individually in the MLM framework, before a full random 
intercepts model is developed by applying the above detailed analysis strategy to 
each subgroup of covariates in the sequence outlined in the previous subsection. 
This results in a MLM with covariates on data and study-level, which may then be 
further developed through the inclusion of country-level covariates in Section 
5.3, given that there is sufficient variability on country-level after adjusting for 
data and study-level covariates.  Finally, random slopes and the variance function 
are assessed in a case study in Section 5.4 of this empirical chapter. Before 
moving on to study methods and introducing the data for this part of the 
empirical exercise, however, further aspects of the analysis strategy are 
explained with respect to missing values in the data.  
 
 
5.2.1.3. Analysis strategy for missing observations 
 
 
Missing data are, generally speaking, observations which we intended to make 
but, for some reason, haven’t (Carpenter & Kenward, 2007). Within this 
empirical exercise, missing data arises from the failure of included studies and 
related sources to report on relevant aspects, for example, patient risk 
characteristics or methodological characteristics. Missing data occurs both on 
data and study-level, and it also occurs in categorical as well as continuous 
variables. There is not one single method, or gold standard, to address missing 
data issues, though multiple imputation of missing data has gained a lot of 
popularity in recent years (Carpenter & Kenward, 2007). The primary aim of 
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missing data imputation is to be able to make valid inferences even in the 
presence of missing data (Carpenter & Kenward, 2007; Carpenter & Goldstein). 
However, this validity depends upon the ‘mechanism’ by which data is missing 
(Carpenter & Goldstein).  
 
 
What is generally referred to as “missingness mechanism” goes back to Little & 
Rubin (1987). The missingness mechanism describes whether data is missing 
completely at random (MCAR), missing at random (MAR) or missing not at 
random (MNAR) (Acock, 2005; Carpenter & Kenward, 2007). Data is missing 
completely at random if the missingness is completely unrelated to the outcome 
(Carpenter & Kenward, 2007).  If data is MCAR, we may simply ignore data points 
with missing values, which leads to listwise deletion of the affected data 
(Carpenter & Kenward, 2007). However, the occurrence of MCAR is rare so that 
the assumption of data missing completely at random is restrictive. (Acook, 
2005; Carpenter & Kenward, 2007; Acook, 2010; Carpenter & Goldstein). Less 
restrictive is the assumption of data missing at random (MAR) (Acook, 2005; 
Carpenter & Kenward, 2007). If we can explain the occurrence of missing data in 
one variable by another variable in the dataset, then the missing data may be 
MAR. (Acook, 2005; Carpenter & Kenward, 2007; Acook, 2010). In this empirical 
exercise, the MAR condition may be satisfied if, for example, missing values in 
the categorical age variable (age_cat) do not depend on the age of the 
respondents, after controlling for, say, gender. According to Acook (2005), the 
issue of MAR is not whether gender can predict age_cat, but whether gender is a 
mechanism to explain whether values in the age variable are missing. The 
variables which are used to explain whether data is missing or not (in this 
example ‘gender’) may be included as auxiliary variables in a model when 
imputing missing values (Acook, 2010). A third mechanism of missingness is 
missing not at random (MNAR). In simple terms, if data are neither MCAR nor 
MAR, then they are MNAR or informatively missing (Carpenter & Kenward, 
2007). Dealing with data MNAR is much more difficult as the observed data does 
not tell anything definite about the ‘relationship between the chance of seeing a 
variable and its “unseen value” or to “describe how the distribution of the data 
differs among data points with missing values’ (Carpenter & Kenward, 2007).   
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The default strategy in many statistical packages, which is only valid under the 
restrictive MCAR assumption, is listwise deletion. In the case of MCAR it may 
provide unbiased estimates. However, the case of MCAR may be very rare, which 
casts into doubt the validity of this approach in many practical applications 
(Acock, 2005; Carpenter & Kenward, 2007). A further problem occurs if the 
sample size is small, which in the case of this empirical exercise, holds for the 
study and country-levels, so that listwise deletion may simply lead to an 
unacceptable loss of power. Apart from listwise deletion, traditional, or ‘ad hoc’ 
approaches of dealing with missing values include pairwise deletion, mean 
substitution (overall mean, or mean of subgroups), regression based single 
imputation or creating a new category for missing values in categorical variables 
(Acook, 2005). A more elaborated approach, which is gaining a lot of popularity 
recently, is multiple imputation (MI) of missing values (Acook, 2005; Acock, 2010; 
Carpenter & Kenward, 2007; Carpenter and Goldstein).  
 
Starting with MI, its idea, which goes back to Rubin (1987), is to treat missing 
values as random variables, and to impute several values for each missing value, 
resulting in a number of complete datasets (Rubin, 1987). The imputed values do 
not contain any unique information, so that the complete dataset restores the 
original variance-covariance matrix (Alemdar, 2009; Acook, 2010). The first step 
in MI is to model the variable with missing values as a response of the other 
variables in the dataset. Then, a (random) draw is being made from the normally 
distributed residuals, which results in the imputed values (Acock, 2005; 
Carpenter & Kenward, 2007, Acock, 2010). These values, as mentioned above, do 
not contain any unique information so that the completed dataset replicates the 
original variance-covariance matrix (Alemdar, 2009). However, as these values 
are imputed from a distribution of possible values, a single imputation is 
inappropriate. Therefore, several values are imputed for each missing value 
(Acock, 2005; Carpenter & Kenward, 2007, Acock, 2010) This results in a number 
of (k) datasets, typically somewhere between 5 and 10 (Acock, 2005). After 
having obtained ‘k’ imputed datasets, the next step involves analysing each 
dataset using the model of interest, in this case the hierarchical three-level 
model, which leads to ‘k’ regression outputs (Acock, 2005). The final step 
combines these ‘k’ regression outputs into one pooled regression-output Acock, 
2005. The underlying assumption for MI is that data is, at least, MAR Acock, 
2005; Carpenter & Kenward, 2007, Acock, 2010. In adding the variability in the 
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imputed values to the variability observed in the dataset, the regression results 
do not suffer from overestimated precision (Acock, 2005; Carpenter & Kenward, 
2007, Acock, 2010). In other words, MI captures the uncertainty associated with 
data being missing (Acock, 2005; Carpenter & Kenward, 2007, Acock, 2010). As 
the imputed values do not contain any additional information than what is 
already contained in the dataset, the resulting inference is valid, i.e. unbiased 
(Acock, 2005; Carpenter & Kenward, 2007, Acock, 2010).  
 
 
However, an important problem arises when considering the multilevel structure 
of the model of interest in this exercise. Carpenter & Goldstein highlight that an 
imputation model ‘must have the right variance structure’. Hence, ‘if a dataset is 
multilevel, then the imputation model must be multilevel too’. In a simulation 
study, Gibson and Oleynik (2003) compared different methods of treating 
missing values in a dataset with a two-level hierarchical data structure. Missing 
values (10% in one analysis and 40% in another) were generated in level two 
variables, and two datasets were produced, one with 30, and one with 160 
higher-level units. Especially when missing values were high (40%) and the 
number of higher-level units was low (30), MI performed poorly compared to 
traditional ‘ad hoc’ approaches. The authors concluded that the poor 
performance of MI in their study may have been due to the fact that the MI 
procedure was not suitable for hierarchical models when values are missing at 
level two.   
 
 
For this reason, alternative options to reflect the multilevel nature of the dataset 
in the imputation model were considered in this thesis. For instance, Carpenter 
and Goldstein developed macros for multiple imputation in MLwiN, but 
unfortunately, it is only capable of handling missing data in level one variables 
which obviously limits its applicability to the current exercise. An alternative to 
Carpenter and Goldsteins macros is ‘Realcom IMPUTE’, a freeware developed by 
the Centre for Multilevel Modelling in Bristol (Goldstein, 2009). The advantage of 
Realcom IMPUTE over the MI macros is that it deals more adequately with 
categorical and normal data and multilevel structures (Goldstein, 2009). The 
procedure has three stages. First, the model of interest is being set up in MLwiN 
where some of the variables have missing data. Secondly, REALCOM-IMPUTE is 
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run. Then, MLwiN uses the output from REALCOM-IMPUTE to produce the model 
estimates (Goldstein, 2009). However, Realcom IMPUTE is currently only capable 
of dealing with two-level hierarchical data, although the author mentions that, in 
some cases, it may be possible to substitute fixed for random effects. 
Nevertheless, the procedure may not yet be fully applicable to more complex 
data structures, as for example the three-level bivariate MLM in this exercise.   
 
 
Finally, to further look into methods of implementing MI in the MLM framework, 
the author posted this problem at ‘MULTILEVEL@JISCMAIL.AC.UK’, an 
international mailing list for researchers involved with MLM. Though some 
suggestions were made to tackle this problem in alternative software 
environments (e.g. implementing the model of interest in MPlus, using STATA for 
both imputation and implementing the model of interest with GLAMM or 
STMIXED, or using AMELIA II instead of Realcom), the overwhelming feedback 
was that each solution would come with its own set of problems and that there 
is, at this point, probably no appropriate solution to this problem in the case of 
particular complex data structures.  
 
 
In conclusion, MI may be, in general, the most sophisticated way to deal with 
missing data. However, problems arise when the multilevel data structure is not 
acknowledged appropriately in the imputation model. Whilst some solutions 
exist to implement multilevel MI, these methods may not yet be advanced 
enough to deal with more complicated data structures like the bivariate three-
level model. This is an area of on-going research, and it may also constitute an 
interesting topic for future research beyond the scope of this project. However, 
for the current exercise, an alternative missing value strategy is required.  
 
 
Hence, regression based single imputation was considered for continuous 
variables, whilst an extra ‘missing category’ was introduced to address missing 
values in categorical data. In regression based single imputation, one predicts the 
missing value from a regression model where the dependent variable is the 
variable affected by missing values, and a vector of explanatory variables which 
may help predicting the value of the dependent variable (e.g. Briggs et al., 2002). 
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Hence, this strategy includes defining an imputation model and selecting a 
number of explanatory variables which one assumes to help predicting the 
missing values in the affected variable (Briggs et al., 2002). After this model has 
been fitted, one can use the results to impute the predicted mean from the 
regression equation given the observed values of the covariates for that data 
point (Briggs et al., 2002). This works well if the data is MAR (Briggs et al., 2002). 
In the case of this empirical exercise, one may, for instance, impute missing 
values on the annual drug cost of the intervention by fitting an OLS regression 
with the covariates ‘timing’, ‘country’, ‘drug_name’ and ‘drug_dose’. After 
running the regression, one may then predict the missing value in ‘drug_cost’ by 
applying the information on the coefficients applicable to the affected data 
points. As stated on missingvalues.org.uk, regression mean imputation ‘can 
generate unbiased estimates of means, associations and regression coefficients 
in a much wider range of settings than simple mean imputation.’ Even though 
the variability of the imputations may be too small, this should be less of a 
concern compared to more ad hoc imputation techniques like simple mean 
imputation or imputing the mean for subgroups (missingvalues.org.uk).  
 
 
To deal with missing values for categorical data, an extra category for missing 
values was created for each affected variable. This allows using the full dataset 
whilst showing how the missing cases differ from those where data has been 
reported. However, one needs to be aware of the fact that this approach 
potentially lumps together very dissimilar cases in one category. In other words, 
the “impact of this strategy depends on how missing values are divided among 
the real categories, and how the probability of a value being missing depends on 
other variables.” (missingdata.org.uk). Bias in any direction may be the 
consequence.  
 
 
In addition to the above, a binary indicator is used to show whether a value has 
been imputed in the variable of interest (e.g. Acook, 2005). If such an indicator 
variable is included in the model of interest, two scenarios are possible. If it is 
not significant, then imputation has increased the sample size without biasing 
the results (Morris et al., 2005). However, if the dummy is significant, then it 
allows estimating an effect for the non-missing values which is not affected by 
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the imputation of missing values (Morris et al., 2005). In other words, this 
method leads to the same regression estimates as listwise deletion as the binary 
indicator variable captures the departure of the imputed cases from the other 
cases in terms of the outcome variable (Acook, 2005). However, one needs to be 
aware that when there are several variables with missing values, and this 
missingness has a common pattern, then using several indicator variables may 
cause a multicollinearity problem (Acook, 2005).  
 
 
Imputing regression based values for continuous data, assigning missing values 
to an extra category for categorical variables, and including an indicator variable 
for missing values is not without controversy in the literature and certainly not 
the ‘best one could do’ (e.g. Acock, 2005). Overestimation of precision and some 
potential for bias make it necessary to interpret results with caution. However 
this strategy might be the ‘best we can currently do’, as the use of MI in the 
presence of complex data structures is an area of on-going research. The next 
section briefly outlines the methods of analysis, which is basically to apply the 
three-level hierarchical model in a random intercepts specification to the data. 
Subsequently, the dataset is summarized in Section 5.2.3, where descriptive 
statistics before and after imputing missing values are reported. Results from 
bivariate statistics and the construction of a full random intercepts model with 
covariates on data and study-level are then presented in Section 5.2.4, before 
this part of the empirical exercise ends with a brief summary and conclusions in 
Section 5.2.5.  
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5.2.2. Methods of analysis for experiment two 
 
 
This exercise applies the three-level hierarchical model with data grouped in 
studies and studies grouped in geographic domains, where data from 
multinational studies is clustered in a separate group on country-level, to a set of 
secondary cost-effectiveness data on statins in the primary and secondary 
prevention of CVD. The model is run in its univariate specification with INMB as 
the only response variable, as well as a bivariate model with ∆C and ∆E as a 
vector of response variables. Table 5.11 summarizes the models to determine 
the appropriate set of covariates on data and study-level.  
 
 
In essence, the only difference between the models run in this part of the 
empirical exercise and the variance components models 1.b and 1.c in part one, 
is the inclusion of a vector of explanatory variables on each hierarchical level, 
denoted with ′8H8:’ (data) and  ′	H	K’ (study) and ‘JHJK’ (country) 
respectively. Note, however, that country-level covariates are only considered 
later in Section 5.3 of this empirical exercise. As before, the intercept term is 
denoted with ‘β’ and subscripts refer to each level of the data hierarchy with ‘i’ 
representing level one, ‘j’ level two, and ‘k’ level three so that ‘v:′ is the error 
term for level three, ‘u:’ the error term for level two and ‘e:’ the error term 
for level one respectively. For the univariate specification it is assumed that 
INMB is normally distributed at each level of the model whilst a bivariate normal 
distribution is assumed for the bivariate model. As in the bivariate variance 
components model before, the response indicator ‘r’ is 1 for ∆C and 0 for ∆E and 
a separate level for this response indicator is fitted below the data-level. Finally, 
the bivariate random intercepts model estimates one error variance for each 
response variable plus their respective covariance on each level. Again, further 
details on the multilevel methodology applied in this empirical exercise are 
available from Chapter 3.  
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Table 5.11: Multilevel models for exercise two 
 
 
Model of interest 
(Three-level hierarchical model) 
Model summary 
 
Three-level hierarchical random intercepts model with cost-effectiveness 
estimates being nested in economic evaluation studies and studies being nested 
in geographic domains.  Data from multinational studies is being clustered in a 
separate group on country-level.  
 
 
 
Unit diagram 
 
 
 
 
 
Univariate model 
specification 
 
 
 
 K~(,  K =  + 8H8K + 	H	K + JHJK + 'K + !K + K 
 
With 'K~(0, L	  !K~(0, "	  K~(0, 	  
Bivariate model 
specification 
 
 
}v,Kv8,K~ ~(,  
 n,K = (n + 8nH8K + 	nH	K+JnHJK + 'nK + !nK + nK ∗ n,K 
 
8,K =  1	(	∆	*%$0	(	∆	*$        	,K = 1 − 8 
 
With: 
P',,K',8,KQ ~ (0, ΩL     where  ΩL = RL,	L,8 L,8	 S 
P!,,K!,8,KQ ~ (0, Ω"      where  Ω" = R",	",8 ",8	 S 
P,,K,8,KQ ~ (0, Ω    where  Ω = R,	,8 ,8	 S 
 
 
CE CE CE CE CE CE CE CE CE 
Study 1 Study 2 Study 3 
Model 2.a 
Country A Country B 
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As before, models were implemented in MLwiN using MCMC estimation 
procedures (Rasbash et al., 2009a; Browne, 2012). A detailed step by step guide 
on how to implement all models in MLwiN can be found in Appendix 3. As 
detailed in the analysis strategy above, covariate selection was supported by 
preliminary analyses, starting off from descriptive statistics for covariates, 
regression based imputation of missing values, as well as further analytical 
procedures to address collinearity between explanatory variables (pairwise 
correlations, polychoric correlations, correspondence analyses) and to reduce 
the complexity of the dataset (e.g. through principal components factor analyses 
or multiple correspondence analysis). Further details on these methods are 
obtainable from the genealogy study reported in Chapter 4. Preliminary analyses 
were performed in STATA 12 and are reported in the following section (5.2.3). A 
final dataset was then exported to MLwiN for bivariate statistics and to build a 
random intercepts model with covariates on data and study-level, and this is 
reported in Section 5.2.4 .  
 
 
 
5.2.3. Data for experiment two and preliminary analyses  
 
 
Details on response variables as well as data and study-level covariates are also 
available from Chapter 4 which focusses on the systematic literature review on 
the cost-effectiveness of statins in the primary and secondary prevention of CVD. 
In addition, further particulars and descriptive statistics for the response 
variables (INMB, ∆C, ∆E), are available from Section 5.1.2 of this empirical 
chapter. In brief, Chapter 4 reports on how the form for abstracting data from 
included studies was developed from a long list of potential variability factors 
drawn from the relevant economic evaluation literature and used to populate a 
dataset for this empirical exercise. The resulting dataset is used here for the 
analysis as outlined above.  
 
 
67 studies were includable in this empirical exercise, providing 2094 estimates of 
incremental net monetary benefit where the authors also decomposed the INMB 
statistic, hence explicitly reporting data on ∆C and ∆E of the healthcare 
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intervention. Within the three-level hierarchical model, data is clustered in 17 
countries which were the focus of the 61 single country studies included in this 
dataset. In addition, 288 data points from six multinational studies are clustered 
in a separate group on country-level, so that the final dataset consists of ni=2094, 
nj=67 and nk=18. As some data is applicable to the UK as a whole, but other data 
only to England/Wales on the one hand or Scotland on the other, three distinct 
categories were introduced to the dataset to reflect these geographic entities. 
Table 5.2 in Section 5.1.2 of this empirical exercise provides an overview of the 
geographic locations represented in the data. Descriptive statistics for all 
covariates considered in this part of the empirical exercise are available from 
Appendix 5. 
 
 
5.2.3.1. Descriptive statistics 
 
 
1064 (50.81%) of all data points refer to secondary prevention, whilst 958 
(45.75%) data points in the sample refer to patients who never experienced a 
CVD event. 72 data points stem from studies which did not discriminate between 
primary and secondary prevention of CVD. For those data points referring to 
primary prevention only, all risk categories are present, with most data referring 
to a 10 year CVD risk between 20% and 30%. This risk was calculated using the 
Framingham risk equation (Anderson et al., 1991) and individual risk factors 
collected within this study. Details are also reported in Chapter 4.  
 
 
Whilst more than one third of all data points (38.16%) refer to male study 
populations, roughly one quarter refers to females (27.51%) or mixed 
populations (26.55%) respectively. In 7.78% of the cases there was no clear 
indication of gender. Descriptive statistics further reveal that mean TCL in the 
overall dataset was 6.68 (SD: 1.204), SBP for all patients was at a mean of 137.48 
(SD: 13.35) and the hypertension status, diabetes status and smoking status was 
positive in 31.7%, 17.5% and 29.1% of all patients under assessment. Further 
patient and disease characteristics are available from Tables 5.1.1 and 5.1.2 of 
Appendix 5 
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Moving on to intervention and comparator characteristics, it turns out that 
simvastatin is by far the most prominent intervention under assessment, with 
1080 (51.58) of all data points referring to this statin. In 87.58% of all cases, the 
intervention was compared to ‘doing nothing’, whilst in 258 data points the 
comparator was a statin, either of a different kind as the intervention, or of the 
same kind but in different dosages. In two cases, the comparator was unclear. 
The mean annual drug cost of the intervention (converted to £-Sterling using 
Purchasing Power Parities (PPP) and updated to 2010 using country specific GDP 
deflators (Shemilt et al., 2008; OECD, 2010) are £521.59. The annual drug cost 
are highest for lovastatin at £932.14 (SD: 515.14), followed by pravastatin at 
£858.00 (SD: 236.67), atorvastatin at £503.89 (SD: 232.19), simvastatin at 
£477.70 (SD: 312.81), rosuvastatin at £337.28 (SD: 247.16) and fluvastatin at 
£293.08 (SD: 103.10) respectively. Finally, the unit cost of the intervention 
(across all statins under consideration) is around £0.05 per mg. Again, per statin, 
unit cost are highest for lovastatin at £0.075/mg (SD: 0.008), followed by 
pravastatin at £0.061/mg  (SD: 0.021), simvastatin at £0.048/mg (SD: 0.033), 
atorvastatin and rosuvastatin at £0.044/mg each (SD: 0.041 and 0.021) and 
fluvastatin at £0.013 (SD: 0.012) respectively.  
 
 
In the majority of cases (62.99%), life years saved was the outcome measure of 
choice compared to 37.01% of data points where QALYs were used to assess the 
incremental effect of statins. If QALYs were used, then utility weights usually 
reflect population preferences (447 vs. 215 of the 775 data points with QALYs). 
The duration of drug treatment in years peaked at 5 to 10 years (37.63%) and 
lifetime (38.87%), whilst almost all data points were affected by some sort of 
extrapolation beyond the latest follow up (92.74%). Accordingly, the time 
horizon was most frequently lifetime with 1333 data points (63.66%), and the 
second most common time horizon was between 10 and 15 years (15.75%). In 
the majority of cases (1328, 63.42%) drug treatment was assumed to last exactly 
as long as the time horizon modelled, and in 766 cases (36.58%) the duration of 
drug treatment in years was shorter than the time horizon under consideration. 
Few studies varied their economic perspective to show the impact of the 
perspective on cost-effectiveness results (e.g. Wagner et al., 2009a). Hence, the 
economic perspective is a variable on data-level. In most cases, authors reported 
to have used a health insurance (NHS) perspective (1369, 65.38%) and in 214 
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cases (10.22%), authors mentioned to have used a societal perspective. In 244 
cases, no perspective was reported whatsoever. However, in this thesis, the 
economic perspective as reported by authors was compared to own judgement 
and in 635 cases there is disagreement between what studies report and what 
the author of this thesis concludes. Hence, the economic perspective, as judged 
in this thesis, is that of the provider in 20 cases (0.96%), that of the health 
insurance (NHS) in 1939 cases (92.60%) and a societal perspective was used in 
135 cases (6.45%). Again, descriptive statistics of covariates are also reported in 
Appendix 5.1 of this empirical exercise.  
 
 
About half (53.72%) of all data points refer to base case analysis, whilst 969 
(46.28%) of data points refer to sensitivity analyses results. If a data point refers 
to sensitivity analyses, the most common variable under assessment was the 
treatment duration or time horizon (288, 13.75%), followed by the discount rate 
for cost or effects (257, 12.27%), and the cost of the intervention (annual drug 
cost), with 86 (4.11%) cases. When looking at sources of effectiveness data, the 
most prominent way to obtain this data was through a systematic review of the 
relevant effectiveness literature and/or a meta-analysis. The second most 
important source of effectiveness data was the 4S trial, a multinational study 
focussing on Scandinavian countries which looked into the effectiveness and 
cost-effectiveness of simvastatin (Scandinavian Simvastatin Survival Study Group, 
1994). Other prominent sources of effectiveness data were the Heart Protection 
study (HPS collaborative group, 2002) with 280 (13.37%) data points and the 
Excel study (Bradford et al., 1990) with 120 (5.73) data points. In total, 19 
different sources of effectiveness data were found in the relevant literature. 
Finally, looking at the geographic specificity of input parameters following the 
example of Barbieri et al (2005), one can see that by far the most common way 
to populate an economic model is to use country specific cost and resource use 
data, but effectiveness data and utility weights from other geographic domains 
(type CR, 1033 data points, 49.33%). Also quite common is the use of unit cost, 
resource use and utility weights from the target country, whilst effectiveness 
data is being transferred from other geographic domains (513, 24.50%). Only 56 
data points (2.67%) were completely target specific, so that the economic model 
was fully populated with target country specific data.  
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Moving on to the study-level, the first group of covariates to consider are general 
study characteristics. 61 out of 67 studies were written in English language, and 
the most common geographic origins of publications included in this exercise 
were Canada and the UK, with 13 studies (19.50%) each, followed by the USA 
with 12 studies (17.91%). Most papers were somehow related through common 
authorship, and considering all relationships between papers published and 
included in this exercise, only 18 papers are not linked to each other, whilst 29 
papers (43.28%) belong to one big group of common authorship. The most 
published authors in the field are Grover and Jonnsson, each involved in seven 
studies, Coupal (six studies) as well as Szucs and Zowal with five studies each. 
The timing of studies (which is not the year of publication) ranges from 1988 to 
2009, with two peaks between 1995 to 1998 and 2005 to 2007. As mentioned, 
the majority of papers focussed on one single country (91.04%), whilst six papers 
(8.96%) were multinational in nature. Industry was involved in the funding of 39 
publications (58.21%), whilst funding was unclear for 17 studies (25.37%). If 
industry funding was available, then the manufacturers most commonly involved 
were Pfizer with 13 studies and Merck with 12 studies in the dataset.   
 
 
Methods on study-level show that most studies (61; 91.04%) relied on secondary 
modelling, whilst only six studies (8.96%) made direct use of individual patient 
data from RCTs. If secondary modelling, the most common model used was a 
Markov state transition model (41; 61.19%). Seven studies (10.45%) were based 
on decision trees, and other modelling approaches involved life tables, or 
discrete event simulation. An important question is how effectiveness was 
measured and modelled within a study, and there are two general approaches. 
Most studies (61.19%) modelled the reduction in risk to experience a CVD event 
in the future to estimate incremental effectiveness. 26 studies (38.81%), 
however, used the intermediate outcome of cholesterol reduction to 
approximate its impact on CVD risk, which then resulted in an estimation of life 
years or QALYs saved. The majority of 35 studies (52.24%) explicitly looked into 
the effect of statins on coronary heart disease (CHD) and cerebrovascular disease 
(CD), whilst 18 studies (26.87%) looked at CHD only. 11 studies (16.42%) looked 
at CHD, CD and peripheral arterial disease (PAD) simultaneously. Inflation 
adjustment of cost estimates to a common baseline year was explicitly reported 
in 18 studies (26.87%), whilst this was unclear in 35 cases (52.24%), If inflation 
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adjustment was applied, the healthcare component of the target countries 
consumer price index was most commonly used (10 studies, 14.93%). Finally, 
currency conversion was applied in 15 studies (22.39%), and the most common 
method of currency conversion was the use of real exchange rates (11, 16.42%).  
 
 
Finally, an indication of study quality was provided by using the QHES instrument 
(Ofman et al., 2003). This quality checklist was applied to each of the 67 studies 
to obtain a summary score (between zero and 100), which may be used as an 
explanatory variable on study-level. Unfortunately, applying the QHES 
instrument was not entirely straightforward, for instance, as some dimensions 
on that checklist are comprised of several sub-categories, so that studies may 
tick part of that dimension, but not each aspect of it. For this reason, two 
approaches were considered when combining scores of individual QHES 
dimensions to one overall score of study quality. First, the instrument was 
applied in a strict sense, meaning that points were only given to a study if each 
sub-category in a particular dimension was ticked positive. Secondly, a pragmatic 
approach was applied, where the score for each dimension was divided by the 
number of subcategories in that dimension and points were allocated for each 
sub-category. Obviously, this resulted in higher scores for most studies in the 
dataset (more details on how the QHES instrument was operationalized are 
available in Chapter 4). Both scores are applied as continuous variables and the 
mean QHES score following strict criteria is 59.36 (SD: 16.33), whilst the 
‘pragmatic approach’ led to a mean score of 69.32 (SD: 13.89). However, scores 
were also converted to categorical variables to better reflect the lack of precision 
when using tools like the QHES instrument, and results indicate that a strict 
application of the QHES better discriminates between studies in the dataset.   
 
 
5.2.3.2. Missing values 
 
As mentioned in Section 5.1.3., there were no missing observations in any of the 
dependent variables (INMB, ∆C, ∆E). However, descriptive statistics show a 
multivariate pattern of missingness (Briggs et al., 2003) with missing values in 
both continuous and categorical variables on data and study-level. Table 5.12 
summarizes missing values both on data and study-level.  
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Table 5.12: Missing values  
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Correlation between missingness 
indicator and response variable 
INMB ∆C ∆E 
TCL Cont. Data Pat/Dis 1193 901 43.03 -0.1106*** 0.3286*** -0.2849*** 
HDL Cont. Data Pat/Dis 1147 947 45.22 -0.1326*** -0.3366*** -0.3098*** 
LDL Cont. Data Pat/Dis 926 1168 55.78 -0.3316*** -0.0015 -0.3103*** 
Hypert Cont. Data Pat/Dis 826 1268 60.55 -0.3231*** -0.1960*** -0.4099*** 
SBP Cont. Data Pat/Dis 1140 954 45.56 -0.1341*** -0.3390*** -0.3125*** 
Smokers Cont. Data Pat/Dis 1141 953 45.51 -0.1364*** -0.3395*** -0.3149*** 
Diab Cont. Data Pat/Dis 1163 931 44.46 -0.1287*** -0.3365*** -0.3062*** 
Age_cat Cat. Data Pat/Dis 2020 74 3.53 0.0178 -0.0631** -0.0183 
Gender_cat Cat. Data Pat/Dis 1931 163 7.78 -0.0103 -0.0602*** -0.0429** 
Risk_cat Cat. Data Pat/Dis 2042 52 2.48 -0.0592*** -0.0229 -0.0679*** 
Intervention Cat. Data Int/comp. 1746 348 16.62 -0.1468*** -0.1486*** -0.2191*** 
Cost_int Cont. Data Int/comp. 1957 137 6.54 -0.0093 -0.101*** -0.0645** 
Unitcost_int Cont. Data Int/comp. 1738 356 17.00 -0.1495*** -0.1526*** -0.2239*** 
Tdd_int Cat. Data Int/comp. 1738 356 17.00 -0.1495*** -0.1526*** -0.2239*** 
Comparator Cat. Data Int/comp. 2092 2 0.10 -0.0076 -0.0140 -0.0148 
Cost_comp Cont. Data Int/comp. 2092 2 0.10 -0.0076 -0.0140 -0.0148 
Unitcost_comp Cont. Data Int/comp. 2083 11 0.53 -0.0175 -0.0830* -0.0373* 
Tdd_comp Cat. Data Int/comp. 2083 11 0.53 -0.0175 -0.0830* -0.0373* 
Elicitation Cat. Data Meth, DL 2077 17 0.81 -0.0238 -0.0224 -0.0346 
Elicit_short Cat. Data Meth, DL 2077 17 0.81 -0.0238 -0.0224 -0.0346 
Population Cat. Data Meth, DL 2008 86 4.11 -0.0311 -0.0604* -0.0625** 
Duration Cat. Data Meth, DL 1974 120 5.73 -0.1667*** 0.3141*** 0.0181 
Duration_short Cat. Data Meth, DL 1974 120 5.73 -0.1667*** 0.3141*** 0.0181 
Fund_inst Cat. Study Gen, SL 50 17 25.37 0.0465 -0.0266 0.0289 
Fund_man Cat. Study Gen, SL 52 15 22.39 -0.0458 -0.0774 -0.0706 
Sec_des Cat. Study Meth, SL 54 13 19.40 -0.0971 0.0464 0.1019 
Infl_adj Cat. Study Meth, SL 32 35 52.24 0.0334 0.1606 0.0937 
Adj_method Cat. Study Meth, SL 32 35 52.24 0.0334 0.1606 0.0937 
Conv_method Cat. Study Meth, SL 63 4 5.97 -0.0149 0.1606 0.0937 
scope Cat. Study Meth, SL 64 3 4.48 -0.1104 0.0066 -0.0917 
 
Most continuous variables are heavily affected by missing values. For instance, 
patient and disease characteristics show missing values between 43% (total 
cholesterol level) up to 60.55% (hypertension status in % of patients). In contrast, 
missing values for continuous intervention and comparator characteristics are 
much lower, with 6.5% for the annual drug cost of the intervention up to 17% for 
the unit cost of the intervention. Missing values in categorical variables on data-
level are generally modest, between 0.1% (comparator) and 7.78% (gender), 
though two categorical variables are affected more strongly by missing values, 
namely ‘intervention’ and the total daily dose thereof with 17% missing values 
each. Moving to categorical variables on study-level, two variables show missing 
values of less than 10% (currency conversion method, 5.97% and scope, 4.48%). 
However, three variables show between 19.4% and 25,37% (secondary design, 
funding manufacturer, and funding institution, and two variables show even 
more than 50% missing values (inflation adjustment and adjustment method). It 
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is therefore questionable whether, from a missing values perspective, these two 
variables should enter multilevel analysis.  
 
 
To gain further insights into the mechanism by which values are missing, a binary 
variable was created for each affected covariate (irrespective of whether 
continuous or categorical in nature) with 1 if a value is missing and 0 otherwise. 
Next, correlations between the response variables and the missing values 
indicators were generated. For this matter, point biserial correlations were 
chosen, a special case of Pearson correlations in which one variable (the 
missningness indicator) is dichotomous, and the other variable (the response 
variable) is continuous in nature (Cox, 1974). Results are presented in Table 5.12 
above. The highly significant correlations between continuous patient and 
disease characteristics and the response variables do not speak in favour of any 
ad hoc imputation method (like simple mean imputation) as there is a high 
potential for bias. However, if auxiliary variables for the imputation model are 
chosen well, bias may be minimised when using a regression based imputation 
approach (missingvalues.org.uk). Note that bias is also addressed through the 
use of binary indicator variables in the MLM framework. If this indicator variable 
is not significant in the model of interest, then imputation increased the sample 
size without biasing the results. However, if significant, then regression estimates 
are equal to those obtained through listwise deletion as the binary indicator 
variable captures the departure of the imputed cases from the other cases in 
terms of the outcome variable (Acock, 2005; Morris et al., 2005).  
 
 
To define a regression based imputation model for continuous variables, the 
dataset was first screened for covariates potentially related to missingness in 
affected variables. Subsequently, a logistic regression model was run with the 
binary missingness indicator of the affected variable as a response and each 
candidate for the imputation model as an explanatory variable (Acock 2010). As a 
result, the set of explanatory variables for the actual imputation model for each 
affected continuous variable was defined as those covariates significant in the 
logistic regression (Acock, 2010). The output from logistic regressions to 
determine variables for the imputation model are reported in Appendix 5.2. Note 
that logit models may experience convergence problems in the case of very few 
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missing values (Acook, 2010). For this reason, imputations for the annual drug 
cost of the comparator as well as the unit cost of the comparator were based on 
the same set of variables as have been chosen for the imputation models of the 
intervention cost and unit cost of the intervention respectively (though the 
variable ‘intervention’ was obviously replaced by the variable ‘comparator’). 
Descriptive statistics of continuous variables before and after imputation of 
missing values can be found in Table 5.13 below.  
 
Table 5.13: Descriptive statistics of continuous variables before and after 
regression based imputation of missing values 
Variable 
Obser-
vations 
Nr. of 
obser-
vations 
imputed 
Mean 
before 
impu-
tation 
SD 
before 
impu-
tation 
Mean 
after 
impu-
tation 
SD after 
impu-
tation 
Difference 
in means 
H0 diff ≠ 0 
 
Pr(|T| > 
|t|) 
tcl 1193 901 6.676 1.204 6.631 1.005 0.045 0.2533 
hdl 1147 947 1.168 0.1023 1.177 0.0924 -0.009** 0.0165 
ldl 926 1168 4.509 1.036 4.639 0.9659 -0.13*** 0.0009 
hypert 826 1268 0.317 0.381 0.341 0.275 -0.024* 0.057 
sbp 1140 954 137.47 13.35 137.92 10.05 -0.45 0.2815 
smokers 1141 953 0.291 0.3348 0.298 0.25 -0.007 0.5002 
diab 1163 931 0.178 0.3491 0.195 0.2662 -0.017 0.1144 
cost_int 1957 137 521.59 335.1 528.84 326.33 -7.25 0.4855 
unitcost_int 1738 356 0.0504 0.0321 0.0459 0.0309 0.0045*** 0.0001 
cost_comp 2092 2 26.06 115.37 26.09 115.32 -0.03 0.9913 
Unitcost_omp 2083 11 0.004 0.018 0.005 0.0285 -0.001 0.0299 
*      Difference in means significant at the 1% level , **    Difference in means significant at the 5% level , ***  
Difference in means significant at the 10% level 
 
 
As can be seen from Table 5.13, means of continuous variables before and after 
imputation are very much in the same range and only in three cases (HDL, LDL 
and unitcost_int) is the difference significant above the 95% confidence level. 
However, a binary variable is included in the MLM to capture the departure of 
the imputed from the non-imputed cases to make sure that imputation does not 
bias regression results (Acock, 2005; Morris et al., 2005). Further, looking at the 
standard deviations before and after imputation shows the main weakness of 
regression based imputation compared to MI. The standard deviations after 
imputation are generally lower than before imputation. This is because of the 
increased sample size and the fact regression based imputation generally leads 
to underestimated variability in the data (missingvalues.org.uk). Nevertheless, 
imputation of missing values allows using the full dataset with 2094 estimates of 
cost-effectiveness clustered in 67 studies and 18 geographic domains. The 
following Subsection 5.2.3.3 focuses on correlations in the data, before bivariate 
statistics are reported in Section 5.2.4.  
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5.2.3.3. Correlations between potential explanatory variables 
 
 
Correlations are assessed between subgroups of potential explanatory variables. 
First, patient and diseases characteristics are considered. As all variables in this 
group are either continuous or ordered categorical, polychoric correlations are 
assessed using a STATA package developed by Kolenikov & Angeles (2004). 
Results are reported in Table 5.14 below. Starting off with measures of 
cholesterol, high collinearity was expected between TCL and LDL as TCL is 
comprised of LDL, HDL and triglycerides (e.g. Friedewald et al., 1972) and as LDL 
is the dominating factor for TCL. Hence, if LDL changes in one direction, so may 
TCL in most cases. As Table 5.14 shows, this expectation was met by the data as 
almost perfect collinearity was observed between both cholesterol measures. 
This observation, plus the previously reported fact that there are much less 
values missing for TCL, speaks in favour of dropping LDL from further analysis. 
Moving on to HDL, its impact on TCL may be offset by simultaneous changes in 
LDL or triglycerides in any direction, which is why neither a strong correlation 
was anticipated between HDL and TCL nor between HDL and LDL. This 
expectation was also met by the data.  
 
Table 5.14: Polychoric correlations between patient and disease characteristics 
 
tcl hdl ldl hypert sbp diab smokers 
age_
cat 
gender
_cat 
risk_
cat 
CVD_his
t 
tcl 1.00 
          
hdl 0.14 1.00 
         
ldl 0.96 0.12 1.00 
        
hypert -0.12 0.00 -0.17 1.00 
       
sbp 0.03 0.18 0.00 0.84 1.00 
      
diab -0.05 0.14 -0.06 -0.12 0.03 1.00 
     
smokers -0.02 -0.15 -0.02 0.84 0.70 -0.20 1.00 
    
age_cat -0.26 -0.12 -0.29 0.12 0.09 0.06 0.00 1.00 
   
gender_cat -0.38 -0.06 -0.39 0.14 0.07 0.05 0.02 0.27 1.00 
  
risk_cat -0.36 -0.17 -0.41 0.45 0.36 -0.12 0.29 0.43 0.59 1.00 
 
CVD_hist -0.31 -0.20 -0.34 0.34 0.25 -0.25 0.19 0.27 0.56 0.86 1.00 
 
 
The next group of variables for which strong correlations were anticipated are 
SBP, hypertension status and smoking status. Again, this expectation was 
confirmed by the data. However, unlike TCL and LDL, which may be used as 
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alternative measures of cholesterol, one may not simply drop say SBP in favour 
of hypertension or smoking status as all variables, though principally concerned 
with the circulation system, measure different aspects of it. On the other hand, if 
simultaneously used in a MLM, one almost certainly runs into problems of 
multicollinearity (e.g.Maddala, 2001). For this reason, principal components 
factor analysis (PCF) was applied to reduce the complexity of the dataset (Acock, 
2010). When applied to the data, ‘PCF identifies components that are composites 
of the measured variables’ (Acock, 2010). PCF may therefore be used when 
developing a scale ‘where one dimension is identified to represent the core of a 
set of items’ (Acock 2010). This scale may then be used as an alternative 
covariate in the MLM, and referred to as circulation related CHD risk. Table 5.15 
below summarizes the results from running a PCF on SBP, hypertension and 
smoking.  
 
Table 5.15: Principal components factor analysis on SBP, hypertension and 
smoking 
Factor Eigenvalue Difference Proportion Cummulative 
Factor1 2.485 2.121 0.828 0.828 
Factor 2 0.364 0.214 0.121 0.949 
Factor 3 0.150 -- 0.050 1 
LR test: independent vs. saturated chi2(3) – 4171.76 Prob>chi2 = -0.0000 
 
 
In PCF, the sum of Eigenvalues equals the number of items, three in this case 
(Bartholomew et al., 2008; Acock, 2010). Hence, from the fact that Factor 1 has 
an Eigenvalue of almost 2.5 (82.5% of the sum of Eigenvalues), one can conclude 
that all three items fall along one dimension. The corresponding factor score, 
which is standardised with a mean of zero and a standard deviation of 1, was 
estimated in STATA 12. This score may be tested as an alternative to the 
components entering the PCF (SBP, hypertension and smoking).  
 
 
Further patient and disease characteristics which are highly correlated are 
‘risk_cat’, an ordered categorical variable encoding CVD risk of patient 
subgroups, and ‘CVD_hist’, an ordered categorical variable encoding the CVD 
related medical history of patients. This is not surprising as the variable ‘risk_cat’ 
is comprised of five risk categories for primary prevention (from very low to 
extreme), plus an extra category for secondary prevention as the Framingham 
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risk equation, which was used to estimate CVD related risk, is not valid if patients 
already experienced a CVD event. As a result, the secondary prevention category 
of ‘risk_cat’, which comprises almost 50% of all data points, perfectly coincides 
with the secondary prevention category of the variable ‘CVD_hist’. Hence, one 
may only consider these variables alternatively and choose the one which best 
improves the fit of the model. Finally, correlations were also observed between 
individual patient risk characteristics and ‘risk_cat’. This is again not surprising as 
individual patient risk factors, such as ‘TCL’, ‘LDL’, ‘gender’, ‘SBP’, ‘smoking 
status’, ‘diabetes’, etc. were used as factors in the Framingham risk equation 
which was applied to derive the categorical risk variable ‘risk_cat’. For this 
reason it is questionable whether issues of multicollinearity permit simultaneous 
use of such variables in a multilevel model.  
 
 
Moving on to characteristics of the intervention and comparator, high 
correlations were expected between the type, the unit cost and the total daily 
dose of either intervention or comparator on the one hand and their respective 
annual drug cost on the other. The reason is that ‘unit cost’, ‘total daily dose’ and 
‘type’ may be regarded as determinants of ‘annual drug cost’ of either the 
intervention or the comparator. Therefore, one may either use annual drug cost 
individually, or a combination of its determinants simultaneously in a MLM 
though the latter choice becomes more problematic as there is also high 
correlation between the total daily dose of the intervention and its respective 
unit cost, which again may cause a multicollinearity problem. Note that 
intervention and comparator have been omitted from Table 5.16 below as they 
are neither continuous nor ordered categorical variables, so that neither Pearson 
nor polychoric correlations apply. However, to confirm expectations, both 
variables were transformed into a set of binaries and point biserial correlations 
were computed to assess the association between brand and annual drug cost. 
In addition to the above, the two variables ‘comparator’ and ‘active_comparator’ 
are almost identical, as the latter is simply a reduced binary version of the 
former. Both variables coincide in 1834 (87.58%) cases where the comparator is 
‘doing nothing’. Hence, simultaneous use in a multilevel model is not indicated.  
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Table 5.16: Polychoric correlations between patient and disease characteristics 
 
Tdd_ 
int 
Unitcost
_int 
Cost_ 
int 
Tdd_ 
comp 
Unitcost_ 
comp 
Cost_ 
comp 
Incr_ 
cost 
Tdd_int 1       
Unitcost_int -0.705 1      
Cost_int -0.021 0.669 1     
Tdd_comp 0.407 -0.420 -0.159 1    
Unitcost_comp 0.449 -0.097 0.172 0.408 1   
Cost_comp 0.361 -0.046 0.284 0.416 0.847 1  
Incr_cost -0.364 0.458 0.267 -0.390 -0.078 -0.055 1 
 
 
Moving on to methodological characteristics on data-level, one can see that, in 
contrast to patient and disease or intervention and comparator characteristics, 
this set of variables is almost exclusively categorical in nature, with discount 
rates on cost and benefits being the only continuous exceptions. For this reason, 
another strategy was considered for assessing associations between categories 
of variables as Pearson correlations, polychoric correlations or point biserial 
correlations do not apply. The same method was used which was previously 
utilised for the genealogy study reported in Chapter 4. The two continuous 
variables DRC and DRB were first transformed into ordered categoricals and 
multiple correspondence analysis was applied to assess which categories of 
variables correspond strongly with each other (Bartholomew et al., 2008; Le 
Roux & Rouanet, 2010). A key advantage of MCA is that it provides a graphical 
presentation of correspondences between categories of variables on a plane 
with corresponding categories being in closer proximity on that plane. However, 
a related disadvantage is that such planes quickly become inextricable due to the 
number of categories under assessment (van Kerm, 1998). In other words, the 
principle ‘garbage in garbage out’ certainly applies to MCA just as much as it 
does other quantitative methods.  
 
 
For this reason, the method is used with caution and methodological variables on 
data-level are first further divided into groups of conceptually related variables, 
and these smaller groups of variables are then separately assessed using MCA if 
appropriate. Methodological variables on data-level are categorized in subgroups 
relating to a) outcome-measurement, b) time horizon and time preference c) 
perspective d) data classification and e) geographic source of input data. MCA 
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was deemed appropriate in three cases. First, ‘outc_measure’, ‘elicitation’ and 
‘population’ were tested as they all relate to the way effectiveness is defined and 
elicited in a study. Secondly, ‘DRC’, ‘DRB’, ‘duration’ ‘extrapol’ ‘horizon’ and 
‘hor_eq_dur’ are tested as variables concerned with time horizon and time 
preference. Finally, whilst including variables on data-level, different 
combinations of general study characteristics and methods on data and study-
level are tested in an explorative exercise to find out whether there are 
correspondences between key characteristics of international methods 
guidelines for economic evaluation in health. If correspondences between 
categories of variables are revealed, a summary score is produced to reduce the 
complexity of the dataset analogously to what has been reported above when 
using PCA for measures of circulation related risk. This summary score may then 
be used as an alternative construct in the MLM.  
 
 
 
Results for running an MCA on ‘outc_measure’, ‘elicitation’ and ‘population’ are 
presented below. The total inertia is a measure of scatter, and the principal 
inertia tells how much of this scatter is captured by each dimension in the model 
(Bartholomew et al., 2008). This has been visualised in a screeplot above (Figure 
5.8) where the principal inertia is plotted for each dimension in the model. In this 
case, the first two dimensions account for 95.82% of the total inertia. This 
indicates a very good fit of the model and the ‘elbow’ in the screeplot, after 
Figure 5.8: Screeplot for MCA on outc_measure, elicitation 
and population 
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which there is only small decrease in inertia, indicates that plotting results on a 
two dimensional space may be appropriate (Bartholomew et al., 2008). 
 
 
Next, the results of the MCA are visualised on a biplot presented in Figure 5.9., 
which clearly shows the correspondences between the categories of the three 
variables. One can see that the horizontal axis, which accounts for 83.3% of the 
total inertia, captures the two alternative measures of effectiveness ‘QALYS’ and 
‘life Years Saved. The vertical axis, on the other hand, captures different methods 
of preference elicitation and it also shows which of these methods were rather 
applied to patient populations, and which methods were rather used to elicit 
information from a general population sample. For instance, time trade off 
questions were usually asked to patients, whilst the health utility index or the 
EQ-5D instrument may have been applied to patients or members of the general 
population. Other choice based methods and the 15-D instrument clearly 
correspond with the category ‘population’, meaning that these methods were 
applied to assess utility weights from a general population sample.  
 
 
 
 
The third step in this analysis is to estimate a correspondence score analogously 
to what has been done using PCF for components of circulation related CVD risk 
Figure 5.9: Biplot for MCA on outc_measure, elicitation and 
population 
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above. This correspondence score may then be used as an alternative covariate 
capturing the concept of outcome measure within the MLM framework.  
 
 
Table 5.17: MCA on ‘outc_measure’, ‘elicitation’ and ‘population’ 
 
Number of obs:  1998 / Total inertia: 1.2008 / Number of axes:  2 
  Principal Inertia Percent Cumulative 
Dimension 1 1 83.28% 83.28% 
Dimension 2 0.1506 12.54% 95.82% 
Dimension 3 1.11e
-31
 0% 95.82% 
Dimension 4 6.93e
-33
 0% 95.82% 
 
 Overall Dimension 1 Dimension 2 
Categories Mass Quality %inertia Coord  sqcorr contrib Coord  sqcorr contrib 
Outc_measure 
LYS 
QALYs 
 
0.220 
0.113 
 
1.000 
1.000 
 
0.094 
0.183 
 
0.717 
-1.394 
 
1.000 
1.000 
 
0.113 
0.220 
 
0.000 
0.000 
 
0.000 
0.000 
 
0.000 
0.000 
Elicitation 
n.a. (LYS) 
TTO 
EQ 5D 
HUI 
15D 
Other choice 
 
0.220 
0.019 
0.039 
0.001 
0.001 
0.054 
 
1.000 
0.841 
0.994 
0.969 
0.938 
0.938 
 
0.094 
0.083 
0.065 
0.002 
0.002 
0.115 
 
0.717 
-1.394 
-1.394 
-1.394 
-1.394 
-1.394 
 
1.000 
0.363 
0.976 
0.876 
0.753 
0.753 
 
0.113 
0.036 
0.076 
0.002 
0.002 
0.104 
 
0.000 
4.116 
0.488 
1.168 
-1.780 
-1.780 
 
0.000 
0.477 
0.018 
0.093 
0.185 
0.185 
 
0.000 
0.317 
0.009 
0.001 
0.003 
0.170 
Population 
n.a. (LYS) 
patient 
population 
 
0.220 
0.034 
0.079 
 
1.000 
0.872 
0.959 
 
0.094 
0.114 
0.153 
 
0.717 
-1.394 
-1.394 
 
1.000 
0.487 
0.853 
 
0.113 
0.066 
0.154 
 
0.000 
3.195 
-1.382 
 
0.000 
0.385 
0.124 
 
0.000 
0.349 
0.151 
 
 
MCA was also performed for a subset of variables relating to time horizon and 
time preference. The variables ‘horizon’, ‘extrapol’ and ‘hor_eq_dur’ led to a 
good overall fit of the model with 81.42% of the total inertia falling on the first 
two dimensions. Results of the respective MCA are presented in Appendix 5.3.  
Again, a correspondence score was calculated for use as a covariate in the MLM. 
Finally, the same procedure was repeated with different subsets of 
methodological characteristics on data-level as well as general study 
characteristics and methodological characteristics on study-level to assess 
whether key characteristics of international methods guidelines show 
correspondences on the biplot. However, further strong correspondences were 
not revealed.  
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5.2.4. Results 
 
 
In Chapter 3 MLMs were developed for the analysis of secondary cost-
effectiveness data from different geographic domains. This chapter also reported 
on a pilot study to test these models and Chapter 4 focussed on a systematic 
literature review and data abstraction exercise on the cost-effectiveness of 
statins for the primary and secondary prevention of CVD which provided the data 
for this empirical exercise. This chapter started off with determining the 
appropriate MLM structure to analyse the data obtained from the systematic 
literature review. Then, an analysis strategy was outlined to assess covariates 
within the MLM framework. The space of available covariates was divided in 
manageable groups of variables; descriptive statistics and missing values analysis 
were reported, as well as correlations between subsets of explanatory variables. 
The results from analysing covariates in the MLMframework assuming fixed 
slopes are reported next. First, bivariate statistics from entering each covariate 
individually in the multilevel framework are reported and discussed. Secondly, a 
model which aims to unravel the maximum amount of country-level variability is 
constructed by including the set of covariates which best controls for variability 
on data and study-level. This model is then carried forward to the analysis of 
country-level variability in Section 5.3 of this empirical chapter.  
 
 
5.2.4.1. Bivariate statistics 
 
Tables 5.18 to 5.23 below contain results of individually testing covariates in the 
univariate and bivariate versions of the three-level hierarchical model which 
groups cost-effectiveness data in the studies it was drawn from and the countries 
it refers to whilst accommodating a separate cluster on country-level for 
multinational study data. Data-level covariates are assessed first, starting off 
with patient and disease characteristics as the arguably most critical source of 
variability in cost-effectiveness data (Sculpher et al., 2004), followed by 
intervention and comparator characteristics and methods on data-level. 
Subsequently, general study characteristics, methods on study-level and study 
quality indicators are tested individually in the models of interest. A binary 
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missingness indicator is used in conjunction with variables where data was 
initially missing (Acock, 2005; Morris et al., 2005). If not significant, this indicates 
that missing data imputation increased the sample for analysis without biasing 
the results. If significant, then the missingness indicator captures the departure 
of the imputed cases from the non-imputed cases and thereby leads to the same 
regression coefficients one would have obtained with stepwise deletion of the 
missing observations (Morris et al., 2005). Models are implemented in MLwiN 
using MCMC estimation procedures (Rasbash et al., 2009a; Browne, 2012). 
Hence, the DIC diagnostic is used to compare the overall fit between models. The 
DIC diagnostic already accounts for differences in the number of parameters to 
estimate, so that its value is directly comparable between a saturated model and 
its respective comparator (Browne, 2012). For bivariate statistics, this 
comparator is obviously the variance components model without covariates. 
Hence, if the DIC decreases when including covariates into the models discussed 
in the first section of this empirical exercise, then this indicates an improved fit of 
the model. However, as Browne (2012) clarifies, the ‘stochastic nature of the 
MCMC algorithm leads to some random variability in the DIC diagnostic 
depending on starting values and random number seeds’. If differences in the DIC 
diagnostic are small, models were hence re-run with different seeds and/or 
starting values.  
 
 
Starting with patient and disease characteristics (Table 5.18 below), almost all 
covariates show the expected sign and are significant on the 5% or even 1% level. 
This holds for all continuous variables (HDL, LDL, SBP, Hypertension, Smokers, 
BP_PCF and Diabetes) with the exception of TCL, for which the coefficient for ∆C 
in the bivariate model does show the anticipated sign but only borders at the 
10% level of significance. Moving on to categorical variables, the coefficient for 
46 to 55 year old patients is not significant in the univariate model. This only 
means that INMBs in this age cohort do not significantly differ from the omitted 
category, which represents patients below the age of 45. For older age groups, 
and especially in the bivariate model, where ‘age_cat’ led to the largest drop in 
the DIC diagnostic compared to all other patient and disease characteristics, the 
coefficients are highly significant. The coefficients observed also accord 
expectations in a sense that better cost-effectiveness estimates associated with 
commencing treatment at younger age ‘reflect the greater potential to prevent 
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events, and thus the higher utility and cost benefits accrued from remaining 
event free health state’ (NICE, 2006). Furthermore, the coefficient for patients 
above the age of 75, which indicates improved cost-effectiveness compared to 
patients aged 65 to 75, may be a result of more secondary prevention patients in 
this age cohort, for whom statin treatment is assumed to be more cost-effective. 
Also in accord with expectations are the coefficients for gender, as statins show 
lower incremental cost, higher incremental effects and hence improved cost-
effectiveness measured in INMBs in males as compared to females. 
 
Table 5.18: Bivariate statistics of patient and disease characteristics 
 
 
 Univariate model Bivariate model 
Explanatory 
variable 
(SE) 
Raw Mean 
(SD) / 
Proportion 
(%) 
INMB 
(2010 £ 
Sterling) 
DIC 
(Benchmark
: 46749  
(%-change)) 
∆C/100 
(2010 £ 
Sterling) 
∆E 
 
DIC 
(Benchmark
: 28735 (%-
change)) 
TCL 6.676 (1.204) 4012 (640)*** 46709 (-0.09%) -6.62 (4.05) 0.103 (0.022)*** 28699 (-0.13%) 
HDL 1.168 (0.102) -47062 (10302)*** 46724 (-0.05%) 210.76 (59.10)*** -0.868 (0.353)** 28709 (-0.09%) 
LDL 4.509 (1.036) 5200 (667)*** 46687 (-0.13%) -8.563 (4.224)** 0.136 (0.022)*** 28677 (-0.20%) 
SBP 137.48 (13.348) 640 (41.35)*** 46509 (-0.51%) -4.024 (0.252)*** 0.008 (0.001)*** 28352 (-1.33%) 
Hypertension 31.70% (38.13%) 23718 (1661)*** 46537 (-0.45%) -92.29 (10.51)*** 0.48 (0.06)*** 28501 (-0.81%) 
Smokers 29.10% (33.48%) 18681 (1859)*** 46641 (-0.23%) -25.60 (11.67)** 0.536 (0.061)*** 28627 (-0.38%) 
BP_PCF 0 (1.00) 6016 (424)*** 46545 (-0.44%) -25.49 (2.68)*** 0.115 (0.014)*** 28501 (-0.81%) 
Diabetes 17.81% (34.91%) 13494 (1834)*** 46692 (-0.12%) -34.36 (11.34)*** 0.341 (0.061)*** 28679 (-0.19%) 
Age_cat 
<45 
46-55 
56-65 
66-75 
>75 
Unclear 
 
322 (15.38%) 
439 (20.96%) 
862 (41.17%) 
299 (14.28%) 
98 (4.68%) 
74 (3.53%) 
 
Omitted 
161 (1333) 
-4819 (1271)*** 
-13295 (1364)*** 
-7301 (2309)*** 
10812 (8776) 
46621 (-0.27%) 
 
Omitted 
-93.70 (7.363)*** 
-136.24 (7.06)*** 
-173.89 (7.51)*** 
-120.61 (12.67)*** 
-110.88 (43.67)** 
 
Omitted 
-0.304 (0.039)*** 
-0.609 (0.037)*** 
-1.023 (0.040)*** 
-0.641 (0.067)*** 
-0.051 (0.271) 
27705 (-3.58%) 
Gender 
Female 
Male 
Mixed sample 
 
576 (27.51%) 
799 (38.16%) 
719 (34.34%) 
 
Omitted  
10184 (955)*** 
5097 (3908) 
46635 (-0.24%) 
 
Omitted 
-33.51 (5.88)*** 
-77.85 (23.58)*** 
 
Omitted 
0.226 (0.031)*** 
-0.071 (0.148) 
28619 (-0.40%) 
Risk_cat 
<10% 
10%-20% 
20%-30% 
30%-40% 
40%-50% 
Secondary 
prevention 
Unclear 
 
193 (9.22%) 
367 (17.53%) 
278 (13.28%) 
140 (6.69%) 
106 (5.06%) 
958 45.75%) 
52 (2.48%) 
 
Omitted 
18319 (1637)*** 
17431 (1767)*** 
14547 (2055)*** 
23145 (2297)*** 
17452 (2057)*** 
13698 (4975)*** 
46590 (-0.34%) 
 
Omitted 
-167.41 (9.06)*** 
-216.62 (9.85)*** 
-236.75 (11.44)*** 
-241.10 (12.80)*** 
-180.06 (11.66)*** 
-176.34 (26.28)*** 
 
Omitted 
0.053 (0.055) 
-0.139 (0.060)** 
-0.306 (0.069)*** 
-0.032 (0.078) 
0.000 (0.070) 
-0.115 (0.178) 
28103 (-2.20%) 
CVD_history 
No 
Yes 
Mixed sample 
 
1064 (50.81%) 
958 (45.75%) 
72 (3.44%) 
 
Omitted 
1506 (1516) 
10325 (7418) 
46750 (0.00%) 
 
Omitted 
3.33 (9.20) 
22.83 (42.62) 
 
Omitted 
0.081 (0.051) 
0.409 (0.270) 
28736 (-0.00%) 
Missingness indicators 
Miss_tcl 901 (43.03%) -1134 (4271) -- -24.16 (24.77) 0.471 (0.120)*** -- 
Miss_hdl 947 (45.22%) -2719 (4296) -- -21.89 (23.57) -0.101 (0.168) -- 
Miss_LDL 1168 (55.78%) -8064 (3776)** -- 34.53 (23.41) -0.109 (0.146) -- 
Miss_sbp 954 (45.56%) 8188 (2583)*** -- -24.66 (22.65) -0.091 (0.166) -- 
Miss_hypert 1268 (60.55%) -2553 (3978) -- -29.90 (20.33) -0.139 (0.145) -- 
Miss_smokers 953 (45.51%) -2269 (4154) -- -31.10 (22.06) -0.129 (0.163) -- 
Miss_bp_pcf 1269 (60.60%) -3795 (3942) -- -22.53 (20.73) -0.150 (0.147) -- 
Miss_diabetes 931 (44.46%) 312 (4285) -- -31.91 (22.52) -0.053 (0.164) -- 
Miss_age_cat 74 (3.53%) -2603 (2381) -- -3.76 (11.56) -0.096 (0.061) -- 
Miss_gend_cat 163 (7.78%) -533 (1495) -- -4.249 (9.32) -0.033 (0.050) -- 
Miss_risk_cat 52 (2.48%) -558 (2383) -- -3.41 (13.04) 0.419 (0.137)*** -- 
* 
*
* 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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More problematic, however, is the categorical variable ‘risk_cat’. Though highly 
significant both for INMBs in the univariate model and ∆C in the bivariate model, 
‘risk_cat’ does not show the pattern one would anticipate where cost-
effectiveness improves continuously with increasing ten year CVD risk. Though it 
may be possible that cost-effectiveness is higher for the highest primary 
prevention group compared to secondary prevention (e.g. Huse et al., 1998), we 
should at least expect a continuous improvement of INMBs with increased CVD 
risk in primary prevention patients. This, however, is not the case, which casts 
into doubt the validity of the findings. What adds to the problem is that 
coefficients for ∆C in the bivariate model are mostly not significant. Obviously, 
one would expect a strong relationship between ‘risk_cat’ and measures of cost-
effectiveness for both ∆C, as statin treatment may prevent future healthcare 
cost, and ∆E, as higher risk groups may have more to benefit from statin 
treatment. Potential reasons for the problems associated with this explanatory 
variable may relate to the way it was constructed from a number of different 
variables abstracted from papers, which were used to estimate CVD risk using 
the Framingham risk equation (Anderson et al., 1991). If data to populate this 
risk equation was not available, a number of alternative means were exploited to 
obtain estimates of 10 year CVD risk (details are available from Chapter 4). 
Resulting risk estimates were then grouped for primary prevention in categories 
of 10% increments, and to capture the whole range of data points in the dataset, 
a category for secondary prevention was also introduced as the Framingham risk 
equation is not valid in patients who already experienced a CVD event (Anderson 
et al., 1991). The complexity of this process and the degree to which raw data 
was manipulated to obtain this categorical variable may have introduced 
additional noise which explains the problems with the coefficients as detailed 
above. In addition, it may be problematic to enter this variable in the final MLM 
in conjunction with individual risk factors such as TCL, HDL, or SBP, as ‘risk_cat’ is 
a summary construct of these individual risk factors and therefore shows a 
considerable degree of collinearity (as observed in the previous Section 5.2.3.3). 
Therefore, multicollinearity problems may be the consequence, which may 
indicate dropping this variable from further analysis even though it leads to a 
considerable change in the DIC diagnostic in the bivariate model.  
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Finally, as can be seen from Table 5.18 above, the history of a CVD event is not a 
significant explanatory variable in the model. As mentioned above, the reason 
may be that very high risk primary prevention groups potentially benefit as 
much, if not more, than some secondary prevention patients (e.g. Huse et al., 
1998), which then leads to a failure in observing significant results for this 
variable. However, simultaneously controlling for individual risk factors may 
address this problem and thereby reveal the actual relationship between CVD 
history and the cost-effectiveness of statins in the primary and secondary 
prevention of CVD.  
 
 
Moving on to intervention and comparator characteristics (Table 5.19 below), 
highly significant coefficients are observed which also accord expectations for 
most continuous variables. Precisely, as annual intervention cost increase, so 
should ∆C, which consequently leads to decreasing INMBs. Annual drug cost may 
have an impact on treatment compliance and hence incremental effects as well, 
but this was not observed in the bivariate model. Likewise the continuous 
variable incremental drug cost, which is nothing but the annual drug cost of the 
intervention minus the annual drug cost of the comparator, shows a highly 
significant positive relationship with ∆C, and an inverse relationship with INMB 
which is also highly significant. However, the annual drug cost of the comparator 
is not in accord with prior expectations as ∆C of the intervention should decrease 
with increasing cost of the comparator, leading to better cost-effectiveness 
results. This was not confirmed by the data as an inverse relationship was 
observed in the univariate model. Finally, unit cost of the intervention and the 
comparator show the same sign as their annual drug cost counterparts, which 
again confirms expectations for the intervention but disagrees with expectations 
for the comparator. A reason may be some degree of correlation between 
intervention cost and comparator cost, meaning that changes in the cost of the 
comparator may be offset by changes in the intervention, so that its impact on 
incremental drug cost and, ultimately, INMBs remains ambiguous. This 
hypothesis may be tested when simultaneously including drug cost of the 
intervention and the comparator in one model in part two of this section.  
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Table 5.19: Bivariate statistics of intervention and comparator characteristics 
 
 
 Univariate model Bivariate model 
Explanatory 
Variable 
Raw Mean (SD) 
/ 
Proportion (%) 
INMB 
(2010 £ Sterling) 
DIC 
(Benchmark: 
46749 
 (%-change)) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
DIC 
(Benchmark: 
28735 
 (%-change)) 
Cost_int 528.84 (326.32) -9.289 (2.173)*** 46733 (-0.03%) 0.112 (0.013)*** 0.000 (0.000) 28658 (-0.27%) 
Unitcost_int 0.046 (0.031) -71638 (29179)** 46741 (-0.02%) 1172 (173)*** 1.484 (0.957) 28696 (-0.14%) 
Cost_comp 26.09 (115.31) -10.59 (4.93)** 46747 (-0.00%) -0.074 (0.029)** -0.001 (0.000) 28726 (-0.03%) 
Unitcost_comp 0.005 (0.029) -67854 (44928) 46748 (-0.00%) -655 (252)*** -4.43 (1.48)*** 28722 (-0.05%) 
Incr_cost 502.75 (314.47) -7.331 (2.201)*** 46739 (-0.02%) 0.134 (0.013)*** 0.000 (0.000) 28643 (-0.32%) 
Intervention 
Simvastatin 
Fluvastatin 
Atorvastatin 
Pravastatin 
Lovastatin 
Rosuvastatin 
unclear 
 
1080 (51.58%) 
41 (1.96%) 
184 (8.79%) 
256 (12.23%) 
125 (5.97%) 
60 (2.87%) 
348 (16.62%) 
 
Omitted 
-3508 (5660) 
-1508 (3073) 
-7058 (4078)* 
-12292 (7360)* 
-1607 (3177) 
-7010 (9370) 
46753 (0.01%) 
 
Omitted 
-30.16 (32.91) 
4.53 (17.34) 
-10.11 (20.20) 
75.26 (30.38)** 
26.68 (18.62) 
23.52 (32.95) 
 
Omitted 
0.179 (0.189) 
0.014 (0,104) 
-0.203 (0.119)* 
-0.349 (0.170)** 
0.073 (0.104) 
0.030 (0.171) 
28729 (-0.02%) 
Tdd_intervention 
Up to 10 mg 
Up to 20mg 
Up to 30mg 
Up to 40mg 
>60mg 
unclear 
 
65 (3.10%) 
259 (12.37%) 
554 (26.46%) 
654 (31.23%) 
206 (9.84%) 
356 (17.00%) 
 
Omitted 
-4876 (4370) 
14940 (6466)** 
-3194 (812)*** 
-7511 (4573) 
-6251 (8589) 
46746 (-0.01%) 
 
Omitted 
44.07 (25.96)* 
36.73 (35.04) 
8.67 (25.58) 
32.48 (26.71) 
-2.49 (46.58) 
 
Omitted 
-0.072 (0.148) 
0.652 (0.255)** 
-0.054 (0.152) 
-0.107 (0.158) 
-0.310 (0.130)** 
28727 (-0.03%) 
Comparator 
Simvastatin 
Fluvastatin 
Atorvastatin 
Pravastatin 
Lovastatin 
Rosuvastatin 
Doing nothing 
Unclear 
 
153 (7.31%) 
3 (0.14%) 
44 (2.10%) 
19 (0.91%) 
24 (1.15%) 
15 (0.72%) 
1834 (87.58%) 
2 (0.10%) 
 
Omitted 
4010 (13100) 
764 (9685) 
1735 (5148) 
75.09 (6117) 
2278 (7682) 
7178 (4249)* 
-614 (15598) 
46751 (0.00%) 
 
Omitted 
-76.51 (77.64) 
-85.10 (56.96) 
-27.36 (31.18) 
-104.7 (37.41)*** 
-63.46 (46.15) 
-23.63 (25.25) 
-25.86 (92.74) 
 
Omitted 
-0.227 (0.431) 
-0.359 (0.355) 
-0.052 (0.169) 
-0.427 (0.211)** 
-0.136 (0.270) 
0.091 (0.152) 
-0.128 (0.398) 
28727 (-0.03%) 
Act_comparator 
no (doing nothing) 
yes (statin) 
 
1834 (87.58%) 
260 (12.42%) 
 
Omitted 
-6545 (2770)** 
46746 (-0.01%) 
 
Omitted 
-34.00 (16.27)** 
 
Omitted 
-0.322 (0.097)*** 
28729 (-0.02%) 
Tdd_comparator 
0mg 
Up to 10mg 
Up to 20mg 
Up to 30mg 
Up to 40mg 
unclear 
 
1834 (87.58%) 
44 (2.10%) 
26 (1.24%) 
24 (1.15%) 
155 (7.40%) 
11 (0.53%) 
 
Omitted 
-6110 (9228) 
-3239 (4652) 
-8588 (12580) 
-8062 (3342)** 
-5023 (12940) 
46747 (0.00%) 
 
Omitted 
-70.81 (49.93) 
-74.05 (26.81)*** 
-89.10 (63.46) 
-4.58 (19.39) 
-75.78 (75.84) 
 
Omitted 
-0.517 (0.332) 
-0.347 (0.153)** 
-0.753 (0.444)* 
-0.269 (0.109)** 
-0.400 (0.506) 
28726 (-0.03%) 
Missingness indicators 
Miss_cost_int 137 (6.54%) 2808 (3919) -- -16.54 (22.26) 0.042 (0.128) -- 
Miss_ucost_int 356 (17.00%) -7388 (9008) -- -26.76 (36.79) -0.372 (0.346) -- 
Miss_cost_comp 2 (0.10%) -3502 (15396) -- -6.97 (90.36) -0.064 (0.509) -- 
Miss_ucost_comp 11 (0.53%) 16038 (18449) -- 141 (104) 1.001 (0.682) -- 
Miss_incr_cost 139 (6.64%) 2155 (3820) -- -31.19 (21.17) -0.041 (0.142) -- 
Miss_intervention 348 (16.62%) -4378 (3434) -- -53.31 (20.40)*** -0.305 (0.118)*** -- 
Miss_tdd_int 356 (17.00%) -1823 (3677) -- -73.74 (20.96)*** -0.310 (0.130)** -- 
Miss_comparator 2 (0.10%) -2956 (12087) -- -7.36 (73.64) -0.128 (0.398) -- 
Miss_tdd_comp 11 (0.53%) 1009 (5818) -- -8.42 (25.47) -0.082 (0.137) -- 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
 
 
Moving on to categorical variables reported in Table 5.19 above, significant 
coefficients become rare. The fact that both the variable ‘intervention’ and 
‘comparator’ show only few coefficients which reach statistical significance may 
speak in favour of the view taken by NICE, essentially saying that ‘a statin is a 
statin is a statin’, implying there is no effectiveness evidence which would justify 
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to favour one statin over another when commencing treatment (Nice, 2008b). 
Non-significant coefficients for the ordered categorical variable encoding the 
total daily dose of the intervention may be explained by the offsetting effect of 
the total daily dose of the comparator technology, meaning that higher doses of 
the intervention may have been compared to higher doses of the comparator, so 
that measures of cost-effectiveness may remain in the same range. This 
hypothesis is supported by a positive polichoric correlation of above 0.4. Only 
the binary variable ‘active comparator’ which indicates whether a statin has 
been compared to another statin or ‘doing nothing’, shows significant 
relationships, which accords expectations. Precisely, comparing the intervention 
to another statin leads to lower ∆E as the comparator may lead to additional 
(quality adjusted) life years. This decrement in ∆E is likely to offset any 
decrement in ∆C, which may stem from the additional annual drug cost of the 
comparator. As a result, cost-effectiveness may be lower when comparing a 
statin to another statin, as opposed to comparing a statin to ‘doing nothing’.  
 
 
The third group of variables to consider are methodological characteristics on 
data-level, i.e. study methods which may vary within individual studies, which 
are reported in Table 5.20 below. Starting with the annual discount rate for ∆C 
and ∆E, we observe highly significant negative relationships in the univariate 
model, as well as a positive relationship for the discount rate on costs and a 
negative relationship for the discount rate on effects in the bivariate model 
which both are highly significant too. For the discount rate on effects, the 
observed relationship is in accord with what one would expect as increasing the 
discount rate decreases the present value of future (quality adjusted) life years 
saved, and hence lowers estimates of INMBs. However, for incremental costs 
things are more difficult. Increasing the discount rate decreases the net present 
value of future drug cost for both the intervention and the comparator (if the 
comparator is not ‘doing nothing’). In addition, the net present value of future 
treatment cost without intervention decreases with increasing the discount rate 
on costs, which in sum may lead to increasing incremental cost of the 
intervention and this, in turn, may lead to a negative relationship between DRC 
and INMB.  
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Table 5.20: Bivariate statistics of methodological characteristics on data-level 
 
  Univariate model Bivariate model 
Explanatory 
variables 
Raw Mean (SD) 
/ 
Proportion (%) 
INMB 
(2010 £ Sterling) 
DIC 
(Benchmark: 
46749  
(%-change)) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
DIC 
(Benchmark: 
28735  
(%-change)) 
DRC 0.039 (0.017) -135022 (32104)*** 46734 (-0.03%) 752.91 (187.16)*** -- 28722 (-0.05%) 
DRB 0.030 (0.018) -215253 (33485)*** 46708 (-0.09%) -- -5915 (1036)*** 28707 (-0.10%) 
MCA_outc 0 (1) 624.83 (1213) 46751 (0.00%) -- 0.082 (0.042)* 28732 (-0.01%) 
MCA_horizon 0 (1) -1433 (1089) 46749 (0.00%) -5.216 (6.325) -0.053 (0.040) 28736 (0.00%) 
Outc_measure 
LYS 
QALYs 
 
1319 (62.99%) 
775 (37.01%) 
 
Omitted 
-1879 (1667) 
46750 (0.00%) 
 
-- 
 
Omitted 
-0.080 (0.052) 
28735 (0.00%) 
Elicitation 
n.a. (LYS) 
TTO 
EQ-5D 
HUI 
15D 
Other choice 
unclear 
 
1319 (62.99%) 
112 (5.35%) 
313 (14.95%) 
6 (0.29%) 
5 (0.24%) 
322 (15.38% 
17 (0.81%) 
 
Omitted 
-6617 (6320) 
1745 (2795) 
-3786 (12963) 
-2203 (17657) 
-8966 (18374) 
-2193 (9456) 
46751 (0.00%) 
 
Omitted 
-- 
-- 
-- 
-- 
-- 
-- 
 
Omitted 
-0.193 (0.210) 
0.010 (0.088) 
-0.203 (0.431) 
-0.073 (0.559) 
-0.047 (0.506) 
-0.045 (0.310) 
28738 (0.01%) 
Elicitation_shor
t 
n.a. (LYS) 
TTO 
EQ-5D 
Other choice. 
unclear 
 
1319 (62.99%) 
112 (5.35%) 
313 (14.95%) 
333 (15.90%) 
17 (0.81%) 
 
Omitted 
-6388 (6436) 
1734 (2788) 
-3556 (9340) 
-2300 (9534) 
46751 (0.00%) 
 
Omitted 
-- 
-- 
-- 
-- 
 
Omitted 
-0.188 (0.204) 
0.008 (0.089) 
-0.083 (0.316) 
-0.053 (0.317) 
28738 (0.01%) 
Population 
n.a. (LYS) 
patient 
population 
unclear 
 
1319 (62.99%) 
215 (10.27%) 
474 (22.64%) 
86 (4.11%) 
 
Omitted 
-4886 (4914) 
1930 (2860) 
-2843 (8841) 
46750 (0.00%) 
 
Omitted 
-- 
-- 
-- 
 
Omitted 
-0.133 (0.155) 
0.006 (0.091) 
-0.029 (0.288) 
28737 (0.01%) 
Duration 
< 5 years 
5 to <10 years 
10 to <15 years 
15 to <20 years 
20 to <25 years 
> 25 years 
(lifet.) 
Unclear 
 
66 (3.15%) 
788 (37.63%) 
175 (8.36%) 
44 (2.10%) 
87 (4.15%) 
814 (38.87%) 
120 (5.73%) 
 
Omitted 
1306 (5654) 
2371 (5473) 
3082 (6068) 
5503 (5954) 
8753 (5535) 
-10290 (12917) 
46733 (-0.03%) 
 
Omitted 
25.09 (30.02) 
11.97 (29.09) 
23.36 (33.22) 
-0.987 (32.50) 
38.77 (29.11) 
215.97 (63.16)*** 
 
Omitted 
0.097 (0.195) 
0.097 (0.190) 
0.145 (0.210) 
0.140 (0.209) 
0.383 (0.194)** 
0.026 (0.503) 
28711 (-0.08%) 
Duration_short 
< 10 years  
10 to 20 years 
> 20 years 
unclear 
 
854 (4078%) 
219 (10.46%) 
901 (43.03% 
120 (5.73%) 
 
Omitted 
1532 (2301) 
6974 (1916)*** 
-13122 (11565) 
46731 (-0.04%) 
 
Omitted 
-3.31 (13.74) 
10.47 (10.98) 
221.93 (56.07)*** 
 
Omitted 
0.040 (0.076) 
0.251 (0.063)*** 
0.134 (0.449) 
28715 (-0.07%) 
Extrapol 
no  
yes  
 
152 (7.26%) 
1942 (92.74%) 
 
Omitted 
3294 (5492) 
46750 (0.00%) 
 
Omitted 
30.29 (32.71) 
 
Omitted 
0.163 (0.213) 
28736 (0.00%) 
Horizon 
< 5 years 
5 to <10 years 
10 to <15 years 
15 to <20 years 
20 to <25 years 
> 25 years 
(lifet.) 
 
17 (0.81%) 
191 (9.12%) 
330 (15.76%) 
132 (6.30%) 
91 (4.35%) 
1333 (63.6%) 
 
Omitted 
888 (10654) 
2710 (10544) 
1804 (10620) 
4993 (10732) 
8336 (10445) 
46741 (-0.02%) 
 
Omitted 
26.83 (59.53) 
18.22 (59.51) 
22.97 (59.92) 
3.369 (60.88) 
43.83 (58.63) 
 
Omitted 
0.089 (0.404) 
0.122 (0.400) 
0.101 (0.403) 
0.138 (0.408) 
0.373 (0.399) 
28724 (-0.04%) 
horizon_short 
< 10 years  
10 to 20 years 
> 20 years 
 
208 (9.93%) 
462 (22.06%) 
1424 (68%) 
 
Omitted 
1424 (2570) 
6600 (2326)*** 
46740 (-0.02%) 
 
Omitted 
-6.02 (15.35) 
8.62 (14.00) 
 
Omitted 
0.020 (0.086) 
0.222 (0.078)*** 
28727 (-0.03%) 
hor_eq_dur 
no 
yes 
 
1328 (63.42%) 
766 (36.58%) 
 
Omitted 
-5832 (2905)** 
46742 (-0.01%) 
 
Omitted 
-1.39 (17.20) 
 
Omitted 
-0.244 (0.104)** 
28726 (-0.03%) 
Persp_rep 
Health 
insurance 
Societal 
Not reported 
 
1369 (65.38%) 
214 (10.22%) 
511 (24.40%) 
 
Omitted 
-8945 (5019)* 
-5650 (5619) 
46750 (0.00%) 
 
Omitted 
40.54 (28.28) 
32.28 (30.60) 
 
-- 
28736 (0.00%) 
Persp_C_concl 
Health 
insurance 
Societal 
Provider 
 
 
 
 
 
1939 (92.60%) 
135 (6.45%) 
20 (0.96%) 
 
 
 
 
Omitted 
13149 (4396)*** 
38984 (5074)*** 
 
 
 
46681 (-0.15%) 
 
 
 
 
Omitted 
-147.19 (26.16)*** 
-394.43 (29.26)*** 
 
 
 
 
-- 
 
 
 
28527 (-0.72%) 
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data_class 
base case 
 efficacy 
baseline risk 
cost (not int.) 
int. cost 
QALYs 
Dur./hor. 
Discount rate 
Other SA 
 
1125 (53.72%) 
12 (0.57%) 
49 (2.34%) 
64 (3.06%) 
86 (4.11%) 
72 (3.44%) 
288 (13.75%) 
257 (12.27%) 
141 (6.73% 
 
Omitted 
-1636 (6017) 
-6308 (3167)** 
-109.16 (2718) 
-632.80 (2198) 
-769.88 (3642) 
-6765 (1762)*** 
955.55 (1408) 
865.04 (2214) 
46732 (-0.04%) 
 
Omitted 
19.87 (36.26) 
69.27 (19.18)*** 
4.18 (16.37) 
18.44 (13.43) 
1.40 (22.00) 
12.69 (10.68) 
37.69 (8.55)*** 
-2.46 (13.07) 
 
Omitted 
0.25 (0.199) 
0.025 (0.103) 
0.017 (0.091) 
0.048 (0.071) 
-0.003 (0.124) 
-0.176 (0.058)*** 
0.162 (0.046)*** 
0.028 (0.072) 
28685 (-0.17%) 
Basecase 
Yes 
No 
 
1125 (53.72%) 
969 (46.28%) 
 
Omitted 
-1337 (1080) 
46749 (0.00%) 
 
Omitted 
24.49 (6.64)*** 
 
Omitted 
0.045 (0.037) 
28720 (-0.05%) 
source_effects 
lit./meta 
PLACI/II 
CARE 
WOSCOPS 
4S 
4S/ WOSCOPS 
EXCEL 
LIPID 
CARDS 
HPS 
TNT 
LIPS 
IDEAL 
STELLAR 
Brown et al 
other 
 
652 (31.14%) 
38 (1.81%) 
88 (4.20%) 
81 (3.87%) 
509 (24.31%) 
46 (2.2%) 
120 (5.73%) 
23 (1.10%) 
28 (1.34%) 
280 (13.37%) 
42 (2.01%) 
33 (1.58%) 
24 (1.15%) 
62 (2.96%) 
22 (1.05%) 
46 (2.20%) 
 
Omitted 
3497 (10297) 
4750 (7842) 
-1070 (8090) 
24051 (6689)*** 
-3978 (15536) 
-10021 (11858) 
10950 (9692) 
5147 (9387) 
12542 (10017) 
1104 (10450) 
2583 (10242) 
-1390 (12260) 
6622 (11866) 
7369 (16660) 
8482 (6959) 
46750 (0.00%) 
 
Omitted 
-7838 (5817) 
-44.62 (44.39) 
-31.44 (45.01) 
1.501 (38.35) 
-9.63 (84.73) 
152.38 (59.15)*** 
-55.55 (54.48) 
-111.79 (50.42)** 
-78.44 (52.70) 
-84.50 (56.08) 
-94-47 (56.40)* 
-95.43 (67.59) 
-71.14 (66.68) 
-93.82 (84.76) 
-33.21 (38.16) 
 
Omitted 
-0.087 (0.421) 
0.067 (0.319) 
-0.068 (0.320) 
0.789 (0.261)*** 
-0.057 (0.605) 
-0.034 (0.417) 
0.230 (0.382) 
-0.229 (0.367) 
0.231 (0.379) 
-0.269 (0.385) 
-0.215 (0.427) 
-0.449 (0.484) 
-0.090 (0.472) 
-0.302 (0.644) 
0.223 (0.272) 
28736 (0.00%) 
4_S + 
No 
yes 
 
1585 (75.69%) 
509 (24.31%) 
 
Omitted 
21041 (5254)*** 
46748 (0.00%) 
 
-- 
 
Omitted 
0.699 (0.172)*** 
28734 (0.00%) 
Barbieri_score_
1 
Type C 
Type CR 
Type CU 
Type CRE 
Type CRU 
Type CREU 
 
186 (8.88%) 
1033 (49.33%) 
113 (5.40%) 
193 (9.22%) 
513 (24.50%) 
56 (2.67%) 
 
Omitted 
6964 (3738)* 
1367 (6563) 
1452 (7308) 
515.29 (6631) 
-1343 (7690) 
46746 (-0.01%) 
 
Omitted 
-36.60 (22.53) 
-15.71 (39.21) 
-82.61 (43.53)* 
-59.34 (37.60) 
-93.00 (46.20)** 
 
Omitted 
0.049 (0.131) 
0.015 (0.227) 
-0.235 (0.304) 
-0.153 (0.262) 
-0.396 (0.314) 
28731 (-0.01%) 
Barbieri_score_
2 
Type 1 
Type 2 
Type 3 
Type 4 
 
186 (8.88%) 
1146 (54.73%) 
706 (33.72%) 
56 (2.67%) 
 
Omitted 
5818 (3321)* 
23.25 (5144) 
-3778 (5809) 
46746 (-0.01%) 
 
Omitted 
-31.74 (19.50) 
-64.11 (31.81)** 
-75.14 (35.96)** 
 
Omitted 
0.049 (0.114) 
-0.185 (0.221) 
-0.343 (0.237) 
28730 (-0.02%) 
Missingness indicators 
Miss_mca_outc 98 (4.68%) -1269 (7184) -- 2.172 (38.57) -0.001 (0.276) -- 
Miss_elicitation 17 (0.81%) -1755 (4226) -- -- 0.074 (0.132) -- 
Miss_population  86 (4.11%) -637.60 (2136) -- -- -0.031 (0.068) -- 
Miss_duration 120 (5.73%) -1224 (1696) -- 22.27 (10.34)** 0.031 (0.055) -- 
* 
** 
*** 
+ 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
No variation on data-level. Will be treated as study-level covariate within further analysis.  
 
Further continuous variables in this subgroup are MCA scores for variables 
concerned with outcome measurement (‘MCA_outcome’) and time horizon 
(‘MCA_horizon’). Neither leads to statistically significant results, as can be seen 
from Table 5.20 above. Likewise, the items used to generate these MCA scores 
fail to produce any significant results. However, very few methodological factors 
on data-level do have highly significant coefficients, one of them being the 
perspective on cost as judged by the author of this thesis. Interestingly, this is in 
sharp contrast to the results obtained when testing the perspective on cost as 
reported by the authors of studies included in this exercise, as results of this 
regression do not reach statistical significance. When looking at the perspective 
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as judged within this thesis, one observes that both a societal and a provider 
perspective are associated with lower incremental cost and improved cost-
effectiveness as compared to the health insurance (NHS) perspective, which was 
left to the omitted category. For the provider perspective this may be due, for 
instance, to not including cost-items which may be considered from a health 
insurance but not from a provider perspective, and for the societal perspective 
this may be due to the inclusion of additional cost savings for the society due to 
CVD prevention with statins, such as avoiding future work loss.  
 
 
As also reported in Table 5.20, whilst most types of sensitivity analyses did not 
significantly differ from base case results when testing the variable ‘data_class’, 
the binary variable basecase (yes/no) was highly significant for incremental cost 
in the bivariate model. Further, three covariates were tested in this group of 
variables which are concerned with data sources for populating the economic 
model. First, estimates of treatment effect were obtained from different 
randomised trials. However, the variable ‘source effects’ shows that only very 
few coefficients are significant, indicating that trial results, even for different 
statins with different comparators, are in the same range. Nevertheless, results 
obtained using data from the 4S study, which is also the trial which most cost-
effectiveness estimates in this empirical exercise are based upon, differ sharply 
from the rest of the dataset. A strong positive and highly significant relationship 
to ∆E in the bivariate model was observed and consequently, a positive and 
highly significant relationship with INMBs in the univariate model too. The fact 
that there was no relationship to ∆C also makes sense as different studies, 
though based on the same effectiveness data, may have used different costing 
methodologies. To control for this potential source of variability in effectiveness 
data, which also leads to a systematic difference in INMBs, a binary variable was 
created which is 1 if the estimate was obtained using 4S data, and zero 
otherwise. Note, however, that this binary variable does not show any variation 
within economic evaluation studies which is why it is treated as a study-level 
covariate in subsequent analyses. Obviously, it would be interesting to look into 
reasons why 4S is associated with better effectiveness and INMB values in the 
current analysis.  
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Finally, the geographic origin of input parameters was systematically assessed by 
creating a variable which captures the degree to which input values represent 
the target location. Precisely, the variable ‘barbieri_score_1’ comprises six 
categories where the category ‘C’ refers to cost-effectiveness data with only unit-
cost estimates being target location specific. Likewise, the category ‘CU’ refers to 
cost-effectiveness estimates based on target specific unit cost data and utility 
weights and so on, up to ‘CUER’, where all main input parameters were based on 
target location specific data. A shorter variant of this variable was also created 
(‘barbieri_score_2’), which categorises data in four groups from ‘1’ (only one 
input parameter target specific) to ‘4’ (all input parameters target specific).  
Details on the way this variable was created can also be obtained from Chapter 
4. As reported in Table 5.20 above, however, neither variant of this variable 
showed any conclusive results if tested individually in the multilevel framework. 
Maybe this changes when testing the variable in conjunction with other 
covariates.  
 
 
Moving on to the study-level, bivariate statistics were first produced for general 
study characteristics, as reported in Table 5.21 below. First of all, timing was 
assessed as a continuous variable. A negative relationship was anticipated with 
∆C, whilst the relationship with ∆E was assumed to be positive. The reason is 
that we may expect both statins becoming cheaper and more effective over 
time, consequently leading to improved cost-effectiveness. However, the data 
only confirms this expectation for ∆C in the bivariate model, whilst coefficients 
for ∆E and INMB are not significant. Moving on to the funding institution, we 
observe that studies mainly funded through industry show higher INMBs and this 
relationship is significant at the 5%-level. However, a similar relationship is not 
observed for ∆C or ∆E in the bivariate model.  
 
 
Next, covariates encoding existing relationships between studies through 
common authorship are tested. These variables resulted from looking into the 
genealogy of economic evaluation studies in Chapter 4 and details on the way 
these covariates were created can be found there. Results reported in Table 5.21 
show that only one group of papers with common authorship clearly depart from 
the rest of the dataset in terms of both ∆C and ∆E in the bivariate model as well 
as INMBs in the univariate model. This group of studies was co-authored by SA 
Grover and this finding confirms the interpretation of the forest plots presented 
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earlier in Section 5.1.4 of this chapter, which already indicated that papers co-
authored by this researcher were clearly out of the range of other studies 
included in this empirical exercise. Apart from common authorship, another 
combining factor between those studies is the use of the same DAM, namely the 
‘CHD life expectancy model’. An interesting topic for the discussion section is to 
look into potential reasons why this model may lead to much higher estimates of 
cost-effectiveness compared to other studies in this empirical exercise. To 
control for this potential source of variability, a binary variable was created 
which is ‘1’ if a data point refers to a study included in this group and ‘0’ 
otherwise.  
 
Table 5.21: Bivariate statistics of general study characteristics 
 
 
 Univariate model Bivariate model 
Explanatory 
Variables 
Raw Mean 
(SD) / 
Proportion 
(%) 
INMB 
(2010 £ 
Sterling) 
DIC 
(Benchmark: 
46749  
(%-change)) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
DIC 
(Benchmark: 
28735  
(%-change)) 
Timing 2000 (5.40) 213.26 (378.04) 46749 (0.00%) -8.09 (1.97)*** -0.018 (0.016) 28733 (-0.01%) 
Language 
English 
German 
 
61 (91.04%) 
6 (8.96%) 
 
Omitted 
-645.17 (7653) 
46749 (0.00%) 
 
Omitted 
-36.06 (50.19) 
 
Omitted 
-0.124 (0.375) 
28735 (0.00%) 
Funding_institution 
RC/gov/uni/other 
Industry 
unclear 
 
11 (16.42%) 
39 (58.21%) 
17 (25.37%) 
 
Omitted 
10803 (5430)** 
12184 (6343)* 
46750 (0.00%) 
 
Omitted 
-48.92 (32.18) 
-32.82 (40.93) 
 
Omitted 
0.168 (0.212) 
0.315 (0.269) 
28736 (0.00%) 
Funding_manuf. 
No manufacturer 
BMS 
MERCK 
Pfizer 
Other  
unclear 
 
11 (16.42%) 
7 (10.45%) 
12 (17.91%) 
13 (19.40%) 
9 (13.43%) 
15 (22.39%) 
 
Omitted 
5683 (7782) 
16389 (6407)** 
14798 (6566)** 
5903 (7364) 
8807 (6546) 
46750 (0.00%) 
 
Omitted 
-57.98 (45.18) 
11.01 (40.15) 
-71.02 (36.63)* 
-80.57 (41.90)* 
-35.84 (41.29) 
 
Omitted 
0.037 (0.318) 
0.597 (0.291)** 
0.190 (0.284) 
-0.134 (0.294) 
0.214 (0.288) 
28737 (0.01%) 
Author_group_long 
No relationships  
Group 01 
Group 02 
Group 03 
Group 04 
Group 05 
Group 06 
Group 07 
Group 08 
Group 09 
Group 10 
Group 11 
Group 12 
 
18 (26.87%) 
4 (5.97%) 
5 (7.46%) 
8 (11.94%) 
4 (5.97%) 
7 (10.45%) 
5 (7.46%) 
3 (4.48%) 
3 (4.48%) 
3 (4.48%) 
3 (4.48%) 
2 (2.99%) 
2 (2.99%) 
 
Omitted 
-6581 (7736) 
-1107 (8100) 
27522 (6222)*** 
-6840 (8704) 
-2107 (6949) 
1411 (7881) 
2051 (9142) 
3119 (9606) 
-2189 (8791) 
-1415 (9306) 
11601 (10848) 
-6715 (11940) 
46748 (0.00%) 
 
Omitted 
65.04 (45.72) 
-36.38 (49.14) 
141.69 (42.38)*** 
94.59 (52.11)* 
-11.39 (44.09) 
-11.25 (46.36) 
-16.51 (55.70) 
-43.97 (55.79) 
-15.44 (48.64) 
-57.38 (55.99) 
-33.69 (57.38) 
0.98 (70.59) 
 
Omitted 
-0.004 (0.315) 
-0.099 (0.310) 
1.438 (0.297)*** 
0.088 (0.309) 
-0.110 (0.287) 
-0.006 (0.272) 
-0.021 (0.351) 
-0.033 (0.352) 
-0.115 (0.303) 
-0.244 (0.344) 
0.289 (0.391) 
-0.178 (0.437) 
28736 (0.00%) 
Author_group_short 
No relationships  
Group 01 
Group 02 
Group 03 
Group 04 
Group 05 
Group 06 
Group 07 
 
18 (26.87%) 
29 (43.28%) 
8 (11.94%) 
3 (4.48%) 
2 (2.99%) 
3 (4.48%) 
2 (2.99%) 
2 (2.99%) 
 
Omitted 
-2249 (4416) 
27044 (6060)*** 
1936 (8603) 
-929.24 (9788) 
-1292 (9286) 
10576 (9728) 
-6883 (11661) 
46748 (0.00%) 
 
Omitted 
6.86 (28.43) 
160.60 (41.37)*** 
-25.89 (58.21) 
-10.87 (59.90) 
-61.32 (55.45) 
-47.50 (58.82) 
10.23 (66.79) 
 
Omitted 
-0.046 (0.167) 
1.522 (0.256)*** 
-0.060 (0.334) 
-0.191 (0.370) 
-0.281 (0.327) 
0.171 (0.361) 
-0.130 (0.394) 
28735 (0.00%) 
Author_Grover 
No 
yes 
 
59 (88.06%) 
8 (11.94%) 
 
Omitted 
28410 (5196)*** 
46747 (0.00%) 
 
Omitted 
147.15 (34.16)*** 
 
Omitted 
1.510 (0.223)*** 
28735 (0.00%) 
Missingness indicators 
Miss_fund_inst 17 (25.37%) 1064 (1185) -- -9.215 (7.289) 0.006 (0.039) -- 
Miss_fund_man 15 (22.39%) 1681 (4748) -- -1.338 (10.36) 0.055 (0.056) -- 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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Moving on to methodological characteristics on study-level for which bivariate 
statistics are reported in Table 5.22, we observe that studies capturing treatment 
effectiveness by modelling the impact of a change in cholesterol levels on 
(quality adjusted) life years show higher ∆C and ∆E than studies directly 
considering the change in CVD risk without making explicit the link from 
intermediate to final outcomes. This relationship is highly significant for both 
components of the INMB statistic in the bivariate model and, in addition to that, 
the impact on ∆E seems to outweigh the impact on ∆C, so that INMBs are also 
higher in studies which explicitly model from intermediate to final outcomes; 
though this relationship only borders at the 5%-level of significance.  
 
Table 5.22: Bivariate statistics of methods on study-level  
 
 
 Univariate model Bivariate model 
 
Raw Mean (SD) 
/ 
Proportion (%) 
INMB 
(2010 £ 
Sterling) 
DIC (Benchmark: 
46749  
(%-change)) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
DIC (Benchmark: 
28735 
 (%-change)) 
General design 
Primary modelling 
Secondary 
modelling 
 
6 (8.96%) 
61 (91.04%) 
 
Omitted 
2527 (7080) 
46749 (0.00%) 
 
Omitted 
51.30 (40.02) 
 
Omitted 
0.244 (0.265) 
28736 (0.00%) 
Secondary design 
N.a. (primary m.) 
Markov model 
Decision tree 
Other 
 
6 (8.96%) 
41 (61.19%) 
7 (10.45%) 
13 (19.40%) 
 
Omitted 
2672 (7033) 
-286.35 (9344) 
3399 (8230) 
46750 (0.00%) 
 
Omitted 
33.86 (46.77) 
126.10 (48.48)*** 
54.54 (46.77) 
 
Omitted 
0.226 (0.287) 
0.470 (0.357) 
0.253 (0.333) 
28737 (0.01%) 
Effect_calc 
CHD risk 
reduction 
Cholest. reduction 
 
41 (61.19%) 
26 (38.81%) 
 
Omitted 
8188 (4368)* 
46749 (0.00%) 
 
Omitted 
84.48 (25.69)*** 
 
Omitted 
0.505 
(0.194)*** 
28735 (0.00%) 
multinational 
no 
yes 
 
60 (89.55%) 
7 (10.45%) 
 
Omitted 
4819 (6896) 
46749 (0.00%) 
 
Omitted 
-31.86 (54.79) 
 
Omitted 
0.036 (0.403) 
28735 (0.00%) 
Infl_adj 
n.a.  
no  
yes 
unclear 
 
12 (17.91%) 
2 (2.99%) 
18 (26.87%) 
35 (52.24%) 
 
Omitted 
-6110 (12836) 
-8759 (6458) 
-1834 (5777) 
46750 (0.00%) 
 
Omitted 
-20.49 (76.33) 
9.22 (40.18) 
43.41 (32.53) 
 
Omitted 
-0.226 (0.507) 
-0.275 (0.290) 
0.211 (0.236) 
28737 (0.01%) 
Adj_method 
n.a. 
simple CPI 
healthcare CPI 
not though 
indicated 
unclear 
 
12 (17.91%) 
8 (11.94%) 
10 (14.93%) 
2 (2.99%) 
35 (52.24%) 
 
Omitted 
-12040 (7767) 
-5143 (7569) 
-4734 (12604) 
-1534 (5801) 
46750 (0.00%) 
 
Omitted 
15.64 (46.62) 
-8.61 (47.75) 
-32.73 (72.63) 
35.73 (33.57) 
 
Omitted 
-0.413 (0.324) 
-0.180 (0.328) 
-0.318 (0.478) 
0.192 (0.233) 
28737 (0.01%) 
Cur_conv 
No 
yes 
 
52 (77.61%) 
15 (22.39%) 
 
Omitted 
4797 (3878) 
46750 (0.00%) 
 
Omitted 
0.297 (23.13) 
 
Omitted 
0.150 (0.151) 
28737 (0.01%) 
Conv_method 
n.a. 
Exchange rates 
unclear 
 
52 (77.61%) 
11 (16.42%) 
4 (5.97%) 
 
Omitted 
6878 (4386) 
-2424 (7582) 
46751 (0.00%) 
 
Omitted 
-0.232 (24.73) 
17.80 (45.42) 
 
Omitted 
0.227 (0.158) 
0.009 (0.286) 
28735 (0.00%) 
Scope  
CAD 
CAD and CD 
CAD, CD and PAD 
unclear 
 
18 (26.87%) 
35 (52.24%) 
11 (16.42%) 
3 (4.48%) 
 
Omitted 
2610 (1781) 
1057 (5628) 
-8031 (11584) 
46749 (0.00%) 
 
Omitted 
40.45 (10.70)*** 
-70.04 (28.55)** 
-6.243 (67.14) 
 
Omitted 
-0.030 (0.059) 
-0.144 (0.226) 
-0.182 (0.460) 
28727 (-0.03%) 
Missingness indicators 
Miss_infl_adj 35 (52.24%) 658.6 (887.1) -- -2.825 (5.383) 0.012 (0.029) -- 
Miss_adj_method 35 (52.24%) 661.8 (887.8) -- -2.849 (5.383) 0.013 (0.222) -- 
Miss_conv_meth. 4 (5.97%) -3968 (3244) -- -28.40 (19.82) -0.227 (0.108)** -- 
Miss_scope 3 (4.48%) 7132 (5290) -- 40.62 (32.32) 0.371 (0.176)** -- 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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Apart from that, the assessment of methods on study-level did not lead to 
noteworthy results, as only one further categorical variable (scope) showed 
significant coefficients for the cost component of the INMB statistic. One may 
expect that studies which do not only look into the impact of statins on coronary 
heart disease (CHD), but also consider conditions as stroke or peripheral arterial 
disease, tend to have lower ∆C than studies which are confined to CHD only. This 
may be due to future cost avoided for a broader range of conditions due to 
prevention with statins. However, analysis shows a highly significant positive 
coefficient for studies which include stroke next to CHD but a negative 
coefficient for studies including CHD, stroke and peripheral arterial disease so 
that results are not entirely conclusive.   
 
 
Finally, the data abstraction exercise reported in Chapter 4 was accompanied by 
applying the QHES instrument to the studies included in this empirical exercise 
(Ofman et al., 2003). This resulted in a score (bound between zero and 100) for 
each study in the dataset which supposedly gives an indication of study quality. 
Though a number of quality checklists exist and the application of such tools is 
not without controversy, this may be regarded as an attempt to control for some 
part of the variability in measures of cost-effectiveness due to differences in the 
methodological rigour with which economic evaluation studies were conducted 
and reported. Further details on why the QHES instrument was chosen out of a 
number of potential checklists, how it was applied to the studies in this empirical 
exercise, which problems were encountered throughout the process, and how 
these problems were addressed within this thesis are reported in Chapter 4.  
 
 
For bivariate statistics, the information obtained from QHES was implemented in 
different ways, resulting in two continuous and two categorical variants of this 
variable. The reason is that the authors who developed QHES defined 
dimensions of study quality of which some are comprised of several 
subcategories (Ofman et al., 2003). This induces the problem that studies may 
score in some but not all subcategories in one dimension. Depending on how 
rigorous one is in the application of this instrument, this may lead to different 
scores for the same study. Therefore, two continuous variables were derived 
(again, further details are available from Chapter 4), and to better reflect the 
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immense uncertainty attached to the data obtained through QHES, the 
continuous data was also transformed to categorical variables with 5 categories 
with increments of 20 between zero and 100. Descriptive statistics show that a 
strict application of the QHES criteria (i.e. not assigning a score for a particular 
dimension if a study does not completely fulfil the criteria) leads to a lower mean 
but higher standard deviation for continuous data, and also a higher spread 
across categories for categorical data.  
 
 
Bivariate statistics reported in Table 5.23 show negative relationships between 
continuous QHES variables and both components of the INMB statistic, whilst 
this relationship is significant at the 1% level for ∆C and at the 5%-level for ∆E. 
This result indicates that a higher study quality (as measured by the QHES 
instrument) is associated with more conservative estimates of incremental 
effects, and also lower estimates of incremental costs compared to studies which 
achieved a lower QHES score. However, significance was not achieved for 
coefficients in the univariate model. Testing the categorical versions of the QHES 
instrument confirms the previous findings, though it is interesting that results do 
not longer reach statistical significance for ∆E in QHES_cat_a, which resulted 
from a strict application of the QHES criteria. This observation indicates that 
results may be interpreted with caution, as they obviously are very sensitive to 
small variations in the way QHES has been operationalized in this empirical 
exercise.  
 
 
Table 5.23: Bivariate statistics of study quality indicators  
 
 
 Univariate model Bivariate model 
 
Raw Mean (SD) 
/ 
Proportion (%) 
INMB 
(2010 £ Sterling) 
DIC 
(Benchmark: 
46749 
 (%-change)) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
DIC 
(Benchmark: 
28735  
(%-change)) 
QHES cont_a 66.23 (17.97) -167.77 (131.06) 46749 (0.00%) -2.244 (0.77)*** -0.013 (0.006)** 28736 (0.00%) 
QHES cont_b 75.34 (15.36) -193.81 (154.60) 46749 (0.00%) -2.545 (0.903)*** -0.015 (0.007)** 28736 (0.00%) 
QHES cat_a 
Up to 40 pts 
41 to 60 pts 
61 to 80 pts 
81 to 100 pts 
 
7 (10.45%) 
31 (46.27%) 
22 (32.84%) 
7 (10.45%) 
 
Omitted 
7039 (7488) 
4112 (7823) 
-321 (9271) 
46749 (0.00%) 
 
Omitted 
-98.03 (38.03)*** 
-140.89 (41.25)*** 
164.97 (49.22)*** 
 
Omitted 
-0.013 (0.293) 
-0.229 (0.321) 
-0.481 (0.391) 
28734 (0.00%) 
QHS cat_b 
Up to 60 pts 
61 to 80 pts 
81 to 100 pts 
 
20 (29.85%) 
40 (59.70% 
7 (10.45%) 
 
Omitted 
-9528 (4565)** 
-12150 (7109)* 
46749 (0.00%) 
 
Omitted 
-71.10 (24.70)*** 
-110.83 (39.46)*** 
 
Omitted 
-0.521 (0.172)*** 
-0.762 (0.276)*** 
28735 (0.00%) 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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5.2.4.2. Random intercepts models with multiple covariates on data and study-
level  
 
 
In this section, a full random intercepts model is developed with covariates on 
data and study-level. The primary objective is to control for variability factors on 
both levels which potentially feed through to the country-level so that further 
country-level variability may be disclosed. This country-level variability is the 
focus of assessment in Section 5.3 of this empirical exercise. In this section, it is 
assumed that slopes of explanatory variables are fixed (this assumption is being 
relaxed in Section 5.4 through the inclusion of random slopes).  As detailed in the 
analysis strategy for this section, the model is being build up from the lower level 
to the higher level, and covariates are added to the model if their coefficients are 
significant and accord expectations and the overall fit of the model improves.  
 
 
The order with which variables are tested has also been laid out in the analysis 
strategy. Patient and disease characteristics are tested first as arguably the most 
critical source of variability in measures of cost-effectiveness (Sculpher et al., 
2004), followed by intervention and comparator characteristics, methods on 
data-level, general study characteristics, methods on study-level and study 
quality indicators. Results from gradually building up the full random intercepts 
model can be obtained from Appendix 5.4. The results from running the final 
model fully specified with covariates on data and study-level are obtainable from 
Table 5.24 below. Each covariate is tested individually, and its impact on overall 
fit and other coefficients with their respective p-values is observed. This bottom 
up approach ensures that the most appropriate set of covariates is chosen out of 
the pool of candidates available in this dataset. Missingness indicators are 
included in the model; however, they are only reported if they reach statistical 
significance. After choosing the most appropriate set of covariates, the impact on 
variability observed on each hierarchical level throughout the development of 
the models of interest is analysed and discussed.    
 
 
Combinations of patient and disease characteristics were tested first in the 
univariate and bivariate versions of the three-level hierarchical model. Results 
are detailed in Appendix 5.4.1. Total cholesterol (which was not significant for ∆C 
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when performing bivariate statistics), SBP and the percentage of patients 
diagnosed with diabetes in the study sample all turned out to be highly 
significant for INMB, ∆C and ∆E, whilst HDL was significant at the 10% level for 
∆C and ∆E in the bivariate model and at the 5% level for INMB in the univariate 
model. SBP turned out to be the variable which best controls for variability in 
cost-effectiveness data due to circulation related CVD risk. As a result, 
hypertension status, smoking status and the factor score obtained from running 
a PCF on SBP, hypertension and smoking were all dropped from the model due 
to strong collinearity with SBP. As before when running bivariate statistics, 
coefficients for the categorical variable encoding the age of the study sample 
turned out to be highly significant and show the previously observed relationship 
with measures of cost-effectiveness. Likewise, the gender variable accords 
expectations and shows highly significant coefficients. Interestingly however, 
CVD-history, which previously failed to show statistically significant coefficients, 
now turns out to be highly significant both for INMBs in the univariate model and 
∆E in the bivariate model. As hypothesized before, this may be due to the fact 
that controlling for individual patient risk factors unravels the actual relationship 
between measures of cost-effectiveness for statin treatment and CVD history, 
which should be positive for patients which previously experienced a CVD event.  
 
 
Adding intervention and comparator characteristics to the model further 
improves its fit (Appendix 5.4.2). The annual drug cost of the intervention is 
highly significant and accords expectations for INMB in the univariate model and 
∆C in the bivariate model. However, the annual drug cost of the comparator was 
dropped from the univariate model as improvement in fit was better when 
including the binary variable ‘active comparator’. The reason may be that both 
variables are highly correlated as the annual drug cost of the comparator is 
always zero when the comparator is ‘doing nothing’ (which is the case in 1834 
(87.58%) of data points). Hence, this binary variable was highly significant for ∆E 
in the bivariate model and significant at the 10% level in the univariate 
framework. In both cases, the coefficient shows the anticipated negative sign as 
one would expect both ∆E and INMBs to decrease if the intervention is 
compared to another statin rather than ‘doing nothing’. Instead of annual drug 
cost, a combination of the variables ‘unit cost’, ‘total daily dose’ and the specific 
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type of intervention or comparator was also tested in the model but results 
indicate a much better fit of the model as described above.  
 
 
The third group of variables to add to the model are methodological 
characteristics on data-level (Appendix 5.4.3). It turned out that only few 
variables show significant coefficients, but these variables improved the fit of the 
model quite dramatically. First of all, the discount rates on cost and effects were 
tested. Whilst both turned out to be significant at first, the discount rate on cost 
was dropped subsequently after including the categorical variable encoding the 
economic perspective taken on costs. A potential explanation for the correlation 
between both variables may be that different studies complied with different 
methods guidelines, which have their idiosyncratic views on both discount rate 
and perspective. Nevertheless, the discount rate on effects remained in the 
model as it was highly significant both for ∆E in the bivariate model and INMBs in 
the univariate framework.  
 
An interesting relationship was observed between the two explanatory variables 
‘horizon’ and ‘duration_eq_horizon’, which encodes whether treatment duration 
lasted as long as the time horizon of the economic model (or shorter). A time 
horizon of 20 years or more leads to higher INMBs and also higher ∆E in the 
bivariate model. Although one may think that longer treatment duration may 
also lead to higher ∆C, this was not observed in the bivariate model. In addition, 
INMBs and incremental effects turned out much more beneficial if the treatment 
with statins did not last as long as the models time horizon, meaning that statin 
treatment appears to be more beneficial when stopped before the end of the 
model lifetime.  Moving on to the variable ‘base case’, which encodes whether a 
data point refers to sensitivity analyses or not, it turns out that sensitivity 
analyses results are associated with both higher ∆C and higher ∆E in the bivariate 
model. This effect was not observed in the univariate model, most likely because 
the positive effect on ∆C is simply offset by the positive effect on ∆E.  
 
Finally, the variable ‘barbieri_score’ was tested in the model, and this led to 
significant coefficients for ∆C in the bivariate model. Precisely, continuously 
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decreasing ∆C is observed with increasing context specificity of the underlying 
input data. A related question is why this variable did not show significant 
coefficients for ∆E or INMBs. A reason may be that transferring effectiveness 
data is much more common than transferring economic data, so that there is 
simply no systematic variation in this relationship on the effectiveness side of the 
INMB statistic. This may then feed through to INMBs, so that the univariate 
model also fails to observe a relationship between context specificity of input 
data and measures of cost-effectiveness. Before moving on to the study-level, 
note that the source of effectiveness data also belongs to the group of 
methodological characteristics on data-level. Whilst this categorical variable did 
only show very little improvement in model fit, it also showed, however, that 
measures of ∆E and INMBs are much more beneficial if the study was based on 
data from the 4S trial. Hence, a binary variable was generated and tested when 
running bivariate statistics (more details are obtainable from the previous 
Section 5.2.4.1). Unlike the categorical variable with categories for each source 
of effectiveness data, which also differs within economic evaluation studies, this 
binary variable does not show any variation on data-level, and is therefore 
considered as a methodological characteristic on study-level further below.  
 
Moving on to this study-level (Appendix 5.4.4), it becomes more difficult finding 
significant coefficients. Timing, for instance, was expected to be an important 
explanatory both for ∆C and ∆E- and therefore also for INMBs. It was, however, 
not statistically significant. In theory, one may expect that statins become both 
less costly and more effective over time, however this was not observed in the 
multilevel models. With respect to incremental cost and INMBs, the explanation 
for this failure to observe significant coefficients may be relatively simple. The 
model already contains variables which encode the annual drug cost of the 
intervention and comparator technologies. If statin treatment becomes less 
costly over time, for instance because of generics which enter the market after 
product patents run out, this should be captured by those variables. 
Consequently, removing those variables from the model results in significant 
coefficients for timing, which accords prior expectations as these coefficients are 
negative for incremental cost and positive for INMBs. However, as the model fit 
is much better with the variables encoding annual drug cost, it was decided to 
keep those variables in the model and rather to drop timing instead.  
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Unfortunately, other variables which encode general study characteristics failed 
to show significant coefficients, for instance language (as papers included in the 
systematic review and data abstraction exercise may have been written in 
English or German). A further number of variables showed only significant 
coefficients in the univariate model, whilst coefficients for ∆C and ∆E were not 
significant. For instance, there was no significant difference between studies 
which were primarily funded by the government, research councils or 
Universities, and those primarily funded by the industry in the bivariate model, 
whilst INMBs were significantly higher (at the 5% level) for industry funding in 
the univariate model. However, this significant relationship disappeared when 
including a binary encoding whether a study uses the CHD life expectancy model 
by Grover et al (1998) and this observation is discussed in more detail with 
respect to the relevant literature (e.g. Miners et al., 2005) in Chapter 6.  
 
 
Assessing general study characteristics was not completely unsuccessful in terms 
of controlling for variability in measures of cost-effectiveness, and the reason for 
this is directly related to the genealogy study reported earlier in Chapter 4. It was 
hypothesized that studies which are ‘genotypically’ related, e.g. through 
common authorship, may also have ‘phenotypic’ characteristics in common, 
which may also lead to correlations in measures of cost-effectiveness. As a result, 
variables were created which encode links between studies included in this 
exercise due to common authorship, and analysis showed that one particular 
group of papers, all published by a group of authors around S.A. Grover, are 
strong outliers both in terms of ∆C and ∆E in the bivariate model and INMBs in 
the univariate framework. This finding confirms what was already indicated by 
the forest plots presented in Section 5.1.4. As a result, including a binary variable 
which is ‘1’ if the paper refers to this group of authors and ‘0’ otherwise leads to 
much higher estimates of INMBs and ∆E, and also elevated estimates of ∆C. 
Apart from common authorship, another similarity between the affected papers 
is the use of the identical DAM to assess cost-effectiveness which was already 
referred to above as the ‘CHD life expectancy model’. What may have caused this 
strong effect on measures of cost-effectiveness within the affected studies is also 
subject of further discussion in Chapter 6.  
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Table 5.24: Random intercepts model fully specified on data and study-level 
 
 
Univariate model Bivariate model 
Explanatory variables 
INMB 
(2010 £ Sterling) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
Fixed part: 
N (countries) 
N (studies) 
N (data) 
18 
67 
2094 
18 
67 
2094 
18 
67 
2094 
Intercept 
(λ=£30.000) 
-50105 716 -1.450 
TCL (SE) 4254 (562)*** -32.66 (3.13)*** 0.040 (0.018)** 
HDL (SE) -31211 (9424)*** 189.25 (53.17)*** -0.523 (0.303)* 
SBP (SE) 703 (35.82)*** -3.37 (0.19)*** 0.012 (0.001)*** 
Diabetes (SE) 15017 (1684)*** -19.44 (8.23)** 0.415 (0.053)*** 
Age_cat (SE) 
<45  
46-55 
56-65 
66-75 
>75 
Unclear 
 
Omitted 
311.4 (1111) 
-5934 (1091)*** 
-15211 (1157)*** 
-6663 (1956)*** 
-4437 (7421) 
 
Omitted  
-95.31 (6.05)*** 
-133.5 (5.95)*** 
-168.4 (6.27)*** 
-130.3 (10.58)*** 
-116.1 (43.39)*** 
 
Omitted 
-0.308 (0.036)*** 
-0.639 (0.035)*** 
-1.066 (0.037)*** 
-0.651 (0.063)*** 
-0.535 (0.230)** 
Gender (SE) 
Female 
Male 
Mixed sample 
 
Omitted 
10329 (841)*** 
11082 (3493)*** 
 
Omitted 
-32.76 (4.52)*** 
-29.01 (22.94) 
 
Omitted 
0.231 (0.027)*** 
0.253 (0.108)** 
CVD_history (SE) 
No 
Yes 
Mixed sample 
 
Omitted 
7985 (1632)*** 
8520 (6103) 
-- 
 
Omitted 
0.228 (0.049)*** 
0.334 (0.189)* 
Cost_intervention -9.08 (1.76)*** 0.129 (0.010)*** -- 
Cost_comparator -- -0.140 (0.023)*** -- 
Active_comparator 
No (doing nothing) 
Yes (statin) 
 
Omitted 
-3845 (2211)* 
-- 
 
Omitted 
-0.274 (0.072)*** 
DRB -133550 (29321)*** -- -3.477 (0.889)*** 
Persp_cost_concl. 
Health insurance (NHS) 
Provider 
Societal 
 
Omitted 
33002 (4416)*** 
15212 (3498)*** 
 
Omitted 
-399.8 (22.88)*** 
-173.9 (19.82)*** 
-- 
Horizon 
< 20 years 
>20 years (lifetime) 
 
Omitted 
3812 (1349)*** 
-- 
 
Omitted 
0.159 (0.042)*** 
Duration=horizon 
yes 
No (treatment 
duration< horizon) 
 
Omitted 
13091 (2437)*** 
-- 
 
Omitted 
0.377 (0.075)*** 
Base case 
Yes 
No  
-- 
 
Omitted 
9.31 (4.95)* 
 
Omitted 
0.066 (0.030)** 
Barbieri_score_2 
Type 1 
Type 2 
Type 3 
Type 4 
-- 
 
Omitted 
-36.56 (15.29)** 
-64.08 (29.76)** 
-95.75 (32.03)*** 
-- 
Author_Grover 
No  
Yes 
 
Omitted 
29138 (5849)*** 
 
Omitted 
162.6 (44.79)*** 
 
Omitted 
1.412 (0.194)*** 
4S 
No 
yes 
 
Omitted 
14295 (5294)*** 
-- 
 
Omitted 
0.495 (0.159)*** 
Scope 
CHD 
CHD and stroke 
CHD, stroke and PAD  
unclear 
 
Omitted 
5535 (1566)*** 
8428 (4822)* 
5984 (9227) 
 
Omitted 
-36.63 (8.08)*** 
-33.78 (31.93) 
-104.5 (64.53) 
-- 
Random part:  	(Country) 444825 3515 0.056  	(Study) 153583808 7797 0.136  	(Data) 188413984 5523 0.196 
VPC - Country 
VPC – Study 
VPC - data 
0.13% 
44.85% 
55.02% 
20.88% 
46.31% 
32.81% 
14.43% 
35.05% 
50.52% 
DIC 
(benchmark) 
45840 
(45844) 
26412 
(26423) 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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Moving on to methods on study-level, only two variables showed significant 
coefficients, namely ‘scope’ and ‘4S’ (Table 5.24). The variable ‘scope’ is a 
categorical which distinguishes between studies which 1) only consider the 
impact of statin treatment on CHD risk, 2) those which also consider the effect of 
prevention with statins on stroke and, 3) those studies which consider the effect 
of statins on CHD risk, stroke and peripheral arterial disease (PAD). Obviously, 
one would expect a positive relationship with ∆E as a broader scope leads to 
consideration of a broader range of beneficial effects from statin prevention. 
Likewise, ∆C may be lower, as a broader range of future healthcare cost may be 
avoided through statin treatment. However, significant coefficients which accord 
expectations were only observed for ∆C and INMBs, whilst coefficients were not 
significant for ∆E.  
 
 
Finally, the variable ‘4S’, which is ‘1’ if a study based its results on evidence from 
the 4S trial, and zero otherwise, was included as a methodological characteristic 
on study-level. This variable arose out of analysing the source of effectiveness 
data, and results indicated that only the 4S study may result in outliers in terms 
of incremental effects and INMBs. The results from running bivariate statistics 
were confirmed when including the binary in the random intercepts model, 
which led to an improvement of fit and strong changes both in study-level and 
country-level variability.  
 
 
Whilst results from gradually adding covariates to the model are obtainable from 
Appendix 5.4, Table 5.24 above reports on the results of running the fully 
specified random intercepts model with covariates on data and study-level. One 
group of variables is missing entirely from this model, i.e. indicators of study 
quality. Unfortunately, results indicate that variables encoding information from 
applying the QHES instrument to the studies included in the dataset, are not 
related to measures of cost-effectiveness. Potential reasons are that either there 
is no relationship between study quality and measures of cost-effectiveness, or 
that the QHES instrument simply failed to capture study quality in an appropriate 
manner, so that it was not possible to disclose any relationship between 
methodological rigour of an economic evaluation study and cost-effectiveness 
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results. The author believes that this latter explanation may be more likely, and 
elaborates further on this issue in the discussion of this empirical exercise.  
 
 
Before moving on to the next section, which is concerned with the assessment of 
country-level variability, it is indicated to make explicit once more how this 
whole exercise relates to the issue of variation in measures of cost-effectiveness 
between countries. For this matter, one may have a closer look at the random 
part of the models reported in Appendix 5.4. If lower-level variability factors feed 
through to higher levels, the actual amount of country-level variability may only 
be unravelled by including the appropriate set of covariates both on data and 
study-level. The multilevel framework offers an excellent platform to investigate 
this hypothesis as it allows higher-level variability to change in any direction with 
the inclusion of lower-level covariates (Hox, 2010). For instance, if Sculpher et al. 
(2004) are right with their statement that the impact of patient characteristics on 
measures of cost-effectiveness ‘feeds through to differences in cost-effectiveness 
observed on higher levels’, than we ought to observe changes in error terms 
relating to each hierarchical level of the model by including such lower-level 
covariates. Obviously, the same holds for study-level covariates, as controlling 
for study characteristics may also impact on the variability in measures of cost-
effectiveness observed between countries.  
 
 
As the model was gradually built up from the lower to the higher level, it is 
possible to map the change in variability on each hierarchical level throughout 
the course of this empirical exercise. If the suspicion holds in the sense that 
variability on lower levels disguises variability on country-level, one should 
observe the country-level gradually becoming an ever more important source of 
variability in measures of cost-effectiveness. Figure 5.10 captures the change in 
the variance partitioning coefficient (VPC) on each hierarchical level throughout 
the course of this empirical exercise. During the first part of this study, which was 
concerned with determining the appropriate MLM structure, variability on data-
level remained relatively constant, whilst the VPC increased on country-level and 
consequently decreased on study-level, especially for ∆C and ∆E in the bivariate 
model. The reason is that multinational study data disguised country-level 
variability in the cross-classified and intermediate models. Grouping data from 
multinational studies in a separate group on country-level disclosed further 
variability between countries, whilst study-level variability decreased 
respectively.  
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Secondly, testing data-level covariates in the model obviously had a very strong 
impact on level-one variability. It led to a sharp drop in VPC on data-level for 
both variability in INMBs in the univariate model as well as variability in ∆C and 
∆E in the bivariate model. However, variability on study-level and country-level 
Figure 5.10. VPC on data, study and country-level throughout this empirical 
exercise 
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increased simultaneously, and this not just in relative terms as measured with 
the VPC, but also in absolute terms, which is getting obvious when comparing 
the figures displayed in Tables 5.4.1 to 5.4.4 in Appendix 5.4. This is very 
compelling evidence in favour of the statement that the effect of lower-level 
variables feeds through to variability in measures of cost-effectiveness between 
studies and, ultimately, countries. It also shows one of the merits of the 
multilevel framework, as the impact of lower-level covariates on each 
subsequent hierarchical level is being made explicit. Unfortunately, however, 
variability on country-level remains very low for INMBs within the univariate 
framework, with just over 1% of the overall variability falling on that particular 
level. This is one focus of attention in the next Section 5.3 of this empirical 
exercise, which is concerned with country-level variability – or the lack thereof – 
in the MLM framework.  
 
Finally, adding study-level covariates also helped controlling for some part of the 
overall variability, particular on study-level. This also led to a change in country-
level variability, which increased further for ∆C but slightly decreased for ∆E and 
INMBs. It is important to mention, though, that the change in VPC observed on 
data-level due to the inclusion of study-level covariates is only a result of the 
overall variability decreasing. As mentioned before, changes on lower-levels may 
impact higher-levels, but not vice versa. Hence, as overall variability decreased, 
the error variances on data-level remained constant, which led their proportion 
of overall variability measured by the VPC to increase.  
 
 
5.2.5. Summary and conclusions for part two of this empirical 
exercise 
 
This section was predominantly concerned with testing covariates in the MLM 
framework on data and study-level and determining a model which best controls 
for variability on these levels, hence disclosing the maximum amount of country-
level variability in measures of cost-effectiveness for statins. Covariates on data 
and study-level were systematically assessed which were drawn from a long list 
of variability factors as obtained from the literature (Sculpher et al., 2004; 
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Goeree et al., 2007) and abstracted from the studies included in the systematic 
literature review reported in Chapter 4.  
 
Following descriptive statistics and the analysis and regression based imputation 
of missing values, a detailed assessment of correlations between potential 
explanatory variables, as well as the application of data reduction techniques, 
such as principal components factor analysis (Rencher, 2002; Acock, 2010) or 
multiple correspondence analysis (Le Roux & Rouanet, 2010), was carried out in 
this exercise. Thereafter, covariates were analysed in the multilevel framework 
assuming fixed slopes within a random intercepts specification (Steele, 2008; 
Rasbash et al., 2009, Hox, 2010) First, bivariate statistics from entering each 
covariate individually in the MLM were reported and discussed. Secondly, a 
model which aims to unravel the maximum amount of country-level variability 
was constructed by including the set of covariates which best controls for 
variability on data and study-level. This model, which was reported above in 
Section 5.2.4.2, is carried forward to the analysis of country-level variability in 
the subsequent Section 5.3 of this empirical chapter.  
 
Some important conclusions can already be drawn from the analysis reported 
above. For instance, adding covariates to the model on data and study-level 
successfully disclosed further variability on country-level, which is a necessary 
condition for assessing country-level covariates in the subsequent section. 
Hence, the model was successful in showing that lower-level variability factors 
feed through to higher levels so that the actual amount of country-level 
variability may only be unravelled by including the appropriate set of covariates 
both on data and study-level. This demonstrates impressively the importance of 
both reflecting appropriately complex data structures and controlling for 
variability on lower levels, even if the main focus is on higher-level (i.e. country-
level) variability. MLM is therefore regarded as an excellent analytic approach for 
this assessment as it allows for both complex data structures and covariate 
adjustment on each hierarchical level (Steele, 2008; Rasbash et al., 2009; Hox, 
2010). The analysis could show that country-level variability was constantly 
increasing with the inclusion of lower-level covariates for the bivariate model, 
which may allow the assessment of covariates on country-level in the bivariate 
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framework. However, a different conclusion has been reached for the univariate 
framework, where country-level variability remained negligible throughout the 
course of this exercise. For this reason, the subsequent Section 5.3 focusses on 
both, covariate adjustment on country-level in the bivariate framework, and 
assessing reasons for a lack of country-level variability in the univariate MLM.   
 
Next to determining a random intercepts model to be carried forward to Section 
5.3 of this empirical exercise, some interesting findings were made along the 
way, which are also discussed in far more detail in Chapter 6. For instance, as 
Sculpher et al. (2004) hypothesized, this exercise could show the tremendous 
importance of variation in patient and disease characteristics, which feeds 
through to variation in measures of cost-effectiveness between studies and 
countries in this empirical exercise. Further, testing intervention and comparator 
characteristics in the model showed that NICE’s view on statins is essentially 
confirmed, which says that ‘for the purposes of initiating therapy, there were no 
data on clinical events to suggest the superiority of any one statin over all the 
others in reducing cardiovascular events’ (NICE, 2006). In other words, testing 
categorical variables which discriminate between different statins in the dataset, 
did not lead to significant results for incremental effects in the bivariate model.   
 
Controlling for study-level variability factors proved far more difficult, especially 
with respect to methodological characteristics, even though the study-level 
appears to be an overriding source of variability in measures of cost-
effectiveness. The non-significance of the timing variable may be explained with 
the inclusion of ‘annual drug-cost’ as an explanatory, as this obviously reflects 
changes in price levels over time. However, only few variables on study-level 
were significant, amongst them a binary which captures whether effectiveness 
data was obtained from the 4S study, as well as a binary which captures whether 
a study uses the ‘CHD life expectancy model’ by Grover et al. (1998). 4S data 
relates to higher effectiveness estimates which also feeds through to INMBs in 
the univariate model, whilst papers by Grover et al. using the CHD life 
expectancy model show higher levels in all outcome variables. These are both 
interesting findings, and the discussion section elaborates in more detail on 
potential explanations.  
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The results with respect to the QHES instrument are somewhat dissapointing. 
Considerable effort went into operationalizing this instrument and to apply it to 
all 67 studies included in this dataset. Though bivariate statistics showed 
statistically significant negative relationships to both components of the INMB 
statistic, which indicates that higher study quality is related to more conservative 
estimates of incremental effects but also lower incremental cost, this result was 
very sensitive to small variations in the way QHES was operationalized - so that 
results may be interpreted with caution. This issue is discussed further in Chapter 
6. Another point for discussion relates to the funding source of papers included 
in this exercise, which indicates higher INMBs for industry funded studies, whilst 
coefficients were not significant in the bivariate model. Finally, a methodological 
aspect was identified which may be referred to future research. The use of 
multiple imputation methods for missing data imputation in multilevel analysis is 
an area of on-going research. Accordingly, methods which are appropriate for 
complex data structures as modelled within this empirical exercise are not yet 
developed. This is the reason why regression based imputation was used for the 
purposes of imputing missing data within this section. Hence, future research 
may look into multilevel multiple imputation methods for multivariate multilevel 
models, cross-classified models, and other complex data structures.  
 
Before discussing research findings in more detail in Chapter 6, the following 
Section 5.3 focusses on the analysis of country-level variability, or the lack 
thereof, using the random intercepts model with data and study-level covariates 
as developed above. Subsequently, a case study shows the relevance of 
modelling random slopes and variance as a function of explanatory variables for 
the transferability problem of economic evaluation data in the final Section 5.4 
of this empirical Chapter.  
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5.3. Objective three: assessing country-level variability 
within the multilevel model framework 
 
 
In Chapter 5.1, we learned that data from multinational studies is likely to 
‘disguise’ country-level variability existing in international cost-effectiveness data 
from single-country studies as country-level variability significantly increased 
when grouping data from multinational studies in a separate cluster on country-
level. This assumption follows the idea that data from multinational studies is not 
independent on country-level and therefore underestimates geographic 
variability in measures of cost-effectiveness. Assigning this data to their 
respective geographic domains ‘infects’ individual country parameters and drags 
them towards each other, with the result that variability on country-level is 
severely underestimated in the cross-classified MLM. For this reason, a three-
level hierarchical model was used to assess covariates on data and study-level in 
Section 5.2 of this empirical exercise, and this model assumes that multinational 
study data is not independent between geographic domains.  
 
 
Assessing data-level and study-level covariates in section 5.2 led to a number of 
important findings. For instance, Sculpher et al. (2004) stated that lower-level 
variability factors, such as patient and disease characteristics, may feed through 
to higher levels, thereby affecting the variability observed between studies and 
countries reflected in the dataset. The MLM framework offers an excellent 
opportunity to make this relationship explicit, as it allows for changes in variation 
in any direction on higher levels induced by covariates on lower levels of the data 
hierarchy (e.g. Hox, 2010). Hence, analysis could show, for instance, that the 
inclusion of patient and disease characteristics in the bivariate model 
successfully controls for some variability on data-level, whilst variability between 
studies and countries actually increases. This is also a compelling argument for 
the use of MLM methodology within this empirical exercise, as, in theory, data 
should become exchangeable on country-level once we controlled for the 
appropriate set of covariates on each level of the data hierarchy (Drummond et 
al., 2009).  
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Furthermore, a number of variability factors on data and study-level were 
discovered which are all associated with variation in measures of cost-
effectiveness for statins in the primary and secondary prevention of CVD. These 
findings are subject for further discussion in Chapter 6. However, two additional 
findings are of utmost relevance for this particular section, which is concerned 
with the assessment of variability in measures of cost-effectiveness between 
geographic domains.  
 
 
First of all, determining the appropriate MLM structure in Section 5.1 and 
including data and study-level covariates in Section 5.2 significantly increased 
variability on country-level for both ∆C and ∆E in the bivariate MLM. The analysis 
started off in Section 5.1 with a VPC on country-level of around 1% for ∆C and 
negligible 0.5% for ∆E respectively. Though, at the end of Section 5.2., country-
level variability is still not a dominant source of variability in measures of cost-
effectiveness, a VPC of around 20% for ∆C and 15% for ∆E indicates that this 
exercise was successful in disclosing variability between geographic domains. 
However, it is also acknowledged that data and study-level variability remain the 
dominant source of variation in international cost-effectiveness data for statins 
in the primary and secondary prevention of CVD, so that one may conclude that 
the ‘appropriate set of covariates’ which Drummond et al. (2009) refer to, has 
not yet been found on data and study-level.   
 
 
Nevertheless, some country-level covariates may be tested within the bivariate 
framework to investigate whether there are characteristics of countries which 
explain part of the variability observed in cost-effectiveness data between 
geographic domains. This is the focus of the second part of this section. Before 
assessing country-level covariates in the bivariate framework, however, there is 
another issue which has to be addressed first. Whilst country-level variability 
increased for both response variables in the bivariate framework, variation 
between countries remains negligible for INMBs in the univariate model, even 
after controlling for variability factors on data and study-level. Therefore, the 
first part of this section focusses on this issue, which is in sharp contrast to the 
results observed in the bivariate model specification.  
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The remainder of this section is organised as follows: Section 5.3.1 outlines the 
plan of analysis for this part of the empirical exercise. Potential reasons for the 
failure to observe an increase in country-level variability in the univariate 
framework are considered, and experiments are designed to test hypothesized 
explanations for this observation. Secondly, the strategy for testing country-level 
covariates in the bivariate model is outlined. Subsequently, Section 5.3.2 
considers the data required for part 3 of this empirical exercise. Country-level 
covariates are introduced and descriptive statistics are reported. A separate 
methods sections has been omitted from this part of the empirical chapter, as 
the models run are identical to those models developed in Section 5.2 of this 
empirical exercise. For this reason, Section 5.3.3 proceeds directly to the results 
of this analysis, starting off with the univariate model which, thus far, failed to 
detect considerable country-level variation, and proceeding to the analysis of 
country-level variability factors, which, at this point, may only be indicated within 
the bivariate framework. However, if further variability on country-level can be 
disclosed in the univariate model, then the inclusion of country-level covariates 
may even be an option in this framework.  
 
 
5.3.1. Plan of analysis for part three of this empirical exercise  
 
 
The aim of this part of the analysis is to assess country-level variability – or the 
lack thereof – in the MLM framework. The two specific objectives which follow 
from this aim are a) to test potential explanations for the failure of the univariate 
model to detect country-level variation and b) to assess country-level covariates, 
at least within the bivariate framework; but potentially also in the univariate 
framework, provided that country-level variation increases after addressing the 
first objective in this section.  
 
 
5.3.1.1. Assessing the lack of country-level variation in the univariate model 
 
Let us consider the lack of country-level variation in the univariate framework 
first. To generate potential explanations for this observation, the best way is to 
concentrate on anything which differs between the response variables in the 
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univariate model, which did not detect considerable country-level variation, and 
the bivariate framework, where the VPC on country-level achieved around 20% 
for ∆C and 15% for ∆E respectively. Obviously, the bivariate model decomposes 
the response variable INMB into its stochastic components ∆C and ∆E. Hence, 
what follows from this fact is also what should be considered in this analysis.  
 
 
First, in order to combine ∆C and ∆E to INMBs, one needs to determine a 
threshold value λ. This threshold values was set constant at £30,000 in Sections 
5.1 and 5.2. Hence, INMBs were calculated so far as follows:  
 [f¤qaqp¤ =	∆
 ∗ λ − ∆,               (1) λ =	£ 30,000 
 
It may be the case that the value of the threshold λ impacts on variability in 
measures of INMB. For instance, if one sets the threshold value λ at zero, this 
means that INMBs reduce to ∆C and, consequently, the variability in measures of 
cost-effectiveness resembles the variability observed for ∆C in the bivariate 
model. Conversely, if one constantly increases λ, the impact of ∆C diminishes as λ 
tends towards infinity. Hence, variability observed resembles the variability in ∆E 
only. Whilst this shows that the threshold value λ needs to be considered when 
looking into the variability in measures of INMB, there is no a priori reason to 
believe that this would impact more strongly on the country-level than it does on 
variability within or between studies in the dataset.   
 
 
Nevertheless, it is relatively straightforward to design an experiment which tests 
the impact of the threshold value on the variability observed on each level. We 
may simply re-run the variance components model developed in Section 5.1 with 
INMBs calculated at different values for the WTP threshold λ. In other words, a 
sensitivity analysis of variability observed on each hierarchical level is performed 
with respect to λ. As a result, we can map variability observed on each level as a 
function of λ, and if there is a significant effect of the WTP threshold on country-
level variability, the random intercepts model developed in Section 5.2 could be 
re-run at this particular threshold value. This may provide a univariate model 
specification which discloses country-level variability through the inclusion of 
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data and study-level covariates at a WTP threshold which minimises the 
obscuring effect of λ on variability in measures of cost-effectiveness between 
countries. Results of this experiment are reported in Section 5.3.3.   
 
 
There may be a second reason for dramatically reduced country-level variability 
in INMBs observed in the univariate model. The variability in one component of 
the INMB statistic may be, at least in part, offset by variability in the other 
component of INMBs. Sections 5.1 and 5.2 already provided some insights into 
the variability in measures of cost-effectiveness which may support this 
hypothesis. The forest plots presented in Section 5.1.4 showed that some 
studies, which are outliers in terms of INMB, did not just show dramatically 
increased measures of ∆E, but also elevated measures of ∆C. In addition, 
bivariate statistics produced in Section 5.2.4.1 and also the random intercepts 
models developed in Section 5.2.4.2 showed that studies produced by S.A. 
Grover et al. using the ‘CHD life expectancy model’ are characterised by elevated 
measures of INMB, ∆E, and ∆C. In other words, elevated mean INMB observed in 
these studies is most likely the result of ∆E being estimated above the average of 
other studies included in this exercise. However, as the CHD life expectancy 
model also led to higher estimates of ∆C, the overall departure from the average 
INMB may be lower than it is for ∆E, due to an offsetting effect of elevated ∆C in 
the same model. In conclusion, a common pattern of variability in both 
components of the INMB statistic may reduce overall variability in incremental 
net monetary benefits.   
 
 
To test this hypothesis, country-level residuals are obtained from MLwiN after 
running the three-level hierarchical variance-components model. Residuals are 
then used to build forest plots analogously to the study-level forest plots of 
Section 5.1.4. If ∆C are positively correlated with ∆E, one should observe a 
similar pattern in both forest plots (i.e. higher incremental cost are associated 
with higher incremental effects and vice versa). As an increase in one component 
of the INMB statistic would then be, at least in part, offset by an increase in the 
other component, this should lead to lower variability observed in the forest plot 
for INMBs. However, interpretation of a visual presentation of the data is not 
unambiguous. For this reason, country-level means for ∆C and ∆E are transferred 
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back to STATA 12 to produce Pearson correlations for the two variables. To test 
correlations in the raw data, the same is done with raw country means for the 
components of the INMB statistic. If the suspicion articulated above holds, 
Pearson correlations should be high, positive, and statistically significant.  
 
 
This test may lead to an explanation for drastically lower country-level variability 
in the univariate model as compared to what has been observed for incremental 
cost and incremental effects in the bivariate framework. However, if this 
offsetting effect between ∆C and ∆E causes lower variability in INMBs, there is 
not much that could be done within this exercise to increase country-level 
variation in the univariate framework. Rather, this finding should be interpreted 
as a compelling argument in favour of decomposing the INMB statistic in the 
bivariate model.  
 
 
5.3.1.2. Testing country-level covariates in the bivariate model 
 
 
Moving on to this bivariate framework, the plan of analysis is to include 
covariates on country-level to test whether they may, in part, explain variability 
in measures of cost-effectiveness between geographic domains. Though 
variability, whilst constantly increasing throughout the course of this empirical 
exercise, may still not be regarded as particularly high on country-level ( country 
VPC of 20% for ∆C and roughly 15% for ∆E respectively), this exercise makes an 
attempt to look into potential causes of this variability on level three of the data 
hierarchy. As with data and study-level covariates, the relevant literature is used 
first to learn about potential causes of variability in measures of cost-
effectiveness between countries. As before, the two publications by Sculpher et 
al. (2004) and Goeree et al. (2007), who reviewed the cost-effectiveness 
literature to compile a list of factors potentially causing variability in measures of 
cost-effectiveness, provided a number of candidates for this assessment. 
Unfortunately, however, operationalizing such candidate variables and obtaining 
data for assessment appeared to be more difficult than it was experienced for 
data and study-level covariates. For instance, country-level variability factors are 
usually not explicitly modelled in economic evaluation studies and therefore not 
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reported in the respective studies either. Hence, alternative data sources are 
required which are reliable and provide estimates which are comparable across 
the range of countries included in the dataset. Therefore, data bases of 
international organisations (WHO, 2012; OECD, 2012; World Bank, 2012) are 
screened for indicators which may serve as a proxy for variability factors 
mentioned by Sculpher et al. (2004) or Goeree et al. (2007). This resulted in a 
considerable number of potential covariates to test in the multilevel framework. 
If data for any of the indicators is missing for a country included in this exercise, 
national sources (i.e. data provided by national departments of health, statistical 
bureaus etc.) are used to fill these gaps (most problematic in this sense was the 
special administrative region of Hong Kong. It was the geographic area for which 
most missing data problems occurred as it is not represented in the WHO data 
repository). If data is still missing after searching for alternative sources, the 
strategy is either to drop the affected variable, or to listwise delete affected data 
points for the particular analysis. Listwise deletion has been chosen as regression 
based imputation is not deemed appropriate for a dataset with only a few 
countries included, and as other ad hoc imputation techniques have a potential 
for bias. Again, this strategy was only applicable to eight data points relating to 
Hong Kong so that, if data for this geographic domain was missing, this resulted 
in a dataset of 2086 data points from 66 studies and applicable to 17 geographic 
domains, including one cluster on country-level for multinational study data.  
 
 
This data from multinational studies is responsible for another issue which has to 
be addressed before proceeding with the analysis. Not dropping this data 
increases the sample size on data and study-level, and grouping it in a separate 
cluster on country-level assures that this data does not disguise existing 
variability between countries. However, the resulting group on country-level 
represents a number of geographic domains, so that the question is how to 
assign values for country-level variables to this particular group. It was decided 
to run all analyses twice, once with the full dataset as used so far, and once with 
a reduced dataset, where all data from multinational studies has been dropped. 
For the full dataset, country-specific data is collected for the geographic domains 
represented in the ‘multinational’ cluster, and a mean value is calculated for the 
affected data points. Though this lumps together a number of potentially 
dissimilar cases, it allows keeping this data in the analysis which improves 
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estimation on data and study-level, and it also assures that country-level 
covariates can be tested without the distorting effect of multinational data on 
country-level for the remaining geographic domains. Bias is not likely to occur in 
any direction as a mean value is calculated from actual, not imputed data, 
though this obviously means that a) results for the group ‘multinational’ are 
essentially meaningless and b) there is likely to be an impact on the precision of 
the estimation procedure. Therefore, all analyses are also conducted using the 
reduced dataset from Section 5.1, where all data from multinational studies has 
been dropped. This procedure results in a dataset with 1806 data points 
clustered in 61 studies and 17 countries.   
 
 
As mentioned before, the models run in this section are identical to those 
developed in Section 5.2 of this empirical exercise, with the exception of 
country-level covariates now being explicitly considered in the model. For this 
reason, methods of analysis have been omitted from this section and the 
interested reader is referred to Section 5.2.2. of the empirical chapter. The next 
section introduces the country-level data required for the assessment as outlined 
above, before results are presented and discussed in Section 5.3.3.  
 
 
5.3.2. Data  
 
 
Assessing reasons for a lack of country-level variability in INMBs observed in the 
univariate MLM framework builds up from data used before in Sections 5.1 and 
5.2. Hence, the data introduced here relates to country-level covariates only, 
which are the focus of the second part of the analysis reported here. Table 5.25 
below summarizes the country-level data obtained from different sources. The 
first column refers to the variable name, whilst the second column provides a 
definition for the respective covariate, including the reference year this data 
refers to. The third column explains how variables relate to the list of variability 
factors as reported by Goeree et al. (2007). Though not all variability factors 
potentially relevant on country-level have been acknowledged in this exercise, 
Table 5.25 shows that covariates selected relate to a considerable number of 
variability factors previously discussed in the health economic literature. 
Columns four to six describe the nature of country-level covariates, provide 
summary statistics and report on respective data-sources. The anticipated 
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relationship between country-level covariates and measures of cost effectiveness 
is reported in columns seven to nine. The last two columns list studies which 
either support or contradict the relationship anticipated between response 
variables and country-level covariates.  
 
 
On the broadest level, GDP per capita and the percentage of GDP devoted to 
healthcare are considered as covariates predominantly encoding the resources 
available for healthcare in a particular country. The variables encoding private, 
governmental or social security expenditure as a percentage of total health 
expenditure or governmental expenditure on health respectively may be 
interpreted as indicators of the organisational structure and the type of 
healthcare system. Precisely, systems within which general government 
expenditure on health is high, may be those classified as NHS like systems, 
whereas social health insurance type systems show higher social security 
expenditure on health as a percentage of general government expenditure on 
health. If private expenditure on health as a percentage of total expenditure on 
health is high, this may be indicative of a predominantly private health insurance 
based system. User fees, co-payments and deductibles are important incentives 
for patients, which were previously mentioned as potentially variability factors 
(Sculpher et al., 2004; Goeree et al., 2007). Consequently, out-of-pocket 
expenditure (OOP) as a percentage of private expenditure on health is assessed 
to address this potential source of country-level variability.  
 
 
As statin prevention may be part of a national action plan to address CVD, the 
existence of such an action plan is encoded in the categorical ‘CVD_policy’. The 
next four variables in Table 5.25 (‘GPs’, ‘nurses’, ‘pharmacists’, ‘beds’) relate to 
variability in available resources (staff, facilities, equipment), and input mix 
(personnel / equipment). The remaining variables in Table 5.25 relate either to 
patient characteristics or disease characteristics respectively. In particular, ‘age’, 
‘life expectancy at birth’ and ‘urban’ relate to variability due to differences in 
demographics, mortality and population density, whilst ‘CVD_death’ may be 
regarded as a measure of mortality due to the disease under consideration. A 
problem with the latter variable is the fact that the WHO, which provided data 
on this covariate, only gives a combined measure of cardiovascular and diabetes 
death per 100,000, so that it is not clear how much of these death`s relate to 
which disease. Results may therefore be interpreted with caution. 
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Table 5.25: Country-level covariates and their anticipated relationship to measures of cost-effectiveness 
Name of 
covariate 
Definition Related variability factors from 
Goeree et al. (2007) 
Nature 
of 
variable 
Mean (SD) / 
Proportion (%) 
Data  
sources 
Anticipated 
relationship to 
Supporting 
evidence 
Contradicting 
evidence 
INMB ∆C ∆E 
GDP GDP per capita, PPP (current international $), 
2009 
Available resources Cont. 35169  (8969) World Bank  
Pos Pos Pos  7, 19 --- 
THE_GDP Total expenditure on health as a percentage 
of gross domestic product, 2009 
Available resources Cont. 9.96 (2.38) WHO / World Bank 
Pos Pos ? 6, 24 --- 
GOV_EXP_T
HE 
General government expend. on health as a 
percentage of total expend. on health, 2009 
Type of insurance coverage Cont. 68.18 (11.44) WHO / World Bank 
Pos Neg Pos 17 --- 
PRIV_EXP_T
HE 
Private expend. on health as a percentage of 
total expenditure on health, 2009 
Type of insurance coverage Cont. 29.67 (12.85) WHO / World Bank 
Neg Pos ? 6 --- 
SOCSEC_GG
E 
Social security expend. on health as a % of 
general gov. expend. on health, 2009 
Type of insurance coverage Cont. 39.47 (37.91) WHO / World Bank 
? ? ? --- --- 
OOP_PRIV_
EXP 
Out-of-pocket expenditure as a percentage 
of private expenditure on health, 2009 
User fees, co-payments, deductibles, 
incentives for patients 
Cont. 65.49 (18.00) WHO / World Bank 
Pos Neg ? 6 --- 
CVD_POLICY Existence of operational policy / strategy / 
action plan for cardiovascular disease? 2010 
Access to programmes and services, 
conventions, norms, guidelines 
Unord. 
cat. 
No: 4 (22.22%) 
Yes: 12 (66.67%) 
Unclear: 2 (11.11%) 
WHO 
Pos Neg Pos --- --- 
GPs Physicians density (per 10 000 population) 
2005-2009 
Available resources, input mix  Cont. 29.13 (7.49) WHO / Hong Kong, Centre 
for Health Protection, DH 
Pos Neg Pos --- --- 
Nurses Nursing and midwifery personnel density 
(per 10 000 population) 2005-2009 
Available resources, input mix  Cont. 82.03 (45.27) WHO / Hong Kong, Centre 
for Health Protection, DH 
Pos Neg Pos --- --- 
Pharmacists Density of pharmaceutical personnel (per 10 
000 population) 2005-2009 
Available resources, input mix  Cont. 7.74 (3.24) WHO / Hong Kong, Centre 
for Health Protection, DH 
Pos Neg Pos --- --- 
Beds Hospital beds per (10 000 population) 2008 – 
2010 
Available resources, input mix  Cont. 51.37 (28.88) WHO / Hong Kong, Centre 
for Health Protection, DH 
Pos Pos Pos --- --- 
Age Population median age (years), 2009 Demographics Cont. 39.87 (3.50) WHO / Hong Kong, Centre 
for Health Protection, DH 
Neg Neg Neg 2, 3, 4, 5, 8, 9, 
10, 12, 14, 15, 
20, 21, 22, 25, 26 
INMB: 2, 3, 5, 
11, 25 / ∆C: 14 / 
∆E: 5, 11, 25 
Relationship may reverse 
for age >65 
Urban Population living in urban areas (%), 2009 Population density Cont. 80.88 (10.39) World Bank ? ? ? --- --- 
Life 
Expectancy 
Life expectancy at birth (in years), 2009 Demographics Cont. 80.06 (2.80) WHO / Hong Kong, Centre 
for Health Protection, DH 
Pos Pos Pos 17 --- 
CVD_death Cardiovascular and diabetes death per 
100000, 2008 
Mortality due to disease Cont. 152.92 (59.84) WHO 
Pos Neg Pos --- --- 
BMI_25 BMI ≥ 25, crude estimate, 2008 Disease interact., comorb., epidemiol. Cont. 53.35 (10.37) WHO Pos Neg Pos 13 --- 
BMI_30 BMI ≥ 30, crude estimate, 2008 Disease interact., comorb., epidemiol. Cont. 22.50 (6.25) WHO Pos Neg Pos 13 --- 
MEAN_BMI Mean BMI, crude estimate, 2008 Disease interact., comorb., epidemiol. Cont. 26.52 (1.22) WHO Pos Neg Pos 13 --- 
TCL_6.2 Raised TCL ≥ 6.2 mmol/L,  crude estimate,  
2008 
Epidemiology Cont. 19.81 (4.15) WHO 
Pos Neg Pos 3, 8, 9, 22 ∆C: 3, 22 
MEAN_TCL Mean TCL (crude estimate), 2008 Epidemiology Cont. 5.26 (0.21) WHO Pos Neg Pos 3, 8, 9, 22 ∆C: 3, 22 
SBP_140 Raised blood pressure (SBP ≥ 140 or DBP ≥ 
90 or on medication, crude estimate, 2008 
Disease interact., comorb., epidemiol. Cont. 42.18 (4.89) WHO 
Pos Neg Pos 3, 8, 12, 16, 22 
INMB: 16 
∆C: 3 
MEAN_SBP Mean Systolic blood pressure, crude 
estimate, 2008 
Disease interact., comorb., epidemiol. Cont. 128.48 (3.42) WHO 
Pos Neg Pos 3, 8, 12, 16, 22 
INMB: 16 
∆C: 3 
GLUCOSE_7 Raised blood glucose ≥ 7.0 mmol/L, 2008 Disease interact., comorb., epidemiol. Cont. 9.58 (1.50) WHO Pos Neg Pos 
1, 3, 9, 10, 16, 
18, 21, 23, 25 
∆C: 3, 18, 23 MEAN_GLU
COSE 
Mean fasting glucose in mmol/L, crude 
estimate, 2008 
Disease interact., comorb., epidemiol. Cont. 4.49 (0.17) WHO 
Pos Neg Pos 
(1) Ashraf et al (1996), (2) CDC-Group (2002), (3) Drummond et al. (1993), (4) Franco et al. (2005), (5) Greving et al. (2011), (6) Grieve et al. (2005), (7) Grieve et al. (2007), (8) Grover et al (1999), (9) Grover et al (2000), (10) Grover et al. (2001), 
(11) Grover et al. (2008), (12) Hamilton et al (1995), (13) Hippisley-Cox et al. (2008), (14) HPS (2006), (15) HPS (2009), (16) Jönsson et al (1999), (17) Manca et al. 2007), (18) Muls et al. (1998), (19) Taghreed et al. (2003), (20) Nherera et al 
(2010), (21) NICE (2006), (22) Perreault et al (1998), (23) Soini et al (2010), (24) Thompson et al. (2006), (25) Tonkin et al. (2006), (36) Ward et al. (2007) 
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The remaining ten variables are measures of CVD risk factors on population level 
relating to obesity, total cholesterol level, blood pressure and blood glucose. An 
important question is why CVD risk factors may enter the MLM on country-level, 
as they were already included as variability factors on data-level. The reason is 
that patient and disease characteristics on data-level refer to differences in study 
populations, whilst the idea with population risk factors is that the cost-
effectiveness of statins on country-level may partly depend on the existence of 
CVD risk factors within the target population of a country. The MLM framework 
offers an excellent opportunity to consider both, differences in study populations 
on data-level, and differences in potential target populations on country-level.  
 
 
 
5.3.3. Results  
 
 
The first part of this section focuses on the assessment of variability in the 
univariate framework, within which it was not possible to disclose a substantial 
amount of variability in INMBs between geographic domains. The second part 
refers to the assessment of country-level variability factors in the bivariate MLM. 
 
 
5.3.3.1. Reasons for a lack of country-level variability in the univariate model  
 
 
As detailed in Section 5.3.1.1., two potential causes of a lack of country-level 
variability are being further assessed in this section, both originating from 
differences between the univariate model, where country-level variability is 
negligibly low, and its bivariate counterpart, where country-level variability was 
observed in both components of the INMB statistic. Results from performing a 
sensitivity analysis on the threshold value λ, which was set constant at £ 30,000 
in Sections 5.1 and 5.2 of this empirical chapter, are reported first, before the 
focus is on the suspicion of a common pattern in measures of ∆C and ∆E on 
country-level. Figure 5.11 below summarizes the results of running the univariate 
variance components model as developed in Section 5.1 of this empirical 
exercise with different values for the WTP threshold λ. Analysis starts with a 
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threshold value of zero. This reduces the INMB statistic to ∆C only, and results in 
terms of variability on each level resemble those observed for incremental cost 
in the bivariate framework.   
 
 
Figure 5.11: Variability in INMBs in the univariate model as a function of the 
threshold value λ 
 
 
 
Gradually increasing λ reduces the country-VPC from just above 10% to below 
0.5%, which is in complete accord with results of the univariate model reported 
in previous sections. Simultaneously, the VPC on data-level increases, whilst the 
study-level VPC remains relatively constant up to a WTP threshold of roughly 
£10,000. Beyond this level, however, the study-level VPC increases gradually as 
the data-level VPC decreases until both measures first cross and then level out 
beyond a threshold of around £40,000 per unit of health gain.  
 
 
Figure 5.11 above leads to several important conclusions. First of all, the 
univariate model run with incremental cost only (which is equivalent to assuming 
λ = 0), resembles the findings for ∆C in the bivariate framework. This validates 
the results of the bivariate MLM. Secondly, increasing the threshold value 
reduces country-level variation, and at a WTP-threshold of £30,000, findings are 
also in accord with the results reported for the univariate model in previous 
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sections. However, we cannot confirm that country-level variation increases 
drastically at any value for λ, and even increasing WTP beyond £500,000, would 
only resemble the results obtained for ∆E in the bivariate framework (which 
again indicates that results are valid). As mentioned before, there is no reason 
why changing the threshold value should have a particular impact on the 
country-level beyond that observed at its extreme values, i.e. λ=0 and λ∞, 
resembling the variation in ∆C and ∆E respectively. In conclusion, we may rule 
out the threshold value as a potential reason for the failure to observe significant 
country-level variation in the univariate model.  
 
 
However, the sensitivity analysis showed that variability does increase at λ=0 and 
λ∞, and this is in accord with the suspicion that there is a common pattern in 
∆C and ∆E on country-level; so that variability in one component of the INMB 
statistic is partly offset by variability in the other component of INMBs. This 
would explain why country-level variability reduces with higher values for λ (as 
variability in ∆C is increasingly offset by corresponding variability in ∆E), and only 
increases again once λ is so high that variability in INMBs only reflects that of ∆E. 
This suspicion is supported by some of the previous findings, especially regarding 
studies using the CHD life-expectancy model, which report both higher 
incremental cost and higher incremental effects for statins in the primary and 
secondary prevention of CVD.  
 
 
Hence, the next task is to further assess the idea that variability in one 
component of the INMB statistic is partly offset by variability in the other 
component of INMBs. This is done by simultaneously looking into country-level 
measures of ∆C, ∆E and INMBs respectively. For this reason, consider the forest 
plots in Figure 5.12 below. 
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Figure 5.12: Forest plots of incremental costs, incremental effects and INMBs on country-level 
 
(Forest plots generated after running a three-level hierarchical random intercepts model and exporting country-level residuals from MLwiN to MS Excel) 
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There appears to be a common pattern in ∆C and ∆E, i.e. if an estimate of 
incremental effects for a particular country is above the pooled mean, so is the 
corresponding measure of incremental cost for the same country. This results in 
variability in ∆E being partly offset by corresponding variability in ∆C in the INMB 
statistic, and this is confirmed by the forest plot on the left showing that 
variability in INMBs is much lower compared to that observed on country-level in 
∆Cs and ∆Es. To rule out that this finding is an artefact from running MLMs 
providing country-level residuals which are subject to shrinkage, the same 
analysis was repeated with raw country means for ∆Cs, ∆Es and INMBs. The 
forest plots (omitted here) appeared to be more ‘noisy’ than that displayed in 
Figure 5.12 above as country means were not shrunken towards the pooled 
mean. Though this somewhat complicated the interpretation of results, a similar 
pattern appeared to be present in the data. However, to confirm this result, 
which is based on the interpretation of a graphical display of the data and 
therefore not unambiguous, Pearson correlations were produced for country-
level mean ∆Cs and ∆Es both after running the three-level model and also for 
country-level means calculated from the raw data. If there is a common pattern 
in mean incremental cost and incremental effects on country-level, then Pearson 
correlations should be high, positive and statistically significant.  
 
 
Generating Pearson correlations in STATA 12 confirmed the results from 
interpreting Figure 5.12 above. A highly significant and positive correlation 
coefficient of 0.968 was found for country-level ∆C and ∆E obtained from the 
three-level hierarchical model. In addition to that, correlation coefficients for the 
raw mean ∆C and ∆E for each country were just as much correlated, with a 
correlation coefficient reaching 0.913. This result is also significant at the 1% 
level and rules out that shrinkage has anything to do with the common pattern 
observed in country-level mean incremental cost and incremental effects.  
 
 
Hence, we may conclude that the lack of country-level variation observed in 
INMBs in the univariate model stems from a common pattern in the country-
level variability for ∆ and ∆E, so that variability in one component of the INMB 
statistic is partly being offset by corresponding variability in the other 
component of the INMB statistic. The discussion in Chapter 6 hypothesizes about 
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potential causes for this common pattern in ∆C and ∆E on country-level. At this 
point, however, one may only conclude that the lack of variability observed in 
the univariate model on country-level is likely to be a result of combining ∆Cs 
and ∆Es to INMBs, so that within the scope of this exercise, there are no further 
means to increase country-level variability in the univariate framework. One 
should interpret this finding as a compelling argument for decomposing the 
INMB statistic within the bivariate model. This bivariate model is the focus of the 
second part of this section, which is entirely concerned with covariates encoding 
potential variability factors on country-level.  
 
 
 
5.3.3.2. Country-level covariates in the bivariate multilevel model  
 
 
Table 5.26 below reports results from individually testing each country-level 
covariate in the bivariate random intercepts model with covariates already 
included on data and study-level. Results from running the same model on the 
reduced dataset where data from multinational studies was dropped are 
reported in Appendix 5.5. Given the relatively low VPC for both ∆C and ∆E 
observed at the end of Section 5.2, the a priori expectation of ascertaining 
significant coefficients on country-level was low. Nevertheless, results show a 
number of coefficients moderately significant at the 10% level or 5% level 
respectively. In addition, coefficients mostly show the anticipated sign and 
reduce the DIC statistic, indicating an improved fit of the multilevel model. 
Results for running the same model on the reduced dataset are almost identical. 
Though coefficients obviously differ in their magnitude, these differences are 
generally negligible, and both signs of coefficients as well as their statistical 
significance accords between both analyses.   
 
 
Whilst GDP per capita as an indicator of a countries economic performance was 
not significant when tested individually in the random intercepts model with 
data and study-level covariates already specified, there was a small but 
significant positive relationship between the total health expenditure as a 
percentage of GDP and incremental effects in the bivariate model. There may be 
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several potential explanations for this observation. Statin utilisation may be 
higher in countries which devote a higher percentage of their GDP to healthcare, 
or the prevalence of CVD risk factors may be different in those countries. In fact, 
when looking at correlations between explanatory variables on country-level, 
one can observe positive and highly significant correlations between ‘THE_GDP’ 
on the one hand and ‘mean_bmi’, ‘mean_sbp’, ‘mean_tcl’ and ‘mean_glucose’ on 
the other. Hence, the positive and significant coefficient of ‘THE_GDP’ may either 
be explained by the fact that countries with higher GDP per capita are also 
characterised by higher levels of CVD risk-factors, or the significant coefficient 
may simply be a statistical artefact because of existing collinearity between the 
above named variables.  
 
Table 5.26:  Individually testing country-level covariates in the three-level 
bivariate random intercepts model 
Bivariate model 
 
Raw Mean (SD) / 
Proportion (%) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
DIC (Benchmark: 
26413  
(%-change)) 
GDP 35169  (8969) 0.001 (0.001) 0.000 (0.000) 26413 (0.000%) 
THE_GDP 9.96 (2.38) 0.109 (1.280) 0.020 (0.008)** 26410 (-0.011%) 
GOV_EXP_THE 68.18 (11.44) -0.215 (0.258) -0.001 (0.002) 26415 (0.008%) 
PRIV_EXP_THE 29.67 (12.85) 0.223 (0.253) 0.000 (0.002) 26414 (0.004%) 
SOCSEC_GGE+ 39.47 (37.91) -0.096 (0.131) 0.001 (0.001) 26413 (0.000%) 
OOP_PRIV_EXP+ 65.49 (18.00) 0.031 (0.182) -0.000 (0.001) 26415 (0.008%) 
CVD_POLICY 
No 
Yes 
Unclear 
 
4 (22.22%) 
12 (66.67%) 
2 (11.11%) 
 
Omitted 
26.72 (19.24) 
19.91 (19.63) 
 
Omitted 
0.108 (0.109) 
-0.094 (0.110) 
26413 (0.000%) 
GPs 29.13 (7.49) -1.005 (0.981) 0.011 (0.005)** 26409 (-0.015%) 
NURSES 82.03 (45.27) 0.041 (0.130) 0.001 (0.001) 26414 (0.004%) 
PHARMACISTS 7.74 (3.24) 1.642 (1.832) 0.019 (0.010)* 26409 (-0.015%) 
BEDS 51.37 (28.88) -0.121 (0.256) 0.002 (0.002) 26410 (-0.011%) 
AGE 39.87 (3.50) -2.003 (1.828) 0.020 (0.001)* 26408 (-0.019%) 
URBAN 80.88 (10.39) 0.268 (0.564) -0.001 (0.003) 26415 (0.008%) 
LIFE_EXPECTANCY 80.06 (2.80) -3.059 (3.408) 0.004 (0.021) 26414 (0.004%) 
CVD_DEATH 152.92 (59.84) 0.114 (0.153) 0.000 (0.001) 26414 0.004%) 
BMI_25+ 53.35 (10.37) 0.434 (0.644) 0.004 (0.004) 26414 0.004%) 
BMI_30+ 22.50 (6.25) 0.559 (0.965) 0.010 (0.006)* 26413 (0.000%) 
MEAN_BMI+ 26.52 (1.22) 2.353 (5.056) 0.060 (0.031)* 26412 (-0.004%) 
TCL_6.2+ 19.81 (4.15) -0.562 (0.858) 0.004 (0.005) 26414 (0.004%) 
MEAN_TCL+ 5.26 (0.21) -18.91 (21.18) 0.177 (0.130) 26412 (-0.004%) 
SBP_140+ 42.18 (4.89) -0.232 (0.748) 0.001 (0.005) 26415 (0.008%) 
MEAN_SBP+ 128.48 (3.42) -0.284 (1.017) -0.001 (0.007) 26415 (0.008%) 
GLUCOSE_7+ 9.58 (1.50) 1.572 (2.061) 0.025 (0.013)* 26410 (-0.011%) 
MEAN_GLUCOSE+ 4.49 (0.17) 14.03 (23.92) 0.356 (0.147)** 26409 (-0.015%) 
* 
** 
*** 
 
+ 
 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
 
Eight data points referring to the special administrative region Hong Kong have been dropped due 
to country-level data missing for this geographic domain 
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Positive and significant coefficients were also observed for variables encoding 
the availability of resources (GPs and pharmacists). More GPS or pharmacists per 
10,000 population may be a reason for better utilisation of statins as they may 
be made available to a higher number of eligible patients and as those patients 
may be better monitored and motivated to comply with statin therapy (for GPs, 
however, the coefficient was not significant when running the model on the 
reduced dataset). Finally, significant coefficients were observed for age, BMI and 
the percentage of population with a blood glucose level of above 7 mmol/L. 
These findings accord expectations as statins should be more effective in 
populations with higher CVD risk.  
 
 
When testing country-level covariates individually in the random intercepts 
model, significant coefficients were only observed for incremental effects, 
whereas none of the covariates tested showed a significant relationship to 
incremental cost in the bivariate model. The same observation was made when 
running the model on the reduced dataset. A potential reason may be the 
presence of confounding factors, which potentially disguise relationships which 
may exist within the data. For this reason, country-level covariates were tested 
simultaneously in the three-level bivariate multilevel model. Results for the full 
dataset are obtainable from Table 5.27 below. Results for the reduced dataset 
are reported in Appendix 5.6. 
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Table 5.27: Bivariate random intercepts model fully specified on data, study 
and country-level 
 
∆C/100 
(2010 £ Sterling) 
∆E 
 
N (countries) 
N (studies) 
N (data) 
18 
67 
2094 
18 
67 
2094 
Intercept 
(λ=£30,000) 
739 -1.500 
TCL (SE) -33.44 (3.13)*** 0.040 (0.018)** 
HDL (SE) 183.11 (53.91)*** -0.521 (0.301)* 
SBP (SE) -3.39 (0.19)*** 0.013 (0.001)*** 
Diabetes (SE) -19.35 (8.30)** 0.441 (0.053)*** 
Age_cat (SE) 
<45  
46-55 
56-65 
66-75 
>75 
Unclear 
 
Omitted  
-95.34 (6.02)*** 
-133.9 (5.91)*** 
-168.8 (6.27)*** 
-131.6 (10.62)*** 
-113.3 (45.68)** 
 
Omitted 
-0.308 (0.036)*** 
-0.639 (0.035)*** 
-1.066 (0.037)*** 
-0.656 (0.063)*** 
-0.512 (0.224)** 
Gender (SE) 
Female 
Male 
Mixed sample 
 
Omitted 
-33.13 (4.52)*** 
-31.11 (22.93) 
 
Omitted 
0.234 (0.027)*** 
0.234 (0.107)** 
CVD_history (SE) 
No 
Yes 
Mixed sample 
-- 
 
Omitted 
0.267 (0.054)*** 
0.345 (0.188)* 
Cost_intervention 0.127 (0.010)*** -- 
Cost_comparator -0.139 (0.022)*** -- 
Active_comparator 
No (doing nothing) 
Yes (statin) 
-- 
 
Omitted 
-0.274 (0.072)*** 
DRB -- -4.127 (0.892)*** 
Persp_cost_concl. 
Health insurance (NHS) 
Provider 
Societal 
 
Omitted 
-401.19 (22.86)*** 
-175.26 (19.70)*** 
-- 
Horizon 
< 20 years 
>20 years (lifetime) 
-- 
 
Omitted 
0.184 (0.045)*** 
Duration=horizon 
yes 
No (treatment duration< 
horizon) 
-- 
 
Omitted 
0.394 (0.076)*** 
Base case 
Yes 
No  
 
Omitted 
9.42 (4.81)* 
 
Omitted 
0.089 (0.030)*** 
Barbieri_score_2 
Type 1 
Type 2 
Type 3 
Type 4 
 
Omitted 
-37.11 (15.26)** 
-66.07 (30.58)** 
-99.09 (32.85)*** 
-- 
Author_Grover 
No  
Yes 
 
Omitted 
156.35 (43.68)*** 
 
Omitted 
1.443 (0.200)*** 
4S 
No 
yes 
-- 
 
Omitted 
0.434 (0.153)*** 
Scope 
CHD 
CHD and stroke 
CHD, stroke and PAD  
unclear 
 
Omitted 
-38.71 (8.76)*** 
-33.40 (34.46) 
-104.78 (64.86) 
-- 
GDP_CAPITA -0.002 (0.001)** -- 
GOV_EXP_THE -0.759 (0.407)* -- 
THE_GDP -- 0.042 (0.010)*** 
AGE_POPULATION -- 0.050 (0.013)*** 
Random part:  	(Country) 3640 0.069  	(Study) 7946 0.137  	(Data) 5517 0.194 
VPC - Country 
VPC – Study 
VPC - data 
21.28% 
46.46% 
32.26% 
17.25% 
34.25% 
48.50% 
DIC 
(benchmark) 
26387 
(26412) 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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As a result of testing different combinations of country-level covariates in the 
three-level MLM with data and study-level covariates already specified, GDP per 
capita and government expenditure on health as a percentage of total health 
expenditure turn out to be negatively related to ∆C in the bivariate model and 
significant at the 5% and 10% level respectively. The same holds for running the 
model on the reduced dataset, with even higher significance levels (1% and 5% 
respectively). Countries with high government spending on health may also be 
characterised by higher market regulations, which may result in differences in 
prices for healthcare which potentially explains lower incremental cost. 
Conversely, countries with higher GDP may have higher prices for healthcare, so 
that future health care cost avoided through statin prevention may result in 
lower ∆C in countries with higher GDP. Finally, both total health expenditure as a 
percentage of GDP and age turn out positive and highly significant for ∆E, which 
confirms findings from testing both variables individually in the model. Again, 
results from running the model on the reduced dataset are in accord with these 
findings, with coefficients even being significant on the 1% level.  
 
 
 
5.3.4. Summary and conclusions for part three of this empirical 
exercise 
 
 
This section was concerned with variability in measures of cost-effectiveness 
between the countries reflected in the dataset. The analysis consisted of two 
parts. The objective of part one was to analyse potential causes for a lack of 
country-level variability in the univariate multilevel framework with INMBs as 
single response variable. Part two, on the other hand, was concerned with 
covariates on country-level in the bivariate framework, within which 
considerably more country-level variability was disclosed before in Sections 5.1 
and 5.2 of this empirical exercise.  
 
 
Two potential reasons where considered for a lack of country-level variability in 
the univariate framework. First, the threshold value λ, which was set constant in 
previous analyses, was suspected to be responsible for lower country-level 
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variability in INMBs as compared to its stochastic components ∆C and ∆E. For this 
reason, a sensitivity analysis was performed within which the model was run at 
different threshold values. For extreme values, this analysis showed similar 
country-level variability as for ∆C and ∆E in the bivariate model. This makes 
intuitive sense as variability in INMBs stems from ∆C alone if λ equals zero, and 
∆E alone if λ tends towards infinity. However, with respect to country-level 
variability, the threshold value may be excluded as a potential reason for a lack 
thereof in the univariate model.  
 
 
Secondly, it was suspected that variability in one component of the INMB 
statistic may be partly offset by variability in the other component. Previous 
analyses in Sections 5.1 and 5.2 of the empirical chapter already indicated that 
this may be the case. For this reason, forest plots with country means and their 
respective confidence intervals were produced for each response variable both 
from the raw data and using country-residuals from running the three-level 
hierarchical model. Analysing these forest plots strengthened the suspicion that 
variability on country-level in one component of the INMB statistic may be partly 
offset by variability in the other component, ultimately leading to drastically 
reduced country-level variability in INMBs. To confirm these results, Pearson 
correlations were produced both for the raw data as well as the country means 
obtained from running the three-level MLM. Correlations were well above 0.9 
and highly significant. It may hence be concluded that the lack of country-level 
variability in INMBs results from combining ∆C and ∆E, which have similar 
patterns of variability, so that variability in one component of the INMB statistic 
is partly being offset by variability of the other component. Potential reasons for 
this observation are considered in the discussion section in Chapter 6.  
 
 
Finally, this section was also concerned with country-level covariates for the 
bivariate model, within which the proportion of country-level variability was 
considerably higher. To rule out that lumping country-level data from 
multinational studies in a separate group on country-level distorts results, this 
analysis was performed both with the full dataset, and a reduced dataset which 
drops data points from multinational studies. Results were almost identical for 
both datasets. Testing country-level covariates individually in the model did not 
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result in any significant covariates for ∆C, whilst government expenditure on 
health as a percentage of total health expenditure, the number of GPs and 
pharmacists per 10,000 inhabitants, the mean population age as well as 
measures of BMI and blood glucose showed significant relationships to ∆E. When 
simultaneously assessing covariates in the final random intercepts model with 
variability factors considered on each hierarchical level, GDP per capita and the 
government expenditure on health as a percentage of total health expenditure 
turned out to be significantly related to ∆C, whilst coefficients for total health 
expenditure as a percentage of GDP and the population age were highly 
significant for ∆E. These results are further discussed in Chapter 6.  
 
 
Assessing country-level covariates in the three-level hierarchical random 
intercepts model concludes the systematic assessment of variability factors on all 
hierarchical levels of the dataset. Results are further discussed in Chapter 6, 
together with findings from the two previous Sections 5.1 and 5.2 of this 
empirical exercise. Before that, however, Section 5.4 of this empirical chapter 
shifts the focus towards a methodological feature of the MLM framework, which 
is hypothesized to relate at its core to the transferability problem of economic 
evaluation in health. A case study shows how random slopes may be added to 
the model, which then allows to explicitly model variation in measures of cost-
effectiveness as a function of explanatory variables. This so called ‘variance 
function’ is then constructed for a number of covariates in the model to show 
how this concept may be utilised to focus research efforts more specifically to 
those questions for which disagreement (i.e. variation) in international cost-
effectiveness data is particularly high.  
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5.4. Objective four: random slopes and the variance 
function 
 
The first section of this empirical exercise was concerned with determining the 
appropriate MLM structure for the analysis of secondary cost-effectiveness data 
of statins in the primary and secondary prevention of CVD. A three-level 
hierarchical model with measures of cost-effectiveness grouped in studies and 
studies grouped in countries was developed where data from multinational 
studies was clustered in a separate group on country-level. This model was 
carried forward to section two of this empirical exercise, where data-level and 
study-level covariates were tested in a random intercepts model to control for 
variability on both levels. Throughout the course of this exercise, further country-
level variability was disclosed for incremental effects and incremental cost in the 
bivariate model, whilst variability on country-level remained negligible for INMBs 
in the univariate framework. Accordingly, in Section 5.3, potential reasons for a 
lack of country-level variation in the univariate model were assessed, and 
covariates on country-level were included in the bivariate model. The analysis 
carried out in Section 5.3 concluded the assessment of variability factors for 
measures of cost-effectiveness on all hierarchical levels of the dataset.  
 
 
This final section of the empirical chapter shifts the focus towards a 
methodological feature of the MLM framework which may address the 
transferability problem of economic evaluation in health at its core. In a first 
step, random slopes are introduced to the models developed. Allowing slopes of 
covariates to vary within the MLM framework is something which other health 
economists already considered in their applications of MLM to economic 
evaluation data (Sculpher et al., 2004; Manca et al., 2005; Thompson et al., 2006; 
Bachmann et al., 2007). Doing so, however, also allows modelling the variation in 
the relationship between explanatory variables and the response variable as a 
function of explanatory variables and this is, to the knowledge of the author, 
something which has neither been considered in the area of health economics in 
general, nor in health economic evaluation in particular. The MLM literature 
refers to this concept as the ‘variance function’ (e.g. Steele, 2008; Rasbash et al., 
2009).  
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This final section of the empirical analysis shows how the variance function 
relates to the transferability problem. The idea is that for the range of values of 
explanatory variables where variance in international cost-effectiveness data is 
low, the transfer of existing evidence to the target location is rather indicated, 
compared to ranges of explanatory variables which show high variability in 
measures of cost-effectiveness. The following Subsection 5.4.1 starts off by 
outlining the plan of analysis for introducing random slopes to the model and 
modelling the variance function, before the methods of analysis are detailed in 
Section 5.4.2. The data used for this analysis has already been described in detail 
before, which is why results are reported directly after the methods of analysis in 
Section 5.4.3.  
 
 
5.4.1. Plan of analysis for part four of this empirical exercise  
 
 
It is important to clarify the rationale behind fitting random slopes to the 
multilevel models developed thus far. In the variance components model applied 
in Section 5.1 of this chapter, the effect of explanatory variables on measures of 
cost-effectiveness was not acknowledged. Therefore, the random intercepts 
model was introduced with multiple explanatory variables on data and study-
level in Section 5.2 of this chapter. Country-level covariates were then added to 
the bivariate model in Section 5.3. However, thus far it was assumed that the 
effect of explanatory variables on measures of cost-effectiveness of statins in the 
primary and secondary prevention of CVD is the same across all higher-level units 
(i.e. studies and/or countries). In other words, the individual regression lines for 
each study (and country) in the dataset were assumed to be parallel to each 
other (Steele, 2008; Rasbash et al., 2009). 
 
 
It is very likely though that the relationship between explanatory variables and 
measures of cost-effectiveness differs between different studies and/or 
countries in the dataset. For instance, it is not unreasonable to assume that, 
even if all studies report a positive relationship between total cholesterol and 
INMB, the slope of this relationship, i.e. the coefficient of the covariate, differs 
between studies. Likewise, the relationship between INMBs and say the annual 
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drug cost of the intervention may be different for different countries in the 
dataset. The MLM framework offers a unique opportunity to account for 
differences in the relationship between explanatory variables and response 
variables across higher-level units (Steele, 2008; Bartholomew et al., 2008; 
Rasbash et al., 2009; Hox, 2010).  
 
 
When allowing the relationship between explanatory variables and the response 
variable to differ between higher-level units, regression lines are no longer 
parallel to each other as they are in the random intercepts model (Steele, 2008; 
Hox, 2010). As long as regression lines run parallel, higher-level variability is only 
reflected in differences between intercepts, whilst variability in slopes is, by 
definition, not existent (Steele, 2008; Rasbash et al., 2009; CMM workshops / 
random slopes). Once slopes are allowed to differ, the variability between group 
regression lines may be different at any value of the explanatory variable (Steele, 
2008; Rasbash et al., 2009; CMM workshops / random slopes). Hence, this 
variability may now be expressed as a function of the explanatory variable 
(Steele, 2008; Rasbash et al., 2009; CMM workshops / random slopes). Further 
details are also available from the MLM Chapter 3 and from the methods of 
analysis section below. Modelling this variance function for a number of 
explanatory variables is the objective of this final section of the empirical 
chapter.  
 
 
To demonstrate the potential value of the variance function for addressing the 
transferability problem in economic evaluation in health, the analysis in this 
section concentrates on patient and disease characteristics, which Sculpher et al. 
(2004) rightfully identified as a critical source of variability in measures of cost-
effectiveness, potentially feeding through to variability between higher-level 
units. The analysis within this project thus far showed that patient and disease 
characteristics are, in fact, an important source of variability, and that the 
inclusion of respective covariates also changed the variation observed on higher 
levels. Additionally, relationships observed between patient and disease 
characteristics and response variables were always highly significant and in 
accord with prior expectations. This is in sharp contrast to study characteristics, 
where only few categorical variables were identified out of a large number of 
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candidates which successfully controlled for some variability on study and / or 
country-level – even though the study-level constitutes a major source of overall 
variability in the data. Likewise, country-level variability was observed to be low, 
even in the bivariate model, and only few variables were found to be related to 
the response variable.  
 
 
Having decided to use data-level covariates which encode characteristics of the 
patient and the disease to demonstrate the concept of the variance function, 
one needs to determine on which level random slopes may be fitted. This could 
be, in theory, any level of the model. However, it was decided to model random 
slopes on the study-level for the following reasons. When considering 
transferability problems in practice, decision makers may have to choose out of a 
number of existing economic evaluation studies applicable to other geographic 
domains. This choice may be based on the ‘degree of similarity’ between study 
characteristics and the target location, which accords the principles of analogical 
reasoning as outlined in Chapter 2. To assess the extent to which available 
studies meet the requirements of the target jurisdiction, decision makers hence 
compare attributes of the studies available with attributes of the target context, 
and decide which of the available international cost-effectiveness studies may be 
most appropriate to inform decisions in the target country. This process is also 
reflected in available transferability checklists, decision charts or indices (e.g. 
Heyland et al., 1996; Späth et al., 1999; Welte et al., 2004; Boulenger et al., 2005; 
Turner et al., 2009; Nixon et al; 2004 & 2009; Antonanzas et al., 2009). In short, 
the choice to make is a choice between existing studies, not geographic domains. 
Only once the decision maker has identified a number of candidate studies which 
meet the requirements of the target jurisdiction, country characteristics may be 
considered to the extent to which they are reflected in the economic evaluation 
in question. However, the analysis within the empirical exercise thus far clearly 
showed that country-level variability is low, even after controlling for a large 
number of potential variability factors on data and study-level. Hence, the 
geographic context within which the available evidence was originally produced 
turned out to be a far less important source of variability in international cost-
effectiveness data than differences between economic evaluation studies, which 
this analysis proved to be the overriding source of the variability in measures of 
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cost-effectiveness. This, in conclusion, constitutes a compelling argument for 
fitting random slopes on study-level.  
 
 
Before proceeding to the methods of analysis, it needs to be clarified once more 
that this chapter aims to demonstrate the value of fitting random slopes and 
modelling the variance function, it is not aimed to provide a systematic 
assessment of random slopes within the MLMs developed in previous sections. 
Doing so would require testing random slopes for all covariates on a ‘parameter 
by parameter’ basis, to avoid building an ‘overparameterized model which suffers 
from serious estimation problems’ (Hox 2011). Secondly, covariates which were 
not significant with fixed slopes may be significant in a random slope 
specification, so that previously excluded covariates would have to be tested 
again (Hox, 2011). Third, random slopes may be fitted to continuous and 
categorical data, and in the case of categorical variables, they may be fitted to 
each category separately (Rasbash et al., 2009). As a result, a systematic and full 
assessment of random slopes within this exercise would include considering an 
enormous amount of variables and categories of categorical variables with 
random slopes being tested on each level in the univariate model as well as each 
side of the bivariate model respectively, and this is clearly not feasible within the 
scope of this exercise.  
 
 
As a result, the following steps are taken for a number of patient and disease 
characteristics (TCL, SBP and smoking) to demonstrate the potential value of the 
variance function for addressing the transferability problem of economic 
evaluation data: 
 
1. running an OLS-regression model to plot an overall mean regression line 
without assuming complex data structures (this serves as baseline for 
analysis and helps demonstrating the relative merits of the multilevel 
model methodology).  
2. running a random intercepts model which results in an overall mean 
regression line and, parallel to that, individual study regression lines for 
each study in the dataset (this model specification is equivalent to the 
models run in Sections 5.2 and 5.3 of this empirical exercise) 
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3. running a random slopes model which allows study-level regression lines 
to differ both with respect to their intercepts and slopes (this model 
specification relaxes the assumption of an identical relationship between 
explanatory variables and response variables for different studies)  
4. Model the variance in the relationship between patient and disease 
characteristics and measures of cost-effectiveness between studies as a 
function of explanatory variables.  
 
Models are run both with INMBs in the univariate framework as well as 
incremental cost and incremental effects in the bivariate framework using 
MCMC estimation in MLwiN (Rabsash et al., 2009a, Browne, 2012) 
 
 
 
5.4.2. Methods of analysis 
 
 
The random slopes model in this section of the empirical analysis is, as before, 
run both in a univariate specification, with INMB as the only response variable, 
as well as a bivariate model, with ∆C and ∆E as a vector of response variables.  
The model of interest is a three-level hierarchical model, which groups data in 
studies and studies in countries respectively. In addition, data from multinational 
studies is being clustered in a separate group on country-level. Table 5.28 below 
summarizes the models relevant for this section.   
 
 
As before in the random intercepts model, we can interpret the parameter ‘’ 
as the intercept and ′	8H8’ as the slope of the pooled regression line. Also 
identical to the univariate random intercepts model, ‘	 ’ is the variance for the 
within-study error term ′		:’ and ‘L	 ’ is the variance of the between country 
error term ‘'K’ respectively. However, in contrast to the random intercepts 
model, the slope is no longer identical between the pooled regression line and 
the individual study regression lines.  
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Table 5.28: Multilevel models for exercise four 
 
 
Model of interest 
(Three-level hierarchical model) 
Model summary 
 
Three-level hierarchical random slopes model with cost-effectiveness estimates 
being nested in economic evaluation studies and studies being nested in 
geographic domains. Data from multinational studies is being clustered in a 
separate group on country-level. Random slopes were fitted on level two to allow 
the relationship between data-level covariates and response variables (INMB, ∆C, 
∆E) to differ between different studies in the dataset.  
Unit Diagram  
 
 
 
Univariate model 
specification 
 
 
 
 K~(,  K =  + 8H8K + 	H	K + JHJK + 'K + !K + !8K + K 
 
With M'KN~(0, ΩL			where  ΩL = ML	 N P!,K!8,KQ ~ (0, Ω"      where  Ω" = R"	"8 "8	 S TKU~(0, Ω			where  Ω = M	 N 
Bivariate model 
specification 
 
 }v,Kv8,K~ ~(,  
 n,K = (n + 8nH8K + 	nH	K+JnHJK + 'nK + !nK + !8nK + nK ∗ n,K 
 8,K =  1	(	∆	*%$0	(	∆	*$        	,K = 1 − 8 
 
With: P',,K',8,KQ ~ (0, ΩL     where  ΩL = RL,	L,8 L,8	 S 
!,,K!,8,K!8,,K!8,8,K~ (0, Ω"      where  Ω" = wxx
xy ",	",8 ",8	"8, "8,8 "8,K	"8,8 "8,88 "88,8 "8,8K	 z{{
{|
 
P,,K,8,KQ ~ (0, Ω    where  Ω = R,	,8 ,8	 S 
 
Hence, special attention needs to be placed on the interpretation of ′Ω" =R "	"8 "8	 S’ in which ‘"8	 ’ is the variance in slopes between studies, ‘"	 ’ is the 
variance in intercepts between studies, and ‘"8’ is the covariance between 
intercepts and slopes (Steele, 2008; Rasbash et al., 2009). This issue is also 
further addressed below. For the bivariate model, the variance and covariance 
CE CE CE CE CE CE CE CE CE 
Study 1 Study 2 Study 3 
Country A Country B 
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between the stochastic components of the INMB statistic need to be considered 
as well, resulting in a 4*4 variance-covariance matrix for ‘Ω"’ on study-level 
(Bartholomew et al., 2008). For the univariate model it is assumed that INMB is 
normally distributed at each level of the model whilst a bivariate normal 
distribution is assumed for the bivariate model. As in the bivariate random 
intercepts model before, the response indicator ‘r’ is 1 for ∆C and 0 for ∆E and a 
separate level for this response indicator has been fitted below the data-level. 
Further details on the multilevel methodology applied in this empirical exercise 
are also available from Chapter 3.  
 
 
As mentioned above, special attention needs to be placed on the variance in 
intercepts between studies ‘"	 ’, the variance between their respective slopes 
‘"8	 ’, as well as the intercept slope covariance, denoted with ‘"8’. In general, a 
random slope model allows not just intercepts, but also the slopes of individual 
regression lines to differ between studies included in the dataset (Steele, 2008; 
Rasbash et al., 2009). This means, if random slopes are assumed in the 
relationship between an explanatory variable and measures of cost-
effectiveness, this allows study regression lines to vary both in their intercepts 
and slopes across the range of values of the explanatory variable (Steele, 2008; 
Rasbash et al., 2009). In other words, study-level variability becomes a function 
of the explanatory variable (Steele, 2008; Rasbash et al., 2009). This has very 
important implications: first of all, the covariance between slope and intercept 
variance tells us about the pattern of individual study regression lines with 
respect to changes in the explanatory variable (Rasbash et al., 2009; MLM 
workshops / random slopes). If this covariance is negative, then study regression 
lines are ‘fanning in’ over the range of the explanatory variable (Steele, 2008; 
Rasbash et al., 2009; MLM workshops / random slopes). Conversely, if ‘"8’ is 
positive, study predictions are fanning out (Steele, 2008; Rasbash et al., 2009; 
MLM workshops / random slopes). An intercept slope covariance of zero 
indicates no particular pattern in individual study regression lines (Steele, 2008; 
Rasbash et al., 2009; MLM workshops / random slopes).   
 
 
Secondly, special attention needs to be placed on where the explanatory variable 
for which a random slope has been fitted is centred (Steele, 2008; Rasbash et al., 
 307 
 
2009). The matrix ′Ω" = R"	8 "8	 S’ defines the relationship between the error 
terms of the intercepts ‘!’ and the error term of the slopes ‘!8’ (Steele, 2008; 
Rasbash et al., 2009).  Depending on where the y-axis cuts the x-axis, one would 
obtain different measures of the between group error term ‘!’, the variance of 
the intercepts between studies ‘"	 ’ and the covariance between slopes and 
intercepts ‘"8’, which is why all parameters must be interpreted 
simultaneously and in the light of where x=0 was placed. (Steele, 2008; Rasbash 
et al., 2009; MLM workshops / random slopes). To illustrate this issue, consider 
Figures 5.13 and 5.14 below. The black line in Figure 5.13 represents the overall 
mean regression line, whilst the green line represents the relationship between 
the explanatory variable x and the measures of cost-effectiveness in one 
particular study. Depending on the value of x, the variability between studies 
changes, which is shown by the red arrows between the overall mean regression 
line and the individual study prediction.  
 
 
Figure 5.14: Resulting variance function for sample 
dataset 
Figure 5.13: Study-level variability depends on value 
of explanatory variable in a random slopes model 
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In relation to that, the variance partitioning coefficient, which tells us about the 
amount of variability attributable to each hierarchical level of the model, now 
depends on the value of the explanatory variable too. It can be shown that 
study-level variability is now a quadratic function of the explanatory variable 
(Steele, 2008), which is shown in equation (1)  
  
 7! + !8H89 = "	 + 2"8H8 + "8	 H8	                         (1) 
 
Accordingly, the VPC may now be expressed as:   
 
+,¤q"n¦ = -.W/ 0	-.WXYXZD0-.X/ YXZD/-.W/ 0	-.WXYXZD0-.X/ YXZD/ 0-1W/                           (2) 
 
Equation (1) is for obvious reasons also referred to as the ‘variance function’ 
which is also displayed in Figure 5.14 above (Steele, 2008; Rasbash et al., 2009).  
This variance function is being modelled for patient and diseases characteristics 
TCL, SBP and smoking. Results are reported in Section 5.4.3 below. It is 
hypothesized that additional information generated through conducting new 
studies in the target country may be particularly valuable for (ranges of) 
explanatory variables where study-level variability is high. Conversely, there may 
be regions of the variance function for which variability in existing data is low, 
and a study produced for the target country would be more likely to produce 
results which are in the same range then existing studies; so that additional 
research may not be indicated and one may rather transfer evidence from 
existing studies to the target domain. Hence, the variance function may be used 
to target research resources more specifically to those questions for which 
study-level variability in measures of cost-effectiveness is particularly high. 
 
 
5.4.3. Results 
 
Table 5.29 below summarizes the results from gradually building up a multilevel 
model with random slopes and modelling the study-level variance as a function 
of total cholesterol level both for INMBs in the univariate model and ∆C and ∆E 
in the bivariate framework. The first row of Table 5.29 shows the predictions 
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from running an OLS regression. Against prior expectations but in full accord with 
pilot study results reported in Chapter 3.4, a negative relationship is obtained 
between INMB and TCL and a positive relationship between ∆C and TCL. As 
elaborated on in Chapter 3.4, the result is likely to be explained by the failure of 
the OLS regression model to capture the difference between within and between 
study effects. Precisely, the relationship between INMB and TCL may be positive 
within each study in the dataset and this is what one would expect to observe 
when running a regression analysis on the respective dataset. However, some 
studies refer to patient populations which are characterised by a poorer health 
status, and this also includes an elevated cholesterol level. Though the positive 
relationship between cholesterol level and statin cost-effectiveness holds within 
these studies, their overall result in terms of INMB may be lower than that of 
studies with otherwise healthier patient populations. As the OLS regression 
model is unable to capture this between-study effect, it results in an overall 
negative relationship between TCL and INMB, and for the same reason, an 
overall positive relationship between TCL and ∆C respectively.   
 
 
The random intercepts model, for which predictions are displayed in the second 
row of Table 5.29 below, takes into account within and between study effects 
and therefore shows the anticipated positive relationship between TCL and INMB 
as well as TCL and ∆E, and also the anticipated negative relationship between 
TCL and ∆C. The pooled regression lines are displayed in red for INMBs, green for 
∆Cs and yellow for ∆Es respectively. Around these pooled regression lines, we 
can see individual study predictions for each of the 67 studies included in the 
dataset. These predictions, however, are all parallel to the pooled regression line 
and therefore only differ by their respective intercepts, which also explains the 
term ‘random intercepts model’ for this class of multilevel models (e.g. Steele, 
2008). In other words, the relationship between TCL and the response variable 
(INMB, ∆C and ∆E) is assumed to be identical between all 67 studies, and this is 
also what has been assumed in Sections 5.2 and 5.3 of this empirical exercise.  
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Table 5.29: Gradually building up a multilevel model with random slopes and modelling study-level variance as a function of explanatory variables 
 
 INMB (univariate model) Incremental cost (bivariate model) Incremental effects (bivariate model) 
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This assumption of zero variation in the relationship between TCL and the 
response variable between studies has been relaxed in the third row of Table 
5.29. By allowing the slope of the data-level covariate TCL to differ between 
studies included in the dataset, we now obtain individual study predictions which 
are no longer parallel to each other (e.g. Steele, 2008). Some studies, for 
instance, show a steeper relationship between TCL and INMB than others, which 
results in a pattern of study-predictions which is ‘fanning out’ for INMBs over the 
range of the explanatory variable. The same fanning out pattern is observed for 
the relationship between TCL and ∆E, whilst the pattern for the relationship 
between TCL and ∆C appears to be ‘fanning in’ at first, but then fanning out 
again for higher values of TCL.  
 
 
Random slopes have been fitted to economic evaluation datasets before, for 
instance by Sculpher et al. (2004), Manca et al. (2005), Thompson et al. (2006) or 
Bachmann et al.  (2007). The covariate most commonly modelled with a random 
slope was the treatment effect across centres in multicentre studies, however, 
Thompson et al (2006) also assumed random slopes for the patient covariate 
‘incontinence status’ across centres in a multicentre observational study. The 
idea was analogous to what is being modelled in this exercise, namely to 
consider variation in patient characteristics between centres which may cause 
variability in cost-effectiveness data across centres participating in the study.  
 
 
Most importantly for the purposes of this particular exercise, the variation 
between individual study predictions for the relationship between TCL and the 
response variable is no longer assumed to be zero, and this variation changes 
with the value of the explanatory variable. The study-level variance is now a 
quadratic function of TCL, and this has been plotted in the fourth row of Table 
5.29 above. For INMBs and ∆Es, we observe constantly increasing study-level 
variation in the relationship between TCL and the response variable, and for ∆Cs 
we can see a concave function where variation in the relationship between TCL 
and incremental cost decreases up to a TCL level of 7.5 mmol/L. Beyond that 
level of TCL, however, study-level variability is beginning to increase again.  
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Next, the same analysis was repeated for the continuous patient and disease 
characteristics systolic blood pressure (SBP) and the percentage of smokers in 
the sample (smoking). Respective variance functions (including the function for 
TCL which was already displayed in Table 5.29 above)) are shown in Table 5.30 
below. To enhance comparability of results, functions for INMB and ∆C were all 
plotted on the same scale.  
 
 
From Table 5.30 below we may draw several conclusions with respect to the 
transferability of measures of cost-effectiveness for the primary and secondary 
prevention of CVD. First of all, variability between studies is constantly increasing 
for the relationship between INMBs and TCL and ∆E’s and TCL respectively, so 
that results may be less transferable the higher the total cholesterol level of the 
study population. The concave variance function for study-level variability in the 
relationship between TCL and ∆C indicates that results may be most transferable 
at a TCL level of around 7.5 mmol/L as variability between studies in measures of 
cost-effectiveness is lowest at this level of total cholesterol. Moving on to SBP, 
there are two important observations to make. First of all, variance functions are 
almost flat, indicating that variability in measures of cost-effectiveness between 
studies is pretty much the same over the whole range of values for SBP. 
However, as the scale used for plotting variance functions both for TCL and SBP 
are the same, we also observe that the variance function is at a much higher 
level for SBP. This demonstrates an important issue when using the variance 
function to make judgements regarding the transferability of results. One has to 
make a judgement regarding the ‘tolerable level of variation’ to accept 
transferred evidence for the target domain. In other words, one has to decide on 
a ‘threshold value’ for variability. Once the variance function exceeds this 
threshold, one may regard the existing evidence as non-transferable and 
therefore consider the conduct of a new study for the target country. 
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Table 5.30: Variance functions for TCL, SBP and smoking 
 INMB (univariate model) Incremental cost (bivariate model) Incremental effects (bivariate model) 
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Finally, variance functions for smoking indicate that agreement between studies 
is highest at around 30% of smokers in the study sample. Beyond that, study-
level variability increases drastically. However, the same problem as mentioned 
for systolic blood pressure applies, and this has been demonstrated in Figure 
5.15 below. As already detailed for SBP, it is unclear where to place the 
horizontal line which represents the threshold for level-two variability. Several 
questions follow. First of all, is there a way to determine such a threshold value 
for study-level variability which may be helpful to guide the decision on whether 
or not to transfer existing evidence to the target country. Secondly, if this 
threshold value may not be determined, is the concept of the variance function 
still helpful to guide transferability decisions, for instance by comparing variance 
functions for several explanatory variables with respect to their relative location 
and shape and thereby determining research priorities for the target country. 
Finally, this exercise utilised data from published economic evaluation studies 
and integrates this data using MLM methodology. Hence, are there alternative 
application areas for the methodology demonstrated above, for instance using 
individual patient data from randomized controlled trials? These questions 
constitute important areas for future research and are addressed further in the 
discussion reported in Chapter 6.  
 
 
Figure 5.15: Determining a threshold value for study-level variance 
 
 
Reject existing 
evidence for target 
country 
Accept existing 
evidence for target 
country 
? 
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5.4.4. Summary and conclusions for part four of this empirical 
exercise 
 
 
The primary aim of this section was to demonstrate a methodological feature of 
the MLM framework which allows modelling variation in international cost-
effectiveness data directly as a function of explanatory variables. Starting off 
from an OLS regression equation, multilevel models were gradually built up both 
in the univariate and bivariate framework. Random slopes were then introduced 
for patient and disease characteristics (TCL, SBP and smoking), and slopes were 
allowed to vary randomly on study-level. This follows the thought that the 
decision makers choice with respect to the transferability problem is one 
between existing studies, and only once the decision maker has identified a 
number of candidate studies which meet the requirements of the target 
jurisdiction, country characteristics may be considered to the extent to which 
they are reflected in the economic evaluation in question. However, the analysis 
in this thesis has shown that the geographic context within which the available 
evidence was originally produced for is a far less important source of variability 
in international cost-effectiveness data than differences between economic 
evaluation studies. This, in conclusion, constitutes a compelling argument for 
fitting random slopes on study-level.  
 
 
After random slopes were fitted to patient and disease characteristics, variation 
in cost-effectiveness data was plotted as a function of explanatory variables. It 
turned out, for instance, that variability between studies is constantly increasing 
for the relationship between INMBs and TCL and ∆E’s and TCL respectively, so 
that results may be less transferable the higher the total cholesterol level of the 
study population. In addition, variance functions turned out to be almost flat for 
SBP, indicating that variability in measures of cost-effectiveness between studies 
is pretty much the same over the whole range of values for SBP. However, the 
overall level of variability in measures of cost-effectiveness with respect to SBP 
was much higher compared to other explanatory variables, so that it may be 
more indicated to focus research resources on this particular patient 
characteristic for the target domain. Finally, variance functions for smoking 
showed that study-level variability increases drastically with an increasing 
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percentage of smokers in the study sample, indicating that cost-effectiveness 
data for populations with a high percentage of smokers may not be transferable 
as evidence from existing studies is not conclusive.  
 
 
Finally, a number of issues have been identified which ought to be addressed in 
future research and are therefore discussed in more detail in Chapter 6. For 
instance, is there a way to determine a ‘threshold value’ for study-level variability 
which may be helpful to guide the decision on whether or not to transfer existing 
evidence to the target country. The discussion section addresses this question by 
drawing an analogy to the ‘value of information’ concept (Claxton et al., 2000) 
Secondly, if there is no rational for determining a threshold value, could the 
concept of the variance function still be helpful to guide transferability decisions, 
for instance by comparing variance functions for several explanatory variables 
with respect to their relative location and shape, and thereby determining 
research priorities for the target country. Finally, are there additional application 
areas where modelling the variance function may be useful which go beyond the 
scope of the integration of secondary cost-effectiveness data from existing 
economic evaluation studies (e.g. applying this concept to individual patient data 
from international multicentre RCTs). These questions are addressed in more 
detail in the next Chapter 6, which entails the overall discussion of this thesis.  
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6. Discussion 
 
 
This chapter provides a discussion of the results generated in this thesis. Findings 
across all chapters are summarised in Section 6.1, before strength and 
weaknesses of the work carried out are being discussed in Section 6.2. Section 
6.3 then discusses findings in the context of existing research in the field. Policy 
implications are summarized in Section 6.4 and recommendations for further 
research are given in Section 6.5. Concluding remarks are provided in the final 
Section 6.6 of this chapter.  
 
 
6.1. Summary of findings 
 
 
The primary aim of this thesis was to address the transferability problem of 
economic evaluation in health by analysing what causes variability in measures 
of cost-effectiveness within and between studies, and ultimately, between 
geographic domains. The review of the economic evaluation literature in Chapter 
2 confirmed that ‘the methods that have been proposed to address the 
transferability issue have often been relatively ad hoc, with the obvious 
consequence that the methodological literature in this area has evolved 
somewhat nonlinearly over time’ (Manca, 2009). In addition, the available 
literature confirms that ‘there is a lack of empirical studies which prevents 
stronger conclusions regarding which transferability factors are most important 
to consider and under which circumstances’ (Goeree et al., 2007). To address 
these issues, MLM was used to analyse variability factors for measures of cost-
effectiveness.  
 
 
In Chapter 2, the transferability problem was defined as an ‘analogical inference’, 
within which a mapping of relevant attributes between a source domain, about 
which more is apparently known, and a, less studied, target domain is produced 
to infer whether the information of interest may also hold in the target setting 
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(Gentner & Markman, 1997; Forbus, 2001; French, 2002). This theoretical 
framework was then linked to the statistical concept of ‘exchangeability’, which 
forms the conceptual basis of multilevel statistical modelling. MLM makes 
explicit the exchangeability assumption and allows for the assessment of 
variability factors of measures of cost-effectiveness within studies, between 
studies, and ultimately, between geographic domains through the assumption of 
conditional independence (Drummond et al., 2009). Chapter 2 concluded with a 
review of the use and applications of MLM within the area of economic 
evaluation in health, and showed that all applications of MLM in this area focus 
on the analysis of IPD from multicentre trials or observational studies, within 
which a strict two-level hierarchical data structure is commonly assumed.  
 
 
In other words, using MLM as a mode for meta-regressing secondary cost-
effectiveness data from published economic evaluation studies is a novelty in 
this area, which is why methods to integrate cost-effectiveness data from 
different studies and across different geographic domains were developed and 
tested in Chapter 3. Starting off from a simple OLS regression equation, complex 
data structures were gradually introduced, resulting in a number of strictly 
hierarchical as well as cross-classified models. Within these models, INMB as a 
single response variable was considered in a univariate framework, as well as the 
stochastic components of the INMB statistic ∆C and ∆E as a vector of response 
variables in a bivariate MLM. Chapter 3 concluded with a pilot study to test these 
models using a subset of cost-effectiveness data on statins for the primary and 
secondary prevention of CVD; as this is an extensively studied area which allows 
for the assumption of random parameters on study and country-level (Snijders, 
2005). Results from the pilot study were promising, and in line with Gelman et al. 
(2004), who state that ‘the valid concern is not about exchangeability, but 
encoding relevant knowledge as explanatory variables where possible.’ However, 
results also showed negligible country-level variation in the cross-classified 
model, and it was suspected that data from multinational studies may disguise 
actual country-level variability. This idea was supported by existing literature, 
which found lower levels of country-level variation in multinational study data 
(e.g. Barbieri et al., 2005), and also the invaluable feedback received from 
presenting pilot study results at various conferences and seminars.  
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After carrying out the pilot study, a systematic literature review was conducted 
to populate a dataset of cost-effectiveness estimates (∆C, ∆E and INMBs), as well 
as additional data encoding potential variability factors. This was the focus of 
Chapter 4. As in the pilot study, statins for the primary and secondary prevention 
of CVD were the focus of assessment, and the dataset previously developed for 
the pilot was complemented with information from a large number of additional 
studies, as well as an extensive list of potential explanatory variables. In total, 67 
studies were included in this empirical exercise, reporting 2094 cost-
effectiveness estimates applicable to 23 geographic domains. Covariates were 
defined from a long list of potential variability factors, as previously reported in 
the literature (Sculpher et al., 2004; Goeree et al., 2007). Results of most studies 
referred to one geographic domain only, whilst six studies were multinational in 
nature, hence causing the strict hierarchical data structure with data clustered in 
studies and studies clustered in countries to break down.  
 
 
Systematically reviewing this literature revealed that studies may be related to 
each other, for instance, through common authorship, the use of identical data 
sources, reuse of a previously published DAM, or simply a common source of 
funding. This, however, may violate the assumption of independence between 
studies, which is necessary to fit the MLMs developed in Chapter 3. If studies are 
related, it might therefore be more appropriate to pool them in one group on 
the study-level. Though this may reduce the number of level-two units, it may be 
more appropriate to fit MLMs to the data, especially when studies are very 
similar. Therefore, the aim of the final section of Chapter 4 was to look into the 
‘genealogy’ of economic evaluation studies on the cost-effectiveness of statins. 
Multiple correspondence analysis was used to ascertain whether studies are 
similar with respect to key characteristics, and once a ‘phenotypic’ similarity was 
disclosed, a ‘genotypic’ relationship between studies was sought. As a result, 
some relationships amongst studies were identified, however, the method did 
not (yet) prove accurate enough to justify the use of alternative MLM structures 
based upon its results. Instead, further explanatory variables were derived with 
the aim of encoding relationships between studies. This exploration into possible 
relationships between published evidence and potential similarities between 
studies’ results may be followed up in future research.   
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Chapter 5 presented the main empirical analysis, and the first section of this 
chapter was predominantly concerned with determining the appropriate MLM 
structure for the integration of published cost-effectiveness data. Starting off 
with the models developed and tested in Chapter 3, Section 5.1 showed that 
appropriate assumptions regarding dependencies in the data are crucial for 
making correct inferences. The pilot study already showed the importance of 
explicitly acknowledging the existence of a study-level in the model, and this 
finding was clearly confirmed by the analysis reported in this section. However, 
the pilot study also showed negligible country-level variability in the cross-
classified model, and as a potential reason, it was hypothesized that the 
assumption of independence between geographic domains may not be adequate 
for multinational study data. If data from multinational studies underestimates 
country-level variation, this potentially disguises country-level variability in the 
rest of the data. Therefore, a three-level hierarchical model, which groups data 
in studies and studies in countries, was run both on a reduced dataset without 
multinational studies, as well as on the full dataset, where data from 
multinational studies was grouped in a separate cluster on country-level. To 
confirm that the lack of country-level variability in the cross-classified model 
results from the data and not from technical issues with model specification and 
implementation, a cross-classified model was also run on an ‘intermediate’ 
dataset, where some multinational study data was assigned to its respective 
target countries, and the rest of the data clustered in a separate group on 
country-level, thereby introducing the cross-classification problem on ‘a lower 
scale’.  
 
As a result, whilst country-level variability was negligible for the cross-classified 
model, it increased dramatically within the bivariate three-level hierarchical 
framework, both for the full as well as for the reduced dataset. In addition, 
running the cross-classified model for the intermediate dataset resulted in 
country-level variability somewhere in between the fully cross-classified model 
and the three-level hierarchical structure. These results clearly confirm that 
country-level variability may be underestimated in multinational studies. 
Potential reasons could be identical trial protocols across centres and countries 
in multinational RCTs (e.g. Ramsey et al., 2005), or assuming transferability of 
input parameters between countries, which consequently results in lower 
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country-level variation in measures of cost-effectiveness (e.g. Barbieri et al., 
2005). As a result, it was decided to take forward the three-level hierarchical 
model to the second part of this empirical exercise, as only this model makes 
appropriate assumptions regarding dependencies in the dataset, permits the 
simultaneous assessment of covariates on data, study, and country-level, and 
allows use of the full dataset by grouping multinational study data in a separate 
group on country-level.  
 
Finally, Section 5.1 assessed, in depth, whether ‘empirical Bayes shrinkage 
estimation’ may be regarded as appropriate in a model which integrates 
secondary data from published economic evaluation studies, where the weight 
of a particular study does not depend on the number of individual patients in the 
sample, but rather on the extent to which subgroup and sensitivity analyses have 
been reported. It could be shown that, due to high between-group variability, 
shrinkage factors are generally very high in this case study, which means that 
shrinkage is, at most, moderate. More importantly, however, this section argued 
that the impact of shrinkage on study means in this exercise depends not just on 
the number of data points abstracted from each study, but also on the within 
and between group variability in the data (i.e. dependencies) and the location of 
each study mean relative to the overall regression mean. This issue is further 
discussed in Section 6.2 of this chapter, which is concerned with the main 
strength and weaknesses of this empirical exercise.  
 
Section 5.2 was concerned with testing covariates on data and study-level and 
determining a model which best controls for variability on these levels; thereby 
disclosing the maximum amount of country-level variability Covariates were 
drawn from a long list of possible variability factors suggested in the literature 
(Sculpher et al., 2004; Goeree et al., 2007). Following descriptive statistics, 
regression based imputation of missing values and a detailed assessment of 
correlations between potential explanatory variables were applied. Further, data 
reduction techniques were used to derive further covariates, including principal 
components factor analysis (Rencher, 2002; Acock, 2010) and multiple 
correspondence analysis (Le Roux & Rouanet, 2010). Thereafter, covariates were 
analysed in a random intercepts model (Steele, 2008; Rasbash et al., 2009, Hox, 
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2010) First, covariates were tested individually in the MLM. Secondly, a model 
with multiple covariates on data and study-level was constructed to reveal the 
maximum amount of country-level variability. This model was also carried 
forward to the analysis of country-level variability in Section 5.3 of the empirical 
chapter.  
 
Adding covariates to the model on the data and study-levels successfully 
disclosed further variability on the country-level. Hence, the model could show 
that lower-level variability factors may feed through to higher levels, which 
demonstrates impressively the importance of both appropriately reflecting 
complex data structures and controlling for variability on lower levels, even if the 
main focus is on higher-level (i.e. country-level) variability (Sculpher et al., 2004). 
The analysis also showed that country-level variability was constantly increasing 
with the inclusion of lower-level covariates in the bivariate (∆C, ∆E) model, 
allowing assessment of covariates on country-level. However, a different 
conclusion was reached for the univariate (INMB) framework, where country-
level variability remained negligible throughout the course of this exercise. This 
finding was assessed in much more detail in Section 5.3 of the empirical chapter 
and is summarized further below.  
 
 In terms of covariates, the analysis carried out in Section 5.2 showed, for 
instance, the importance of patient and disease characteristics for variability in 
measures of cost-effectiveness, which also feeds through to the study and 
country-level. Further, testing intervention and comparator characteristics in the 
model showed that NICE’s view on statins is essentially confirmed, which says 
that ‘for the purposes of initiating therapy, there were no data on clinical events 
to suggest the superiority of any one statin over all the others in reducing 
cardiovascular events’ (NICE, 2006). On the other hand, controlling for study-
level variability factors proved far more difficult, especially with respect to 
methodological characteristics; even though the study-level turned out to be a 
major source of variability in cost-effectiveness data. Only few variables on 
study-level were statistically significant, amongst them a binary which captures if 
effectiveness data was obtained from the 4S study, as well as a binary which 
captures whether the study uses the ‘CVD life-expectancy model’ by Grover et al 
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(1998). Using 4S data significantly increased estimates of ∆E in the bivariate 
model and INMB in the univariate model, whilst papers by Grover et al., which all 
use the CVD life-expectancy model, showed higher levels in all outcome 
variables. The discussion in Section 6.2 elaborates in more detail why studies 
utilising 4S data or the CVD life-expectancy model provide results which are so 
different to other studies included in this empirical exercise.  
 
 
Section 5.3 addressed variability in measures of cost-effectiveness between 
countries. The first objective was to analyse potential causes for a lack of 
country-level variability in the univariate MLM with INMB as single response 
variable. The second objective was to analyse covariates on country-level in the 
bivariate framework with ∆C and ∆E as response variables, within which 
considerably more country-level variability was disclosed in Sections 5.1 and 5.2.  
 
 
Two potential reasons were considered for a lack of country-level variability in 
the univariate framework. First, the threshold value λ, which was set constant in 
previous analyses, was altered and models were run at different threshold 
values. For extreme values, this analysis showed similar country-level variability 
as for ∆C and ∆E in the bivariate model. This makes intuitive sense, as variability 
in INMBs stems from ∆C alone if λ equals zero, and ∆E alone if λ tends towards 
infinity. However, for the continuum between these extreme cases, variability on 
country-level remained negligibly low, so that we may exclude λ as a potential 
reason for a lack of country-level variability in the univariate model. Secondly, 
based on analyses carried out in Sections 5.1 and 5.2, it was suspected that 
variability in one component of the INMB statistic may be partly offset by 
variability in the other component. For this reason, forest plots with country 
means and their respective confidence intervals were produced for each 
response variable both from the raw data and using country-residuals from the 
three-level hierarchical model. In addition, Pearson correlations were calculated 
for the raw data as well as the country means obtained from the three-level 
MLM. Forest plots showed similar patterns in ∆C and ∆E and correlations were 
well above 0.9 and highly significant. It may hence be concluded that the lack of 
country-level variability in INMBs results from combining ∆C and ∆E, which have 
similar patterns of variability, so that variability in one component of the INMB 
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statistic is partly offset by variability in the other component. Potential reasons 
for this observation are considered further below.  
 
 
Finally, this section was also concerned with country-level covariates for the 
bivariate model. To test whether ‘lumping’ country-level data from multinational 
studies in a separate group on country-level distorts results, this analysis was 
performed both with the full dataset, and a reduced dataset in which data points 
from multinational studies were dropped. Results were almost identical for both 
datasets. Testing country-level covariates individually in the model did not result 
in any significant covariates for ∆C, whilst government expenditure on health as 
a percentage of total health expenditure, the number of GPs and pharmacists 
per 10,000 inhabitants, the mean population age, as well as measures of BMI and 
blood glucose showed significant relationships to ∆E. When covariates were 
simultaneously assessed in the final random intercepts model with variability 
factors considered on each hierarchical level, GDP per capita and the 
government expenditure on health as a percentage of total health expenditure 
was significantly related to incremental cost, whilst coefficients for total health 
expenditure as a percentage of GDP and mean population age were highly 
significant for ∆E. These results are also discussed below.  
 
 
Section 5.4 shifted the focus towards a methodological feature of the MLM 
framework. The primary aim was to demonstrate how modelling variation in 
international cost-effectiveness data directly as a function of explanatory 
variables relates to the transferability problem. First, random slopes were 
modelled for patient and disease characteristics (TCL, SBP and smoking). Then, 
variation in cost-effectiveness data was plotted as a function of explanatory 
variables. It turned out, for instance, that variability between studies is 
constantly increasing for the relationship between INMBs and TCL and ∆E’s and 
TCL respectively, so that results may be less transferable the higher the total 
cholesterol level of the study population. In addition, variance functions were 
almost flat for SBP, indicating that variability in measures of cost-effectiveness 
between studies is pretty much the same over the whole range of values for SBP. 
However, the overall level of variability in measures of cost-effectiveness with 
respect to SBP was much higher compared to other explanatory variables, so 
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that it may be more indicated to focus research resources for the target domain 
on this particular patient characteristic. Finally, variance functions for smoking 
showed that study-level variability increases drastically with an increasing 
percentage of smokers in the study sample, indicating that cost-effectiveness 
data for populations with a high percentage of smokers may not be transferable 
as evidence from existing studies shows high variability.  
 
 
The following section discusses the strength and weaknesses of the empirical 
analysis. Thereafter, findings are discussed in the context of existing research in 
the field in Section 6.3, before summarizing policy implications in Section 6.4. 
Finally, Section 6.5 discusses potential areas for further research, before a 
conclusion is provided in Section 6.6.  
 
 
6.2. Strength and weaknesses of the analysis 
 
 
Probably the biggest strength of the empirical analysis also constitutes its main 
weakness, namely the use of secondary cost-effectiveness data from published 
economic evaluation studies. On the one hand, this ensured quick access to the 
data required to carry out this research. More importantly, however, secondary 
data from published studies may be more appropriate for analysing variability 
factors than the use of IPD from multinational trials. Trials usually implement 
strict protocols which may be identical across centres and countries (e.g. Ramsey 
et al., 2005). These protocols, though crucial to ensure the internal validity of 
trial results, artificially reduce the variability which may exist between centres 
and countries under real world conditions (Ramsey et al., 2005; Barbieri et al., 
2005). Secondary data from published economic evaluation studies, which are 
more likely to have been designed to inform decisions under real world 
conditions, may better reflect this variability. Furthermore, using IPD from one 
trial may not allow for the assessment of factors causing variability in cost-
effectiveness between studies, which has been identified as an overriding source 
of variability within this project.  
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However, several problems arise when using secondary data from published 
economic evaluation studies in a multilevel statistical analysis of factors causing 
variability in measures of cost-effectiveness. For instance, the assumption of 
random parameters on study and country level, which is necessary to fit 
multilevel models, may be violated for the current exercise. On study level, strict 
inclusion and exclusion criteria specified, for instance, that only studies which 
explicitly report values for components of the INMB statistic may be considered. 
However, as earlier studies may be more likely to report their results in terms of 
ICERs (without making explicit values for ∆E and ∆C), this may bias the dataset 
towards studies which were published more recently. This, in turn, may affect 
results as evidence suggests that not just study methods evolved, but statins also 
became cheaper and more effective over time. It may also affect the variability 
observed between studies, as more recent studies may build upon experiences 
(and results) of earlier studies, which may lead to a converging effect in terms of 
variability over time.  
 
 
Methodological standards may be more widely adapted in some countries 
compared with others and therefore favour the inclusion of studies from 
particular countries into this exercise. This may bias the dataset towards 
particular jurisdictions, (e.g. Canada, UK). On the other hand, it was not possible 
to acquire data for countries of low or medium levels of economic attainment, 
with the exception of Hungary. As a result, the low country-level variability 
observed in the empirical analysis may partly be a result of the fact that only high 
income countries were represented in the data. Finally, issues with the 
assumption of randomness may not only relate to higher level units. Problems 
did arise, for instance, if a study reported cost-effectiveness as ICERS and data on 
either ∆C or ∆E was available, which allowed decomposing the ICER-statistic. If, 
however, the use of statins resulted in cost-savings, studies rightly omitted 
resulting negative ICERs, which meant that ∆C and ∆E could not be calculated 
and the respective data point had to be dropped. This resulted in a loss of data 
points providing evidence in strong support of statins, which in turn, may have 
biased response variables downwards in the current exercise.  
 
 
 327 
 
Apart from issues with the assumption of randomness, the problem of ‘empirical 
Bayes shrinkage estimation’ was identified as a major cause for concern within 
the MLM framework if data stems from published economic evaluation studies. 
Shrinkage may only be a consequence of differences in the way subgroup or 
sensitivity analyses were performed and reported, which is not indicative of the 
size of the underlying study sample. This problem was considered and 
extensively discussed in Section 5.1.5 of the empirical chapter. In brief, due to 
high between study variability, shrinkage factors are generally high in this 
exercise, which means that shrinkage is, at most, moderate. More importantly, 
however, the impact of shrinkage on study means depends not just on the 
number of data points per study, but also the within and between study 
variability in the data (i.e. dependencies) and the location of study means 
relative to the overall regression mean. With respect to ‘dependency’, shrinkage 
makes sense as one would rather drag studies towards each other if between-
study variability is low. With respect to location, shrinkage may also be justified 
as one would not want outlying studies to bias regression results. For ‘group 
size’, however, a distinction was made between country groups and study 
groups. With respect to countries, giving higher gravity to countries for which 
more evidence is available, may also be justified, even if the underlying data 
stems from published economic evaluation studies. With respect to studies, 
there may be arguments both in favour as well as against the appropriateness of 
shrinkage and it is recommended to further look into methodologies for 
assigning weights to studies and to implement this information within the MLM 
framework.  
 
 
Despite these issues, the use of MLM is considered a major strength of this 
thesis. MLM makes explicit the exchangeability assumption, which ‘mediates’ 
between assumptions of either identical or independent parameters (e.g. 
Spiegelhalter et al., 2000 & 2004), and allows integrating secondary cost-
effectiveness data from different studies and different countries without ignoring 
that study and country residuals are not independent. Further, through the 
assumption of conditional independence, one may assess the impact of 
variability factors modelled as covariates on each level of the data hierarchy. As 
Gelman et al. (2004) put it ‘in this way exchangeable models become almost 
universally applicable, because any information to distinguish different units 
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should be encoded.’ (Gelman et al., 2004 cited from Manca et al., 2007). As 
multilevel models treat country-parameters as randomly drawn from a common, 
prior distribution, we have to ask ourselves, however, about the potential 
consequences of violations to this assumption within the current exercise. On 
study-level and country-level, bias may occur if some studies did have a greater 
chance to be selected into the sample than others, and potential reasons for this 
to happen have been considered further above. However, unlike OLS regression, 
which treats β coefficient as if they were fixed constants, the MLM approach 
controls for systematic differences between higher level units if they are 
reflected in the dataset. And even if these differences are not reflected in the 
data collected (as it is, for instance, the case with the level of economic 
attainment on country-level) the MLM approach ensures at least that parameter 
estimates do not suffer from wrongly estimated precision (i.e. suggesting a 
relationship, when in fact, there is none).  
 
 
In this respect, the analysis carried out in this thesis goes far beyond the work of 
other researchers in the field. In particular, Barbieri et al. (2005) shared a similar 
aim and the authors claim to have provided ‘the most comprehensive analysis to 
date of the variation in the results of cost-effectiveness studies, of drugs, in 
Europe’. Nevertheless, their approach was based on a rather descriptive analysis 
of relevant studies with the major limitation that all variability in cost-
effectiveness data was assigned to the country-level. This may be misleading as 
the results of this project show that differences within and between studies 
account for most of the variability in measures of cost-effectiveness. 
Furthermore, Barbieri et al. (2005) were not able to control for a number of 
variability factors simultaneously. However, there may be complicated 
interactions between different variability factors, which require careful 
consideration and systematic assessment. MLM allows simultaneous assessment 
of variability factors within studies, between studies and between countries, and 
therefore provides a more appropriate methodological framework for the 
analysis of factors causing variability in cost-effectiveness data.  
 
 
Further to that, MLMs were also specified in a bivariate framework, hence 
allowing for the simultaneous assessment of ∆C and ∆E as a vector of response 
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variables (Bartholomew et al., 2008; Nixon et al., 2005; Pinto et al., 2005; Manca 
et al., 2007; Grieve et al., 2007; Bachmann et al., 2007; Willan et al., 2008; Grieve 
et al., 2010). This has several advantages: First, the approach does not require a 
new regression to be estimated for each value of the cost-effectiveness 
threshold (Manca et al., 2007). Secondly, the correlation between the two 
stochastic components of the INMB statistic is explicitly modelled. Finally, the 
bivariate model allows assessing the differential impact of covariates on each 
response variable whilst acknowledging that ∆C and ∆E are, themselves, 
correlated.  
 
 
Finally, the method applied in this thesis allows explicit modelling of variability in 
measures of cost-effectiveness as a function of explanatory variables (e.g. 
Rasbash et al., 2009). Allowing slopes of covariates to vary randomly in the MLM 
framework is something other health economists have implemented before 
within their applications of MLM to IPD from multinational trials or observational 
studies (Sculpher et al., 2004; Manca et al., 2005; Thompson et al., 2006; 
Bachmann et al., 2007). However, doing so also allows modelling variation in the 
response variable as a function of explanatory variables and this is, to the 
knowledge of the author, something which has neither been considered in the 
area of health economics in general, nor in health economic evaluation in 
particular. The MLM literature refers to this concept as the ‘variance function’ 
(e.g. Steele, 2008; Rasbash et al., 2009) and Section 5.4 of the empirical chapter 
showed how the variance function relates to the transferability problem. A 
number of questions were phrased with respect to the variance function, and 
these are discussed further as potential areas for future research in Section 6.5 
of this chapter.  
 
 
Moving on from the methodological framework of MLM, a further strength of 
the analysis is that explanatory variables were systematically derived from a list 
of factors previously suggested in the literature as possible constraints on the 
transferability of cost-effectiveness evidence (Sculpher et al., 2004; Goeree et al., 
2007). This is believed to be the first attempt of a systematic assessment of such 
variability factors. Other researchers have tested selected covariates on patient, 
centre or country-level within a two-level hierarchical model applied to IPD (e.g. 
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Grieve et al., 2005 & 2007; Thompson et al., 2006; Manca et al., 2007; Petrinco 
et al., 2009; Edbrooke et al., 2011), and only one study (Barbieri et al., 2005) 
aimed to analyse country-level variability in cost-effectiveness data. However, all 
of these studies limited their analysis to a small number of selected variables. 
The research carried out within this thesis, however, began with a long list of 
candidates ascertained from the literature (Sculpher et al., 2004; Goeree et al., 
2007) to develop and test a data abstraction form to populate a dataset for the 
empirical analysis. This resulted in an extensive list of covariates on data, study 
and country-level, and a random intercepts model with multiple covariates on 
each hierarchical level was specified which best controls for variability in cost-
effectiveness data for statins in the primary and secondary prevention of CVD.  
 
 
Before moving on to a discussion of the findings generated in this project, it 
should be highlighted that the empirical analysis was based on data collected for 
one intervention area only. The intervention of statins for the primary and 
secondary prevention of CVD was chosen as it has been extensively researched 
in the past, meaning that a sufficient number of includable studies and countries 
was hypothesized to be present to justify the assumption of random parameters 
on study and country-level. This resulted in a large dataset with a 2094 data 
points referring to 67 studies and 23 geographic domains. Nevertheless, all 
results are intervention specific, and though it was not feasible to carry out 
another case study within this project, this may be regarded as a general 
weakness of this thesis. Furthermore, all countries represented in the dataset 
have high levels of economic attainment and even variation in health related 
indicators was generally low. The implication is that the quantitative results 
should be interpreted with caution. Section 6.4 below will provide examples of 
how the results of this thesis may be used in a policy environment and elaborate 
on the potential pitfalls in doing so. However, the generalisability of findings 
beyond statins in particular and pharmacological interventions more generally 
should be established in future analysis through replication in other intervention 
areas and a wider range of countries at different levels of economic attainment. 
The generalisability of the method may be limited to those intervention areas 
which received similar attention than statins in the primary and secondary 
prevention of CVD.  
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6.3. Discussion of findings  
 
6.3.1. Variability in measures of cost-effectiveness on data, study 
and country-level  
 
Probably one of the most important findings of both the pilot study and the 
empirical analysis is low country-level variation across all models and subsets of 
the data analysed. Or put differently, whilst country-level variation was present, 
its proportion compared to variability within and between studies was low for ∆C 
and ∆E in the bivariate model, and negligible for INMB in the univariate model. A 
number of potential reasons for this observation were considered throughout 
the analysis carried out within this project.   
 
First of all, a negligible country VPC in the cross-classified MLMs relates to 
inappropriate assumptions about the independence of data from multinational 
studies on country-level. Due to much lower country-level variability in data from 
multinational studies, this data should not be treated as independent on 
country-level. Rather, pooling it in a separate group on country-level, thereby 
removing its disguising effect from other country-parameters, disclosed further 
country-level variability in the bivariate model. In 2005, Barbieri et al. reached a 
similar conclusion, stating that ‘it can be seen that the extent of variability is 
lower for multicounty studies than single country studies’ and ‘this may be 
because, in a multicounty study, the analysts give more active consideration to 
the harmonization of data and analyses.’  
 
 
Related to that, two of the six multinational studies are primary modelling 
studies, i.e. directly assessing the cost-effectiveness of statins using IPD from 
multinational RCTs. The remaining four studies are secondary modelling studies, 
employing DAM to estimate the cost-effectiveness of statins. With respect to 
primary modelling studies (Johannesson et al., 1996; Jonnsson et al, 1999), the 
lack of country-level variation may relate to a widely discussed trade-off 
between the internal and external validity of trial evidence. For instance, 
Baltussen et al. stated already in 1999 that ‘policy-makers need cost-effectiveness 
information that is both internally and externally valid. The latter aspect is often 
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ignored and refers to the relevance of the results of economic trials to the specific 
decision-making context of the policy-maker’. Increasing internal validity in a trial 
may, however, come at the cost of lower external validity for each target 
jurisdiction. For instance, stringent inclusion and exclusion criteria, which are 
identical across centres, increase the internal validity of results - but treatment 
populations may not reflect target populations in any of the trial countries 
(Marshal & Hux, 2009). Likewise, standardised trial protocols minimise the 
potential for bias. However, variability with respect to differences in clinical 
practice between countries is literally non-existent in the data. As a result, a 
multinational RCT ‘doesn’t have any value or existence except in the degree to 
which it captures the reality as observed in the original setting’ (Sleigh, 1997).  
 
 
Further to that, two of the six multinational studies in question (Johannesson et 
al., 1996; Jonnsson et al., 1999) achieve ‘context specificity’ of their results only 
through the use of country-specific unit cost data, whilst all other input 
parameters are identical across the jurisdictions included. Three studies (Grover 
et al., 2001; Szucs et al., 2004; Taylor et al., 2009) vary both unit cost and 
resource use data to achieve context-specificity, whilst one study (Lindgren et al., 
2007) applies context-specific unit cost and utility values, whilst resource use 
data and effectiveness data was transferred from a different country. In 
conclusion, as Barbieri et al (2005) already emphasized, this practice may lead to 
differing degrees of country-level variability within the affected data. As a result, 
decision makers ought to be very critical about the applicability of multinational 
study data to their particular context, even if their country is explicitly 
considered in the study. A careful consideration of each aspect of the study 
which potentially impacts on the context-specificity of its results may be 
indicated.  
 
 
Another reason for low country-level variation, especially in the univariate 
model, relates to the INMB statistic itself. This exercise showed that country-
level variability is much higher in ∆C and ∆E than it is in the INMB statistic. 
Section 5.3 provides an explanation for this observation, as variability for both ∆C 
and ∆E share a similar pattern, which means that variability in one component of 
the INMB statistic is partly ‘being offset’ by variability in the other component, 
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hence leading to reduced country-level variability in INMBs. The author is not 
aware of studies which hypothesized or empirically looked into this issue, which 
is why, at this point, we can only guess about potential causes for this ‘similar 
pattern’ in the country-level variability of ∆C and ∆E. A potential reason may be a 
structural relationship between the two components of the INMB statistic. CVD 
prevention with statins may lead to an increased life expectancy, which, in turn, 
may expand the period within which statins are consumed. Hence, higher ∆E 
may naturally be associated with higher ∆C, which would explain a common 
pattern in their variability. As a result, variability in one component may partly be 
offset by variability in the other component of the INMB statistic. Future 
research should assess whether this common pattern in the components of the 
INMB statistic is specifically related to statins, or more generally present in 
pharmacological interventions, preventative interventions or even other 
intervention areas.  
 
 
If the proportion of country-level variability is low in all models run within the 
empirical analysis, this also means that the proportion of variability in cost-
effectiveness data due to within and between-study differences must be high. 
Hence, another key message from the empirical analysis is that, for statins in the 
primary and secondary prevention of CVD, differences within studies (e.g. 
relating to subgroup and sensitivity analyses) and differences between studies 
(e.g. methodological study characteristics), are far more important sources of 
variability in published cost-effectiveness data than differences between the 
countries reflected in that data. However, whilst the analysis in Section 5.2 of 
this empirical chapter was very successful in controlling for within-study 
variability, it was generally difficult to ascertain significant covariates on study-
level.  
 
 
6.3.2. Variability factors on data-level 
 
 
Starting off with data-level covariates, patient and disease characteristics turned 
out to be key variability factors, feeding through to variability between studies 
and countries in the dataset as previously hypothesized by Sculpher et al. (2004). 
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MLM provides an excellent framework to make explicit the impact of patient and 
disease characteristics on study and country-level variability, as it assigns 
respective variance partitions to each hierarchical level modelled (e.g. Steele, 
2008). Further, testing intervention and comparator characteristics in the model 
showed that this is also an important source of variability on data-level, 
especially with respect to annual drug cost. However, on the effectiveness side, 
NICE’s view on statins was essentially confirmed, which says that ‘for the 
purposes of initiating therapy, there were no data on clinical events to suggest 
the superiority of any one statin over all the others in reducing cardiovascular 
events’ (NICE, 2006).  
 
 
Some data-level covariates may also be discussed in the light of the little existing 
empirical evidence on variability factors for measures of cost-effectiveness. 
Barbieri et al. (2005) explored issues surrounding variability of economic 
evaluations of pharmaceuticals in Western Europe and concluded that ‘the 
extent of variation across countries in effectiveness, resource use or unit costs, 
allowed by the researcher’s chosen methodology was the most important 
variability factor for measures of cost-effectiveness.’ In other words, the more 
studies utilize context-specific data, the higher the variability in measures of 
cost-effectiveness between countries. To confirm this hypothesis, categorical 
variables were developed and tested which classify data points with respect to 
their degree of ‘context specificity’ of input parameters. Descriptive statistics 
showed that, within this exercise, by far the most common way to populate a 
model was to use country specific unit cost and resource use data, but 
effectiveness data and utility weights from other geographic domains (type CR: 
1033 data points, 49.33%). Only 56 data points (2.67%) were generated with a 
model fully populated with target specific data. Within the final random 
intercepts model specified with covariates on data and study-level, coefficients 
of this categorical variable were significant at least at the 5%-level, negative and 
constantly decreasing for ∆C in the bivariate model. This indicates lower 
incremental cost with higher context specificity.  
 
 
Hence, results of this thesis essentially confirm the conclusions of Barbieri et al 
(2005). However, the analysis within this thesis goes much further. The impact of 
 335 
 
‘context Specificity’ was actually quantified after controlling for a number of 
potential confounders. This means that, after controlling for differences in study 
populations, intervention cost and methods on data-level, significant coefficients 
could be ascertained for context specificity. Secondly, by decomposing the INMB 
statistic, it could be shown that the impact of context specificity is strongest for 
∆C, whilst coefficients were not significant for ∆E or INMBs. It may be the case 
that transferring effectiveness data is much more common than transferring 
economic data, so that there is simply no systematic country variation on the 
effectiveness side of the INMB statistic. This may then feed through to INMBs, so 
that the univariate model also fails to show significant relationships between 
context specificity and measures of cost-effectiveness. Finally, whilst the analysis 
of Barbieri et al. (2005) relied on a rather descriptive analysis of ICERS within 
multinational studies, the analysis within this thesis utilised data from both single 
country and multinational studies within a quantitative analysis accounting for 
the hierarchical structure of the underlying data, confounding effects of other 
explanatory variables in the model, and the fact that multinational study-data 
does not justify the assumption of independence on country-level, thereby 
producing much more reliable results.  
 
 
6.3.3. Variability factors on study-level 
 
 
Moving on to the study-level, the ‘appropriate set of covariates’ proved to be a 
far more difficult to determine. Out of a large number of candidate variables, 
there were only few significant results: a binary capturing whether the study 
used the ‘CHD life expectancy model’ by Grover et al. (1998); a binary capturing 
whether effectiveness data was elicited from the 4S study; and a categorical 
encoding the scope of assessment (i.e. whether studies looked into CHD only, 
CHD and stroke, or CHD, stroke and PAD). Whilst it makes intuitive sense that the 
scope of assessment alters cost-effectiveness results, it may be indicated to look 
into potential reasons why 4S and studies by Grover et al. resulted in significant 
coefficients.   
 
 
 336 
 
With respect to studies published by Grover et al., features of the CVD life-
expectancy model as well as other study characteristics were analysed to elicit 
potential explanations for elevated cost-effectiveness results. One reason may 
be that the CVD life-expectancy model combines a number of features which all 
turned out to be positively related to measures of cost-effectiveness when 
individually tested in the MLM. In particular, the CVD life-expectancy model is a 
Markov model and the authors estimated treatment effectiveness by modelling 
the effect of statin treatment on cholesterol reduction and multivariate 
regression was used to estimate the effect of cholesterol reduction on CVD 
related mortality (e.g. Grover et al., 1998). More importantly, however, when 
validating their model, Grover et al (1998) compare the difference in CHD and 
stroke related mortality between intervention and control arms predicted by the 
model with the mortality observed in a number of clinical trials. Whilst predicted 
values were almost all within the range of CIs generated from trial data, these CIs 
were large and almost all of the predicted values exceeded observed trial results. 
Hence, the CVD life-expectancy model may overestimate the impact of statin 
treatment on CVD related mortality, which may lead to higher ∆C, ∆E and INMBs 
compared to other studies. 
 
 
Moving on to 4S data, existing meta-analyses on the effectiveness of statins in 
the primary and secondary prevention of CVD do not provide an indication of 
higher effectiveness estimates. (Ward et al., 2007). In other words, whilst 4S data 
favours treatment over control, estimates were well within the range of other 
statin trials (RR for 4S: 0.71, 95%CI: 0.59-0.85 versus all placebo controlled trials 
in Ward et al., 2007, RR: 0.84, 95%CI: 0.78-0.9). Hence, there must be other 
reasons for elevated ∆C observed in the bivariate model for 4S related data. One 
reason could relate to the prevention category, as 4S relates to secondary 
prevention for which statin effectiveness is well established. However, respective 
covariates have been tested extensively within this exercise so that this should 
have been picked up before. In addition, other data points within the analysis 
also refer to secondary prevention, whilst they elicited effectiveness data from 
other sources (e.g. CARE, LIPID or PLAC I & II). In conclusion, it was not possible 
to identify potential causes for elevated estimates of ∆E for 4S in the bivariate 
model. It may hence be indicated to further assess differences between 
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economic evaluation studies relying on 4S and those which elicited effectiveness 
data from other sources to find out what causes this significant difference in ∆E.  
 
 
A number of covariates on study-level expected to be related to variability in 
measures of cost-effectiveness were not included in the final model. For 
instance, industry funding was positively related to INMBs at the 5% level, whilst 
coefficients were not significant for ∆C or ∆E in the bivariate model. A positive 
relationship between industry funding and the cost-effectiveness of health 
technologies has previously been discovered by Miners et al. (2005). The authors 
undertook a retrospective pairwise comparison of evidence submitted to NICE’s 
technology appraisal programme by manufacturers of the relevant health 
technologies and by contracted university based assessment groups and 
conclude that ‘the estimated incremental cost-effectiveness ratios submitted by 
manufacturers were on average significantly lower than those submitted by the 
assessment groups. These results show that an important role of NICE’s appraisal 
committee, and of decision makers in general, is to determine which economic 
evaluations, or parts of evaluations, should be given more credence’.  
 
 
One variability factor on study-level, which has been previously identified by 
Barbieri et al (2005), was not significantly related to measures of cost-
effectiveness within the empirical analysis of this project. Precisely, Barbieri et al 
(2005) showed that the general study design (i.e. trial based or model based) 
explains some of the variability in measures of cost-effectiveness across 
countries. This was not confirmed within the current analysis. Further to that, 
results were especially disappointing with respect to the QHES instrument. 
Considerable effort was undertaken to operationalize this instrument and apply 
this quality checklist to all 67 studies included in this dataset. Though bivariate 
statistics showed statistically significant negative relationships to both 
components of the INMB statistic, results were very sensitive to small variations 
in the way QHES was operationalized for this empirical exercise, so that results 
may be interpreted with highest caution.  
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6.3.4. Variability factors on country-level 
 
 
As mentioned, country-level variability was negligible in the univariate 
framework, and though considerably higher in the bivariate model, the country 
VPC did not exceed 21% for ∆C and 15% for ∆E respectively. Nevertheless, a 
number of country-level covariates were tested in the bivariate model, and very 
small but statistically significant negative relationship between ∆C and GDP per 
capita as well as between ∆C and government spending as a percentage of total 
health expenditure were found. Likewise, a number of explanatory variables 
showed significant positive relationships with ∆E, amongst them total health 
expenditure as a percentage of GDP per capita, the number of GPs and 
pharmacists per 10,000 population, as well as population age, BMI and blood 
glucose levels. Though coefficients of country-covariates were mostly 
moderately significant and in accord with prior expectations, results should be 
interpreted with some caution. As mentioned, the country VPC was low, even for 
∆C and ∆E in the bivariate model. This may not accord findings of Barbieri et al. 
(2005) who found considerable variation between countries. However, in their 
study, the authors did not assign variation in measures of cost-effectiveness to 
their respective levels (i.e. data, study, and country) and therefore, assign all 
variability observed to the country-level. This exercise applied a more 
sophisticated method using MLM, which allows partitioning the variation in the 
data, thereby making explicit how much variability refers to differences within 
studies, between studies and between geographic domains.  
 
 
Barbieri et al. (2005) conclude that ‘differences in cost-effectiveness results 
between countries are not systematic’. Though only few significant country-
coefficients were found in this thesis and country-level variability was generally 
low, a different conclusion has been reached within this thesis. The observation 
of small country-coefficients may be explained by the fact that countries 
included in this empirical exercise were quite similar with respect to the country-
characteristics tested in the model. In particular, only developed countries were 
considered, showing mostly similar levels of economic attainment and variation 
in health related indicators is also generally low. In addition, unlike single level 
OLS regression models, MLMs ensure that standard errors for higher-level 
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covariates are not underestimated (Steele, 2008; Rasbash et al., 2009; Hox, 
2010). Hence, if country-level covariates still turn out to be significant in the 
three-level hierarchical model, this provides a strong indication that there may 
be systematic differences between countries. In conclusion, whilst differences 
within and between studies constitute the overriding source of variability in 
measures of cost-effectiveness, this project did show that there may be small but 
statistically significant systematic differences in measures of cost-effectiveness 
between countries. Further research may replicate this analysis within other 
intervention areas which also allows the inclusion of a wider range of countries 
at different levels of economic attainment.   
 
 
 
6.4. Key policy implications 
 
A number of researchers concerned with the transferability of economic 
evaluation results believe that ‘the economic question of whether an activity 
adds more to well-being than the alternative uses of the same resources in a 
particular community cannot be answered by reference to the costs and 
consequences of the same activity in a different community (Birch & Gafni, 2003). 
Other researchers argue that economic evaluation is transferable if ‘(a) potential 
users can assess their applicability to their setting and (b) they are applicable to 
that setting’ (e.g. Späth et al., 1999; Boulenger et al., 2005) 
 
 
Nevertheless, as Birch and Gafni further state, the validity of the method of 
valuation cannot be established independent of the setting in which it is to be 
used’ and even if the methods of valuation are valid in each setting, the authors 
pose the question of whether this implies that ‘numbers produced by application 
of the methods are generalisable across individuals and settings.’ Birch & Gafni 
(2003) conclude that the ‘generalisability of the validity of a method of valuation 
does not imply generalisability of the resulting valuations’ A similar opinion is 
being shared by Vale (2010).  
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However, one may argue that findings of this thesis mediate between these 
extreme viewpoints; just like the exchangeability assumption, which provides the 
theoretical foundation for MLM, mediates between the opposing assumptions of 
either identical or independent study and country parameters in a multilevel 
model. In line with Drummond et al (2009), this research builds up from the 
believe that the transfer of evidence from one country to another may hold if 
‘the analyst has identified the appropriate set of covariates for the 
exchangeability assumption to hold; and the characteristics of the country of 
interest are represented appropriately by countries in the dataset’ (Drummond et 
al., 2009).  
 
 
The question is then how the results generated within the empirical exercise may 
be used and interpreted for policy purposes. Having quantified variability factors 
for measures of cost-effectiveness, one may use the bivariate random intercepts 
model with covariates on data, study and country level developed in chapter 5.3 
to predict incremental cost and incremental effects for countries for which data 
is missing. For instance, for a male patient within the age cohort of 56 to 65, with 
a mean TCL of 6.5, HDL of 1.02, SBP of 133 and a history of CVD, predicting ∆C 
and ∆E for a country with a mean population age of 39, an annual GDP per capita 
of £25.000, 75% government expenditure on health as a percentage on total 
health expenditure and 11% of total health expenditure as percentage of GDP, 
results in 1.63 ∆E and £6,727 ∆C respectively. This result refers to either LYS or 
QALYS (as the outcome measure was not a significant variability factor for 
statins) and further assumes annual drug cost for statins of £520, a lifetime 
horizon and a health insurance perspective, and that statins are compared to 
‘doing nothing’ at a 3.5% discount rate on incremental effects. Having predicted 
both components of the INMB statistic for the country of interest, we can now 
calculate the cost-effectiveness for statins for the above specified patient cohort 
in this country, resulting in an ICER of £4,128, or an INMB of £42,165 at a WTP 
threshold for a unit of health gain of £30,000. (Likewise, for a WTP threshold of 
say 15.000, the respective INMB would be £17.723) Hence, in the absence of 
location specific data, prediction results support the use of statins for the 
specified patient cohort in the country of interest.  
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However, these results should be interpreted with caution. Most importantly, 
immense uncertainty results from high variability in measures of cost-
effectiveness observed in the data. This uncertainty may be quantified for the 
prediction results by applying statistical simulation methods which allow 
computation of the predicted values, their standard deviation as well as 
confidence intervals around predicted values (Taghreed et al., 2003). However, 
additional work would be required to allow performing such a simulation 
exercise within the bivariate MLM to obtain relevant parameters for predicting 
uncertainty. In this context, the concept of the variance function may be 
considered as in interesting alternative. The MLM framework allows modelling 
variability in measures of cost-effectiveness explicitly as a function of covariates, 
and chapter 5.4 introduced examples of plotting variability in INMB, ∆C and ∆E as 
a function of TCL, SBP, smoking status and diabetes status. It could be shown, for 
instance, that variability in measures of cost effectiveness increases with 
increasing blood pressure, and this could be utilised to focus research resources 
on further work for high blood pressure patients. The variance function will also 
be addressed as a potential area for future research below.  
 
 
Nevertheless, variability in the existing data is vast, and this exercise showed the 
difficulties of finding the “appropriate set of covariates” for the exchangeability 
assumption to hold. This proved to be a major challenge in this empirical 
exercise, especially with respect to differences between studies, which account 
for a large proportion of the overall variability in international cost-effectiveness 
data. In addition, potential violations of the MLM assumptions, for instance with 
respect to random parameters, or the appropriateness of shrinkage estimation 
within secondary data analysis, may lead to biased coefficients, which may 
ultimately lead to biased prediction results for ∆C and ∆E if one was using the 
models generated within this exercise for prediction. The policy implication 
which follows with respect to using the models developed for prediction is that 
after careful consideration of factors potentially causing variability in cost-
effectiveness data, one may use prediction results to inform decisions in 
countries for which this data is missing. However, because of the immense 
variability in the data, the problem of defining the ‘appropriate set of covariates’ 
and additional uncertainty from transferring data to locations for which it was 
not originally produced, decision makers ought to be very critical about the 
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information provided from prediction. Finally, the aim of this thesis was not to 
provide a tool for prediction, but – more fundamentally - to assess potential 
variability factors for cost-effectiveness data and to provide a method with which 
this could be done using secondary data from published economic evaluation 
studies.  
When considering transferability problems in practice, decision makers may have 
to choose from a number of existing economic evaluation studies applicable to 
different geographic domains. This choice should be based on the ‘degree of 
similarity’ between study characteristics and the target location, which accords 
the principles of analogical reasoning as outlined in Chapter 2. To assess the 
extent to which available studies meet the requirements of the target 
jurisdiction, decision makers ought to compare attributes of the studies available 
with attributes of the target country, and decide which of the available 
international cost-effectiveness studies may be most appropriate to inform 
decisions in the target country. In short, the choice within the existing data is, 
first of all, a choice between existing studies, not countries. Only once the 
decision maker has identified a number of candidate studies which meet the 
minimum requirements of the target jurisdiction, country characteristics may be 
considered to the extent to which they are reflected in the economic evaluation 
in question. However, the analysis within the empirical exercise of this thesis 
showed that the proportion of country-level variability is low, even after 
controlling for a large number of potential variability factors on data and study-
level. Hence, the geographic context within which the available evidence was 
originally produced turned out to be a less important source of variability in 
international cost-effectiveness data than differences between economic 
evaluation studies. This constitutes a key take home of this thesis, though it 
needs to be emphasized that the generalizability of these results should be 
evaluated in future research.  
 
 
Testing the generalisabilty of the results outside of statins could be done by 
replicating this analysis for different interventions to test the findings of this 
thesis, and a number of recommendations may simplify such a potential future 
exercise. For instance, a future study could, on the basis of this thesis, focus only 
on bivariate multilevel models for secondary data integration which cluster data 
in studies and countries, either with or without considering cross-classified data 
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structures. Secondly, populating a dataset may be simplified. For instance, 
experiences from this thesis may be used to more rapidly develop an appropriate 
data abstraction form for a similar exercise.  However, this thesis also showed 
that such an exercise crucially depends on a certain degree of consistency across 
studies with respect to the reporting of economic evaluation data.  Improving 
consistency would also improve the transparency and comparability of economic 
evaluation results in general, which is why it is strongly recommended to further 
develop and improve the acceptance of international standards for conducting 
and reporting economic evaluation studies in health.  
 
 
6.5. Areas for future research  
 
Probably one of the most interesting methodological areas for future research 
relates to the use of the variance function to express variability in measures of 
cost-effectiveness as a function of explanatory variables. In Section 5.4 of the 
empirical chapter, random slopes were fitted to the model, and variation in cost-
effectiveness data was plotted as a function of explanatory variables. It turned 
out, for instance, that variability between studies is constantly increasing for the 
relationship between INMBs and TCL and ∆E’s and TCL, so that results may be 
less transferable from the existing data to out of sample locations the higher the 
TCL of the target population. In addition, variance functions were almost flat for 
SBP, though the overall level of variability was much higher, suggesting to focus 
research resources on this patient characteristic in the target domain. In 
conclusion, for ranges of values of explanatory variables where variation in cost-
effectiveness data is high, uncertainty increases when transferring cost-
effectiveness results, which also increases the value of new evidence for the 
target country 
 
 
A number of issues for future research have been identified with respect to the 
variance function. For instance, is there a way to determine a ‘threshold value’ 
for variability in cost-effectiveness data which may guide decisions on whether or 
not to transfer existing evidence to the target country? To address this issue, it 
may be helpful to draw an analogy to the ‘value of information’ concept. 
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Precisely, Claxton et al. (2000) state that ‘the expected costs of uncertainty can 
also be interpreted as the expected value of perfect information (EVPI) since 
perfect information (an infinite sample) can eliminate the possibility of making 
the wrong decision. It is also the maximum a decision maker should be willing to 
pay for additional evidence to inform this decision in the future. If the EVPI 
exceeds the expected costs of additional research then it is potentially cost-
effective to acquire more information by conducting additional research’. In the 
context of transferability of economic evaluation data, one may interpret higher 
variability in measures of cost-effectiveness as higher uncertainty for the target 
setting. In other words, if variability in measures of cost-effectiveness in the 
existing evidence increases, so does the expected cost of uncertainty within the 
target country. Hence, one may transfer evidence for ranges of explanatory 
variables for which variability in measures of cost-effectiveness is low, and 
consider additional research for ranges of explanatory variables which show high 
variability in cost-effectiveness data. However, how to assign monetary values to 
different levels of variability, or how else to determine a threshold value for 
variability to decide upon the transfer of evidence to the target setting, are 
future research questions. 
 
 
In addition to that, one may also consider the application of the variance 
function in different research contexts, for instance within economic evaluation 
using IPD collected alongside multinational multicentre studies. A number of 
researchers already considered two-level hierarchical models for the analysis of 
multicentre trial or observational data (Sculpher et al., 2004; Grieve et al., 2005; 
Willan et al., 2005; Manca et al., 2005; Nixon et al., 2005; Pinto et al, 2005; 
Thompson et al., 2006; Manca et al., 2007; Grieve et al., 2007; Bachmann et al., 
2007; Coupe et al., 2007; Willan et al., 2008; Petrinco et al., 2009; Grieve et al., 
2010; Edbrooke et al., 2011). Some of these applications also allowed for random 
slopes of explanatory variables (Sculpher et al., 2004; Manca et al., 2005; 
Thompson et al., 2006; Bachmann et al., 2007). However, none of the existing 
studies modelled the variance function to show how variability in measures of 
cost-effectiveness changes as a function of explanatory variables. This, however, 
could be very informative within the context of a multicentre study, as it makes 
explicit how variability changes between centres, or countries, with respect to 
explanatory variables. In conclusion, heterogeneity between patients, centres 
 345 
 
and countries with respect to explanatory variables could be made explicit 
through the use of the variance function within the MLM framework, and it is 
suggested to address this issue in future research. 
 
 
Another area for future research has been identified when systematically 
reviewing the economic evaluation literature on statins in the primary and 
secondary prevention of CVD. Studies within this area seemed to be strongly 
related through common authorship, identical data sources, re-use of a 
previously published DAM, etc. As such relationships may cast into question the 
independence assumption of data on study-level, a ‘genealogy study’ was 
conducted which has been reported in Section 4.3. This exercise used MCA to 
explore ‘phenotypic similarities’ between published economic evaluation studies, 
and subsequently, it was aimed to identify ‘genotypic relationships’ which may 
explain the similarities across studies. The initial aim of this exercise was to 
confirm the appropriate MLM structure and to make sensible assumptions 
regarding dependencies of data on study-level. However, though the method 
was not (yet) accurate enough to base alternative MLM structures upon its 
findings, the method did show some potential so that future research should 
look into the use of MCA within the context of study-genealogy.  
 
 
Two technical issues for further research were identified with respect to MLM. 
First, the issue of shrinkage has been discussed earlier within the context of 
integrating secondary data from published economic evaluation studies. Within 
this discussion, the use of MLwiN’s weighting facility was mentioned. The idea is 
that information from particular studies could be regarded as being 
‘oversampled’ in the current dataset as it stems from studies where subgroup 
and sensitivity analyses were carried out more extensively. Hence, one may 
argue that out of the space of cost-effectiveness estimates, some estimates did 
have a greater ‘probability’ of being selected into the sample than others. 
Without weighting, however, the model assumes that each data point did have 
the same chance of being selected into the sample (CMM, 2011). As MLwiNs 
weighting facility is currently not available within MCMC estimation, it is 
suggested to pick up on the issue of weighting to ‘counteract’ shrinkage when 
using MLM for secondary data integration in future research.  
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The second technical issue within the MLM framework to be addressed in future 
research relates to multilevel multiple imputation of missing data. It has been 
previously pointed out that an imputation model ‘must have the right variance 
structure’. Hence, ‘if a dataset is multilevel, then the imputation model must be 
multilevel too’ (Carpenter & Goldstein). Therefore, a number of software tools 
were considered which may allow multilevel multiple imputation, for instance, 
MI macros for MLwiN (Carpenter & Goldstein) or Realcom IMPUTE (Goldstein, 
2009). However, none of these tools were capable of dealing with more 
complicated data structures like the bivariate three-level model. This is an area 
of on-going research, and it would also constitute an interesting area for future 
research which goes beyond the scope of this project. 
 
 
Finally, with respect to the empirical findings, the overriding priority for future 
research is, as mentioned above, to replicate this work within other intervention 
areas to test the robustness of its results. As previously highlighted, the empirical 
analysis was based on data collected for one intervention area only. Hence, 
results are intervention specific. Further to that, all countries represented in the 
dataset are developed countries, showing mostly similar levels of economic 
attainment and even variation in health related indicators was generally low. In 
conclusion, it is strongly recommended to replicate this research in other 
intervention areas to test its key findings. For instance, is there is the same 
‘disguising effect’ of multinational study data on variability in measures of cost-
effectiveness between countries in other intervention areas? Secondly, how does 
variability in measures of cost-effectiveness spread across different levels of the 
data hierarchy. In particular, does the finding that variability in measures of cost-
effectiveness is primarily due to differences within and between studies, not 
countries, also hold for other intervention areas? Third, is there a similar pattern 
in country-level variability in ∆C and ∆E which reduces country-level variation in 
INMBs in other disease areas, e.g. outside the area of disease prevention, or 
pharmacological interventions? If so, what may be potential reasons for such a 
similar pattern in variability within the components of the INMB statistic. Finally, 
what are the most important variability factors for measures of cost-
effectiveness in different intervention areas, and to which level do they belong. 
All these questions should be addressed when replicating this research within 
other intervention areas in future research.  
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6.6. Concluding remarks 
 
 
The aim of this thesis was to explore the transferability of economic evaluation 
results produced for one geographic area to another location of interest. 
Multilevel statistical models were developed for the integration of published 
international cost-effectiveness data to assess the impact of contextual effects 
on country-level; whilst controlling for baseline characteristics within, and across, 
a set of economic evaluation studies. Explanatory variables were derived from a 
list of factors suggested in the literature as possible constraints on the 
transferability of cost-effectiveness evidence. The approach was illustrated using 
published estimates of the cost-effectiveness of statins for the primary and 
secondary prevention of cardiovascular disease Results show that the proportion 
of variation at the country-level observed depends on the appropriate multilevel 
model structure and never exceeds 15% for incremental effects and 21% for 
incremental cost respectively. Key sources of variability are patient and disease 
characteristics, intervention cost and a number of methodological characteristics 
defined on the data-level. There were fewer significant covariates on the study 
and country-levels. The findings of the empirical work carried out within this 
thesis suggest that variability in cost-effectiveness data is primarily due to 
differences between studies, not countries. Further, comparing different models 
suggests that data from multinational studies severely underestimates country-
level variability. Additional research is needed to test the robustness of these 
conclusions on other sets of cost-effectiveness data, to further explore the 
appropriate set of covariates, and to foster the development of multilevel 
statistical modelling for economic evaluation data in health.  
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Appendices 
 
 
Appendices for Chapter 2 
 
Appendix 2.1: Search strategy for SCOPUS (Medline, Embase, 
Science Direct) 
 
Initial search performed in SCOPUS on September 13th 2010 and updated on May, 23rd 
2012. 166 hits exported from SCOPUS to RefWorks 
 
1 ALL(multilevel OR hierarchical OR empirical bayes OR shrinkage OR random effects)  70696 
2 TITLE-ABS-KEY-AUTH(economics OR economic evaluation OR cost-effectiveness OR 
cost effectiveness OR cost OR effectiveness  or technology assessment)  
40224 
3 #1 and #2 166 
 
 
Appendix 2.2: Search strategy for Web of Knowledge  
 
Initial search performed in Web of Science on September 13th 2010 and updated on 
May, 23rd 2012. 246 hits exported from SCOPUS to Rewforks 
 
1 TITLE(multilevel OR hierarchical OR empirical bayes OR shrinkage OR random effects)  246 
2 TITLE(economics OR economic evaluation OR cost-effectiveness OR cost effectiveness 
OR cost OR effectiveness  or technology assessment)  
254945 
3 #1 and #2 246 
 
 
Appendix 2.3: Search strategy for HEED  
 
Initial search performed in HEED on September 13th 2010 and updated on May, 23rd 
2012. 246 hits exported from SCOPUS to Rewforks 
 
1 ALL(multilevel OR hierarchical OR empirical bayes OR shrinkage OR random effects)  51 
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Appendices for Chapter 3 
 
Appendix 3.1: Step by step guide for implementing univariate 
models in MLwiN using MCMC estimation 
 
1. If not already included, create data-id variable which is a vector of consecutive 
numbers from 1 to 2094. (using data manipulation / generate) 
2. sort data on ‘data_ID’ within ‘Study ID’ within ‘Country ID’ (using data 
manipulation / sort)  
3. Create a constant vector taking the value 1 for every data point in the dataset. 
This will be needed to model the intercepts. (using data manipulation, generate 
vector, constant vector, copies (1) value (1)  
4. Set up a two-level hierarchical model with data clustered in studies 
5. Run the two-level model in IGLS to obtain starting values 
6. Add random structure at level 3 (country) 
7. Change to MCMC estimation 
8. Click on model/MCMC/classifications and tick ‘treat levels as cross-classified (for 
the cross-classified model only) 
9. Go to C1096 and change country-level variance from 0 to 0.001 
10. Click start 
 
 
Appendix 3.2: Step by step guide for implementing bivariate models 
in MLwiN using MCMC estimation 
 
1. If not already included, create data-id variable which is a vector of consecutive 
numbers from 1 to 2094. (using data manipulation / generate) 
2. Divide incremental cost by 100. Though in theory irrelevant, a vast difference in 
the error variance between both response variables may distort the estimation 
process.  
3. Sort data on ‘data_ID’ within ‘country-ID’ within ‘study-ID’ (using data 
manipulation / sort)  
4. create a constant variable, taking the value 1 for every individual in the dataset. 
This will be needed to model the intercepts. 
5. Press the ‘responses’ button and select ‘incr_cost_div’ and ‘incr_effect’ in 
equations window. This will set up the bivariate model 
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6. Click on ‘resp’ in the Equations window and specify a 4 level structure with level 
4 being ‘Study ID’, level 3 being ‘Country ID’, level 2 being the sequence 
generated in Step 4, and level 1 being the ‘resp_indicator’ (which is already 
specified as level 1 since we are fitting a multivariate model) 
7. Press Add Term, selected ‘cons’, and click ‘add separate coefficients’.  
8. Click on each of the newly entered terms and tick all the boxes so that there will 
be a random effect at all three conceptual levels of the model (study, country, 
and data). 
9. Click on ‘Add Term’ and add explanatory variables with separate coefficients for 
each response and centred around the grand mean of the variable.  
10. Run the model in IGLS 
11. If a warning appears about the variance-covariance matrix not being positive 
definite several times: this happens sometimes during IGLS estimation and the 
model may not converge, but sometimes if pressing Yes (perhaps several times) 
to continue estimation the model will eventually converge.   
12. Some variances in the model were estimated zero. Zero variances are not 
acceptable starting values for MCMC. Go to the names window, column 1096, 
click on view data. This will display the variances and covariances calculated. If 
there are zero values, edit them to 0.001 as MCMC estimation requires a 
positive definite starting value of the variances.  
13. Change to MCMC estimation 
14. Click on Model, MCMC, classifications, tick the box ‘treat levels as cross-
classified’ (for the cross-classified model only) 
15. Click on model, hierarchy viewer to check model structure: Model should display 
2094 units in 67 studies and 23 countries.  
16. Click on start in the equations window, model will run 5000 iterations. However 
burning in and iterations may be changed when switching to MCMC estimation.  
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Appendices for Chapter 4 
 
Appendix 4.1: Search strategy for OVID (Medline and British Nursing 
Index) 
 
Search performed in OVID on April, 15th, 2011. Search strategy adapted from Ward et al 
(2007). 703 hits exported from OVID to Rewforks 
 
1 statin$.tw. 17605 
2 simvastatin.tw. 4709 
3 pravastatin.tw. 2802 
4 lovastatin.tw. 1232 
5 fluvastatin.tw. 2706 
6 atorvastatin.tw. 3620 
7 rosuvastatin.tw. 1043 
8 Hmg$.tw. 13658 
9 Co-reductase inhibitor$.tw. 3 
10 Hydroxymethylglutaryl-CoA Reductase Inhibitors/ 15387 
11 Anticholesteremic Agents/ or pravastatin/ or simvastatin/ or lovastatin.mp. (mp=title, 
original title, abstract, name of substance word, subject heading word, unique 
identifier) 
19281 
12 Lipid lowering.tw. 8035 
13 Or/1-12 48550 
14 Coronary disease/ 120990 
15 (coronary or heart or arter$).mp. (mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier) 
1516737 
16 Cerebrovascular disorders/ 41308 
17 Stroke.tw. 103629 
18 Or/14/17 1585408 
19 13 and 18 15788 
20 Economics/ 25995 
21 Exp “Costs and Cost Analysis”/ 38645 
22 Cost allocation/ 1893 
23 Cost-benefit analysis/ 50450 
24 Cost control/ 18629 
25 Cost savings/ 6959 
26 Exp “cost of Illness”/ 52112 
27 Health care costs/ 20932 
28 Drug costs/ 10226 
29 Health expenditures 11814 
30 Exp economics, pharmaceutical/ or exp economics/ or exp economics, medical 434969 
31 Exp”Fees and Charges”/  7674 
32 Exp Budgets/ 10867 
33 (high adj cost).tw. 4938 
34 (low adj cost).tw. 14369 
35 Cost utility.tw. 1626 
36 (fiscal or funding or financial or finance).tw. 58679 
37 (health?care adj cost).tw. 612 
38 (cost adj estimate).tw. 119 
39 (cost adj variable).tw. 27 
40 (unit adj cost).tw. 461 
41 (economics$ or pharmacoeconomics$ or price$ or pricing).tw. 26902 
42 Or/20-41 492126 
43 19 and 42 703 
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Appendix 4.2: Search Strategy for SCOPUS (Medline, Embase and 
Science Direct) 
 
Search performed in SCOPUS on April, 16th, 2011. 883 hits exported from SCOPUS to 
Refworks 
 
((statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR 
rosuvastatin OR hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase 
inhibitors OR anticholesteremic agents OR lipid lowering) AND (TITLE-ABS-KEY(cost OR cost-
effectiveness OR cost-utility OR cost-benefit)) AND (coronary disease OR heart disease OR 
cerebrovascular disorders OR stroke)) 
 
 
Appendix 4.3: Search strategy for Academic Search Complete 
(Business Source Premier and CINAHL) 
 
Search performed in Academic Search Complete on April, 16th, 2011. 305 hits exported 
from Academic search complete to Refworks 
 
(statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR rosuvastatin OR 
hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase inhibitors OR anticholesteremic 
agents OR lipid lowering ) and ( cost OR cost-effectiveness OR cost-utility OR cost-benefit ) and ( coronary 
disease OR heart disease OR cerebrovascular disorders OR stroke)  
 
Limiters - Exclude MEDLINE records  
Search modes - Boolean/Phrase  
 
 
Appendix 4.4: Search strategy for Health Economics Evaluation 
Database (HEED) 
 
Search performed in HEED on April, 19th, 2011. 226 hits exported from HEED to Refworks 
 
((statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR rosuvastatin OR 
hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase inhibitors OR anticholesteremic 
agents OR lipid lowering ) and (cost OR cost-effectiveness OR cost-utility OR cost-benefit) and (coronary 
disease OR heart disease OR cerebrovascular disorders OR stroke))  
 
 
Appendix 4.5: Search strategy for JStor 
 
Search performed in JStor on April, 19th, 2011. 569 hits exported from JStor to Refworks 
 
((anticholesteremic agents OR lipid lowering OR statin OR simvastatin OR pravastatin OR lovastatin OR 
fluvastatin OR atorvastatin OR rosuvastatin OR hmg OR coa-reductase inhibitor) AND (cost OR cost-
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effectiveness OR cost-utility OR cost-benefit) AND (coronary disease OR heart disease OR cerebrovascular 
disorders OR stroke)) 
 
Search was restricted to articles and reviews only (no pamphlets or ‘miscellaneous’) The 
reason was that the search engine provides a high number of non-relevant hits (e.g. 
front and back matters of journals, provided that the search terms appear on them) This 
restriction limited the number of hits from 1366 to 569. Secondly, all search terms were 
applied to ‘full text’ as Jstor only stores abstracts for about 10% of their papers listed.   
 
 
Appendix 4.6: Search strategy for Pubmed 
 
Search performed in Pubmed on April, 19th, 2011. 843 hits exported from Pubmed to 
Refworks 
#1 statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR 
rosuvastatin OR hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa 
reductase inhibitors OR anticholesteremic agents OR lipid lowering 
69648 
#2 cost OR cost-effectiveness OR cost-utility OR cost-benefit 480968 
#3 coronary disease OR heart disease OR cerebrovascular disorders OR stroke 1141994 
#4 #1 and #2 and #3 843 
 
 
Appendix 4.7: Search strategy for Web of knowledge  
 
Search performed in Web of Knowledge on April, 19th, 2011 
- 676 hits exported from Web of Science to Refworks 
- 292 hits exported from Biosis Previews to Refworks 
-  
Topic=(statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR rosuvastatin 
OR hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase inhibitors OR 
anticholesteremic agents OR lipid lowering) AND Topic=(cost OR cost-effectiveness OR cost-utility OR cost-
benefit) AND Topic=(coronary disease OR heart disease OR cerebrovascular disorders OR stroke) 
 
Web of knowledge hosts the databases Web of science, Medline and Biosis Previews. 
The search was conducted separately for Web of Science and Biosis Previews and 
subsequently exported to RefWorks. As Medline was covered by previous searches, this 
database was excluded here.  
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Appendix 4.8: Search strategy for CRD (includes DARE, HTA and 
NHS-EED) 
 
Search performed in CRD on April, 19th, 2011. 177 hits exported from CRD to Refworks 
 
(statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR rosuvastatin OR 
hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase inhibitors OR anticholesteremic 
agents OR lipid lowering) AND (cost OR cost-effectiveness OR cost-utility OR cost-benefit) AND (coronary 
disease OR heart disease OR cerebrovascular disorders OR stroke) 
 
Appendix 4.9: Search strategy for Wiley Online Library 
 
Search performed in Wiley Online Library on April, 20th, 2011. 537 hits exported from 
Wiley Online Library to Refworks 
 
statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR rosuvastatin OR hmg 
OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase inhibitors OR anticholesteremic agents 
OR lipid lowering in Abstract OR statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR 
atorvastatin OR rosuvastatin OR hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase 
inhibitors OR anticholesteremic agents OR lipid lowering in Publication Titles AND coronary disease OR 
heart disease OR cerebrovascular disorders OR stroke in FullText AND cost OR cost-effectiveness OR cost-
utility OR cost-benefit in FullText 
 
Search was limited to title and abstract (Statin search terms) and full text for other 
search terms as the Wiley search engine searches in all fields otherwise (including 
references). Hence, without this limiter the search would have resulted in more than 
15000 hits. 
 
Appendix 4.10: Search strategy for Cochrane Library 
 
Search performed in Cochrane Library on April, 21th, 2011 
• 71 hits exported to RefWorks from Cochrane Database of Systematic 
Reviews(CDSR) 
• 24 hits exported to RefWorks from Cochrane Central Register of Controlled Trials 
• 81 hits exported to RefWorks from Cochrane Methodology Register 
• 2 hits exported to RefWorks from Database of Abstracts of Reviews of Effects 
(DARE) 
• 17 hits exported to RefWorks from Health Technology Assessment Database (HTA) 
• 216 hits exported to RefWorks from NHS Economic Evaluation Database (NHS EED) 
 
(statin OR simvastatin OR pravastatin OR lovastatin OR fluvastatin OR atorvastatin OR rosuvastatin OR 
hmg OR co-reductase inhibitor OR hydroxymethylglutaryl-coa reductase inhibitors OR anticholesteremic 
agents OR lipid lowering) and (cost OR cost-effectiveness OR cost-utility OR cost-benefit) and (coronary 
disease OR heart disease OR cerebrovascular disorders OR stroke) 
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Appendix 4.11: Systematic reviews, meta-analyses, opinion pieces, 
etc. on the cost-effectiveness of statins which were hand-searched 
for relevant references (in alphabetical order of the first author) 
 
 
ID Reference 
R1 
ARA, R., RAFIA, R., WARD, S.E., WIERZBICKI, A.S., REYNOLDS, T.M., REES, A. & PANDOR, A., 2009. 
Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute 
and chronic perspective. Expert Review of Pharmacoeconomics & Outcomes Research, 9(5), pp. 
423-433.  
R2 
BROWN A D & GARBER, A.M., 1998. Cost effectiveness of coronary heart disease prevention 
strategies in adults. In: Aspects of Hypertension Management; Mallarkey, G., eds., ADIS 
International Ltd; Auckland, New Zealand 
R3 
COUKELL, A.J. & WILDE, M.I., 1998. Pravastatin - A pharmacoeconomic review of its use in primary 
and secondary prevention of coronary heart disease. PharmacoEconomics, 14(2), pp. 217-236.  
R4 
FARMER, J.A., 1998. Economic implications of lipid-lowering trials: current considerations in 
selecting a statin. American Journal of Cardiology, 82(6A), pp. 26M-31M.  
R5 
FRANCO, O.H., PEETERS, A., LOOMAN, C.W. & BONNEUX, L., 2005. Cost effectiveness of statins in 
coronary heart disease. Journal of Epidemiology & Community Health, 59(11), pp. 927-933 
R6 
GREENHELD, W., WILSON, J., BAYLISS, S. & HYDE, C., 2008. The clinical and cost-effectiveness of 
intensive versus standard lipid lowering with statins in the prevention of cardiovascular events 
amongst patients with acute coronary syndromes: a systematic review (Structured abstract). West 
Midlands Health Technology Assessment Collaboration.  
R7 
GROVER, S.A., 1999. The cost effectiveness of preventing cardiovascular diseases. Canadian Journal 
of Cardiology, 15, pp. 114G-116G.  
R8 
GUMBS, P.D., VERSCHUREN, M.W.M., MANTEL-TEEUWISSE, A., DE WIT, A.G., DE BOER, A. & 
KLUNGEL, O.H., 2007. Economic evaluations of cholesterol-lowering drugs: a critical and systematic 
review. PharmacoEconomics, 25(3), pp. 187-199.  
R9 
HAY, J.W., YU, W.M. & ASHRAF, T., 1999. Pharmacoeconomics of lipid-lowering agents for primary 
and secondary prevention of coronary artery disease. PharmacoEconomics, 15(1), pp. 47-74.  
R10 
JACOBSON, T.A., 1997. Preventing coronary heart disease in the managed care era: improving the 
cost-effectiveness of lipid-lowering therapy with HMG-CoA reductase inhibitors. The American 
Journal of Managed Care, 3, pp. 29-41. 
R11 
JACOBSON, T.A., SCHEIN, J.R., WILLIAMSON, A. & BALLANTYNE, C.M., 1998. Maximizing the cost-
effectiveness of lipid-lowering therapy. Archives of Internal Medicine, 158(18), pp. 1977-1989.  
R12 
KORTT M A & ARMSTRONG.,E.P., 1998. Cholesterol-lowering therapy interventions: a 
pharmacoeconomic assessment. Disease Management and Health Outcomes, 4(4), pp. 193-203. 
R13 
KREUZER, J. & KUBLER, W., 2001. Secondary prevention after cardiac infarct; therapeutic efficiency-
-cost-benefit ratio. Internist, 42(5), pp. 713-719.  
R14 
LINDGREN, P. & JÖ¶NSSON, B., 2009. From 4S to IDEAL: The health economics of the statin trials. 
European Journal of Cardiovascular Prevention and Rehabilitation, 16(2), pp. 138-143.  
R15 
MAC NEIL, P., 1998. Economic aspects of hypercholesterolemia treatment with HMG-CoA 
reductase inhibitors: a review of recent developments. Canadian Journal of Cardiology, 14, pp. 14A-
16A.  
R16 
MALHOTRA, H.S. & GOA, K.L., 2001. Atorvastatin: An updated review of its pharmacological 
properties and use in dyslipidaemia. Drugs, 61(12), pp. 1835-1881.  
R17 
MORRIS, S., MCGUIRE, A., CARO, J. & PETTITT, D., 1997. Strategies for the management of 
hypercholesterolaemia: a systematic review of the cost-effectiveness literature (Brief record). 
Journal of Health Service Research & Policy, 2(4), pp. 231-250 
R18 
NEYT, M., DE LAET, C., VAN BRABANDT, H., FRANCO, O. & RAMAEKERS, D., 2009. Cost-effectiveness 
of statins in the primary prevention of cardiovascular disease: a systematic review and economic 
analysis for Belgium. Acta Cardiologica, 64 (1), pp. 1-10 
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R19 THOMPSON, D. & OSTER, G., 1992. Cost-effectiveness of drug therapy for hypercholesterolaemia: a 
review of the literature. PharmacoEconomics, 2(1), pp. 34-42 
R20 
PERRAS, C. & BALADI, J.F., 1998. A clinical and economic review of HMG-CoA reductase inhibitors in 
coronary heart disease - summary. Canadian Coordinating Office for Health Technology Assessment 
(CCOHTA). Technology Overview: Pharmaceuticals Issue 12 
R21 
PERRAS, C. and BALADI, J., 1997. HMG-CoA reductase inhibitors: a review of published clinical trials 
and pharmacoeconomic evaluations - nonsystematic review. Canadian Coordinating Office for 
Health Technology Assessment (CCOHTA). CCOHTA Report 5E.  
R22 
PLOSKER, G.L. & LYSENG-WILLIAMSON, K., 2007. Atorvastatin: A pharmacoeconomic review of its 
use in the primary and secondary prevention of cardiovascular events. PharmacoEconomics, 25(12), 
pp. 1031-1053.  
R23 RECKLESS, J.P.D., 2000. Cost-effectiveness of statins. Current Opinion in Lipidology, 11(4), pp. 351-
356.  
R24 SCHWARTZ, J.S., 1999. Comparative economic data regarding lipid-lowering drugs. American Heart 
Journal, 137(5), pp. S97-S104.  
R25 
SKREPNEK, G.H., 2005. Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of 
dyslipidemia and prevention of CHD. Expert Review of Pharmacoeconomics and Outcomes 
Research, 5(5), pp. 603-623.  
R26 SMITH, D.G., 2003. Pharmacoeconomics of lipid-lowering drugs. Current Atherosclerosis Reports, 
5(1), pp. 67-72.  
R27 
VAN DER WEIJDEN, T., KNOTTNERUS, J. A., AMENT, A.J.H.A, STOFFERS, H.E.J.H. & GROL, R.P.T.M., 
1998. Economic evaluation of cholesterol-related interventions in general practice. An appraisal of 
the evidence. Journal of Epidemiology and Community Health, 52, pp. 586-594 
R28 
WARD, S., LLOYD JONES, M., PANDOR, A., HOLMES, M., ARA, R., RYAN, A., YEO, W. & PAYNE, N., 
2007. A systematic review and economic evaluation of statins for the prevention of coronary 
events. Health Technology Assessment, 11(14), pp. 1-160.  
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Appendix 4.12: Original research articles meeting the inclusion 
criteria of the systematic literature review on the cost-effectiveness 
of statins in the primary and secondary prevention of CVD  
(in alphabetical order of the first author) 
 
 
ID Reference 
18 
ALONSO, R., FERNANDEZ DE BOBADILLA, J., MENDEZ, I., LAZARO, P., MATA, N. & MATA, P., 2008. 
Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive 
therapy. Rev. Esp. Cardiol., 61(4), pp. 382-393.  
19 
ANNEMANS, L., MARBAIX, S., WEBB, K., VAN GAAL, L. & SCHEEN, A., 2010. Cost effectiveness of 
atorvastatin in patients with type 2 diabetes mellitus  - a pharmacoeconomic analysis of the 
collaborative atorvastatin diabetes study in the Belgian population. Clinical Drug Investigation, 30(2), 
pp. 133-142.  
67 
ARA, R., PANDOR, A., STEVENS, J., REES, A. and RAFIA, R., 2009. Early high-dose lipid-lowering therapy 
to avoid cardiac events: a systematic review and economic evaluation. Health Technology 
Assessment, 13(34), pp. 1-74.  
20 
ARAUJO, D.V., BAHIA, L., SOUZA, C.P.R. & PAVÃ£O, A.L.B., 2007. Cost-effectiveness and budget 
impact analysis of rosuvastatin and atorvastatin for LDL-cholesterol and cardiovascular events 
lowering within the SUS scenario. International Journal of Atherosclerosis, 2(3), pp. 189-194.  
1 
ASHRAF, T., HAY, J.W., PITT, B., WITTELS, E., CROUSE, J., DAVIDSON, M., FURBERG, C.D. & RADICAN, 
L., 1996. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. 
American Journal of Cardiology, 78(4), pp. 409-414.  
37 
BERGER, K., KLOSE, G. & SZUCS, T.D., 1997. Economic aspects of drug therapy exemplified by 
pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart 
disease patients. Medizinische Klinik, 92(6), pp. 363-369.  
2 
CARO, J., KLITTICH, W., MCGUIRE, A., FORD, I., NORRIE, J., PETTITT, D., MCMURRAY, J. & SHEPHERD, 
J., 1997. The West of Scotland coronary prevention study: economic benefit analysis of primary 
prevention with pravastatin. BMJ, 315(7122), pp. 1577-1582.  
58 
CARO, J.J., HUYBRECHTS, K.F., KLITTICH, W.S., JACKSON, J.D. & MCGUIRE, A., 2003. Allocating funds 
for cardiovascular disease prevention in light of the NCEP ATP III guidelines. American Journal of 
Managed Care, 9(7), pp. 477-489.  
59 
CDC DIABETES COST-EFFECTIVENESS GROUP, 2002. Cost-effectiveness of intensive glycemic control, 
intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA, 
287(19), pp. 2542-2551.  
65 
CHAN, P.S., NALLAMOTHU, B.K., GURM, H.S., HAYWARD, R.A. & VIJAN, S., 2007. Incremental benefit 
and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. 
Circulation, 115(18), pp. 2398-2409.  
60 
CHAU, J., CHEUNG, B.M., MCGHEE, S.M., LAUDER, I.J., LAU, C.P. & KUMANA, C.R., 2001. Cost-
effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong 
Kong. Hong Kong Medical Journal, 7(4), pp. 360-368.  
39 
DAVIES, A., HUTTON, J., O'DONNELL, J. & KINGSLAKE, S., 2006. Cost-effectiveness of rosuvastatin, 
atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. 
British Journal of Cardiology, 13(3), pp. 196-202.  
64 
DRUMMOND, M.F., MCGUIRE, A. & FLETCHER, A., 1993. Economic evaluation of drug therapy for 
hypercholesterolemia in the UK. University of York, CHE discussion paper No 104.  
23 
FRANCO, O.H., DER KINDEREN, A.J., DE LAET, C., PEETERS, A. & BONNEUX, L., 2007. Primary 
prevention of cardiovascular disease: cost-effectiveness comparison. International Journal of 
Technology Assessment in Health Care, 23(1), pp. 71-79.  
15 
GANZ, D.A., KUNTZ, K.M., JACOBSON, G.A. & AVORN, J., 2000. Cost-effectiveness of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. 
Annals of Internal Medicine, 132(10), pp. 780-787.  
62 
GLICK, H., HEYSE, J.F., THOMPSON, D., EPSTEIN, R.S., SMITH, M.E. & OSTER, G., 1992. A model for 
evaluating the cost-effectiveness of cholesterol-lowering treatment. International Journal of 
Technology Assessment in Health Care, 8(4), pp. 719-734.  
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24 
GREVING, J., VISSEREN, F., DE WIT, G. & ALGRA, A., 2011. Statin treatment for primary prevention of 
vascular disease: whom to treat? Cost-effectiveness analysis. BMJ (Clinical research ed.), 342, pp. 
d1672.  
3 
GROVER, S.A., COUPAL, L., PAQUET, S. & ZOWALL, H., 1999. Cost-effectiveness of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular 
disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. 
Archives of Internal Medicine, 159(6), pp. 593-600.  
4 
GROVER, S.A., COUPAL, L., ZOWALL, H. & DORAIS, M., 2000. Cost-effectiveness of treating 
hyperlipidemia in the presence of diabetes : who should be treated?. Circulation, 102(7), pp. 722-727.  
16 
GROVER, S.A., COUPAL, L., ZOWALL, H., ALEXANDER, C.M., WEISS, T.W. & GOMES, D.R.J., 2001. How 
Cost-Effective is the Treatment of Dyslipidemia in Patients with Diabetes but without Cardiovascular 
Disease? Diabetes Care, 24(1), pp.45-50 
61 
GROVER, S.A., HO, V., LAVOIE, F., COUPAL, L., ZOWALL, H. & PILOTE, L., 2003. The importance of 
indirect costs in primary cardiovascular disease prevention: Can we save lives and money with 
statins? Archives of Internal Medicine, 163(3), pp. 333-339.  
22 
GROVER, S.A., COUPAL, L. & LOWENSTEYN, I., 2008. Preventing cardiovascular disease among 
Canadians: Is the treatment of hypertension or dyslipidemia cost-effective? Canadian Journal of 
Cardiology, 24(12), pp.891-898 
5 
HAMILTON, V.H., RACICOT, F.E., ZOWALL, H., COUPAL, L. & GROVER, S.A., 1995. The cost-
effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the 
benefits of increasing HDL-C. JAMA, 273(13), pp. 1032-1038.  
25 
HEART PROTECTION STUDY COLLABORATIVE GROUP, 2009. Statin Cost-Effectiveness in the United 
States for People at Different Vascular Risk levels. Circulation.Cardiovascular Quality & Outcomes, 
2(2), pp. 65-72.  
52 
HEART PROTECTION STUDY COLLABORATIVE GROUP, MIHAYLOVA, B., BRIGGS, A., ARMITAGE, J., 
PARISH, S., GRAY, A. and COLLINS, R., 2006. Lifetime cost effectiveness of simvastatin in a range of 
risk groups and age groups derived from a randomised trial of 20,536 people. BMJ, 333(7579), pp. 
1145.  
57 
HJALTE, K., LINDGREN, B., PERSSON, U. & OLSSON, A.G., 1989. Lipid lowering therapy: Cost estimates 
in Sweden. In: Lewis, B., Assman, G., eds. The social and economic context of coronary prevention. 
Current medical Literature: Proceedings of the international task force for prevention of coronary 
heart disease.  
47 
JOHANNESSON, M., BORGQUIST, L., JONSSON, B. & LINDHOLM, L.H., 1996. The cost effectiveness of 
lipid lowering in Swedish primary health care. The CELL Study Group. Journal of Internal Medicine, 
240(1), pp. 23-29.  
6 
JOHANNESSON, M., JONSSON, B., KJEKSHUS, J., OLSSON, A.G., PEDERSEN, T.R. & WEDEL, H., 1997. 
Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary 
heart disease. The New England Journal of Medicine, 336, pp.332-336 
14 
JONSSON, B., COOK, J.R. & PEDERSEN, T.R., 1999. The cost-effectiveness of lipid lowering in patients 
with diabetes: results from the 4S trial. Diabetologia, 42(11), pp. 1293-1301.  
13 
JONSSON, B., JOHANNESSON, M., KJEKSHUS, J., OLSSON, A.G., PEDERSEN, T.R. & WEDEL, H., 1996. 
Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study 
(4S). European Heart Journal, 17(7), pp. 1001-1007.  
26 
KHOURY, H., WAGNER, M., MERIKLE, E., JOHNSON, S.J. and ROBERTS, C., 2009. Cost-effectiveness of 
atorvastatin in the primary prevention of major cardiovascular events in patients with type 2 diabetes 
in Canada. Canadian Journal of Diabetes, 33(4), pp. 363-374.  
27 
KONGNAKORN, T., WARD, A., ROBERTS, C.S., O'BRIEN, J.A., PROSKOROVSKY, I. & CARO, J.J., 2009. 
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. 
Value in Health, 12(6), pp. 880-887.  
21 
LINDGREN, P., ERIKSSON, J., BUXTON, M., KAHAN, T., POULTER, N., DAHLOF, B., SEVER, P., WEDEL, H., 
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9 
PHAROAH, P.D. & HOLLINGWORTH, W., 1996. Cost effectiveness of lowering cholesterol 
concentration with statins in patients with and without pre-existing coronary heart disease: life table 
method applied to health authority population. BMJ, 312(7044), pp. 1443-1448.  
54 
RAIKOU, M., MCGUIRE, A., COLHOUN, H.M., BETTERIDGE, D.J., DURRINGTON, P.N., HITMAN, G.A., 
NEIL, H.A.W., LIVINGSTONE, S.J., CHARLTON-MENYS, V. & FULLER, J.H., 2007. Cost-effectiveness of 
primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the 
Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 50(4), pp. 733-740.  
55 
RAMSEY, S.D., CLARKE, L.D., ROBERTS, C.S., SULLIVAN, S.D., JOHNSON, S.J. & LIU, L.Z., 2008. An 
economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 
diabetes. PharmacoEconomics, 26(4), pp. 329-339.  
30 
ROSEN, V.M., TAYLOR, D.C., PAREKH, H., PANDYA, A., THOMPSON, D., KUZNIK, A., WATERS, D.D., 
DRUMMOND, M. & WEINSTEIN, M.C., 2010. Cost effectiveness of intensive lipid-lowering treatment 
for patients with congestive heart failure and coronary heart disease in the US. PharmacoEconomics, 
28(1), pp. 47-60.  
31 
SCUFFHAM, P.A. & CHAPLIN, S., 2005. A cost-effectiveness analysis of fluvastatin in patients with 
diabetes after successful percutaneous coronary intervention. Clinical therapeutics, 27(9), pp. 1467-
1477.  
56 
SCUFFHAM, P.A. & CHAPLIN, S., 2004. An economic evaluation of fluvastatin used for the prevention 
of cardiac events following successful first percutaneous coronary intervention in the UK. 
PharmacoEconomics, 22(8), pp. 525-535.  
32 
SCUFFHAM, P.A. & KOSA, J., 2006. The cost-effectiveness of fluvastatin in Hungary following 
successful percutaneous coronary intervention. Cardiovascular Drugs & Therapy, 20(4), pp. 309-317.  
46 
SIGVANT, B., HENRIKSSON, M., LUNDIN, F. & WAHLBERG, E., 2011. Asymptomatic peripheral arterial 
disease: is pharmacological prevention of cardiovascular risk cost-effective? European journal of 
cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, 
Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 
18(2), pp. 254-261.  
43 
SLEJKO, J.F., PAGE, R.L.,2ND & SULLIVAN, P.W., 2010. Cost-effectiveness of statin therapy for vascular 
event prevention in adults with elevated C-reactive protein: implications of JUPITER. Current Medical 
Research & Opinion, 26(10), pp. 2485-2497.  
41 
SOINI, E.J., DAVIES, G., MARTIKAINEN, J.A., HU, H.X., TUNCELI, K. & NISKANEN, L., 2010. Population-
based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. 
Current Medical Research & Opinion, 26(1), pp. 25-36.  
40 
SPAANS, J.N., COYLE, D., FODOR, G., NAIR, R., VAILLANCOURT, R., GROVER, S.A. & COUPAL, L., 2003. 
Application of the 1998 Canadian cholesterol guidelines to a military population: health benefits and 
cost effectiveness of improved cholesterol management. Canadian Journal of Cardiology, 19(7), pp. 
790-796.  
 376 
 
11 
SZUCS, T.D., BERGER, K., MÄRZ, W. and SCHÄFER, J.R., 2000. Cost-effectiveness of pravastatin in 
secondary prevention in patients with myocardial infarction or instable angina in Germany. An 
analysis on the basis of the LIPID trial. Herz, 25(5), pp. 487-494.  
45 
SZUCS, T.D., BERTEL, O., DARIOLI, R., GUTZWILLER, F. & MORDASINI, R., 2000. Pharmacoeconomic 
evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or 
unstable angina pectoris. An analysis based on the LIPID Study. Praxis, 89(18), pp. 745-752.  
10 
SZUCS, T.D., GUGGENBERGER, G., BERGER, K., MÄRZ, W. & SCHÄFER, J.R., 1998. Pharmacoeconomic 
evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with 
average cholesterol levels. An analysis for Germany based on the CARE study. Herz, 23(5), pp. 319-
329.  
49 
SZUCS, T.D., KLOSE, G. & DUSING, R., 2004. Cost-effectiveness of atorvastatin for the prevention of 
coronary disease. An analysis of the ASCOT study. Deutsche Medizinische Wochenschrift, 129(25-26), 
pp. 1420-1424.  
33 
TAYLOR, D.C.A., PANDYA, A., THOMPSON, D., CHU, P., GRAFF, J., SHEPHERD, J., WENGER, N., GRETEN, 
H., CARMENA, R., DRUMMOND, M. & WEINSTEIN, M.C., 2009. Cost-effectiveness of intensive 
atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and 
Germany, based on the treating to new targets study. European Journal of Health Economics, 10(3), 
pp. 255-265.  
34 
TONKIN, A.M., ECKERMANN, S., WHITE, H., FRIEDLANDER, D., GLASZIOU, P., MAGNUS, P., KIRBY, A., 
MULRAY, S., DENTON, M., SALLABERGER, M., HUNT, D., SIMES, J. & LIPID STUDY, G., 2006. Cost-
effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute 
coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID 
study. American Heart Journal, 151(6), pp. 1305-1312.  
48 
TROCHE, C.J., TACKE, J., HINZPETER, B., DANNER, M. & LAUTERBACH, K.W., 1998. Cost-effectiveness 
of primary and secondary prevention in cardiovascular diseases. European Heart Journal, 19(Suppl C), 
pp. 59-65.  
53 
TSEVAT, J., KUNTZ, K.M., ORAV, E.J., WEINSTEIN, M.C., SACKS, F.M. & GOLDMAN, L., 2001. Cost-
effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol 
levels. American Heart Journal, 141(5), pp. 727-734.  
12 
VAN HOUT, B.A. & SIMOONS, M.L., 2001. Cost-effectiveness of HMG coenzyme reductase inhibitors; 
whom to treat?. European Heart Journal, 22(9), pp. 751-761.  
35 
WAGNER, M., LINDGREN, P., MERIKLE, E., GOETGHEBEUR, M. & JÖNSSON, B., 2009a. Economic 
evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 
mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-
Points Through Aggressive Lipid-Lowering (IDEAL) trial. Canadian Journal of Cardiology, 25(11), pp. 
e362-e369.  
36 
WAGNER, M., GOETGHEBEUR, M., MERIKLE, E., PANDYA, A., CHU, P. & TAYLOR, D.C., 2009b. Cost-
effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of 
atorvastatin, for secondary prevention of cardiovascular disease in Canada. Canadian Journal of 
Clinical Pharmacology, 16(2), pp. e331-45.  
66 
WARD S, LLOYD JONES M, PANDOR A, HOLMES M, ARA R, RYAN A, et al., 2007. Systematic review and 
economic evaluation of statins for the prevention of coronary events. Health Technology Assessment, 
11(14) 
 
 
 
 
 
 
 
 
 
 
 
 
 377 
 
Appendix 4.13: final data abstraction form  
1/3 - study-level information 
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Final data abstraction form  
2/3 – QHES-assignment 
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Final data abstraction form  
3/3 - data-level information 
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Appendices for Chapter 5 
 
 
Appendix 5.1: Descriptive statistics of data and study-level 
covariates 
 
Appendix 5.1.1:  Descriptive statistics of patient and disease characteristics – 
continuous variables 
 
Variable Obs. missing in % Min Max Mean Std. Dev. 
tcl 1193 901 43.03% 4.5 10.35 6.676 1.204 
hdl 1147 947 45.22% 0.9 1.55 1.168 0.102 
ldl 926 1168 55.78% 1.9 8.2 4.509 1.035 
hypert 826 1268 60.55% 0 1 0.317 0.381 
sbp 1140 954 45.56% 120 164.7 137.475 13.348 
smokers 1141 953 45.51% 0 1 0.291 0.335 
diab 1163 931 44.46% 0 1 0.178 0.349 
 
 
 
Appendix 5.1.2: Descriptive statistics of patient and disease characteristics – 
categorical variables 
 
Variable 
category 
Frequency 
(full sample: 2094) 
In % cummulative 
Age_cat 
- <45 
- 46 to 55 
- 56 to 65 
- 66 to 75  
- > 75 
- Unclear (missing) 
 
322 
439 
862 
299 
98 
74 
 
15.38% 
20.96% 
41.17% 
14.28% 
4.68% 
3.53% 
 
15.38% 
36.35% 
77.51% 
91.79% 
96.47% 
100% 
Gender_cat 
- Female 
- Male  
- Mixed study sample 
- Unclear (missing) 
 
576 
799 
556 
163 
 
27.51% 
38.16% 
26.55% 
7.78% 
 
27.51% 
65.56% 
92.22% 
100% 
CHD_history 
- No (primary prevention) 
- Yes (secondary prevention) 
- Mixed study sample 
 
1064 
958 
72 
 
50.81% 
45.75% 
3.44% 
 
50.81% 
96.56% 
100% 
Risk_cat* 
- Very low (<10%) 
- Low (<20%) 
- Medium (<30%) 
- High (<40%) 
- Very high (> 40%) 
- Secondary prevention 
- Unclear (missing)  
 
193 
367 
278 
140 
106 
958 
52 
 
9.22% 
17.53% 
13.28% 
6.69% 
5.06% 
45.75% 
2.48% 
 
9.22% 
26.75% 
40.02% 
46.71% 
51.77% 
97.52% 
100% 
* defined as 10 year CHD risk estimated using patient risk factors reported above using Framingham risk equation (reference)  
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Appendix 5.1.3 Descriptive statistics of intervention and comparator 
characteristics – continuous variables 
 
Variable   
(in 2010 £-Sterling) 
Obs. missing in % Min Max Mean Std. Dev. 
Cost_int 1957 137 6.54% 21.48 1917.56 521.59 335.10 
Unitcost_int 1738 356 17.00% 0.0012 0.1773 0.05 0.032 
Cost_comp 2092 2 0.10% 0 1002.36 26.06 115.37 
Unitcost_comp 2083 11 0.53% 0 0.156 0.0037 0.018 
Incr_int_cost 1727 367 17.53% -0.1255 0.1773 0.0461 0.039 
 
 
 
Appendix 5.1.4: Descriptive statistics of intervention and comparator 
characteristics– categorical variables 
 
Variable 
category 
Frequency 
(full sample: 2094) 
In % cumulative 
Intervention (brand name) 
- Simvastatin 
- Fluvastatin 
- Atorvastatin 
- Pravastatin 
- Lovastatin 
- Rosuvastatin 
- Unclear (missing) 
 
1080 
41 
184 
256 
125 
60 
348 
 
51.58% 
1.96% 
8.79% 
12.23% 
5.97% 
2.87% 
16.60% 
 
51.58% 
53.54% 
62.33% 
74.56% 
80.53% 
83.40% 
100% 
TDD-intervention (total daily dose) 
- Up to 10 mg 
- Up to 20 mg 
- Up to 30 mg 
- Up to 40 mg 
- > 60 mg 
- Unclear (missing) 
 
65 
259 
554 
654 
206 
356 
 
3.10% 
12.37% 
26.46% 
31.23% 
9.84% 
17.00% 
 
3.10% 
15.47% 
41.93% 
73.16% 
83.00% 
100% 
Comparator  
- Simvastatin 
- Fluvastatin 
- Atorvastatin 
- Pravastatin 
- Lovastatin 
- Rosuvastatin 
- Doing nothing 
- Unclear (missing) 
 
153 
3 
44 
19 
24 
15 
1834 
2 
 
7.31% 
0.14% 
2.10% 
0.91% 
1.15% 
0.72% 
87.58% 
0.1% 
 
7.31% 
7.45% 
9.55% 
10.46% 
11.61% 
12.33% 
99.90% 
100% 
Comparator_short 
- Doing nothing 
- Simvastatin 
- Other 
 
1834 
153 
107 
 
87.58% 
7.31% 
5.11% 
 
87.58% 
94.98% 
100% 
Active_comparator 
- yes 
- no (doing nothing) 
- unclear (missing) 
 
260 
1834 
0 
 
12.42% 
87.58% 
-- 
 
12.42% 
100% 
-- 
TDD-comp (total daily dose) 
- 0 mg (doing nothing) 
- Up to 10 mg 
- Up to 20 mg 
- Up to 30 mg 
- Up to 40 mg 
- Unclear (missing) 
 
1834 
44 
26 
24 
155 
11 
 
87.58% 
2.10% 
1.24% 
1.15% 
7.40% 
0.53% 
 
87.58% 
89.68% 
90.92% 
92.07% 
99.47% 
100% 
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Appendix 5.1.5: Descriptive statistics of methods on data-level – continuous 
variables 
 
Variable   
(in 2010 £-Sterling) 
Obs. missing in % Min Max Mean Std. Dev. 
DRC 2094 0 0% 0 10% 3.94% 1.66% 
DRB 2094 0 0% 0 10% 2.99% 1.81% 
 
 
 
Appendix 5.1.6: Descriptive statistics of methods on data-level – categorical 
variables 
 
Variable 
category 
Frequency 
(full sample: 2094) 
In % cumulative 
Outcome_measure 
- LYS 
- QALYs 
 
1319 
775 
 
62.99% 
37.01% 
 
62.99% 
100% 
Elicitation 
- N.a. (LYS) 
- TTO 
- EQ-5D 
- Other choice based method 
- Unclear (missing) 
 
1319 
112 
313 
333 
17 
 
62.99% 
5.35% 
14.95% 
15.90% 
0.81% 
 
62.99% 
68.34% 
83.29% 
99.19% 
100% 
Population 
- N.a. (LYS) 
- Patient 
- Population 
- Unclear (missing) 
 
1319 
215 
474 
86 
 
62.99% 
10.27% 
22.64% 
4.11% 
 
62.99% 
73.26% 
95.90% 
100% 
Duration 
- < 5years 
- 5 to <10 years 
- 10 to <15 years 
- 15 to <20 years  
- 20 to <25 years 
- > 25 years (lifetime) 
- Unclear (missing) 
 
66 
788 
175 
44 
87 
814 
120 
 
3.15% 
37.63% 
8.36% 
2.10% 
4.15% 
38.87% 
5.73% 
 
3.15% 
40.78% 
49.14% 
51.24% 
55.39% 
94.26% 
100% 
Duration_short 
- < 10 years 
- 10 to < 20 years 
- >20 years 
- Unclear (missing) 
 
854 
219 
901 
120 
 
40.78% 
10.46% 
43.03% 
5.73% 
 
40.78% 
51.24% 
94.27% 
100% 
Extrapolation beyond follow up? 
- Yes 
- No 
 
1942 
152 
 
92.74% 
7.26% 
 
92.74% 
100% 
Horizon 
- < 5 years 
- 5 to < 10 years 
- 10 to < 15 years 
- 15 to < 20 years 
- 20 to < 25 years 
- > 25 years (lifetime) 
 
17 
191 
330 
132 
91 
1333 
 
0.81% 
9.12% 
15.76% 
6.30% 
4.35% 
63.66% 
 
0.81% 
9.93% 
25.69% 
32.00% 
36.34% 
100% 
Horizon_short 
- ≤ 10 years 
- ≤ 20 years 
- > 20 years 
 
208 
462 
1424 
 
9.93% 
22.06% 
68.00% 
 
9.93% 
32.00% 
100% 
Horizon_eq_duration 
- Yes 
- No 
 
1328 
766 
 
63.42% 
36.58% 
 
63.42% 
100% 
Perspective_reported 
- Health insurance (NHS) 
- Societal 
- No perspective reported 
 
1369 
214 
511 
 
65.38% 
10.22% 
24.40% 
 
65.38% 
75.60% 
100% 
Perspective_cost_concluded 
- Provider 
- Health insurance (NHS) 
- Societal 
 
20 
1939 
135 
 
0.96% 
92.60% 
6.45% 
 
0.96% 
93.55% 
100% 
Perspective_benefits_concluded 
- Patient 
 
2094 
 
100% 
 
100% 
Perspective_discrepancy 
- No 
- yes 
 
1459 
635 
 
69.68% 
30.32% 
 
69.68% 
100% 
Data_class (sensitivity analysis) 
- base case 
 
1125 
 
53.72% 
 
53.72% 
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- efficiency of intervention 
- CVD risk at baseline 
- Cost (not intervention) 
- Cost of intervention 
- QALYs 
- Treatm. duration / time horizon 
- Discount rate 
- Other sensitivity analysis 
12 
49 
64 
86 
72 
288 
257 
141 
0.57% 
2.34% 
3.06% 
4.11% 
3.44% 
13.75% 
12.27% 
6.73% 
54.30% 
56.64% 
59.69% 
63.80% 
67.24% 
80.99% 
93.27% 
100% 
Basecase 
- Yes 
- No (sensitivity analysis) 
 
1125 
969 
 
46.28% 
53.72% 
 
46.28% 
100% 
Source_effectivenes data 
- Literature / meta analysis 
- PLAC I/II 
- CARE 
- WOSCOPS 
- 4S 
- 4S and WOSCOPS 
- EXCEL 
- LIPID 
- CURVES 
- CARDS 
- ASCOTT 
- HPS 
- SPARCL 
- TNT 
- LIPS 
- IDEAL 
- STELLAR 
- CELL 
- other 
 
652 
38 
88 
81 
509 
46 
120 
23 
12 
28 
6 
280 
8 
42 
33 
24 
62 
8 
34 
 
31.14% 
1.81% 
4.20% 
3.87% 
24.31% 
2.20% 
5.73% 
1.10% 
0.57% 
1.34% 
0.29% 
13.37% 
0.38% 
2.01% 
1.58% 
1.15% 
2.69% 
0.38% 
1.62% 
 
31.14% 
32.95% 
37.15% 
41.02% 
65.33% 
67.53% 
73.26% 
74.36% 
74.93% 
76.27% 
76.55% 
89.92% 
90.31% 
92.31% 
93.89% 
95.03% 
97.99% 
98.38% 
100% 
Barbieri_1 
- Type C 
- Type CR 
- Type CU 
- Type CRE 
- Type CRU 
- Type CREU 
 
186 
1033 
113 
193 
513 
56 
 
8.88% 
49.33% 
5.40% 
9.22% 
24.50% 
2.67% 
 
8.88% 
58.21% 
63.61% 
72.83% 
97.33% 
100% 
Barbieri_2 
- Type 1 
- Type 2 
- Type 3 
- Type 4 
 
186 
1146 
706 
56 
 
8.88% 
54.73% 
33.72% 
2.67% 
 
8.88% 
63.61% 
97.33% 
100% 
 
 
 
 
 
 
 
Appendix 5.1.7: Descriptive statistics of general study characteristics – 
continuous variables 
 
Variable   
(in 2010 £-Sterling) 
Obs. missing in % Min Max Mean Std. Dev. 
Timing_cont* 67 0 0% 1988 2009 2000 5.7 
* timing was also defined as a categorical variable (see table x.8 below) 
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Appendix 5.1.8: Descriptive statistics of general study characteristics – 
categorical variables 
 
Variable 
category 
Frequency 
(full sample: 67) 
In % cumulative 
Language 
- English 
- German 
 
61 
6 
 
91.04% 
8.96% 
 
91.04% 
100% 
Paper_origin 
- Australia 
- Belgium  
- Brazil 
- Canada 
- Finland 
- Germany 
- Hong Kong 
- Japan 
- Netherlands 
- Spain 
- Sweden 
- Switzerland 
- UK 
- UK (England / Wales) 
- UK (Scotland) 
- USA 
- Scandinavian countries 
- North America (USA / 
Canada) 
- Multi_country 
 
1 
2 
1 
13 
2 
6 
1 
1 
3 
1 
7 
1 
6 
6 
1 
12 
1 
1 
1 
 
1.49% 
2.99% 
1.49% 
19.40% 
2.99% 
8.96% 
1.49% 
1.49% 
4.48% 
1.49% 
10.45% 
1.49% 
8.96% 
8.96% 
1.49% 
17.91% 
1.49% 
1.49% 
1.49% 
 
1.49% 
4.48% 
5.97% 
25.37% 
28.36% 
37.31% 
38.81% 
40.30% 
44.78% 
47.27% 
56.72% 
58.21% 
67.16% 
76.12% 
77.61% 
95.52% 
97.01% 
98.51% 
100% 
Author_group_long 
- No relationships 
- Group 1 
- Group 2 
- Group 3 
- Group 4 
- Group 5 
- Group 6 
- Group 7 
- Group 8 
- Group 9 
- Group 10 
- Group 11 
- Group 12 
 
18 
4 
5 
8 
4 
7 
5 
3 
3 
3 
3 
2 
2 
 
26.87% 
5.97% 
7.46% 
11.94% 
5.97% 
10.45% 
7.46% 
4.48% 
4.48% 
4.48% 
4.48% 
2.99% 
2.99% 
 
26.87% 
32.84% 
40.30% 
52.24% 
58.21% 
68.66% 
76.12% 
80.60% 
85.07% 
89.55% 
94.03% 
97.01% 
100% 
Author_group_short 
- No relationships 
- Group 1 
- Group 2 
- Group 3 
- Group 4 
- Group 5 
- Group 6 
- Group 7 
 
18 
29 
8 
3 
2 
3 
2 
2 
 
26.87% 
43.28% 
11.94% 
4.48% 
2.99% 
4.48% 
2.99% 
2.99% 
 
26.87% 
70.15% 
82.09% 
86.57% 
89.55% 
94.03% 
97.01% 
100% 
Timing_cat 
- 1988 
- 1990 
- 1991 
- 1992 
- 1993 
- 1995 
- 1996 
- 1997 
- 1998 
- 1999 
- 2000 
- 2002 
- 2003 
- 2004 
- 2005 
- 2006 
- 2007 
 
2 
1 
1 
1 
2 
7 
8 
4 
6 
1 
1 
4 
2 
2 
9 
3 
7 
 
2.99% 
1.49% 
1.49% 
1.49% 
2.99% 
10.45% 
11.94% 
5.97% 
8.96% 
1.49% 
1.49% 
5.97% 
2.99% 
2.99% 
13.43% 
4.48% 
10.45% 
 
2.99% 
4.48% 
5.97% 
7.46% 
10.45% 
20.90% 
32.84% 
38.81% 
47.76% 
49.25% 
50.75% 
56.72% 
59.70% 
62.69% 
76.12% 
80.60% 
91.04% 
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- 2008 
- 2009 
3 
3 
4.48% 
4.48% 
95.52% 
100% 
Multinational 
- No (single country study) 
- Yes (multinational study) 
 
61 
6 
 
91.04% 
8.96% 
 
91.04% 
100% 
Funding_institution 
- Industry 
- RC/Government / University 
- Unclear  
 
39 
11 
17 
 
58.21% 
16.42% 
25.37% 
 
Funding_manufacturer 
- No manufacturer 
sponsoring 
- Bristol Myers Squibb 
- MERCK 
- Pfizer 
- Other (Sandoz / AZ / 
Novartis) 
- unclear 
 
11 
7 
12 
13 
9 
15 
 
16.42% 
10.45% 
17.91% 
19.40% 
13.43% 
22.39% 
 
 
 
 
 
Appendix 5.1.9: Descriptive statistics of methods variables on study-level – 
categorical variables 
 
Variable 
category 
Frequency 
(full sample: 67) 
In % cumulative 
General_design 
- primary modelling 
- secondary modelling 
 
6 
61 
 
8.96% 
91.04% 
 
8.96% 
100% 
Primary_design 
- n.a. (primary modelling) 
- RCT 
 
61 
6 
 
91.04% 
8.96% 
 
91.04% 
100% 
Secondary_design 
- N.a. (primary modelling) 
- Markov model 
- Decision tree 
- Other  
 
6 
41 
7 
13 
 
8.96% 
61.19% 
10.45% 
19.40% 
 
 
Effect_calculation 
- CHD risk reduction 
- Cholesterol reduction 
 
41 
26 
 
61.19% 
38.81% 
 
61.19% 
100% 
Infl_adjustent 
- n.a. 
- yes 
- no 
- unclear (missing) 
 
12 
18 
2 
35 
 
17.91% 
26.87% 
2.99% 
52.24% 
 
Adjustment_method 
- n.a. 
- simple consumer price 
index 
- healthcare component of 
CPI 
- no adjustment though 
indicated 
- unclear (missing) 
 
12 
8 
10 
2 
35 
 
17.91% 
11.94% 
14.93% 
2.99% 
52.24% 
 
Currency_conversion 
- no 
- yes 
 
52 
15 
 
77.61% 
22.39% 
 
77.61% 
100% 
Conversion_method 
- n.a. 
- exchange rates 
- unclear 
 
52 
11 
4 
 
77.61% 
16.42% 
5.97% 
 
Scope 
- CAD 
- CAD and CD 
- CAD, CD, and PAD 
- unclear 
 
18 
35 
11 
3 
 
26.87% 
52.24% 
16.42% 
4.48% 
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Appendix 5.1.10:  Descriptive statistics of study quality indicators – continuous 
variables 
 
Variable   
(in 2010 £-Sterling) 
Obs. missing in % Min Max Mean Std. Dev. 
QHES cont (a) 67 0 0% 27.00 100 59.36 16.33 
QHES cont (b) 67 0 0% 40.83 100 69.32 13.89 
 
 
 
 
Appendix 5.1.11: Descriptive statistics of study quality indicators– categorical 
variables 
 
Variable 
category 
Frequency 
(full sample: 2094) 
In % cumulative 
QHES_cat (a) 
- up to 40 pts 
- up to 60 pts 
- up to 80 pts 
- up to 100 pts 
 
7 
31 
22 
7 
 
10.45% 
46.27% 
32.84% 
10.45% 
 
10.45% 
56.72% 
89.55% 
100% 
QHES_cat (b) 
- up to 60 pts 
- up to 80 pts 
- up to 100 pts 
 
20 
40 
7 
 
29.85% 
59.70% 
10.45% 
 
29.85% 
89.55% 
100% 
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Appendix 5.2: Logit models to determine candidate variables for 
regression based missing data imputation.  
 
Appendix 5.2.1: Logit model for predicting missingness in TCL (d_tcl) 
 
Obs 880 
LR chi2(14) 155.99 
Prob > chi2 0.0000 
Pseudo R2 0.8508 
Log likelihood =  -13.672772 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
INMB .0001087 .0001675 0.65 0.516 -.0002196 .000437 
incr_cost .0001818 .0002351 0.77 0.439 -.000279 .0006426 
incr_effect* 0 (omitted)     
ldl 2.848177 1.430478 1.99 0.046 .0444929 5.651862 
Hypert -.8160491 3.089475 -0.26 0.792 -6.871309 5.239211 
Smokers 2.205601 2.481486 0.89 0.374 -2.658022 7.069224 
Diab 5.205515 1.09153 4.77 0.000 3.066156 7.344874 
Risk_cat -.0364881 .0190707 -1.91 0.056 -.073866 .0008898 
age_cat 9.040136 3.042482 2.97 0.003 3.076982 15.00329 
gender_cat -13.5595 4.344545 -3.12 0.002 -22.07466 -5.044351 
intervention -.1216281 .5415385 -0.22 0.822 -1.183024 .9397679 
tdd_int .1155115 .4737433 0.24 0.807 -.8130083 1.044031 
source_effects -1.871774 .6713426 -2.79 0.005 -3.187582 -.5559669 
effect_loc 8.564003 2.342514 3.66 0.000 3.972761 13.15525 
effect_calc -32.63791 12.5298 -2.60 0.009 -57.19586 -8.07995 
timing -1.398225 .5252533 -2.66 0.008 -2.427703 -.3687474 
scope -.9660147 2.59417 -0.37 0.710 -6.050494 4.118465 
_cons 2541.819 996.2151 2.55 0.011 589.2737 4494.365 
*omitted because of collinearity 
 
 
Appendix 5.2.2: Logit model for predicting missingness in LDL (d_lcl) 
 
Obs 795 
LR chi2(14) 377.99 
Prob > chi2 0.0000 
Pseudo R2 0.8057 
Log likelihood =  -45.573484 
 
Explanatory Coefficient 
Standard 
Error 
Z P>|z| 95% CI lower 95%CI upper 
INMB -.0000233 .0000152 -1.53 0.125 -.0000531 6.47e-06 
incr_cost .0002016 .0000457 4.41 0.000 .0001121 .0002911 
incr_effect 0 (omitted)     
hdl 7.713941 4.228739 1.82 0.068 -.5742357 16.00212 
tcl .822659 .4027575 2.04 0.041 .0332689 1.612049 
hypert -4.220478 1.537086 -2.75 0.006 -7.233111 -1.207846 
smokers 6.507383 1.826005 3.56 0.000 2.928479 10.08629 
diab -.8737671 1.376445 -0.63 0.526 -3.57155 1.824015 
risk_cat -.4342001 .4188733 -1.04 0.300 -1.255177 .3867765 
age_cat 1.4256 .5339265 2.67 0.008 .3791233 2.472077 
gender_cat 1.64863 .7275759 2.27 0.023 .2226078 3.074653 
intervention .7144262 .2901476 2.46 0.014 .1457474 1.283105 
tdd_int -2.500186 .7446502 -3.36 0.001 -3.959673 -1.040698 
source_effects -.367101 .146308 -2.51 0.012 -.6538594 -.0803425 
effect_loc -.8106235 .2784211 -2.91 0.004 -1.356319 -.2649281 
effect_calc -1.863518 1.742071 -1.07 0.285 -5.277914 1.550878 
Timing .1152788 .0088053 13.09 0.000 .0980207 .1325368 
_cons 4.278564 9.612571 0.45 0.656 -14.56173 23.11886 
*omitted because of collinearity 
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Appendix 5.2.3: Logit model for predicting missingness in HDL (d_hdl) 
 
Obs 1156 
LR chi2(14) 190.63 
Prob > chi2 0.0000 
Pseudo R2 0.4929 
Log likelihood =  -98.063952 
 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
INMB -.0004334 .0000807 -5.37 0.000 -.0005915 -.0002753 
incr_cost -.0005195 .0000951 -5.46 0.000 -.0007058 -.0003332 
incr_effect 0 (omitted)     
tcl .2634234 .1850258 1.42 0.155 -.0992205 .6260673 
age_cat -.8988485 .2469747 -3.64 0.000 -1.38291 -.4147869 
gender_cat -1.088738 .3228125 -3.37 0.001 -1.721439 -.4560372 
tdd_int -.4200735 .1622744 -2.59 0.010 -.7381255 -.1020215 
effect_loc -.0796008 .0674007 -1.18 0.238 -.2117039 .0525022 
timing -.1552515 .0659099 -2.36 0.018 -.2844325 -.0260705 
_cons 315.0081 133.1114 2.37 0.018 54.11462 575.9017 
*omitted because of collinearity 
 
 
 
Appendix 5.2.4: Logit model for predicting missingness in hypertension status 
(d_hypert) 
 
Obs 870 
LR chi2(14) 541.44 
Prob > chi2 0.0000 
Pseudo R2 0.6935 
Log likelihood =  -119.65464 
 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
INMB .0000686 .0000707 0.97 0.332 -.00007 .0002071 
incr_cost -.0006677 .0001274 -5.24 0.000 -.0009173 -.0004181 
incr_effect 0 (omitted)     
tcl -8.352446 1.33393 -6.26 0.000 -10.9669 -5.737992 
hdl 27.93644 4.224154 6.61 0.000 19.65725 36.21563 
ldl 3.970261 1.108581 3.58 0.000 1.797483 6.143039 
smokers -1.13448 .7142796 -1.59 0.112 -2.534442 .2654823 
sbp .0116166 .0252213 0.46 0.645 -.0378163 .0610495 
diab .3329223 .7134978 0.47 0.641 -1.065508 1.731352 
risk_cat .4547893 .18705 2.43 0.015 .0881781 .8214004 
age_cat .5698994 .5308344 1.07 0.283 -.4705168 1.610316 
gender_cat 6.137617 1.015317 6.05 0.000 4.147632 8.127602 
intervention 1.503188 .3332428 4.51 0.000 .850044 2.156332 
tdd_int 1.498864 .2670696 5.61 0.000 .9754172 2.022311 
source_effects .5667746 .097632 5.81 0.000 .3754194 .7581297 
effect_loc -1.078352 .1925064 -5.60 0.000 -1.455658 -.7010466 
timing -2.439659 .3163449 -7.71 0.000 -3.059683 -1.819634 
_cons 4877.341 631.6731 7.72 0.000 3639.284 6115.397 
*omitted because of collinearity 
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Appendix 5.2.5: Logit model for predicting missingness in systolic blood 
pressure (d_sbp) 
 
Obs 1156 
LR chi2(14) 190.94 
Prob > chi2 0.0000 
Pseudo R2 0.4937 
Log likelihood =  -97.910332 
 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
INMB -.0004355 .0000816 -5.34 0.000 -.0005954 -.0002756 
incr_cost -.000507 .0000951 -5.33 0.000 -.0006933 -.0003207 
incr_effect 0 (omitted)     
tcl .2822932 .188329 1.50 0.134 -.0868249 .6514113 
age_cat -.8940499 .25166 -3.55 0.000 -1.387294 -.4008054 
gender_cat -1.088431 .3247331 -3.35 0.001 -1.724896 -.4519657 
tdd_int -.4445926 .1783034 -2.49 0.013 -.7940608 -.0951243 
source_effects -.0372382 .0689759 -0.54 0.589 -.1724285 .0979521 
effect_loc -.1243427 .1103292 -1.13 0.260 -.3405841 .0918986 
timing -.134513 .0745366 -1.80 0.071 -.280602 .011576 
_cons 274.882 149.112 1.84 0.065 -17.37211 567.1362 
*omitted because of collinearity 
 
 
Appendix 5.2.6: Logit model for predicting missingness in smoking status 
(d_sbp) 
 
Obs 1156 
LR chi2(14) 178.38 
Prob > chi2 0.0000 
Pseudo R2 0.4612 
Log likelihood =  -104.19084 
 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
INMB -.0004828 .0000867 -5.57 0.000 -.0006527 -.000313 
incr_cost -.0005183 .0000969 -5.35 0.000 -.0007082 -.0003284 
incr_effect 0 (omitted)     
tcl .2836354 .1835382 1.55 0.122 -.0760929 .6433636 
gender_cat -1.1206 .3096537 -3.62 0.000 -1.72751 -.5136898 
source_effects -.1210404 .0460367 -2.63 0.009 -.2112707 -.0308101 
effect_loc -.1490165 .082239 -1.81 0.070 -.310202 .012169 
timing .0042349 .0560054 0.08 0.940 -.1055337 .1140035 
_cons -4.790422 112.0651 -0.04 0.966 -224.4341 214.8532 
*omitted because of collinearity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 390 
 
Appendix 5.2.7: Logit model for predicting missingness in diabetes status 
(d_diab) 
 
Obs 1156 
LR chi2(14) 190.94 
Prob > chi2 0.0000 
Pseudo R2 0.4937 
Log likelihood =  -97.910332 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
INMB -.0004355 .0000816 -5.34 0.000 -.0005954 -.0002756 
incr_cost -.000507 .0000951 -5.33 0.000 -.0006933 -.0003207 
incr_effect 0 (omitted)     
tcl .2822932 .188329 1.50 0.134 -.0868249 .6514113 
age_cat -.8940499 .25166 -3.55 0.000 -1.387294 -.4008054 
gender_cat -1.088431 .3247331 -3.35 0.001 -1.724896 -.4519657 
tdd_int -.4445926 .1783034 -2.49 0.013 -.7940608 -.0951243 
source_effects -.0372382 .0689759 -0.54 0.589 -.1724285 .0979521 
effect_loc -.1243427 .1103292 -1.13 0.260 -.3405841 .0918986 
timing -.134513 .0745366 -1.80 0.071 -.280602 .011576 
_cons 274.882 149.112 1.84 0.065 -17.37211 567.1362 
*omitted because of collinearity 
 
 
 
Appendix 5.2.8: Logit model for predicting missingness in annual drug cost of 
the intervention (d_cost_int) 
 
Obs 1023 
LR chi2(14) 600.09 
Prob > chi2 0.0000 
Pseudo R2 0.8593 
Log likelihood =  -49.116343 
 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
tcl .726719 .7577476 0.96 0.338 -.7584391 2.211877 
country_id -.2816622 .0729227 -3.86 0.000 -.4245881 -.1387362 
source_effects -.3320263 .323819 -1.03 0.305 -.9666998 .3026472 
drc -20.06777 25.96249 -0.77 0.440 -70.95332 30.81779 
timing .3121932 .2199898 1.42 0.156 -.1189788 .7433653 
duration 1.584883 .6175211 2.57 0.010 .3745642 2.795202 
horizon -2.46523 .4960683 -4.97 0.000 -3.437506 -1.492954 
cur_conv .8132378 6.585694 0.12 0.902 -12.09449 13.72096 
conv_method 0 (omitted)*     
data_class -.1335485 .0814788 -1.64 0.101 -.2932441 .0261471 
incr_cost -.0002244 .0000791 -2.84 0.005 -.0003794 -.0000693 
INMB -.000273 .0000871 -3.13 0.002 -.0004437 -.0001023 
intervention -3.594461 .822772 -4.37 0.000 -5.207064 -1.981857 
tdd_int -.1106023 .7985756 -0.14 0.890 -1.675782 1.454577 
multinational 7.047884 6.490862 1.09 0.278 -5.673972 19.76974 
_cons -619.529 438.5537 -1.41 0.158 -1479.078 240.0204 
*omitted because of collinearity 
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Appendix 5.2.9: Logit model for predicting missingness in unit cost of the 
intervention (d_unitcost_int) 
 
Obs 1053 
LR chi2(14) 92.62 
Prob > chi2 0.0000 
Pseudo R2 0.3397 
Log likelihood =  -90.004987 
 
 
Explanatory Coefficient Standard Error Z P>|z| 95% CI lower 95%CI upper 
tcl .4250457 .2163829 1.96 0.049 .000943 .8491484 
Intervention .6177555 .2122761 2.91 0.004 .2017021 1.033809 
country_id -.1241907 .0342685 -3.62 0.000 -.1913558 -.0570257 
drc -46.91049 19.82648 -2.37 0.018 -85.76969 -8.0513 
timing -.1787341 .0575271 -3.11 0.002 -.2914852 -.0659831 
duration .9724997 .242166 4.02 0.000 .497863 1.447136 
cur_conv .8163021 .7922189 1.03 0.303 -.7364184 2.369023 
conv_method 0 (omitted)     
data_class -.2238029 .097233 -2.30 0.021 -.414376 -.0332297 
incr_cost -.0003556 .0001011 -3.52 0.000 -.0005538 -.0001574 
INMB -.000019 .0000203 -0.93 0.350 -.0000589 .0000209 
_cons 353.1313 115.2612 3.06 0.002 127.2236 579.0391 
*omitted because of collinearity 
 
 
 
Appendix 5.2.10: Logit model for predicting missingness in the annual drug cost 
of the comparator (d_cost_comp) 
 
Due to very few missing values, logit models did not converge for d_cost_comp. 
Therefore, imputation models for the cost of the comparator are based on the same set 
of explanatory variables as the model for the intervention cost, with the explanatory 
‘intervention’ replaced by the explanatory ‘comparator’.  
 
 
 
Appendix 5.2.11: Logit model for predicting missingness in the unit cost of the 
comparator (d_unitcost_comp) 
 
Due to very few missing values, logit models did not converge for d_unitcost_comp. 
Therefore, imputation models for the cost of the comparator are based on the same set 
of explanatory variables as the model for the intervention cost, with the explanatory 
‘intervention’ replaced by the explanatory ‘comparator’.  
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Appendix 5.3: Multiple correspondence analysis on ‘horizon’ 
‘extrapol’ and ‘hor_eq_dur’ 
 
 
Number of obs:  2094 / Total inertia: 0.26199  / Number of axes:  2 
  
 Principal Inertia Percent Cumulative 
Dimension 1 0.20677 78.92% 78.92% 
Dimension 2 0.00654 2.5% 81.42% 
Dimension 3 6.24e
-32
 0.00% 81.42% 
Dimension 4 6.93e
-33
 0.00% 81.42% 
 
 Overall Dimension 1 Dimension 2 
Categories Mass Quality %inertia Coord  sqcorr contrib Coord  sqcorr contrib 
horizon 
< 5 years 
5 to 10 years 
10 to 15 years 
15 to 20 years 
20 to 25 years 
>  25 years 
 
0.003 
0.030 
0.053 
0.021 
0.014 
0.212 
 
0.773 
0.799 
0.827 
0.774 
0.553 
0.764 
 
0.069 
0.336 
0.008 
0.019 
0.015 
0.033 
 
4.960 
3.342 
-0.370 
-0.747 
0.074 
-0.382 
 
0.762 
0.798 
0.698 
0.493 
0.004 
0.746 
 
0.067 
0.340 
0.007 
0.012 
0.000 
0.031 
 
3.402 
0.505 
0.893 
3.169 
-4.689 
-0.331 
 
0.011 
0.001 
0.128 
0.281 
0.548 
0.018 
 
0.031 
0.008 
0.042 
0.211 
0.319 
0.023 
extrapolation 
No 
Yes 
 
0.024 
0.309 
 
0.797 
0.797 
 
0.399 
0.031 
 
4.072 
-0.319 
 
0.794 
0.794 
 
0.401 
0.031 
 
1.297 
-0.102 
 
0.003 
0.003 
 
0.041 
0.003 
Hor_eq_dur 
No 
Yes  
 
0.211 
0.122 
 
1.052 
1.052 
 
0.033 
0.059 
 
0.439 
-0.761 
 
0.964 
0.964 
 
0.041 
0.071 
 
-0.747 
1.295 
 
0.088 
0.088 
 
0.118 
0.204 
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Appendix 5.4:  Gradually building up a random intercepts model 
with data and study-level covariates 
 
Appendix 5.4.1: Random intercepts model with patient and disease 
characteristics 
 
 
 
Univariate model Bivariate model 
 
INMB 
(2010 £ Sterling) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
Fixed part: 
N (countries) 
N (studies) 
N (data) 
18 
67 
2094 
18 
67 
2094 
18 
67 
2094 
Intercept 
(λ=£30.000) 
-25176 725  -0.621 
TCL (SE) 4153 (588)*** -28.32 (3.50)*** 0.037 (0.018)** 
HDL (SE) -26588 (10341)** 102.5 (55.57)* -0.629 (0.342)* 
SBP (SE) 706 (37.05)*** -3.31 (0.22)*** 0.012 (0.001)*** 
Diabetes (SE) 15261 (1750)*** -24.51 (9.23)*** 0.421 (0.005)*** 
Age_cat (SE) 
<45  
46-55 
56-65 
66-75 
>75 
Unclear 
 
Omitted 
98.73 (1162) 
-5976 (1131)*** 
-15240 (1206)*** 
-6692 (2047)*** 
5207 (8436) 
 
Omitted  
-93.92 (6.72)*** 
-133.2 (6.69)*** 
-167.4 (7.11)*** 
-130.3 (11.9)*** 
-97.02 (51.2)* 
 
Omitted 
-0.311 (0.037)*** 
-0.644 (0.036)*** 
-1.070 (0.038)*** 
-0.663 (0.065)*** 
-0.145 (0.280)*** 
Gender (SE) 
Female 
Male 
Mixed sample 
 
Omitted 
10330 (874)*** 
6839 (4122)* 
 
Omitted 
-34.0 (5.07)*** 
-57.6 (25.3)** 
 
Omitted 
0.228 (0.028)*** 
0.074 (0.131)*** 
CVD_history (SE) 
No 
Yes 
Mixed sample 
 
Omitted 
7090 (1589)*** 
9511 (7656) 
-- 
 
Omitted 
0.219 (0.049)*** 
0.260 (0.254) 
Random part:  	(Country) 6274573 2452 0.117  	(Study) 299288384 8661 0.371  	(Data) 204568400 7077 0.201 
VPC - Country 
VPC – Study 
VPC - data 
1.23% 
58.67% 
40.10% 
13.48% 
47.61% 
38.91% 
16.98% 
53.85% 
29.17% 
DIC 
(benchmark) 
46013 
(46749) 
26993 
(28735) 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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Appendix 5.4.2: Random intercepts model with patient/disease and 
intervention/ comparator characteristics 
 
 
 
Univariate model Bivariate model 
 
INMB 
(2010 £ Sterling) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
Fixed part: 
N (countries) 
N (studies) 
N (data) 
18 
67 
2094 
18 
67 
2094 
18 
67 
2094 
Intercept 
(λ=£30.000) 
-24788 701 -0.549 
TCL (SE) 4236 (590)*** -30.62 (3.31)*** 0.035 (0.018)* 
HDL (SE) -26962 (10506)** 132.23 (53.66)** -0.567 (0.334)* 
SBP (SE) 705 (37.37)*** -3.29 (0.21)*** 0.012 (0.001)*** 
Diabetes (SE) 14941 (1753)*** -20.32 (8.89)** 0.424 (0.055)*** 
Age_cat (SE) 
<45  
46-55 
56-65 
66-75 
>75 
Unclear 
 
Omitted 
71.28 (1159) 
-5986 (1138)*** 
-15263 (1206)*** 
-6724 (2032)*** 
5369 (8531) 
 
Omitted  
-94.27 (6.62)*** 
-133.8 (6.36)*** 
-167.9 (6.80)*** 
-131.6 (11.6)*** 
-100.2 (44.69)** 
 
Omitted 
-0.312 (0.036)*** 
-0.645 (0.035)*** 
-1.070 (0.038)*** 
-0.664 (0.064)*** 
-0.184 (0.276) 
Gender (SE) 
Female 
Male 
Mixed sample 
 
Omitted 
10344 (876)*** 
6772 (2032)*** 
 
Omitted 
-33.89 (4.93)*** 
-48.48 (21.14)** 
 
Omitted 
0.228 (0.027)*** 
0.047 (0.130) 
CVD_history (SE) 
No 
Yes 
Mixed sample 
 
Omitted 
7032 (1606)*** 
10196 (7573) 
-- 
 
Omitted 
0.225 (0.050)*** 
0.2323 (0.262) 
Cost_intervention -8.932 (1.863)*** 0.133 (0.010)*** -- 
Cost_comparator -- -0.146 (0.024)*** -- 
Active_comparator 
No (doing nothing) 
Yes (statin) 
 
Omitted 
-4729 (2468)* 
-- 
 
Omitted 
-(0.313 (0.078)*** 
    
Random part:  	(Country) 6801933 2916 0.122  	(Study) 284972576 6543 0.345  	(Data) 202350848 6574 0.200 
VPC - Country 
VPC – Study 
VPC - data 
1.38% 
57.67% 
40.95% 
18.19% 
40.81% 
41.00% 
18.29% 
51.72% 
29.99% 
DIC 
(benchmark) 
45990 
(46013) 
26840 
(26993) 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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Appendix 5.4.3:  Random intercepts model with patient/disease characteristics, 
intervention/comparator characteristics and methodological characteristics on 
data-level.  
 
 
 
Univariate model Bivariate model 
 
INMB 
(2010 £ Sterling) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
Fixed part: 
N (countries) 
N (studies) 
N (data) 
18 
67 
2094 
18 
67 
2094 
18 
67 
2094 
Intercept 
(λ=£30.000) 
-36030 789 -0.881 
TCL (SE) 4447 (571)*** -33.47 (3.10)*** 0.041 (0.019)** 
HDL (SE) -27145 (10219)*** 125.32 (51.69)** -0.585 (0.330)* 
SBP (SE) 707 (35.76)*** -3.36 (0.19)*** 0.012 (0.001)*** 
Diabetes (SE) 14525 (1700)*** -21.48 (8.27)*** 0.409 (0.054)*** 
Age_cat (SE) 
<45  
46-55 
56-65 
66-75 
>75 
Unclear 
 
Omitted 
171.8 (1117) 
-5858 (1095)*** 
-15155 (1163)*** 
-6450 (1973)*** 
2810 (8729) 
 
Omitted  
-95.5 (6.01)*** 
-134.7 (5.99)*** 
-169.2 (6.31)*** 
-131.3 (10.51)*** 
-111.2 (47.52)** 
 
Omitted 
-0.311 (0.036)*** 
-0.643 (0.035)*** 
-1.067 (0.038)*** 
-0.653 (0.063)*** 
-0.299 (0.286) 
Gender (SE) 
Female 
Male 
Mixed sample 
 
Omitted 
10395 (849)*** 
6851 (4114)* 
 
Omitted 
-34.62 (4.50)*** 
-54.76 (23.95)** 
 
Omitted 
0.227 (0.027)*** 
0.028 (0.140) 
CVD_history (SE) 
No 
Yes 
Mixed sample 
 
Omitted 
5788 (1586)*** 
7541 (7474) 
-- 
 
Omitted 
0.195 (0.050)*** 
0.230 (0.249) 
Cost_intervention -8.64 (1.81)*** 0.128 (0.010)*** -- 
Cost_comparator -- -0.143 (0.023)*** -- 
Active_comparator 
No (doing nothing) 
Yes (statin) 
 
Omitted 
-5040 (2425)** 
-- 
 
Omitted 
-(0.313 (0.078)*** 
DRB -131318 (29557)*** -- -3.674 (0.904)*** 
Persp_cost_concl. 
Health insurance (NHS) 
Provider 
Societal 
 
Omitted 
35105 (4421)*** 
17744 (3636)*** 
 
Omitted 
-397.6 (23.36)*** 
-175.13 (20.42)*** 
-- 
Horizon 
< 20 years 
>20 years (lifetime) 
 
Omitted 
4394 (1383)*** 
-- 
 
Omitted 
0.156 (0.044)*** 
Duration equals 
horizon 
yes 
No (treatment 
duration< horizon) 
 
Omitted 
9580 (2557)*** 
-- 
 
Omitted 
0.309 (0.084)*** 
Base case 
Yes 
No  
-- 
 
Omitted 
11.59 (5.01)** 
 
Omitted 
0.064 (0.030)** 
Barbieri_score_2 
Type 1 
Type 2 
Type 3 
Type 4 
-- 
 
Omitted 
-33.42 (15.37)** 
-62.43 (30.76)** 
-93.21 (33.19)*** 
-- 
Random part:  	(Country) 5436921 3366 0.131  	(Study) 306533088 10845 0.334  	(Data) 188981600 5548 0.196 
VPC - Country 
VPC – Study 
VPC - data 
1.09% 
61.19% 
37.72% 
17.04% 
54.89% 
28.08% 
19.82% 
50.53% 
29.65% 
DIC 
(benchmark) 
45846 
(45990) 
26425 
(26840) 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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Appendix 5.4.4:  Random intercepts model fully specified on data-level and 
general study characteristics on study-level.  
 
 
 
Univariate model Bivariate model 
 
INMB 
(2010 £ Sterling) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
Fixed part: 
N (countries) 
N (studies) 
N (data) 
18 
67 
2094 
18 
67 
2094 
18 
67 
2094 
Intercept 
(λ=£30.000) 
-43548 770 -1.315 
TCL (SE) 4333 (565)*** -33.90 (3.14)*** 0.040 (0.018)** 
HDL (SE) -27193 (9616)*** 130.73 (52.47)** -0.545 (0.308)* 
SBP (SE) 704 (35.76)*** -3.36 (0.19)*** 0.012 (0.001)*** 
Diabetes (SE) 14715 (1677)*** -21.80 (8.27)*** 0.417 (0.053)*** 
Age_cat (SE) 
<45  
46-55 
56-65 
66-75 
>75 
Unclear 
 
Omitted 
284.5 (1119) 
-5798 (1096)*** 
-15144 (1158)*** 
-6548 (1963)*** 
-1121 (7663) 
 
Omitted  
-95.62 (6.04)*** 
-134.5 (5.95)*** 
-169.3 (6.21)*** 
-131.6 (10.70)*** 
-117.7 (43.67)*** 
 
Omitted 
-0.307 (0.036)*** 
-0.638 (0.035)*** 
-1.065 (0.038)*** 
-0.651 (0.063)*** 
-0.424 (0.240)* 
Gender (SE) 
Female 
Male 
Mixed sample 
 
Omitted 
10434 (837.1)*** 
13315 (3721)*** 
 
Omitted 
-34.62 (4.50)*** 
-39.31 (24.91) 
 
Omitted 
0.231 (0.027)*** 
0.251 (0.116)** 
CVD_history (SE) 
No 
Yes 
Mixed sample 
 
Omitted 
6481 (1555)*** 
7085 (6512) 
-- 
 
Omitted 
0.225 (0.050)*** 
0.349 (0.199)* 
Cost_intervention -8.97 (1.78)*** 0.127 (0.010)*** -- 
Cost_comparator -- -0.138 (0.023)*** -- 
Active_comparator 
No (doing nothing) 
Yes (statin) 
 
Omitted 
-4483 (2334)* 
-- 
 
Omitted 
-0.296 (0.073)*** 
DRB -131950 (29615)*** -- -3.372 (0.878)*** 
Persp_cost_concl. 
Health insurance (NHS) 
Provider 
Societal 
 
Omitted 
33077 (4423)*** 
15238 (3600)*** 
 
Omitted 
-399.6 (23.22)*** 
-175.9 (20.76)*** 
-- 
Horizon 
< 20 years 
>20 years (lifetime) 
 
Omitted 
3748 (1358)*** 
-- 
 
Omitted 
0.153 (0.043)*** 
Duration=horizon 
yes 
No (treatment 
duration< horizon) 
 
Omitted 
11093 (2423)*** 
-- 
 
Omitted 
0.326 (0.076)*** 
Base case 
Yes 
No  
-- 
 
Omitted 
11.58 (5.03)** 
 
Omitted 
0.067 (0.029)** 
Barbieri_score_2 
Type 1 
Type 2 
Type 3 
Type 4 
-- 
 
Omitted 
-35.19 (15.69)** 
-62.06 (32.57)* 
-93.38 (34.99)*** 
-- 
Author_Grover 
No  
Yes 
 
Omitted 
33704 (5909)*** 
 
Omitted 
161.7 (45.71)*** 
 
Omitted 
1.590 (0.192)*** 
Random part:  	(Country) 974342 4041 0.074  	(Study) 194371968 8876 0.155  	(Data) 189051856 5547 0.196 
VPC - Country 
VPC – Study 
VPC - data 
0.25% 
50.57% 
49.18% 
21.89% 
48.07% 
30.04% 
17.41% 
36.47% 
46.12% 
DIC 
(benchmark) 
45844 
(45846) 
26423 
(26425) 
* 
** 
*** 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
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Appendix 5.5: Individually testing country-level covariates in the 
three-level bivariate random intercepts model (reduced dataset) 
Bivariate model 
 
Raw Mean (SD) / 
Proportion (%) 
∆C/100 
(2010 £ Sterling) 
∆E 
 
DIC (Benchmark: 22596  
(%-change)) 
GDP 37506 (3693) 0.001 (0.001) 0.000 (0.000) 22598 (0.009%) 
THE_GDP 10.83 (2.23) 0.346 (1.471) -0.024 (0.009)*** 22595 (-0.004%) 
GOV_EXP_THE 73.48 (11.77) -0.180 (0.280) -0.003 (0.002) 22599 (0.013%) 
PRIV_EXP_THE 25.73 (11.99) 0.213 (0.275) -0.003 (0.002) 22600 (0.018%) 
SOCSEC_GGE+ 12.78 (23.06) -0.096 (0.159) 0.001 (0.001) 22602 (0.027%) 
OOP_PRIV_EXP+ 55.59 (15.74) 0.061 (0.205) -0.000 (0.001) 22602 (0.022%) 
CVD_POLICY 
No 
Yes 
Unclear 
 
4 (23.52%) 
12 (70.59%) 
1 (5.88%) 
 
Omitted 
37.409 (25.48) 
2.563 (23.94) 
 
Omitted 
0.111 (0.119) 
-0.077 (0.117) 
22601 (0.000%) 
GPs 26.54 (4.91) -1.143 (1.411) 0.008 (0.007) 22601(-0.022%) 
NURSES 96.37 (23.59) 0.091 (0.145) 0.000 (0.001) 22602 (0.027%) 
PHARMACISTS 7.35 (1.59) 3.079 (2.249) 0.034 (0.011)*** 22991 (-0.022%) 
BEDS 36.24 (8.33) -0.053 (0.461) 0.001 (0.002) 22602 (-0.027%) 
AGE 39.53 (1.53) -2.063 (2.149) 0.050 (0.013)*** 22601 (-0.022%) 
URBAN 85.03 (5.45) -0.034 (0.779) -0.003 (0.004) 22602 (0.027%) 
LIFE_EXPECTANCY 80.18 (0.70) -8.164 (5.399) 0.020 (0.028) 22597 (0.004%) 
CVD_DEATH 134.98 (12.84) 0.399 (0.256) 0.000 (0.001) 22599 (0.013%) 
BMI_25+ 60.53 (5.20) 0.744 (0.931) 0.009 (0.005)* 22601 (-0.009%) 
BMI_30+ 26.52 (3.43) 0.907 (1.302) 0.017 (0.008)** 22599 (-0.018%) 
MEAN_BMI+ 27.37 (0.60) 3.915 (7.537) 0.114 (0.042)*** 22597 (-0.027%) 
TCL_6.2+ 20.72 (3.33) -0.655 (1.013) -0.006 (0.006) 22601 (0.022%) 
MEAN_TCL+ 5.33 (0.13) -22.124 (27.940) 0.112 (0.156) 22601 (-0.022%) 
SBP_140+ 39.92 (4.83) -0.084 (0.818) 0.005 (0.005) 22602 (0.027%) 
MEAN_SBP+ 126.99 (3.62) -0.156 (1.111) -0.008 (0.006) 22601 (0.022%) 
GLUCOSE_7+ 9.58 (1.65) 2.106 (2.249) 0.033 (0.013)** 22596 (-0.000%) 
MEAN_GLUCOSE+ 5.52 (0.12) 29.703 (28.329) 0.401 (0.161)** 22596 (-0.000%) 
* 
** 
*** 
 
+ 
 
significant at the 10%-level 
significant at the 5%-level 
significant at the 1%-level 
 
Eight data points referring to the special administrative region Hong Kong have been dropped due to country-level data 
missing for this geographic domain 
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Appendix 5.6: Bivariate random intercepts model fully specified on 
data, study and country-level (reduced dataset) 
 
∆C/100  
(2010 £ Sterling) 
∆E 
N (countries) 
N (studies) 
N (data) 
17 
61 
1806 
17 
61 
1806 
Intercept 
(λ=£30.000) 
261.65 -0.017 
TCL (SE) -32.91 (3.30)*** 0.067 (0.016)*** 
HDL (SE) 233.30 (61.89)*** -0.842 (0.311)*** 
SBP (SE) -3.45 (0.21)*** 0.012 (0.001)*** 
Diabetes (SE) -51.40 (14.67)*** 0.673 (0.073)*** 
Age_cat (SE) 
<45  
46-55 
56-65 
66-75 
>75 
Unclear 
 
Omitted  
-93.04 (6.75)*** 
-128.65 (6.59)*** 
-163.23 (7.041)*** 
-127.41 (11.43)*** 
-114.59 (44.59)** 
 
Omitted 
-0.258 (0.034)*** 
-0.523 (0.033)*** 
-0.853 (0.036)*** 
-0.568 (0.057)*** 
-0.416 (0.240)* 
Gender (SE) 
Female 
Male 
Mixed sample 
 
Omitted 
-32.55 (5.23)*** 
-25.02 (28.37) 
 
Omitted 
0.145 (0.026)*** 
0.123 (0.130) 
CVD_history (SE) 
No 
Yes 
Mixed sample 
-- 
 
Omitted 
0.371 (0.057)*** 
0.321 (0.201) 
Cost_intervention 0.119 (0.011)*** -- 
Cost_comparator -0.131 (0.024)*** -- 
Active_comparator 
No (doing nothing) 
Yes (statin) 
-- 
 
Omitted 
-0.306 (0.069)*** 
DRB -- -3.920 (0.843)*** 
Persp_cost_concl. 
Health insurance (NHS) 
Provider 
Societal 
 
Omitted 
-403.34 (24.11)*** 
-182.05 (21.27)*** 
-- 
Horizon 
< 20 years 
>20 years (lifetime) 
-- 
 
Omitted 
0.197 (0.060)*** 
Duration=horizon 
yes 
No (treatment duration< horizon) 
-- 
 
Omitted 
0.406 (0.072)*** 
Base case 
Yes 
No  
 
Omitted 
9.62 (5.94) 
 
Omitted 
0.099 (0.029)*** 
Barbieri_score_2 
Type 1 
Type 2 
Type 3 
Type 4 
 
Omitted 
-37.41 (39.85) 
-60.23 (44.82) 
-93.04 (46.48)** 
-- 
Author_Grover 
No  
Yes 
 
Omitted 
170.07 (62.28)*** 
 
Omitted 
1.439 (0.238)*** 
4S 
No 
yes 
-- 
 
Omitted 
0.441 (0.209) 
Scope 
CHD 
CHD and stroke 
CHD, stroke and PAD  
unclear 
 
Omitted 
-39.26 (9.30)*** 
-30.16 (37.59) 
-110.51 (72.56) 
-- 
GDP_CAPITA -0.003 (0.001)*** -- 
GOV_EXP_THE -1.029 (0.483)** -- 
THE_GDP -- 0.062 (0.013)*** 
AGE_POPULATION -- 0.070 (0.018)*** 
Random part:  	(Country) 4010 0.086  	(Study) 8688 0.165  	(Data) 6232 0.159 
VPC - Country 
VPC – Study 
VPC - data 
23.45% 
50.80% 
36.44% 
21.50% 
41.25% 
39.75% 
DIC 
(benchmark) 
22571 
(22596) 
* significant at the 10%-level / ** significant at the 5%-level / ***significant at the 1%-level 
 399 
 
 
